<!doctype html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover">
  <title>APEX & Trust Prototype</title>
  <link rel="stylesheet" href="../../apex_trust_panel.css">
  <style>
    @keyframes ticker {
      0% { transform: translateX(0); }
      100% { transform: translateX(-50%); }
    }
    @media (max-width: 768px) {
      #scorecard-ticker { animation: ticker 15s linear infinite; }
    }
  </style>
</head>
<body>
  <!-- CONSOLIDATED STICKY HEADER BLOCK -->
  <div style="position: sticky; top: 0; z-index: 9999; margin: 0; padding: 0; width: 100%; overflow: hidden;">
    
    <!-- Page Header -->
    <div style="background: rgb(26, 35, 54); padding: 0.3rem 1.5rem; margin: 0; border-bottom: 1px solid rgba(10, 132, 255, 0.2);">
      <div style="display: flex; align-items: center; gap: 16px;">
        <div style="font-size: 18px; font-weight: 700; color: white;">üî•APEX Intelligence Terminal</div>
      </div>
    </div>

    <!-- Stock Info Header -->
    <div id="stock-info-header" style="margin: 0; padding: 0;">
      <!-- COMPANY INFO HEADER -->
      <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.75rem; background: rgb(26, 35, 54); box-shadow: 0 2px 8px rgba(0,0,0,0.3); border-bottom: 1px solid rgba(10, 132, 255, 0.4); padding: 0.6rem 1.5rem; margin: 0; width: 100%; position: relative; border-radius: 8px 8px 0 0;">
        <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.6rem; width: 100%; overflow: hidden;">
          <!-- Ticker & Company Name (Left) -->
          <div style="flex: 1 1 auto; min-width: 100px; max-width: 180px;">
            <div id="header-ticker" style="color: white; font-size: 0.95rem; font-weight: 800; letter-spacing: 0.5px;">--</div>
            <div id="header-company" style="color: rgba(255,255,255,0.6); font-size: 0.65rem; line-height: 1; margin-top: 1px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</div>
          </div>
          
          <!-- Key Metrics (Center) - 3 columns -->
          <div style="display: flex; gap: 0.5rem; align-items: center; flex: 2 1 auto; overflow: hidden;">
            <!-- Current Price (with currency) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">
                Price <span id="header-currency" style="color: #f59e0b; font-size: 0.5rem; font-weight: 600;">--</span>
              </div>
              <div id="header-price" style="color: white; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Market Cap -->
            <div style="text-align: center; min-width: 55px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Cap</div>
              <div id="header-mcap" style="color: #10b981; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Exchange (combined Market + Exchange) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Exchange</div>
              <div id="header-exchange" style="font-size: 0.75rem; font-weight: 700; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
          </div>
        </div>
      </div>
      
      <!-- Details Row -->
      <div style="display: flex; gap: 1.5rem; font-size: 0.65rem; background: rgb(26, 35, 54); box-shadow: 0 2px 6px rgba(0,0,0,0.2); border-bottom: 1px solid rgba(10, 132, 255, 0.2); padding: 0.35rem 1.5rem 0.4rem 1.5rem; margin: 0; text-align: left; border-radius: 0 0 8px 8px;">
        <div style="display: flex; align-items: center; gap: 0.4rem; min-width: 100px;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Sector:</span>
          <span id="header-sector" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
        <div style="display: flex; align-items: center; gap: 0.4rem; flex: 1; overflow: hidden;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Ind:</span>
          <span id="header-industry" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
      </div>
    </div>

    <!-- Bloomberg Scorecard Ticker -->
    <div style="background: rgb(26, 35, 54); border-left: 3px solid #0a84ff; padding: 0.5rem 0; margin: 0; font-family: 'Courier New', monospace; font-size: 13px; letter-spacing: 0.5px; box-shadow: 0 2px 4px rgba(0,0,0,0.2); overflow: hidden; width: 100%;">
      <div id="scorecard-ticker" style="display: flex; white-space: nowrap; animation: ticker 20s linear infinite; width: max-content;">
        <div class="ticker-content" style="display: flex; align-items: center; gap: 1.5rem; padding: 0 1.5rem; flex-shrink: 0;">
          <span style="color: rgba(255,255,255,0.6); font-size: 11px; text-transform: uppercase; font-weight: 600;">SCORECARD</span>
          <span id="scorecard-apex" style="background: #10b981; color: white; padding: 6px 12px; border-radius: 6px; font-weight: 700; font-size: 13px;">APEX SCORE:--</span>
          <span id="scorecard-setup" style="color: #3B82F6; font-weight: 700;">SETUP:--</span>
          <span id="scorecard-trust" style="color: #8B5CF6; font-weight: 700;">TRUST:--</span>
          <span id="scorecard-panic" style="color: #EF4444; font-weight: 700;">PANIC:--</span>
          <span id="scorecard-comp" style="color: #F59E0B; font-weight: 700;">COMPRESSION:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-timing" style="color: #3b82f6; font-weight: 700;">TIMING:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-action" style="color: #ef4444; font-weight: 700;">ACTION:--</span>
        </div>
      </div>
    </div>
  </div>

  <div class="container">
    <!-- Narrative Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="4" width="16" height="12" stroke="#10B981" stroke-width="1.5" fill="none" rx="2"/>
        <line x1="5" y1="4" x2="5" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="15" y1="4" x2="15" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="2" y1="7" x2="18" y2="7" stroke="#10B981" stroke-width="1.5"/>
        <circle cx="8" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="12" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="16" cy="11" r="1.2" fill="#10B981"/>
      </svg>
      <span style="color: #10B981; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Company in 30 Seconds</span>
    </div>

    <!-- Narrative Card Stack -->
    <div class="card-stack" id="narrative-stack" style="position: relative; min-height: 180px; overflow: visible; touch-action: pan-y; user-select: none; margin-bottom: 30px;">
      <!-- Card 1: What They Do -->
      <div class="card component-card stack-card narrative-card" data-index="0" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(0%) scale(1); opacity: 1; pointer-events: auto; z-index: 10;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <rect x="3" y="3" width="10" height="10" stroke="#10B981" stroke-width="1.5" fill="none" rx="1"/>
            <path d="M6 3 L6 1 M10 3 L10 1 M3 6 L13 6" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
            <circle cx="8" cy="9" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">What They Do <span class="info-icon" data-field="what" data-tooltip="Company business model and core operations" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Company business model and core operations')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-what" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 2: Why It Matters -->
      <div class="card component-card stack-card narrative-card" data-index="1" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <circle cx="8" cy="8" r="6" stroke="#10B981" stroke-width="1.5" fill="none"/>
            <circle cx="8" cy="8" r="2" fill="#10B981"/>
            <path d="M8 2 L8 6 M8 10 L8 14 M2 8 L6 8 M10 8 L14 8" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Why It Matters <span class="info-icon" data-field="why" data-tooltip="Market significance and investment thesis" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Market significance and investment thesis')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-why" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 3: Current State -->
      <div class="card component-card stack-card narrative-card" data-index="2" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <path d="M2 12 L5 9 L8 11 L14 4" stroke="#10B981" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
            <circle cx="5" cy="9" r="1.5" fill="#10B981"/>
            <circle cx="8" cy="11" r="1.5" fill="#10B981"/>
            <circle cx="14" cy="4" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Current State <span class="info-icon" data-field="state" data-tooltip="Latest company situation and metrics" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Latest company situation and metrics')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-state" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Narrative Stack Navigation -->
      <div class="stack-nav" style="bottom: -35px;">
        <div class="stack-dots">
          <span class="stack-dot narrative-dot" data-index="0"></span>
          <span class="stack-dot narrative-dot" data-index="1"></span>
          <span class="stack-dot narrative-dot" data-index="2"></span>
        </div>
        <div class="stack-label" style="color: #10B981;">Company</div>
      </div>
    </div>

    <!-- Scorecard Breakdown Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="6" width="3" height="12" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="7" y="3" width="3" height="15" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="12" y="8" width="3" height="10" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="17" y="5" width="1" height="13" rx="0.5" stroke="#fff" stroke-width="1.5" fill="none"/>
        <circle cx="10" cy="1" r="1.5" fill="#fff"/>
      </svg>
      <span style="color: #fff; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Scorecard Breakdown</span>
    </div>

    <!-- Main swipeable cards -->
    <div id="component-grid"></div>

    <!-- Bloomberg Phase 2: Collapsible Sections -->
    <div class="bloomberg-sections" style="margin-top: 20px;">
      <!-- CrashDash Intelligence -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('crashdash')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(59, 130, 246, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="crashdash-arrow" style="color: #3b82f6; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px;">CrashDash Intelligence</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">INDUSTRY PATTERNS ¬∑ RECOVERY PATHS</span>
        </div>
        <div id="crashdash-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="crashdash-data">Loading...</div>
        </div>
      </div>

      <!-- Catalyst Pipeline -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('catalyst')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(16, 185, 129, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="catalyst-arrow" style="color: #10b981; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #10b981; text-transform: uppercase; letter-spacing: 0.5px;">Catalyst Pipeline</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">UPCOMING EVENTS ¬∑ TIMELINE</span>
        </div>
        <div id="catalyst-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="catalyst-data">Loading...</div>
        </div>
      </div>

      <!-- Market Tape -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('market')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(245, 158, 11, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="market-arrow" style="color: #f59e0b; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #f59e0b; text-transform: uppercase; letter-spacing: 0.5px;">Market Tape</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">SOCIAL SENTIMENT ¬∑ TRENDS</span>
        </div>
        <div id="market-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="market-data">Loading...</div>
        </div>
      </div>

      <!-- Investment Decision -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('decision')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(239, 68, 68, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="decision-arrow" style="color: #ef4444; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #ef4444; text-transform: uppercase; letter-spacing: 0.5px;">Investment Decision</span>
          </div>
          <span id="decision-status" style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">ANALYSIS ¬∑ ACTION</span>
        </div>
        <div id="decision-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="decision-data">Loading...</div>
        </div>
      </div>

      <!-- Top 5 Recent RNS -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('rns')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(6, 182, 212, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="rns-arrow" style="color: #06b6d4; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #06b6d4; text-transform: uppercase; letter-spacing: 0.5px;">Top 5 Recent RNS</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">REGULATORY NEWS ¬∑ ANNOUNCEMENTS</span>
        </div>
        <div id="rns-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="rns-data">Loading...</div>
        </div>
      </div>
    </div>

    <!-- Bloomberg Terminal Footer (Collapsible) -->
    <div id="footer-container" style="margin-top: 40px; background: linear-gradient(180deg, #0a1628 0%, #020617 100%); border: 1px solid #1e293b; border-radius: 12px; overflow: hidden; box-shadow: 0 20px 50px rgba(0,0,0,0.5);">
        <!-- Header Bar (Always Visible) -->
        <div style="background: rgba(59, 130, 246, 0.08); border-bottom: 1px solid rgba(59, 130, 246, 0.2); padding: 12px 16px; cursor: pointer;" onclick="toggleFooter()">
            <div style="display: flex; align-items: center; justify-content: space-between; gap: 8px; width: 100%;">
                <div style="display: flex; align-items: center; gap: 8px; flex: 1; min-width: 0; overflow: hidden;">
                    <div style="width: 8px; height: 8px; background: #3b82f6; border-radius: 50%; box-shadow: 0 0 12px rgba(59, 130, 246, 0.6); flex-shrink: 0;"></div>
                    <span style="font-family: 'Courier New', monospace; font-size: 12px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">APEX Intelligence Terminal</span>
                    <span id="footer-toggle-icon" style="font-size: 14px; color: #3b82f6; transition: transform 0.3s ease; flex-shrink: 0; margin-left: auto;">‚ñº</span>
                </div>
            </div>
            <div style="font-family: 'Courier New', monospace; font-size: 9px; color: rgba(255, 255, 255, 0.4); letter-spacing: 0.3px; margin-top: 6px; overflow: hidden;">
                GENERATED: <span style="color: #06b6d4;" id="footerDate"></span> ‚Ä¢ SESSION: <span style="color: #10b981;">LIVE</span>
            </div>
        </div>
        
        <!-- Collapsible Content Section -->
        <div id="footer-content" style="display: none;">
            <!-- Content Grid -->
            <div style="padding: 24px; display: grid; grid-template-columns: 1fr 1fr; gap: 24px;">
                <!-- Left Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- System Information -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #3b82f6; margin-bottom: 8px; text-transform: uppercase; letter-spacing: 1px;">System Information</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.7); display: flex; gap: 16px; flex-wrap: wrap; align-items: center;">
                            <span><span style="color: rgba(255, 255, 255, 0.4);">VERSION:</span> <span style="color: #06b6d4; font-weight: 700;">APEX v5.0</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">ENGINE:</span> <span style="color: #10b981;">CrashDash Intelligence</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">COVERAGE:</span> <span style="color: #a855f7;">LSE AIM Micro-Caps</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">SOURCES:</span> <span style="color: #ef4444;">RNS ‚Ä¢ Social ‚Ä¢ Trends</span></span>
                        </div>
                    </div>
                    
                    <!-- Risk Disclosure -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #ef4444; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Risk Disclosure</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.5); line-height: 1.6;">
                            This analysis is provided for informational purposes only and does not constitute financial advice. AIM micro-cap securities carry significant volatility and liquidity risks. Past performance does not guarantee future results. Always conduct your own due diligence and consult with a qualified financial advisor before making investment decisions.
                        </div>
                    </div>
                </div>
                
                <!-- Right Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- Platform Overview -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #10b981; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Platform Overview</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.7); line-height: 1.6;">
                            APEX Intelligence Terminal combines technical analysis, sentiment tracking, and regulatory news monitoring to identify high-probability contrarian setups in distressed micro-cap equities. Our proprietary scoring system evaluates setup quality, panic intensity, and compression patterns to surface opportunities before institutional recognition.
                        </div>
                    </div>
                    
                    <!-- Target Users -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #a855f7; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Target Users</div>
                        <div style="display: flex; flex-wrap: wrap; gap: 8px;">
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(168, 85, 247, 0.1); border: 1px solid rgba(168, 85, 247, 0.3); border-radius: 4px; color: #a855f7; font-weight: 600;">PROP TRADERS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(59, 130, 246, 0.1); border: 1px solid rgba(59, 130, 246, 0.3); border-radius: 4px; color: #3b82f6; font-weight: 600;">HEDGE FUNDS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(16, 185, 129, 0.1); border: 1px solid rgba(16, 185, 129, 0.3); border-radius: 4px; color: #10b981; font-weight: 600;">QUANT TEAMS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(239, 68, 68, 0.1); border: 1px solid rgba(239, 68, 68, 0.3); border-radius: 4px; color: #ef4444; font-weight: 600;">RESEARCH DESKS</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Bottom Bar -->
            <div style="background: rgba(2, 6, 23, 0.6); border-top: 1px solid rgba(59, 130, 246, 0.15); padding: 12px 24px;">
                <div style="display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px; font-family: 'Courier New', monospace; font-size: 10px;">
                    <div style="color: rgba(255, 255, 255, 0.4);">¬© 2026 APEX Intelligence ‚Ä¢ All Rights Reserved</div>
                    <div style="display: flex; align-items: center; gap: 20px; color: rgba(255, 255, 255, 0.5);">
                        <span>STATUS: <span style="color: #10b981; font-weight: 700;">‚óè OPERATIONAL</span></span>
                        <span>LATENCY: <span style="color: #06b6d4; font-weight: 700;">12ms</span></span>
                        <span>BUILD: <span style="color: #a855f7; font-weight: 700;">5.0.2</span></span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function toggleFooter() {
            const content = document.getElementById('footer-content');
            const icon = document.getElementById('footer-toggle-icon');
            
            if (content.style.display === 'none') {
                content.style.display = 'block';
                icon.style.transform = 'rotate(180deg)';
            } else {
                content.style.display = 'none';
                icon.style.transform = 'rotate(0deg)';
            }
        }

        // Mobile-friendly tooltip popover
        function showTooltipPopover(event, tooltipText) {
            event.stopPropagation();
            
            // Close any existing popover
            const existing = document.getElementById('tooltip-popover');
            if (existing) existing.remove();
            
            // Create popover
            const popover = document.createElement('div');
            popover.id = 'tooltip-popover';
            popover.style.cssText = 'position:fixed;background:rgba(20,25,40,0.98);color:#e5e7eb;padding:10px 14px;border-radius:6px;font-size:12px;line-height:1.4;max-width:250px;border:1px solid rgba(16,185,129,0.3);z-index:10000;box-shadow:0 4px 12px rgba(0,0,0,0.4);backdrop-filter:blur(8px);word-wrap:break-word';
            popover.textContent = tooltipText;
            document.body.appendChild(popover);
            
            // Position near clicked element
            const rect = event.target.getBoundingClientRect();
            popover.style.left = Math.min(rect.left, window.innerWidth - 270) + 'px';
            popover.style.top = (rect.bottom + 8) + 'px';
            
            // Close on outside click
            setTimeout(() => {
                document.addEventListener('click', closeTooltip, { once: true });
            }, 0);
        }

        function closeTooltip() {
            const popover = document.getElementById('tooltip-popover');
            if (popover) popover.remove();
        }
    </script>
  </div>
  
  <!-- Mobile Responsive Styles -->
  <style>
    @media(max-width:768px){
        body{padding:10px!important}
        .container{max-width:100%!important}
        #footer-container{margin-top:20px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:12px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:repeat(2,1fr)!important;gap:10px!important}
        div[style*="padding: 24px"]{padding:16px!important}
        div[style*="padding: 12px 16px"]{padding:10px 12px!important}
        div[style*="gap: 20px"]{gap:14px!important}
        div[style*="font-size: 11px"]{font-size:10px!important}
        div[style*="font-size: 12px"]{font-size:11px!important}
        div[style*="font-size: 13px"]{font-size:12px!important}
    }
    @media(max-width:480px){
        body{padding:6px!important}
        .container{padding:0!important;margin:0!important}
        #footer-container{margin-top:16px!important;margin-left:6px!important;margin-right:6px!important}
        #footer-container > div:first-child{padding:8px 10px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:8px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:1fr!important;gap:6px!important;padding:8px 10px!important}
        div[style*="grid-template-columns: repeat(2"]{grid-template-columns:1fr!important;gap:6px!important}
        div[style*="padding: 24px"]{padding:10px!important}
        div[style*="padding: 12px 16px"]{padding:8px 10px!important}
        div[style*="padding: 14px 16px"]{padding:8px 10px!important}
        div[style*="padding: 18px"]{padding:10px!important}
        div[style*="gap: 20px"]{gap:8px!important}
        div[style*="gap: 30px"]{gap:10px!important}
        div[style*="gap: 24px"]{gap:10px!important}
        div[style*="gap: 16px"]{gap:6px!important}
        div[style*="gap: 12px"]{gap:6px!important}
        div[style*="gap: 8px"]{gap:4px!important}
        div[style*="font-size: 9px"]{font-size:8px!important}
        div[style*="font-size: 10px"]{font-size:8px!important}
        div[style*="font-size: 11px"]{font-size:9px!important}
        div[style*="font-size: 12px"]{font-size:10px!important}
        div[style*="font-size: 13px"]{font-size:11px!important}
        div[style*="padding: 6px 12px"]{padding:4px 6px!important;font-size:7px!important}
        div[style*="line-height: 1.8"]{line-height:1.4!important}
        div[style*="line-height: 1.6"]{line-height:1.3!important}
        div[style*="line-height: 1.5"]{line-height:1.2!important}
        /* Footer system info on mobile - stack vertically and shrink */
        div[style*="display: flex; gap: 16px; flex-wrap: wrap; align-items: center"] {
          flex-direction: column!important;
          align-items: flex-start!important;
          gap: 4px!important;
          font-size: 7px!important;
        }
    }
  </style>
  
  <script>window.__APEX_PROFILE = {
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "FAB.L",
  "generated_at": "2026-02-11T23:07:15.944372Z",
  "top_card": {
    "ticker": "FAB.L",
    "company_name": "Fusion Antibodies plc",
    "sector": "Healthcare",
    "market_cap_gbp": 19378391,
    "days_active": 651,
    "apex_score_100": 49,
    "confidence_score_100": 40,
    "ai_final_score_25": 10,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 49/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Fusion Antibodies plc",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 19378391,
      "current_close_price": 15.5
    },
    "basics": {
      "ticker": "FAB.L",
      "current_price": 15.5,
      "ath": 255.0,
      "atl": 2.8,
      "ath_date": "2020-09-18",
      "atl_date": "2024-07-10",
      "week_52_high": 21.0,
      "week_52_low": 5.6,
      "week_52_high_date": "2025-09-24",
      "week_52_low_date": "2025-05-09",
      "drawdown_from_ath_pct": 93.92,
      "data_start": "2020-01-02",
      "data_end": "2026-02-11",
      "total_bars": 1539
    },
    "latest_signal": {
      "date": "2024-05-01",
      "scan_date": "2026-01-26",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 3.275,
      "drawdown_pct": 92.72,
      "ai_score": 8.0,
      "rsi": 22.2,
      "cycle_position": 0.1245,
      "holding_period_days": 651,
      "current_pnl_pct": 373.28,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -30.39,
      "Rally_Count": 2,
      "days_since_last_high": 13,
      "last_high_date": "2026-01-13",
      "lock_in_reached": true,
      "lock_in_date": "2025-12-12",
      "best_rally_pct": 487.79
    },
    "best_historical_signal": {
      "signal_date": "2023-11-24",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "entry_price": 3.2,
      "peak_price": 21.0,
      "peak_date": "2025-09-24",
      "rally_pct": 556.25,
      "days_to_peak": 670,
      "ai_score": 12.0
    },
    "all_historical_signals": [
      {
        "signal_id": "FAB.L_2023-05-19",
        "signal_date": "2023-05-19",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 7.75,
        "current_price": 13.4,
        "current_return_pct": 72.9,
        "best_rally_pct": 148.39,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 983,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-05-22",
        "signal_date": "2023-05-22",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 6.5,
        "current_price": 13.4,
        "current_return_pct": 106.15,
        "best_rally_pct": 196.15,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 980,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-05-23",
        "signal_date": "2023-05-23",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 7.65,
        "current_price": 13.4,
        "current_return_pct": 75.16,
        "best_rally_pct": 151.63,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 979,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-05-30",
        "signal_date": "2023-05-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.0,
        "current_price": 13.4,
        "current_return_pct": 123.33,
        "best_rally_pct": 220.83,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 972,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-06-05",
        "signal_date": "2023-06-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.625,
        "current_price": 13.4,
        "current_return_pct": 138.22,
        "best_rally_pct": 242.22,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 6,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 966,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-06-06",
        "signal_date": "2023-06-06",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.0,
        "current_price": 13.4,
        "current_return_pct": 91.43,
        "best_rally_pct": 175.0,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 965,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-06-07",
        "signal_date": "2023-06-07",
        "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.625,
        "current_price": 13.4,
        "current_return_pct": 102.26,
        "best_rally_pct": 190.57,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 964,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-06-08",
        "signal_date": "2023-06-08",
        "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.75,
        "current_price": 13.4,
        "current_return_pct": 98.52,
        "best_rally_pct": 185.19,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 963,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-07-27",
        "signal_date": "2023-07-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.0,
        "current_price": 13.4,
        "current_return_pct": 91.43,
        "best_rally_pct": 175.0,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 914,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-11-02",
        "signal_date": "2023-11-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 5.025,
        "current_price": 13.4,
        "current_return_pct": 166.67,
        "best_rally_pct": 283.08,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 816,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-11-09",
        "signal_date": "2023-11-09",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 3.9,
        "current_price": 13.4,
        "current_return_pct": 243.59,
        "best_rally_pct": 393.59,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 809,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-11-10",
        "signal_date": "2023-11-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 3.6,
        "current_price": 13.4,
        "current_return_pct": 272.22,
        "best_rally_pct": 434.72,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 808,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-11-24",
        "signal_date": "2023-11-24",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 3.2,
        "current_price": 13.4,
        "current_return_pct": 318.75,
        "best_rally_pct": 501.56,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 794,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2023-11-27",
        "signal_date": "2023-11-27",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 3.45,
        "current_price": 13.4,
        "current_return_pct": 288.41,
        "best_rally_pct": 457.97,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 791,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2024-02-14",
        "signal_date": "2024-02-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 4.2,
        "current_price": 13.4,
        "current_return_pct": 219.05,
        "best_rally_pct": 358.33,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 712,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2024-02-22",
        "signal_date": "2024-02-22",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 3.95,
        "current_price": 13.4,
        "current_return_pct": 239.24,
        "best_rally_pct": 387.34,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 704,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2024-02-23",
        "signal_date": "2024-02-23",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 3.8,
        "current_price": 13.4,
        "current_return_pct": 252.63,
        "best_rally_pct": 406.58,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 703,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2024-04-30",
        "signal_date": "2024-04-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 3.225,
        "current_price": 13.4,
        "current_return_pct": 315.5,
        "best_rally_pct": 496.9,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 636,
        "status": "historical"
      },
      {
        "signal_id": "FAB.L_2024-05-01",
        "signal_date": "2024-05-01",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 3.275,
        "current_price": 13.4,
        "current_return_pct": 309.16,
        "best_rally_pct": 487.79,
        "best_rally_date": "2025-12-12",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -30.39,
        "days_since_last_high": 13,
        "lock_in_reached": true,
        "age_days": 635,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 19,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 347.44,
      "median_rally_pct": 317.91,
      "best_rally_pct": 556.25,
      "worst_rally_pct": 170.97
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-11 20:06:42 UTC",
    "volatility": {
      "atr_normalized": 7.78,
      "stddev_20d": 0.3466
    },
    "trends": {
      "intelligence_signal": "DOWNTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 49/100 indicates moderate opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 2 rallies, 488% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "FAB.L",
      "latest": [
        {
          "title": "Holding(s) in Company",
          "announcement_date": "4th Feb 2026",
          "release_time": "3:27 pm",
          "source": "RNS",
          "content": "4 Feb 2026 15:27\nRNS Number : 7532R\nFusion Antibodies PLC\n04 February 2026\n4 February 2026\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nHolding(s) in Company\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, was informed today that Rathbones Investment Management Ltd (ultimately controlled by Rathbones Group Plc) now holds 9,679,837 ordinary shares of 4 pence each in the Company, representing approximately 7.74 per cent. of the Company's issued share capital. These shares are registered in the name of Rathbones Nominees Limited.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.\nThe range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM\u00a0platform and\u00a0cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nAt every stage, our client's vision is central to how we work in\ncombining the latest technological advances with cutting edge science.\nIn this work our world-class discovery (\nOptiMAL\u00ae\nand OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)\nto\nensure the best molecule goes to the clinic.\nFusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our\nIntegrated Therapeutic Antibody Services (\"ITA\") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.\nFusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.\nFusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.\nWhile therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUAPPUPQGAC",
          "rns_number": "RNS Number : 7532R"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "2nd Feb 2026",
          "release_time": "11:33 am",
          "source": "RNS",
          "content": "2 Feb 2026 11:33\nRNS Number : 3413R\nFusion Antibodies PLC\n02 February 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nFusion Antibodies plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nUnicorn Asset Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUnicorn AIM VCT plc\nCity and country of registered office (if applicable)\nTeignmouth, Devon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n30 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n02 February 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n6.66%\n6.66%\n8,320,366\nPosition of previous notification (if\napplicable)\n5.65%\n5.65%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nOrdinary shares\nGB00BDQZGK16\n8,320,366\n6.66%\nSUBTOTAL 8. A\n8,320,366\n6.66%\nB 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 125,021,878\nPlace of completion\nUnicorn Asset Management Limited, Preachers Court, Charterhouse, Chartehouse Square, London, EC1M 6AU\nDate of completion\n02 February 2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUGWPUPQGGP",
          "rns_number": "RNS Number : 3413R"
        },
        {
          "title": "Total Voting Rights",
          "announcement_date": "30th Jan 2026",
          "release_time": "5:00 pm",
          "source": "RNS",
          "content": "Today 17:00\nRNS Number : 1535R\nFusion Antibodies PLC\n30 January 2026\n30 January 2026\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nTotal Voting Rights\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces\u00a0that the issued share capital of the Company at the date of this announcement comprises\n125,021,878\nordinary shares of\u00a04 pence each with one voting right per share (\"Ordinary Shares\"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is\n125,021,878\n.\nThe above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.\nThe range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM\u00a0platform and\u00a0cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nAt every stage, our client's vision is central to how we work in\ncombining the latest technological advances with cutting edge science.\nIn this work our world-class discovery (\nOptiMAL\u00ae\nand OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)\nto\nensure the best molecule goes to the clinic.\nFusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our\nIntegrated Therapeutic Antibody Services (\"ITA\") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.\nFusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.\nFusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.\nWhile therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRBSGDBGSXDGLG",
          "rns_number": "RNS Number : 1535R"
        },
        {
          "title": "Issue of Director Shares",
          "announcement_date": "27th Jan 2026",
          "release_time": "7:05 am",
          "source": "RNS",
          "content": "27 Jan 2026 07:05\nRNS Number : 4327Q\nFusion Antibodies PLC\n27 January 2026\n27 January 2026\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nIssue of Director Shares\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces, further to the notification of the conditional placing and subscription to raise approximately \u00a31.4 million (before expenses) (the \"\nFundraise\n\") released earlier today (the \"\nFundraise Announcement\n\"), the Company has issued 308,720 new ordinary shares of 4p each in the share capital of the Company (\"\nOrdinary Shares\n\") to certain\nexecutive Directors at a deemed subscription price equal to the Fundraise issue price of 13 pence per new Ordinary Share (the \"\nIssue Price\n\") in satisfaction of a portion of their bonuses for the year ended 31 March 2025 (the \"\nDirector\nShares\n\").\nAs disclosed in the Company's annual report and accounts for the year ended 31 March 2025 (as announced on 4 September 2025), the remuneration committee recommended, and the board of directors of Fusion (the \"\nBoard\n\" or the \"\nDirectors\n\") accepted, a bonus award for Adrian Kinkaid (CEO) and Richard Buick (CSO) each of 20% of their gross salary, against their maximum contractual bonus of 45% and 40% respectively. In recognition that the Company is still controlling costs tightly and cognisant of the cash position, it was agreed that the bonus award be split into two components: 40% cash and the remainder to be satisfied via the issue of new Ordinary Shares once the Company was in an open period.\nAs separately indicated in Fundraise Announcement, the Board has now resolved to issue and allot, in aggregate,\n308,720\nnew Ordinary Shares to Adrian Kinkaid (CEO) and Richard Buick (CSO) at a deemed issue price equal to the Issue Price and pursuant to the authorities previously granted at the\nCompany's annual general meeting held on 16 October 2025,\nas follows:\nDirector\nAmount of bonus award to be received in Director Shares\nNo. of Director Shares issued\nTotal holding of Ordinary Shares post issue\nPercentage of enlarged issued share capital1\nAdrian Kinkaid\n\u00a323,846.94\n183,438\n1,033,438\n0.83%\nRichard Buick\n\u00a316,286.66\n125,282\n1,125,282\n0.90%\n1\nBased on the enlarged issued share capital of the Company following the issue of the Director Shares, the Placing Shares and the Subscription Shares, as defined in the Fundraise Announcement.\nAdmission to trading on AIM\nApplication has been made to the London Stock Exchange plc for the New Ordinary Shares to be admitted to trading on AIM (\"\nAdmission\n\"). It is currently anticipated that Admission will become effective and that dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on or around\n30\nJanuary 2026.\nTotal voting rights\nOn Admission, the Company will have 125,021,878 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 125,021,878 and this figure may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\nDefined terms in this announcement shall have the same meaning as defined in the Fundraise Announcement, unless otherwise defined herein.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nDirector/PDMR UK MAR disclosures\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\n1.\nAdrian Kinkaid\n2.\nRichard Buick\n2\nReason for the notification\na)\nPosition/status\n1. Chief Executive Officer\n2.\nChief Scientific Officer\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nFusion Antibodies plc\nb)\nLEI\n213800KBAYRC9VOQ9V39\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of 4p each in Fusion Antibodies plc\nIdentification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16\nb)\nNature of the transaction\nIssue of Director Shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n1.\n1\n3 pence\n183,438\n2.\n1\n3 pence\n125,282\nd)\nAggregated information:\n- Aggregated volume\n- Price\nN/A\ne)\nDate of the transaction\n27 January 2026,\nto be completed on 30 January 2026\nf)\nPlace of the transaction\nOutside a trading venue\nAbout Fusion Antibodies plc\nFusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.\nThe range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM\u00a0platform and\u00a0cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nAt every stage, our client's vision is central to how we work in\ncombining the latest technological advances with cutting edge science.\nIn this work our world-class discovery (\nOptiMAL\u00ae\nand OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)\nto\nensure the best molecule goes to the clinic.\nFusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our\nIntegrated Therapeutic Antibody Services (\"ITA\") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.\nFusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.\nFusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.\nWhile therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHAKABNOBKDBDB",
          "rns_number": "RNS Number : 4327Q"
        },
        {
          "title": "Placing and Subscription to raise approx \u00a31.4m",
          "announcement_date": "27th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "27 Jan 2026 07:00\nRNS Number : 4325Q\nFusion Antibodies PLC\n27 January 2026\nTHIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED (\"EUWA\")) (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n27 January 2026\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nPlacing and Subscription to raise approximately \u00a31.4 million\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces\nthat it has conditionally raised approximately \u00a31.4\nmillion (before expenses)\nthrough the issue of\n11,056,905\nnew ordinary shares of 4 pence each in the\nCompany (\"\nOrdinary Shares\n\") at a\nprice of 13 pence per new Ordinary Share\n(the \"\nIssue Price\n\"), as follows:\n\u00b7\napproximately \u00a31.4 million (before expenses) has been raised by way of a placing of a total of 10,904,121 new Ordinary Shares (the \"\nPlacing Shares\n\") at the Issue Price with new investors and existing shareholders (the \"\nPlacing\n\"); and\n\u00b7\nColin Walsh, Non-Executive Director, has directly subscribed with the Company for\n152,784\nnew Ordinary Shares (the \"\nSubscription Shares\n\") at the Issue Price (the \"\nSubscription\n\", and together with the Placing, the \"\nFundraise\n\"), raising \u00a319,861.92 (before expenses).\nAllenby Capital Limited (\"\nAllenby Capital\n\") and Shard Capital Partners LLP (\"\nShard\n\") are acting as the Company's joint brokers in connection with the Placing.\nKey highlights\n\u00b7\nPlacing and Subscription to raise approximately \u00a3\n1.4 million\n(before expenses) through the issue of\n11,056,905 new Ordinary\nShares at the Issue Price.\n\u00b7\nThe Issue Price is equal to the closing bid price of an Ordinary Share on\n26\nJanuary 2026.\n\u00b7\nThe Fundraise is being conducted utilising all of the existing share authorities available to the Board to issue shares for cash on a non-pre-emptive basis, as approved at the Company's annual general meeting held on 16 October 2025 (the \"\n2025 AGM\n\").\n\u00b7\nShortly following the publication of this announcement, the Company intends to issue 308,720 new Ordinary Shares (the \"\nDirector Shares\n\") to certain executive directors at a deemed subscription price equal to the Issue Price in satisfaction of a portion of their bonuses for the year ended 31 March 2025, further details of which are outlined below.\n\u00b7\nThe Placing is not being underwritten by Allenby Capital or Shard.\nAdrian Kinkaid, Chief Executive Officer of Fusion Antibodies plc, commented:\n\"\nThe successful validation and formal launch of our OptiMAL\u00ae platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time.\n\"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders.\"\nFurther details of the Fundraise are set out below.\nBackground to and reasons for the\nFundraise\nThrough the successful collaboration with the National Cancer Institute (\"\nNCI\n\") in the United Sates, the directors of the Company (the \"\nDirectors\n\" or together, the \"\nBoard\n\") believe that the Company has now validated the OptiMAL\u00ae platform with the platform performing in line with and in certain instances exceeding target performance parameters laid out by the Company.\nThe formal launch of the OptiMAL\u00ae platform took place on 15 December 2025 at the Antibody Engineering and Therapeutics conference in San Diego, an established conference which attracts a wide range of technical experts in the antibody discovery field. Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time.\nThe Directors believe that the initial soundings and market research, including discussions with a number of potential clients, have been very positive. Many of the organizations approached in the pre-launch phase have expressed an interest in the OptiMAL\u00ae platform including disclosure of target details under non-disclosure agreements, resulting in multiple opportunities being registered in the Company's sales opportunities pipeline, which has a combined potential value in excess of \u00a31 million. While these opportunities remain at an early stage and will take some time to convert (if at all), the level of interest in the OptiMAL\u00ae platform provides encouraging signs of the commercial potential of this platform.\nAgainst the backdrop of the formal launch of the OptiMAL\u00ae platform and the reasons outlined above, the Board believes that it is well positioned for significant growth but remains cautiously mindful of the potential market volatility and the inherent science-based risks in the work being undertaken by its clients, which can potentially impact the visibility of revenue streams.\nThe Board is aware of the significant advantages that the Company's proprietary platforms including OptiMAL\u00ae, OptiPhageTM and AI/ML-abTM can provide to clients in their pursuit of new antibody therapeutics and so are supportive of accelerating the commercialisation of these platforms starting with OptiMAL\u00ae.\nReasons for the\nFundraise\nAs previously announced, it had been a key focus of the Board for the Company to achieve cash flow breakeven without needing to raise additional funds. While the Company was on track to achieve this, the extremely tight control of costs that would have been required would impact on the speed of the roll out of a commercially robust OptiMAL\u00ae platform by the Company and the dedicated marketing activities required post formal launch. The Board considers that it is in the best interests of the Company and its shareholders to conduct the Fundraise in order to provide the capital for the commercialisation of the OptiMAL\u00ae platform, associated equipment and global marketing activities, to improve the overall cash position of the business and provide it with increased working capital to generate supporting data for its key proprietary platforms, namely OptiMAL\u00ae, OptiPhageTM and Mammalian Display.\nUse of proceeds\nThe net proceeds receivable by the Company pursuant to the Fundraise, being approximately \u00a31.3 million, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL\u00ae platform, to invest in the Company's commercial activities and for general working capital purposes. The commercial plans will focus on increasing the Company's presence in key geographic markets, such as North America, and promoting OptiMAL\u00ae through various marketing activities, including but not limited to, attendance at key industry conferences and follow on business development trips.\nDetails of the Placing and the Subscription\nThe Placing will result in the issue of a total of 10,904,121 Placing Shares and the Subscription will result in the issue of 152,784 Subscription Shares, in each case at the Issue Price. Together, the Placing and Subscription has raised \u00a31,437,397.65 before expenses for the Company. The Placing Shares and the Subscription Shares will be issued on a non-pre-emptive basis pursuant to the authorities granted to the Board at the 2025 AGM.\nThe Placing Shares and the Subscription Shares, when issued and fully paid, will rank\npari passu\nin all respects with the existing Ordinary Shares in issue and therefore will rank equally for all dividends or other distributions declared, made or paid after the issue of the Placing Shares and the Subscription Shares.\nAllenby Capital and Shard have entered into a Placing Agreement with the Company pursuant to which Allenby Capital and Shard have, on the terms and subject to the conditions set out therein, undertaken to use their respective reasonable endeavours to procure subscribers for the Placing Shares at the Issue Price. The Placing Agreement contains certain warranties and indemnities from the Company in favour of Allenby Capital and Shard. The Placing is not being underwritten by Allenby Capital, Shard or any other person.\nDirector participation in the Subscription\nColin Walsh, a Non-Executive Director of the Company, has subscribed for 152,784 Subscription Shares at the Issue Price pursuant to the Subscription. Following Admission (as defined below), Mr Walsh will have a total direct and indirect beneficial interest in 3,531,785 Ordinary Shares, equivalent to approximately 2.82% of Fusion's total issued ordinary share capital (as enlarged by the issue of the Placing Shares, the Subscription Shares and the Director Shares). 715,284 of these Ordinary Shares are held directly, 211,618 are held by Crescent Capital III GP Limited (\"\nCrescent III Ltd\n\"), which is controlled by Mr Walsh, 1,204,883 are held by Walsh Strategic Management Limited (\"\nWSML\n\"), another company controlled by Mr Walsh and 1,400,000 are held by HamNiv (GP) Limited, a subsidiary of Crescent Capital NI Limited. Mr Walsh is the founder and Chief Executive Officer of Crescent Capital NI Limited.\nThe tables below, which have been provided in accordance with the requirements of the UK Market Abuse Regulation, provide further details of the transactions.\nProposed issue of Director Shares\nAs disclosed in the Company's annual report and accounts for the year ended 31 March 2025, the remuneration committee recommended, and the Board accepted, a bonus award for Adrian Kinkaid (CEO) and Richard Buick (CSO) each of 20% of their gross salary, against their maximum contractual bonus of 45% and 40% respectively. In recognition that the Company is still controlling costs tightly and cognisant of the cash position, it was agreed that the bonus award be split into two components: 40% cash and the remainder to be satisfied via the issue of new Ordinary Shares once the Company was in an open period.\nTherefore, immediately following the publication of this announcement, 308,720 new Ordinary Shares will be issued and allotted to Adrian Kinkaid (CEO) and Richard Buick (CSO) at a deemed subscription price equal to the Issue Price and pursuant to the authorities previously granted at the 2025 AGM, as follows:\nDirector\nAmount of bonus award to be received in Director Shares\nNo. of Director Shares to be issued\nAdrian Kinkaid\n\u00a323,846.94\n183,438\nRichard Buick\n\u00a316,286.66\n125,282\nA further announcement will be provided following the issue and allotment of the Director Shares.\nAdmission to trading on AIM\nApplication will be made to the London Stock Exchange plc for the Placing Shares, the Subscription Shares and, once issued, the Director Shares (together, the \"\nNew Ordinary Shares\n\") to be admitted to trading on AIM (\"\nAdmission\n\"). It is currently anticipated that Admission will become effective and that dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on or around\n30 January\n2026.\nTotal voting rights\nOn Admission, the Company will have 125,021,878 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 125,021,878 and this figure may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\nfusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nThis announcement is made in accordance with the Company's obligations under Article 17 of UK MAR and the person responsible for arranging for the release of this announcement on behalf of Fusion is Adrian Kinkaid, Chief Executive Officer.\nDirector/PDMR UK MAR disclosures\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nColin Walsh\n2\nReason for the notification\na)\nPosition/status\nNon-Executive Director\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nFusion Antibodies plc\nb)\nLEI\n213800KBAYRC9VOQ9V39\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of 4p each in Fusion Antibodies plc\nIdentification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16\nb)\nNature of the transaction\nPurchase of new Ordinary Shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n1\n3p\n1\n52,784\nd)\nAggregated information:\n- Aggregated volume\n- Price\nN/A\ne)\nDate of the transaction\n2\n6\nJanuary 2026 to be completed on 30 January 2026\nf)\nPlace of the transaction\nOutside a trading venue\nIMPORTANT NOTICES\nNotice to Distributors\nSolely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended and as this is applied in the United Kingdom (\"\nMiFID II\n\"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II and Regulation (EU) No 600/2014 of the European Parliament, as they form part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended; and (c) local implementing measures (together, the \"\nMiFID II Product Governance Requirements\n\"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any \"\nmanufacturer\n\" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Ordinary Shares have been subject to a product approval process, which has determined that such securities are: (i) compatible with an end target market of retail investors who do not need a guaranteed income or capital protection and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the \"\nTarget Market Assessment\n\"). The Ordinary Shares are not appropriate for a target market of investors whose objectives include no capital loss. Notwithstanding the Target Market Assessment, distributors should note that: the price of the Ordinary Shares may decline and investors could lose all or part of their investment; the Ordinary Shares offer no guaranteed income and no capital protection; and an investment in the Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital projection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Fundraise. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Allenby Capital and Shard will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the shares and determining appropriate distribution channels.\nForward Looking Statements\nThis announcement includes statements that are, or may be deemed to be, \"forward-looking statements\". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms \"believes\", \"estimates\", \"plans\", \"anticipates\", \"targets\", \"aims\", \"continues\", \"expects\", \"intends\", \"hopes\", \"may\", \"will\", \"would\", \"could\" or \"should\" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include matters that are not facts. They appear in a number of places throughout this announcement and include statements regarding the Directors' beliefs or current expectations. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement.\nNotice to overseas persons\nThis announcement does not constitute, or form part of, a prospectus relating to the Company, nor does it constitute or contain any invitation or offer to any person, or any public offer, to subscribe for, purchase or otherwise acquire any shares in the Company or advise persons to do so in any jurisdiction, nor shall it, or any part of it form the basis of or be relied on in connection with any contract or as an inducement to enter into any contract or commitment with the Company.\nThis announcement is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into Australia, Canada, Japan, New Zealand or the Republic of South Africa or any jurisdiction into which the publication or distribution would be unlawful. This announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire shares in the capital of the Company in Australia, Canada, Japan, New Zealand, the Republic of South Africa or any jurisdiction in which such offer or solicitation would be unlawful or require preparation of any prospectus or other offer documentation or would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Persons into whose possession this announcement comes are required by the Company to inform themselves about, and to observe, such restrictions.\nThis announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.\nGeneral\nNeither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) or any previous announcement made by the Company is incorporated into, or forms part of, this announcement.\nAllenby Capital, which is authorised and regulated by the FCA in the United Kingdom, is acting as Nominated Adviser and Joint Broker to the Company in connection with the Placing. Allenby Capital will not be responsible to any person other than the Company for providing the protections afforded to clients of Allenby Capital or for providing advice to any other person in connection with the Fundraise. Allenby Capital has not authorised the contents of, or any part of, this announcement, and no liability whatsoever is accepted by Allenby Capital for the accuracy of any information or opinions contained in this announcement or for the omission of any material information, save that nothing shall limit the liability of Allenby Capital for its own fraud.\nShard, which is authorised and regulated by the FCA in the United Kingdom, is acting as\u00a0Joint Broker to the Company\u00a0in connection with the Placing. Shard will not be responsible to any person other than the Company for providing the protections afforded to clients of Shard or for providing advice to any other person in connection with the Fundraise. Shard has not authorised the contents of, or any part of, this announcement, and no liability whatsoever is accepted by Shard for the accuracy of any information or opinions contained in this announcement or for the omission of any material information, save that nothing shall limit the liability of Shard for its own fraud.\nAbout Fusion Antibodies plc\nFusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.\nThe range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM\u00a0platform and\u00a0cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nAt every stage, our client's vision is central to how we work in\ncombining the latest technological advances with cutting edge science.\nIn this work our world-class discovery (\nOptiMAL\u00ae\nand OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)\nto\nensure the best molecule goes to the clinic.\nFusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our\nIntegrated Therapeutic Antibody Services (\"ITA\") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.\nFusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.\nFusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.\nWhile therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOESEFFWMEMSEDF",
          "rns_number": "RNS Number : 4325Q"
        }
      ],
      "themes": [
        "funding",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 1558,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "DOWNTREND"
    },
    "volatility": {
      "atr_normalized": 7.78,
      "stddev_20d": 0.3466
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-19th Dec 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430482Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on negotiations with NCI regarding OptiMAL",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/update-on-negotiations-with-nci-regarding-optimal-vc5jv2f8teypybp.html",
          "rns_number": "RNS Number : 1835M",
          "full_content": "19 Dec 2025 07:00\nRNS Number : 1835M\nFusion Antibodies PLC\n19 December 2025\n19 December 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nUpdate on negotiations with NCI regarding OptiMAL\u00ae\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that following the validation project run with the National Cancer Institute (\"\nNCI\n\") between November 2023 and earlier this year, the NCI has expressed an interest in continuing to use OptiMAL\u00ae as a frontline human antibody discovery platform for a range of targets. Consequently, the NCI has provided Fusion with a proposal to extend the collaboration agreement entered in November 2023 (the \"\nAgreement\n\") to allow screening of several named targets.\nHaving reviewed the initial proposal for an extension to the Agreement, Richard Buick, CSO, and Adrian Kinkaid, CEO, met with Mitchell Ho of the NCI at the recent Antibody Engineering and Therapeutics conference in San Diego. The discussions included options to extend the NCI's use of OptiMAL\u00ae and various administrative pathways to achieve this. The immediate needs of NCI are to support current and imminent screening projects using OptiMAL\u00ae. The latest discussions also encompassed possible additional projects with enhanced ownership for Fusion Antibodies.\nNegotiations regarding the expanded proposed programme are expected to continue into early 2026. Due to the scale of the proposal, formal approval processes at the US National Institutes of Health (of which the NCI is part) are likely to take several further months to complete. While discussions are progressing, there is no assurance that an extension to the Agreement will be reached, nor as to the timing or final terms of such an extension.\nAdrian Kinkaid, Chief Executive Officer of Fusion Antibodies, commented:\n\"The NCI's interest in continuing to use OptiMAL\u00ae is a strong validation of the platform following the initial programme. We are encouraged by the constructive discussions around extending the collaboration and supporting additional targets, while recognising that formal approval processes are still ongoing.\"\nFurther updates will be provided in due course.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nFusion Antibodies wants to keep its investors up to date with developments in the Company technology and offerings. We have therefore created a space on the Investor Hub which in contains an increasing number of videos providing more information which may be of interest to investors. This can be found here,\nhttps://investorhub.fusionantibodies.com/s/1b6535\n.\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody discovery including using the proprietary OptiMAL\u00ae platform, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 290 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug d",
          "content_length": 5799
        },
        "ingested_at": "2026-01-21T02:20:26.430515Z"
      },
      {
        "event_id": "RNS-19th Dec 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430532Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on negotiations with NCI regarding OptiMAL",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/update-on-negotiations-with-nci-regarding-optimal-u7svqvtvgq5jkwg.html",
          "rns_number": "RNS Number : 1835M",
          "full_content": "19 Dec 2025 07:00\nRNS Number : 1835M\nFusion Antibodies PLC\n19 December 2025\n19 December 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nUpdate on negotiations with NCI regarding OptiMAL\u00ae\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that following the validation project run with the National Cancer Institute (\"\nNCI\n\") between November 2023 and earlier this year, the NCI has expressed an interest in continuing to use OptiMAL\u00ae as a frontline human antibody discovery platform for a range of targets. Consequently, the NCI has provided Fusion with a proposal to extend the collaboration agreement entered in November 2023 (the \"\nAgreement\n\") to allow screening of several named targets.\nHaving reviewed the initial proposal for an extension to the Agreement, Richard Buick, CSO, and Adrian Kinkaid, CEO, met with Mitchell Ho of the NCI at the recent Antibody Engineering and Therapeutics conference in San Diego. The discussions included options to extend the NCI's use of OptiMAL\u00ae and various administrative pathways to achieve this. The immediate needs of NCI are to support current and imminent screening projects using OptiMAL\u00ae. The latest discussions also encompassed possible additional projects with enhanced ownership for Fusion Antibodies.\nNegotiations regarding the expanded proposed programme are expected to continue into early 2026. Due to the scale of the proposal, formal approval processes at the US National Institutes of Health (of which the NCI is part) are likely to take several further months to complete. While discussions are progressing, there is no assurance that an extension to the Agreement will be reached, nor as to the timing or final terms of such an extension.\nAdrian Kinkaid, Chief Executive Officer of Fusion Antibodies, commented:\n\"The NCI's interest in continuing to use OptiMAL\u00ae is a strong validation of the platform following the initial programme. We are encouraged by the constructive discussions around extending the collaboration and supporting additional targets, while recognising that formal approval processes are still ongoing.\"\nFurther updates will be provided in due course.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nFusion Antibodies wants to keep its investors up to date with developments in the Company technology and offerings. We have therefore created a space on the Investor Hub which in contains an increasing number of videos providing more information which may be of interest to investors. This can be found here,\nhttps://investorhub.fusionantibodies.com/s/1b6535\n.\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody discovery including using the proprietary OptiMAL\u00ae platform, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 290 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug d",
          "content_length": 5799
        },
        "ingested_at": "2026-01-21T02:20:26.430548Z"
      },
      {
        "event_id": "RNS-16th Dec 2025-launchof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430562Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Launch of OptiMAL platform",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/launch-of-optimal-platform-1e0bulwulbqabow.html",
          "rns_number": "RNS Number : 7820L",
          "full_content": "16 Dec 2025 11:04\nRNS Number : 7820L\nFusion Antibodies PLC\n16 December 2025\n16 December 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nLaunch of the OptiMAL\u00ae Human Antibody Discovery platform\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the official launch of the OptiMAL\u00ae platform for the discovery of novel human antibodies. The OptiMAL\u00ae platform incorporates the Company's na\u00efve, synthetic library of antibody sequences and the Mammalian Display used to select individual antibodies from the Library against a target of interest. As has been previously announced by the Company, the OptiMAL\u00ae library and the method for designing the Library are protected under US patent no. US12378696 and patents pending in other territories.\nThe official launch of the OptiMAL\u00ae platform took place at the Antibody Engineering and Therapeutics conference in San Diego with a speaker presentation by Dr. Richard Buick, CSO, followed by poster presentations and an exhibit booth. CEO Adrian Kinkaid also attended the official launch of OptiMAL\u00ae.\nRichard Buick, CSO of Fusion, said\n:\n\"I am delighted to see the culmination of several years' work presented to an audience of antibody industry peers and look forward to the future of using this technology to bring more human therapeutic antibodies to the market.\"\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCFFEFFMEISESE",
          "content_length": 4540
        },
        "ingested_at": "2026-01-21T02:20:26.430576Z"
      },
      {
        "event_id": "RNS-11th Dec 2025-mammalia",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430589Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Mammalian Display video",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/FAB/mammalian-display-video-mqbddrz20u4dqw7.html",
          "rns_number": "RNS Number : 0994L",
          "full_content": "11 Dec 2025 07:00\nRNS Number : 0994L\nFusion Antibodies PLC\n11 December 2025\nREACH - Non-regulatory announcement*\n11 December 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nMammalian Display\nvideo\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that ahead of the commercial launch of the OptiMAL\u00ae Human Antibody Discovery platform at the Antibody Engineering and Technology conference in San Diego on 15 December 2025, Fusion has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science and technology behind the Company's Mammalian Display technology. The technology has been combined with Fusion's Opti-library to create the OptiMAL\u00ae library. OptiMAL\u00ae is intended to be used to discover novel human antibodies against any target. The mammalian display platform library design and method is protected by US patent US12378696. The Mammalian Display technology can also be used with other antibody libraries.\nThe video can be viewed on the Investor Hub section of Fusion's website at,\nhttps://investorhub.fusionantibodies.com/s/7ea305\n.\nOther Mammalian Display technologies are available and have been summarised in the scientific literature e.g. Slavny P, Hegde M, Doerner A, Parthiban K, McCafferty J, Zielonka S and Hoet R (2024) Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects. Front. Immunol. 15:1469329. doi: 10.3389/fimmu.2024.1469329.\nFusion Antibodies has compared its own Mammalian Display technology to the competitor platforms in the review article and identified several superior advantages. The most significant are its transduction efficiency of over 70% and its ability to support very large libraries, exceeding 10\u2079 variants. These are summarised in the table below:\nTechnology\nOptiMAL\u00ae\nRetrocyte Display\nOther Lentiviral mammalian display\nTransposase-mediated integration\nNuclease-directed integration\nRecombinase-mediated integration\nIntegration Efficiency\n>70%\n<5%\n0.5-5%\n6-7.5%\n0.5-5%\n1.7%\nReported library sizes\n>109\n106-108\n106\n106\n106-108\n106-108\nIf shareholders or prospective investors have further queries regarding the Mammalian Display platform, please submit questions you may have regarding this update using the facility provided.\nInvestor Presentation and Q&A: OptiMAL\u00ae Launch\nAdrian Kinkaid, CEO of Fusion will provide a pre-recorded presentation and Q&A session on the OptiMAL\u00ae\u00a0launch\u00a0from the Antibody Engineering & Therapeutics Conference via the Company's Investor Hub on Tuesday, 16 December 2025, at 16:00 GMT.\nThe presentation is open to all existing and potential shareholders. Questions are encouraged and can be pre-submitted via the webinar page.\nRegister and submit your questions here:\nhttps://investorhub.fusionantibodies.com/webinars/mPqXOr-optimal-r-launch-investor-q-a\nNo material new information will be included in the presentation or Q&A.\nFusion Antibodies wants to keep its investors up to date with developments in the Company technology and offerings. We have therefore created a space on the Investor Hub which in contains an increasing number of videos providing more information which may be of interest to investors. This can be found here,\nhttps://investorhub.fusionantibodies.com/s/1b6535\n.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmace",
          "content_length": 6900
        },
        "ingested_at": "2026-01-21T02:20:26.430607Z"
      },
      {
        "event_id": "RNS-25th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430620Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/holdings-in-company-qyu3yuf50ghsduu.html",
          "rns_number": "RNS Number : 9395I",
          "full_content": "25 Nov 2025 12:11\nRNS Number : 9395I\nFusion Antibodies PLC\n25 November 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BDQZGK16\nIssuer Name\nFUSION ANTIBODIES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nMaven Capital Partners UK LLP\nCity of registered office (if applicable)\nGlasgow\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nMaven Renovar VCT PLC\nLondon\nEngland and Wales\n5. Date on which the threshold was crossed or reached\n21-Nov-2025\n6. Date on which Issuer notified\n25-Nov-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n2.759604\n0.000000\n2.759604\n3136463\nPosition of previous notification (if applicable)\n3.859412\n0.000000\n3.859412\n4386463\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BDQZGK16\n3136463\n2.759604\nSub Total 8.A\n3136463\n2.759604%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n25-Nov-2025\n13. Place Of Completion\nGlasgow\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLPPGRUGUPAGPA",
          "content_length": 3749
        },
        "ingested_at": "2026-01-21T02:20:26.430633Z"
      },
      {
        "event_id": "RNS-24th Nov 2025-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430646Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Financial Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/half-year-financial-report-wpwfn0n5i5czinr.html",
          "rns_number": "RNS Number : 6141I",
          "full_content": "24 Nov 2025 07:00\nRNS Number : 6141I\nFusion Antibodies PLC\n24 November 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n24 November 2025\nFusion Antibodies plc\n(\"\nFusion Antibodies\n\", \"\nFusion\n\"\nor the\n\"Company\n\")\nHalf year Report\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces its unaudited interim results for the six months ended 30 September 2025 (\"H1 FY2026\").\nFinancial highlights\n\u00b7\nRevenues of \u00a30.84 million (H1 FY2025: \u00a31.2 million; H2 FY2025: \u00a3755k)\n\u00b7\nExpenditure on R&D increased: \u00a3350k (H1 FY2025: \u00a30.18 million)\n\u00b7\nLoss reduced by 32% to \u00a30.51 million (H1 FY2025: \u00a30.76 million)\n\u00b7\nCash position in the bank at 30 September 2025 was \u00a30.25m (31 March 2025: \u00a30.4m) with a further \u00a3543k owed by existing debtors\nOperational highlights\n\u00b7\nUS patent no.\nUS12378696\nwas granted covering the Library design and method for the Opti-library used in OptiMAL\u00ae\n\u00b7\nValidation project for OptiMAL\u00ae being run with\nthe National Cancer Institute (\"NCI\")\ndelivered hits against the three selected targets including antibodies with very high affinity (single digit nM) for both proteins and peptides\n\u00b7\nNew contracts for cell line development\n\u00b7\nTwo separate new contracts, both covering humanisation of multiple targets, announced with specialist divisions of large pharmaceutical companies\n\u00b7\nFormal commercial launch of OptiMAL\u00ae at the Antibody Engineering & Therapeutics conference in San Diego 15-17 December 2025 on track\n\u00b7\nPositive pre-launch feedback regarding OptiMAL\u00ae from prospective clients with multiple expressions of interest\no\nPotential value of the initial pipeline for OptiMAL\u00ae/mammalian display is c. \u00a31m\n\u00b7\nCosts continue to be carefully controlled with cash position as at 21 November 2025 better than at the period end\nCommenting on the interim results, Adrian Kinkaid, CEO of Fusion Antibodies plc, said:\n\"\nThe Company has made substantial progress towards its core strategic objective of developing OptiMAL\u00ae in readiness for a commercial launch of the technology. During the validation project, run with the NCI, the platform consistently generated high quality antibodies against a range of targets and exceeded our expectations in terms of affinities achieved, especially against peptide targets. Crucially, the ultimate proof of validation is that the NCI themselves wish to continue using OptiMAL\u00ae as a front-line means of identifying human antibodies against a wide range of targets for years to come. Now that the US government shutdown has been brought to an end, we expect to be making progress in securing an agreement which allows the NCI to continue to use OptiMAL\u00ae.\n\"The validation project with NCI has also exemplified the ability to transfer the technology to another laboratory and so signalled the potential for a highly scalable, and profitable, licensing-based business model. This positions Fusion Antibodies to generate significantly greater long-term value beyond its existing custom services business.\n\"Having had a presence at several recent industry conferences, including ELRIG Drug Discovery, BIO Europe, PEGS Europe, we have received feedback from prospective clients with several expressing an interest in trialling the technology. Prospective clients also see the Mammalian Display part of OptiMAL\u00ae, which also offers best-in-class performance, to be well suited to other libraries. The Company is keen to exploit the platform for such additional libraries to complement the Opti-library application. Such libraries include AI/ML designed libraries and non-human libraries for diagnostics and veterinary medicine applications.\n\"So far as our existing platforms and offerings are concerned we have seen some very encouraging 'wins', especially for humanisation and cell line development. This has been achieved with a backdrop of challenging geopolitical and economic conditions which have slowed the progression of clients' funding and therefore their projects. I remain hopeful that as conditions improve, we will see a significant growth in outsourced projects as clients seek to rapidly start new projects to meet the growing demand for therapeutic and diagnostic antibodies.\n\"Whilst the recognised revenue for this period is down against the corresponding figure for H1 FY2025, it has increased against the immediately preceding six months (H2 FY2025) and reflects improving performance by the Company as well as being suggestive of a recovering market, one which Fusion is increasingly well placed to exploit.\"\nInvestor presentations\nFusion will host a presentation on the results open to all investors via the Investor Meet Compan",
          "content_length": 30094
        },
        "ingested_at": "2026-01-21T02:20:26.430660Z"
      },
      {
        "event_id": "RNS-21st Nov 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430673Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/notice-of-results-0kyvmcijogdr86x.html",
          "rns_number": "RNS Number : 4242I",
          "full_content": "21 Nov 2025 07:00\nRNS Number : 4242I\nFusion Antibodies PLC\n21 November 2025\n21 November 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nNotice of results\nInvestor presentation\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces it will release its unaudited interim results for the six months ended 30 September 2025 on Monday, 24 November 2025.\nFusion will host an online live presentation open to all investors on Tuesday, 25 November at 11.00am GMT, delivered by Dr Adrian Kinkaid, CEO and Stephen Smyth, interim CFO.\nThe Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on its results whilst additionally providing an update on the business and current trading.\nInvestors can sign up to Investor Meet Company for free and add to meet Fusion Antibodies plc via the following link:\nhttps://www.investormeetcompany.com/fusion-antibodies-plc/register-investor\n.\nFor those investors who have already registered and added to meet the Company, they will automatically be invited. Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the \"Ask a Question\" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORFLFSELDLIFIE",
          "content_length": 4799
        },
        "ingested_at": "2026-01-21T02:20:26.430686Z"
      },
      {
        "event_id": "RNS-13th Nov 2025-optimall",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430699Z",
        "source": "LSE_RNS",
        "data": {
          "title": "OptiMAL Library video",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/FAB/optimal-library-video-6lysnfjqj1989p5.html",
          "rns_number": "RNS Number : 3019H",
          "full_content": "13 Nov 2025 07:00\nRNS Number : 3019H\nFusion Antibodies PLC\n13 November 2025\nREACH - Non-regulatory announcement*\n13 November 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nOptiMAL Library video\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nhas prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science and technology behind the Company's Opti-library of antibody sequences.\nThe Opti-library design and method is protected by US patent no. 17/287,441. It has been combined with Fusion's mammalian display platform to create the OptiMAL\u00ae library, and it intended to be used to discover novel human antibodies against any target. OptiMAL\u00ae is due for commercial launch in December 2025.\nThe video can be viewed on the Investor Hub section of Fusion's website at,\nhttps://investorhub.fusionantibodies.com/s/7ea305\n.\nThis video is the latest in a series of videos providing shareholders and investors with more information on the Company's technological platforms and service offerings. These videos can be found here\nhttps://investorhub.fusionantibodies.com/s/1b6535\n.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\n*About Reach announcements\nThis is a Reach announcement. Reach is an\u00a0investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to\u00a0distribute\u00a0media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAGPGBPGUPAGQP",
          "content_length": 4705
        },
        "ingested_at": "2026-01-21T02:20:26.430711Z"
      },
      {
        "event_id": "RNS-3rd Nov 2025-optimal\u00ae",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430727Z",
        "source": "LSE_RNS",
        "data": {
          "title": "OptiMAL\u00ae R&D Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/optimal174-rd-update-5n1z6fo3puk9huj.html",
          "rns_number": "RNS Number : 7807F",
          "full_content": "3 Nov 2025 07:00\nRNS Number : 7807F\nFusion Antibodies PLC\n03 November 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nOptiMAL\n\u00ae\nR&D Update\nValidation of OptiMAL\u00ae for the isolation of specific antibodies against proteins and peptides\nOn track for the commercial launch of OptiMAL\u00ae in December 2025\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update to the OptiMAL\u00ae project being performed under the collaboration agreement (the \"\nAgreement\n\") with the National Cancer Institute (\"\nNCI\n\"), details of which were originally announced on\n28 November 2023\n.\nHaving already demonstrated superior single digit nM affinities for antibodies against protein targets, as detailed in the announcement on\n17 September 2025\n, the Company can report that OptiMAL\u00ae has been now shown to be similarly successful with smaller peptide targets.\nPeptides are often used as antigens as they can be designed to represent specific epitopes (regions of the protein) for the antibodies generated. They are also easier and more cost effective to synthesize. However, they are less immunogenic which can result in poorer antibodies. This is not the case with OptiMAL\u00ae as no immune response is required.\nThis evidence will better enable Fusion to propose the use of OptiMAL\u00ae for a wider range of targets, thereby broadening the accessible market and increasing revenue potential. The next steps are to test the antibodies in cell-based assays at the NCI, to evaluate their potential to become therapeutic drug candidates.\nThis latest finding provides further validation of OptiMAL\u00ae as a platform for the isolation of specific antibodies against proteins and peptides and places the Company on track for the commercial launch of OptiMAL\u00ae at the Antibody Engineering and Therapeutics conference in December 2025. Work continues within Fusion to further optimise and expand the OptiMAL\u00ae platform.\nNCI, part of the US National Institutes of Health, is the US federal government's principal agency for cancer research and training. Pursuant to the Agreement, Fusion has provided NCI with access to\nOptiMAL\u00ae for use in the discovery of novel antibodies against targets selected by NCI. This Agreement is due to continue until November 2025, however,\nthe NCI has asked to extend its use of the OptiMAL\u00ae platform for use against further targets in the coming years. Negotiations are underway to establish mutually agreeable terms for an extended agreement.\nDr. Adrian Kinkaid, CEO of Fusion Antibodies plc, commented:\n\"We are again delighted with the performance of the OptiMAL\u00ae platform providing very high affinity antibodies against peptides, a prevalent but challenging target class. The latest developments provide us with a more solid foundation with which to address a wider market and positions OptiMAL\u00ae as the potential front line discovery platform of choice for human therapeutic antibody discovery.\"\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develo",
          "content_length": 6326
        },
        "ingested_at": "2026-01-21T02:20:26.430741Z"
      },
      {
        "event_id": "RNS-27th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430755Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/holdings-in-company-ridodmq92oa2bsp.html",
          "rns_number": "RNS Number : 9895E",
          "full_content": "27 Oct 2025 15:38\nRNS Number : 9895E\nFusion Antibodies PLC\n27 October 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BDQZGK16\nIssuer Name\nFUSION ANTIBODIES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nMaven Capital Partners UK LLP\nCity of registered office (if applicable)\nGlasgow\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nMaven Renovar VCT PLC\nLondon\nEngland and Wales\n5. Date on which the threshold was crossed or reached\n24-Oct-2025\n6. Date on which Issuer notified\n27-Oct-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n3.859412\n0.000000\n3.859412\n4386463\nPosition of previous notification (if applicable)\n4.162000\n0.000000\n4.162000\n4716463\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BDQZGK16\n4386463\n3.859412\nSub Total 8.A\n4386463\n3.859412%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n27-Oct-2025\n13. Place Of Completion\nGlasgow\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLPPGMWUUPAGAM",
          "content_length": 3748
        },
        "ingested_at": "2026-01-21T02:20:26.430767Z"
      },
      {
        "event_id": "RNS-16th Oct 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430780Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/result-of-agm-mewdhevnuz9wxen.html",
          "rns_number": "RNS Number : 7103D",
          "full_content": "16 Oct 2025 13:31\nRNS Number : 7103D\nFusion Antibodies PLC\n16 October 2025\nFusion Antibodies plc\n(\"\nFusion\n\" or the \"\nCompany\n\")\nResult of AGM\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the annual general meeting (\"AGM\") held earlier today, all resolutions were duly passed.\nFull details of the voting results will be available on the Company's website\nhere\n.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nRegulatory news | Fusion Antibodies plc investor hub\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGMFBTTMTTBBPA",
          "content_length": 3941
        },
        "ingested_at": "2026-01-21T02:20:26.430792Z"
      },
      {
        "event_id": "RNS-16th Oct 2025-agmstate",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430805Z",
        "source": "LSE_RNS",
        "data": {
          "title": "AGM statement and H1 trading update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/agm-statement-and-h1-trading-update-ccz7gp2tcja8bjw.html",
          "rns_number": "RNS Number : 5659D",
          "full_content": "16 Oct 2025 07:00\nRNS Number : 5659D\nFusion Antibodies PLC\n16 October 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n16 October 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nAGM statement and H1 trading update\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the Company's AGM, being held later today, Simon Douglas, Chairman, will provide the following update on trading for the first half of the current financial year ending 31 March 2026\n(\"HY26\"):\n\"Unaudited revenues for HY26 were approximately \u00a3838k (H1 2025: \u00a31.2m, FY25: \u00a31.96m). Whilst down on the prior year H1, they represent a notable increase on the second half of last year (H2 2025: \u00a3755k) and, unlike last year, we anticipate an even stronger performance in H2 supported by our robust existing order book, promising sales opportunities pipeline and better market sentiment. Unaudited gross margin for the period was 30%, compared to 22% in the prior year which reflects our improved operational efficiency and our ability to create value. Cash as at 30 September 2025 was \u00a3251k and is tracking in line with management's expectations.\n\"During the period, the Company achieved a significant milestone with the grant of our US patent covering the OptiMAL\u00ae library design and method and has continued our collaboration with the National Cancer Institute (\"NCI\"). The collaboration has generated a strong performance of OptiMAL\u00ae and resulted in the NCI's desire to continue to use the platform for more of their antibody discovery projects over the coming years.\n\"Among a range of new contract wins, we were selected to develop a stable cell line for a US based biotechnology company and were awarded multiple contract wins for humanisation projects with divisions of major pharmaceutical companies, further demonstrating our recognised expertise in antibody engineering. Investor and stakeholder engagement has been significantly strengthened through a series of investor presentations including face to face meetings in London and Belfast as well as further development of the interactive investor hub at investorhub.fusionantibodies.com.\n\"Cash continues to be carefully managed and, as set out in the Company's FY25 results announced on 4 September 2025, based on internal estimates the Company has a cash runway into FY27 and remains on plan with our strategic goals including the launch of OptiMAL\u00ae in December which we believe will herald a new stage in the Company's development and open up new markets and revenues.\"\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nRegulatory news | Fusion Antibodies plc investor hub\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological adv",
          "content_length": 6376
        },
        "ingested_at": "2026-01-21T02:20:26.430819Z"
      },
      {
        "event_id": "RNS-8th Oct 2025-contract",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430832Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Contract win",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/contract-win-s8lxzs752hfakuw.html",
          "rns_number": "RNS Number : 4350C",
          "full_content": "8 Oct 2025 07:00\nRNS Number : 4350C\nFusion Antibodies PLC\n08 October 2025\n8 October 2025\nFusion Antibodies plc\n(\"\nFusion\n\"\u00a0or the\n\"Company\n\")\nContract Win\nNew multi-target Humanisation project with\nglobal pharmaceutical company\nFusion Antibodies plc (AIM: FAB),\nspecialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces that it has been selected to proceed with a new multi-target Integrated Therapeutic Antibody Services project\n(the \"\nProject\n\") with the Antibody Centre of Excellence of a European-based global pharmaceutical company (the \"\nClient\n\") under a Master Service Agreement (\"\nMSA\n\") signed earlier in the year. The Project will include humanisation and supply elements.\nHumanisation is the process required to make antibodies which were derived from non-human sequences, typically from mouse or rabbit antibodies, suitable for use as human therapeutics. Fusion will humanise a family of VHH antibody fragments for the Client. The Project also involves the expression, purification and supply of research materials.\nThe selection of Fusion for this Project again demonstrates the Company's ability to secure contracts with major pharmaceutical businesses. This is seen as a significant part of the Company's strategy of reducing dependence on more volatile smaller clients, but also in seeking to exploit the Company's novel technologies such as OptiMAL\u00ae.\nThis will hopefully drive sustainable growth, strengthen market positioning and open further new commercial opportunities.\nWork in relation to the Project is expected to be completed within the current financial year and the Company expects to generate revenues of not less than \u00a3175,000.\nAdrian Kinkaid, CEO of Fusion, said:\n\"We are delighted to have been selected to humanise a family of VHH antibody fragments for our Client. It is particularly gratifying that a client of this magnitude and recognised expertise, with all the resources available to them, has selected Fusion to undertake this critical work. It reflects both our position as providers of world-class antibody engineering services\nand our ability to deliver innovative, high-quality solutions for long-lasting partnerships\n. We look forward to working with our Client to bring better antibodies to the clinic more rapidly.\"\nNavigate to our Interactive Investor hub here:\nhttps://investorhub.fusionantibodies.com/\n. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nRegulatory news | Fusion Antibodies plc investor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 285 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is",
          "content_length": 5689
        },
        "ingested_at": "2026-01-21T02:20:26.430845Z"
      },
      {
        "event_id": "RNS-19th Sep 2025-postingo",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430859Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Posting of Annual Report & Notice of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/posting-of-annual-report-notice-of-agm-57xbdmhck6766g4.html",
          "rns_number": "RNS Number : 1048A",
          "full_content": "19 Sep 2025 12:58\nRNS Number : 1048A\nFusion Antibodies PLC\n19 September 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nPosting of Annual Report & Notice of AGM\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces that the Annual Report and Accounts for the year ended 31 March 2025 and the Notice of the Company's Annual General Meeting (\"\nAGM\n\") is being posted to shareholders today.\nThe Notice of AGM and accompanying form of proxy will shortly be available to download from the Company website here:\nhttps://www.fusionantibodies-ir.com/\n.\nThe AGM will be held on Thursday, 16 October 2025 at 11.00 a.m. at the offices of Fusion Antibodies plc,\u00a01 Springbank Road, Springbank Industrial Estate, Belfast\u00a0BT17 0QL.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOAKZGMLMLVGKZM",
          "content_length": 3949
        },
        "ingested_at": "2026-01-21T02:20:26.430871Z"
      },
      {
        "event_id": "RNS-17th Sep 2025-optimalr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430884Z",
        "source": "LSE_RNS",
        "data": {
          "title": "OptiMAL R&D Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/optimal-rd-update-tmk2j9s6k4ywm4d.html",
          "rns_number": "RNS Number : 5910Z",
          "full_content": "17 Sep 2025 07:00\nRNS Number : 5910Z\nFusion Antibodies PLC\n17 September 2025\n17 September 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nOptiMAL\n\u00ae\nR&D\nUpdate\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update to the OptiMAL\u00ae project being performed under the collaboration agreement (the \"\nAgreement\n\") with the National Cancer Institute (\"\nNCI\n\").\nThe NCI Research Collaboration, which was originally announced on 28 November 2023, is due to continue until November 2025. However, the NCI has asked to extend its use of the OptiMAL\u00ae platform for use against further targets in the coming years. Negotiations are now underway to establish mutually agreeable terms for an extended agreement.\nIn January 2025, Fusion announced that the NCI had identified a number of antibody expressing cells as positively binding to their target of interest, and that the Company would verify the binding of these cells. For the three targets of interest that the NCI identified positive cells, we are pleased to report that we have confirmed that the antibodies produced from these cells do bind each of their respective targets. The antibodies have been expressed and purified from independent cells and tested for their binding affinity in a standard process. The binding affinities are within the range expected for commercially viable antibodies including a number of hits with estimated affinities in the single digit nM range. This exceeded our expectations and is a good selling point for the OptiMAL\u00ae platform. In addition, Fusion has supplied the NCI with these recombinantly produced antibodies, and the NCI has validated their function against relevant human cells. The next steps are to test the antibodies in cell-based assays at the NCI to evaluate their potential to become therapeutic drug candidates.\nThe target antigens used included proteins and linear peptides, representing two of the most commonly used antigen types. OptiMAL\u00ae proved to be successful in identifying hits against both classes of antigen.\nThe screens have also identified weaker binders including antibodies with an estimated affinity of >800nM demonstrating that even weaker binders can be identified using OptiMAL\u00ae. Consequently, confirming the OptiMAL\u00ae platform's suitability for use against a wide range of target product profiles including those where less tight binding is required. At the other extreme, the Company has used known antibodies of very high (pM) affinity and demonstrated that these can also be recovered in the screening process. Combined, the results achieved to date indicates the OptiMAL\u00ae platform to be suitable for a nearly six-log dynamic range of affinities.\nTogether, this represents significant progress in the validation of OptiMAL\u00ae as a platform for the isolation of specific antibodies against targets selected by the NCI. Work continues within Fusion to further optimise and expand the OptiMAL\u00ae platform.\nNCI, part of the US National Institutes of Health, is the U.S. federal government's principal agency for cancer research and training. Pursuant to the Agreement, details of which were announced by the Company on 28 November 2023, Fusion has provided NCI with access to\nOptiMAL\u00ae for use in the discovery of novel antibodies against targets selected by NCI\n.\nDr. Richard Buick, CSO of Fusion Antibodies plc, commented:\n\"We are very happy to report on the progress in securing validation of the OptiMAL\u00ae platform by the NCI. The antibodies produced and purified by Fusion are now being tested in cell-based assays at the NCI to verify if they have potential to become therapeutic drug candidates.\"\nDr. Mitchell Ho, Deputy Chief, Laboratory of Molecular Biology, National Cancer Institute commented\n: \"\nThe OptiMAL\u00ae platform is performing very well in our hands. Using the library, we have isolated binders for multiple antigens in cancer, and my lab is currently evaluating their potential for cancer therapy and/or diagnostics.\"\nDr. Adrian Kinkaid, CEO of Fusion Antibodies plc, commented:\n\"We are extremely pleased with the performance of the OptiMAL\u00ae platform to date. In some ways it has exceeded our aspirations. It is also most gratifying that the NCI, our key collaborators in the validation process, wish to continue using OptiMAL\u00ae for years to come. I am confident this will help them fulfil their mission and to progress multiple therapeutic and diagnostic projects targeting the widest range of cancers.\"\nAs a reminder, Fusion will be hosting an in-person investor presentation this afternoon at 2.30pm in Victoria, Central London. To register for details, please email\nfusion@walbrookpr.com\nand state you would like to attend the London event.\nThe Company will also be hosting an in-person investor presentation tomorrow, 18 September in Belfast. To register for details, please email\nfusion@walbrookpr.com\nand state you would like to attend th",
          "content_length": 8363
        },
        "ingested_at": "2026-01-21T02:20:26.430897Z"
      },
      {
        "event_id": "RNS-8th Sep 2025-belfasti",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430910Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Belfast investor presentation",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/FAB/belfast-investor-presentation-vsjav2igzkrkwh8.html",
          "rns_number": "RNS Number : 2746Y",
          "full_content": "8 Sep 2025 07:00\nRNS Number : 2746Y\nFusion Antibodies PLC\n08 September 2025\nREACH - Non-regulatory announcement*\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nBelfast\nInvestor presentation\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that further to the Company's notification on 26 August 2025, the Fusion will host an in-person investor presentation in Belfast, Northern Ireland on Thursday, 18 September 2025.\nRegistered guests are welcomed from 4.15pm with the investor presentation scheduled to start at 4.30pm in Belfast City Centre.\nTo register to attend, please send an email to\nfusion@walbrookpr.com\n.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\n*About Reach announcements\nThis is a Reach announcement. Reach is an\u00a0investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to\u00a0distribute\u00a0media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAZZGGLDKDGKZM",
          "content_length": 4227
        },
        "ingested_at": "2026-01-21T02:20:26.430922Z"
      },
      {
        "event_id": "RNS-4th Sep 2025-finalres",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430935Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Final Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/final-results-f3927ph7feu7apw.html",
          "rns_number": "RNS Number : 9290X",
          "full_content": "4 Sep 2025 07:00\nRNS Number : 9290X\nFusion Antibodies PLC\n04 September 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n4 September 2025\nFusion Antibodies plc\n(\"\nFusion\n\"\nor the\n\"Company\n\")\nFinal results\nand\nInvestor presentations\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces\nits final results for the year ended 31 March 2025.\nCommercial and operational highlights (including post period end)\n\u00b7\nAudited revenues for FY2025 of \u00a31.97m (FY2024: \u00a31.14m)\n\u00b7\nIncreased activity in the second half of FY2025 including the continuation of the collaboration agreement with the National Cancer Institute for the use of OptiMAL\u00ae\n\u00b7\nPlacing announced in March 2025, raising \u00a31.17m (before expenses) for general working capital and investment into commercial activities\n\u00b7\nSignificant increase in sales pipeline opportunities during the second half of FY2025\n\u00b7\nGrant of U.S. Patent for OptiMAL\u00ae\n\u00b7\nCash position as at 31 March 2025 of \u00a30.4m (31 March 2024: \u00a31.2m)\nAdrian Kinkaid, CEO of Fusion Antibodies commented\n: \"\nWe were very pleased to deliver an improved FY2025. We made significant progress in improving revenues and in Fusion's strategic development in key new markets such as Diagnostics which has reduced our exposure to the more volatile VC funded biotech sector. We also announced large contract wins in May 2024 and again in February 2025, the latter being the source of three further contract wins announced on 27 August 2025.\n\"In addition, we secured significant grant funding through the excellent Future Medicines Institute (FMI) initiative announced in December 2024. This in turn helped Fusion to apply for a further grant in conjunction with Queen's University Belfast for the DR5 project, which Fusion secured in the current financial year.\n\"We also made very significant progress with our flagship OptiMAL\u00ae programme. This progress was achieved largely through Fusion's collaboration with the National Cancer Institute (NCI) and the successful \u00a31.17m fundraise. The successful fundraise allowed Fusion to increase its internal research and development (R&D) efforts to validate hits from the NCI as well as to commit to increased sales and marketing towards building a formal launch of OptiMAL\u00ae as a service later in 2025.\n\"We are increasingly positive about the improved position of the Company, and we look forward to realising the true potential of the business going forward. Lastly, we are always grateful to our dedicated shareholders for their constant support.\"\nInvestor presentations (online and in-person)\nThe Company will\nhost an\nonline live investor presentation on\nMonday, 15 September 2025\nat 11am BST, delivered by Dr Adrian Kinkaid, CEO and Stephen Smyth, interim CFO. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management.\nThe presentation will be hosted through the digital platform Investor Meet Company (\"IMC\").\nInvestors can sign up to Investor Meet Company for free and add to meet Fusion Antibodies plc via the following link:\nhttps://www.investormeetcompany.com/fusion-antibodies-plc/register-investor\n.\nFor those investors who have already registered and added to meet the Company, they will automatically be invited. Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the \"Ask a Question\" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.\nIn-person London investor event\nAs announced by the Company on 26 August 2025, the Company will also host an in-person investor presentation in London on Wednesday, 17 September 2025\nat 2.30pm. To register for this, please email\nfusion@walbrookpr.com\n.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/s/b8d633\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 ",
          "content_length": 85714
        },
        "ingested_at": "2026-01-21T02:20:26.430948Z"
      },
      {
        "event_id": "RNS-28th Aug 2025-contract",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430961Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Contract Win",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/contract-win-1jm92sr2ktehg6f.html",
          "rns_number": "RNS Number : 9469W",
          "full_content": "28 Aug 2025 07:00\nRNS Number : 9469W\nFusion Antibodies PLC\n28 August 2025\n28 August 2025\nFusion Antibodies plc\n(\"\nFusion\n\"\u00a0or the\n\"Company\n\")\nContract Win\nFusion Antibodies plc (AIM: FAB),\nspecialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces that it has been selected to proceed with a new humanisation project\n(the \"\nHumanisation Project\n\") under an existing Master Service Agreement (the \"\nAgreement\n\") with a US based specialty division of a global pharmaceutical company (the \"\nClient\n\").\nWhile the Company expects to generate modest revenues from the\nHumanisation Project, it\ndemonstrates Fusion's ability to win contracts with 'Big Pharma' companies. This is seen as a significant part of the Company's strategy not only in reducing dependence on more volatile smaller clients, but also in seeking to exploit its novel technologies such as OptiMAL\u00ae.\nWork in relation to the Humanisation Project is expected to complete within the current financial year.\nAdrian Kinkaid, CEO of Fusion, said:\n\"We are delighted to have been selected to humanise a family of antibodies for our Client. It is particularly gratifying that a client of this magnitude and with all the resources available to it has selected Fusion to undertake this critical work. We look forward to continuing to work with our Client to fulfil our mission to bring better antibodies to the clinic more rapidly.\nThe Humanisation Project highlights the world class reputation that Fusion has for delivering high quality therapeutic antibodies\n.\n\"\nWhilst revenues from the new Humanisation Project will be relatively modest, winning this contract provides recognition of our expertise in this highly competitive market. We look forward building on the excellent relationship with our Client\n.\"\nNavigate to our Interactive Investor hub here:\nhttps://investorhub.fusionantibodies.com/\n. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://investorhub.fusionantibodies.com/s/b8d633\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part",
          "content_length": 5186
        },
        "ingested_at": "2026-01-21T02:20:26.430975Z"
      },
      {
        "event_id": "RNS-27th Aug 2025-contract",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.430988Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Contract wins with existing client",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/contract-wins-with-existing-client-6rgi9we754hxvq0.html",
          "rns_number": "RNS Number : 7388W",
          "full_content": "27 Aug 2025 07:00\nRNS Number : 7388W\nFusion Antibodies PLC\n27 August 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n27 August 2025\nFusion Antibodies plc\n(\"\nFusion\n\"\u00a0or the\n\"Company\n\")\nContract wins with existing client\nFusion Antibodies plc (AIM: FAB),\nspecialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces that it has been selected to proceed with three follow on projects to the stable Cell Line Development project\n(the \"\nCLD Project\n\") announced on 27 February 2025. The original contract and the follow-on contracts (the \"\nNew Contracts\n\") all operate under a collaborative research and development agreement (the \"\nAgreement\n\") with a US based biotechnology company (the \"\nClient\n\").\nWork in relation to the CLD Project under the original contract was expected to last between six to nine months.\nThe New Contracts build on the successful progress to date with the original project, extending its scope and establishing a further new engineering project for the Client.\nThe New Contracts are valued at c. $460,000, of which a minimum of $400,000 is expected to be recognised in the current financial year ending 31 March 2026.\nAdrian Kinkaid, CEO of Fusion, said:\n\"We are delighted to extend our agreement with this significant client and to add a further earlier stage project to the pipeline of work we are undertaking with them. We look forward to continuing to work with our Client to bring better antibodies to the clinic more rapidly.\nThese New Contracts and the CLD Project highlights the strong reputation that Fusion has for delivering high quality therapeutic antibodies and their associated cell lines\n: a part of our offering with excellent scope for growth.\n\"\nNavigate to our Interactive Investor hub here:\nhttps://investorhub.fusionantibodies.com/\n. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.\nEnquiries:\nInvestor questions on this announcement\nhttps://investorhub.fusionantibodies.com/s/b8d633\nWe encourage all investors to share questions on this announcement via our investor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\nfusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS",
          "content_length": 5413
        },
        "ingested_at": "2026-01-21T02:20:26.431002Z"
      },
      {
        "event_id": "RNS-26th Aug 2025-investor",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431014Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Investor presentations",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/FAB/investor-presentations-6vtfg29yt0mzprm.html",
          "rns_number": "RNS Number : 4907W",
          "full_content": "26 Aug 2025 07:00\nRNS Number : 4907W\nFusion Antibodies PLC\n26 August 2025\nREACH - Non-regulatory announcement*\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nInvestor presentations\nResults update\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that management will host two investor presentations in September and October 2025.\nLondon investor event\nThe London investor event will take place on Wednesday, 17 September 2025 at 2.30pm. To register to attend this event, please use the link below or email\nfusion@walbrookpr.com\n.\nI would like to attend the Fusion Antibodies London presentation.\nProactive Investors event\nThe Company will also present at the Proactive One2One Investor Forum on Thursday, 9 October 2025 at The Chesterfield Mayfair, 35 Charles Street, London, W1J 5EB. The event will start at 6.00pm. You can register to attend this event\nhere\n.\nThe Company also intends to hold another investor event in Belfast city centre in September 2025, further details of which will be announced in due course. To register your interest to attend this event, please send an email using this\nlink\n.\nThe Company will be publishing its results for the year ended 31 March 2025 in the first half of September 2025 and further details will be provided in due course.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\n*About Reach announcements\nThis is a Reach announcement. Reach is an\u00a0investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to\u00a0distribute\u00a0media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAPTMITMTMTBIA",
          "content_length": 4879
        },
        "ingested_at": "2026-01-21T02:20:26.431027Z"
      },
      {
        "event_id": "RNS-5th Aug 2025-grantofu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431039Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Grant of U.S. Patent for OptiMAL",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/grant-of-us-patent-for-optimal-avmo2f5uhj75u6e.html",
          "rns_number": "RNS Number : 0032U",
          "full_content": "5 Aug 2025 07:00\nRNS Number : 0032U\nFusion Antibodies PLC\n05 August 2025\n5 August 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nGrant of U.S. Patent for OptiMAL\u00ae\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, is pleased to announce\u00a0that the Company's patent application no. 17/287,441 (the \"\nPatent\n\") has been granted by the United States Patent and Trademark Office (the \"\nU.S. Patent Office\n\"). The grant of the Patent follows the receipt of a notice of allowance in respect of the Patent from the U.S. Patent Office, details of which were announced by the Company on 22 May 2025.\nTo view the supporting video by CEO Adrian Kinkaid and ask questions, please go to the Fusion investor hub:\nhttps://investorhub.fusionantibodies.com/link/8r6bdr\nThe Patent entitled \"Antibody Library and Method\", concerns the library of antibodies that is currently screened within Fusion's OptiMAL\u00ae platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide \"Opti\" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation.\nThe Company is also progressing patent applications in respect of the OptiMAL\u00ae Library in several other territories worldwide including Europe, China and Japan.\nHaving secured the US patent, the Company is now targeting a scientific presentation at the Antibody Engineering and Therapeutics conference in San Diego in December 2025 and working toward a commercial launch of OptiMAL\u00ae at this event.\nRichard Buick, CSO of Fusion, said:\n\"I am really pleased that the U.S. Patent Office has granted the OptiMAL\u00ae Library patent application. This confirms our unique approach to antibody library design and protects Fusion's OptiMAL\u00ae antibody library for years to come.\"\nAdrian Kinkaid, CEO of Fusion, said:\n\"\nThis good news arrives at an almost perfect point in time as we confirm the desired binding properties of antibodies discovered using OptiMAL\u00ae and as we prepare for the formal commercial launch of the service.\n\"\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0)20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0)207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nInvestor Hub\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://investorhub.fusionantibodies.com/link/rJaa9e\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and/or expressed over 750 antibodies and successfully completed over 250 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the informat",
          "content_length": 5292
        },
        "ingested_at": "2026-01-21T02:20:26.431053Z"
      },
      {
        "event_id": "RNS-24th Jul 2025-issuenot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431066Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue Notification: US Patent Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/issue-notification-us-patent-update-qmt8hxzhrurgtjn.html",
          "rns_number": "RNS Number : 4382S",
          "full_content": "24 Jul 2025 10:56\nRNS Number : 4382S\nFusion Antibodies PLC\n24 July 2025\n24 July 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nIssue Notification: US Patent Update\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces\u00a0that the United States Patent and Trademark Office (the \"\nU.S. Patent Office\n\") has published a patent issue notification (the \"\nIssue Notification\n\") in respect of the Company's patent application no. 17/287,441 (the \"\nPatent Application\n\"). A patent issue notification is\u00a0a document informing an applicant that their patent application has been approved and is scheduled to be granted. The Issue Notification indicates that the patent will be granted on 5 August 2025.\nThe Patent Application, entitled \"Antibody Library and Method\", concerns the library of antibodies that is currently screened within Fusion's OptiMAL\u00ae platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide \"Opti\" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation.\nFurther patent applications and examination processes are continuing in several other territories worldwide including Europe, China and Japan.\nAdrian Kinkaid, CEO of Fusion, said:\n\"\nThis news takes us another step forward in gaining patent protection for our Opti discovery platforms including OptiMAL\u00ae. Whilst the patent itself has not yet granted, we are excited to have taken a further step toward this important milestone which we believe would represent significant value creation for the business.\n\"\nNavigate to our Interactive Investor hub here:\nhttps://investorhub.fusionantibodies.com/\n. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0)20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0)207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nInvestor Hub\nWe encourage all investors to share questions on this announcement via our investor hub\nhttps://investorhub.fusionantibodies.com/link/Pbnn4P\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and/or expressed over 750 antibodies and successfully completed over 250 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see",
          "content_length": 5041
        },
        "ingested_at": "2026-01-21T02:20:26.431079Z"
      },
      {
        "event_id": "RNS-11th Jul 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431092Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/directorpdmr-shareholding-he62boa4sx5ap2p.html",
          "rns_number": "RNS Number : 6335Q",
          "full_content": "11 Jul 2025 07:00\nRNS Number : 6335Q\nFusion Antibodies PLC\n11 July 2025\n11 July 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nDirector/PDMR Shareholding\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces a change in Colin Walsh's beneficial interest in the Company's issued ordinary share capital (\"\nOrdinary Shares\n\").\nOn 7 July 2025, Crescent Capital III LP (\"\nCrescent III LP\n\"), a venture capital fund which has been a shareholder in Fusion since prior to the Company's admission to trading on AIM, distributed the 613,382 Ordinary Shares it held to the participants in the fund. Crescent III LP was managed by Crescent Capital NI Limited, a company of which Mr Walsh is the founder and CEO. 211,618 Ordinary Shares were distributed to Crescent Capital III GP Limited (\"\nCrescent III Ltd\n\"), which is controlled by Mr Walsh, and 58,271 Ordinary Shares were distributed to Walsh Strategic Management Limited (\"\nWSML\n\"), another company controlled by Mr Walsh.\nFollowing these distributions, Colin Walsh now has a total direct and indirect beneficial interest in 3,379,001 Ordinary Shares, equivalent to approximately 2.97% of Fusion's total issued ordinary share capital. 562,500 of these Ordinary Shares are held directly, 211,618 are held by Crescent III Ltd, 1,204,883 are held by WSML and 1,400,000 are held by HamNiv (GP) Limited, a subsidiary of Crescent Capital NI Limited.\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nColin Walsh\n2\nReason for the notification\na)\nPosition/status\nNon-Executive Director\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nFusion Antibodies plc\nb)\nLEI\n213800KBAYRC9VOQ9V39\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nordinary shares of 4p each in Fusion Antibodies plc\nIdentification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16\nb)\nNature of the transaction\nTransfer of Ordinary Shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\nNil\nNil\n211,618\n58,271\nd)\nAggregated information\n- Aggregated volume\n- Price\n- see above\n-\nsee above\ne)\nDate of the transaction\n7 July 2025\nf)\nPlace of the transaction\nOutside a trading venue\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to t",
          "content_length": 5883
        },
        "ingested_at": "2026-01-21T02:20:26.431117Z"
      },
      {
        "event_id": "RNS-2nd Jun 2025-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431131Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/total-voting-rights-el5z1v5vg3j19k0.html",
          "rns_number": "RNS Number : 8917K",
          "full_content": "2 Jun 2025 07:00\nRNS Number : 8917K\nFusion Antibodies PLC\n02 June 2025\n2 June 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nTotal Voting Rights\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces\u00a0that the issued share capital of the Company at the date of this announcement comprises\u00a0113,656,253 ordinary shares of\u00a04 pence each with one voting right per share (\"Ordinary Shares\"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 113,656,253.\nThe above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nInvestor questions on this announcement\nInvestor hub\nWe encourage all investors to share questions\non this announcement via our investor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"\nCRO\n\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRDGGDUSXXDGUG",
          "content_length": 4080
        },
        "ingested_at": "2026-01-21T02:20:26.431143Z"
      },
      {
        "event_id": "RNS-22nd May 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431156Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on U.S. Patent for OptiMAL\u00ae",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/update-on-us-patent-for-optimal174-wnxpzzs0k9m0hv3.html",
          "rns_number": "RNS Number : 8425J",
          "full_content": "22 May 2025 14:33\nRNS Number : 8425J\nFusion Antibodies PLC\n22 May 2025\n22 May 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nUpdate on U.S. Patent for OptiMAL\u00ae\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the United States Patent and Trademark Office has issued a notice of allowance in respect of the Company's U.S. patent application no. 17/287,441 (the \"\nPatent Application\n\").\nThe Patent Application entitled \"Antibody Library and Method\", concerns the library of antibodies that is currently screened within Fusion's OptiMAL\u00ae platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide \"Opti\" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation.\nReceipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.\nFurther announcements will be made at the appropriate time.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDUUUORVKUVUAR",
          "content_length": 4271
        },
        "ingested_at": "2026-01-21T02:20:26.431169Z"
      },
      {
        "event_id": "RNS-8th May 2025-investor",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431181Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Investor presentation",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/FAB/investor-presentation-4tnd6tct2mc42i4.html",
          "rns_number": "RNS Number : 7207H",
          "full_content": "8 May 2025 07:00\nRNS Number : 7207H\nFusion Antibodies PLC\n08 May 2025\nREACH - Non-regulatory announcement*\n8 May 2025\nFusion Antibodies plc\n(\"\nFusion\n\" or the \"\nCompany\n\")\nInvestor presentation\nFusion Antibodies plc (AIM: FAB),\nspecialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces that\nit will host an\nonline live presentation on\nThursday, 22 May\nat 11.30am, delivered by Dr Adrian Kinkaid, CEO and Stephen Smyth, interim CFO to accompany the recent trading update.\nThe Company is committed to providing an opportunity for all existing and potential investors to hear directly from management, who will discuss the recent trading update for FY 2025.\nThe presentation will be hosted through the digital platform Investor Meet Company (\"IMC\").\nInvestors can sign up to Investor Meet Company for free and add to meet Fusion Antibodies plc via the following link:\nhttps://www.investormeetcompany.com/fusion-antibodies-plc/register-investor\nFor those investors who have already registered and added to meet the Company, they will automatically be invited. Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the \"Ask a Question\" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.\n*About Reach announcements\nThis is a Reach announcement. Reach is an\u00a0investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to\u00a0distribute\u00a0media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may",
          "content_length": 5499
        },
        "ingested_at": "2026-01-21T02:20:26.431195Z"
      },
      {
        "event_id": "RNS-7th May 2025-issueofs",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431208Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of shares to non-executive directors",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/issue-of-shares-to-non-executive-directors-5civbx7vi646y49.html",
          "rns_number": "RNS Number : 5778H",
          "full_content": "7 May 2025 07:00\nRNS Number : 5778H\nFusion Antibodies PLC\n07 May 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n7 May 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nIssue of shares to non-executive directors\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces the\nissue of new ordinary shares of 4p each in the capital of the Company (\n\"Ordinary Shares\"\n) to certain non-executive directors of the Company in satisfaction of part of their salary and fees for the six-month period ended 31 March 2025.\nAs disclosed in the Company's annual report and accounts for the year ended 31 March 2024 (as announced on 5 September 2024), the Company's non-executive directors agreed to receive part of their salary in new Ordinary Shares until the end of the financial year ending 31 March 2025 (\"\nFY25\n\"), in order to assist the Company as it continues to carefully control its cash flows.\nIn total, 338,113 new Ordinary Shares have been issued (the \"\nDirector Shares\n\") at a deemed issue price of 6.1p per Ordinary Share, being the closing mid-market price of an Ordinary Share on the date of grant, as follows:\nDirector\nAmount of salary/fees received in Director Shares\nNo. of Director Shares\nTotal holding of Ordinary Shares post issue\nPercentage of enlarged share capital\nSimon Douglas\n\u00a33,750\n61,475\n1,061,0621\n0.93%\nColin Walsh2\n\u00a313,500\n221,311\n3,109,1123\n2.74%\nMatthew Baker\n\u00a33,375\n55,327\n292,902\n0.26%\n1\nExcludes Ordinary Shares held by relatives of Simon Douglas.\n2\nHeld by Walsh Strategic Management Limited, a company controlled by Colin Walsh\n3\nIncludes 600,000 Ordinary Shares already held by Walsh Strategic Management Limited, a company controlled by Colin Walsh and 1,400,000 Ordinary Shares held by Hamniv (GP) Limited, a subsidiary of Crescent Capital NI Limited (\"Crescent Capital\"). Colin Walsh is the Chief Executive and founder of Crescent Capital.\nAdmission to trading on AIM\nApplication has been made to the London Stock Exchange plc for the Director Shares to be admitted to trading on AIM (\"\nAdmission\n\"). It is anticipated that Admission will become effective and that dealings in the Director Shares will commence on AIM at 8.00 a.m. on or around 12 May 2025.\nTotal voting rights\nOn Admission, the Company will have\n113,656,253\nOrdinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be\n113,656,253\nand this figure may be used by Shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner ",
          "content_length": 7667
        },
        "ingested_at": "2026-01-21T02:20:26.431222Z"
      },
      {
        "event_id": "RNS-6th May 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431235Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/directorpdmr-shareholding-uzkbvya76d6vtej.html",
          "rns_number": "RNS Number : 5037H",
          "full_content": "6 May 2025 10:53\nRNS Number : 5037H\nFusion Antibodies PLC\n06 May 2025\n6 May 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nDirector/PDMR Shareholding\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that Adrian Kinkaid, Chief Executive Officer of Fusion, has\npurchased 100,000 ordinary\nshares of 4 pence each in the Company (\"\nOrdinary Shares\n\") at a price of 6.18 pence per Ordinary Share. Following this purchase, Adrian Kinkaid directly holds 850,000 Ordinary Shares, representing approximately 0.75 per cent. of the Company's issued share capital.\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nAdrian Kinkaid\n2\nReason for the notification\na)\nPosition/status\nChief Executive Officer\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nFusion Antibodies plc\nb)\nLEI\n213800KBAYRC9VOQ9V39\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nordinary shares of 4p each in Fusion Antibodies plc\nIdentification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16\nb)\nNature of the transaction\nPurchase of Ordinary Shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n6.18p\n100,000\nd)\nAggregated information\n- Aggregated volume\n- Price\n- see above\n-\nsee above\ne)\nDate of the transaction\n6 May 2025\nf)\nPlace of the transaction\nXLON, London Stock Exchange\nEnquiries:\nInvestor questions on this announcement\nWe encourage all investors to share questions on this announcement via our investor hub\nInvestor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provi",
          "content_length": 5058
        },
        "ingested_at": "2026-01-21T02:20:26.431249Z"
      },
      {
        "event_id": "RNS-6th May 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431262Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/holdings-in-company-2is1a1665kxh90t.html",
          "rns_number": "RNS Number : 5002H",
          "full_content": "6 May 2025 10:38\nRNS Number : 5002H\nFusion Antibodies PLC\n06 May 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BDQZGK16\nIssuer Name\nFUSION ANTIBODIES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nOther\nComments\nPlease refer to the additional information section of the form for information - no change to the position.\n3. Details of person subject to the notification obligation\nName\nMaven Capital Partners UK LLP\nCity of registered office (if applicable)\nGlasgow\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nMaven Renovar VCT PLC\nLondon\nEngland and Wales\n5. Date on which the threshold was crossed or reached\n01-May-2025\n6. Date on which Issuer notified\n06-May-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n4.162000\n0.000000\n4.162000\n4716463\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BDQZGK16\n4716463\n4.162000\nSub Total 8.A\n4716463\n4.162000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nMaven Renovar VCT PLC was previously Amati AIM VCT plc.The name change occurred following a change of Investment Manager from Amati Global Investors (AGI) to Maven Capital Partners UK LLP (Maven).There has been no change to the position held by the Company, the notification has been submitted for information on the name change only.\n12. Date of Completion\n06-May-2025\n13. Place Of Completion\nGlasgow\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUQWAUPAUBQ",
          "content_length": 4122
        },
        "ingested_at": "2026-01-21T02:20:26.431274Z"
      },
      {
        "event_id": "RNS-6th May 2025-tradingu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431286Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Trading update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/trading-update-c7lmy91s0t6r8i2.html",
          "rns_number": "RNS Number : 3339H",
          "full_content": "6 May 2025 07:00\nRNS Number : 3339H\nFusion Antibodies PLC\n06 May 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n\u200b\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nYear-end trading statement\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an unaudited trading update for the financial year ended 31 March 2025 (\"\nFY2025\n\").\nHighlights\n\u00b7\nUnaudited revenues for FY2025 of \u00a31.96m (FY2024: \u00a31.14m).\n\u00b7\nAchievements in the second half of FY2025 included:\no\nFuture Medicines Institute (\"\nFMI\n\") grant funding was announced on 4 December 2024 providing access to approximately \u00a31m of direct non-dilutive funding for the Company and access to other FMI assets including facilities and staff and access to up to \u00a35m of new capital equipment;\no\nFurther purchase orders received under a master services agreement (\"\nMSA\n\") with a leading diagnostics company;\no\nCell line development project received with a US based biotechnology client announced on 27 February 2025;\no\nPositive momentum in the ongoing collaboration agreement with the National Cancer Institute (\"\nNCI\n\"):\n\u00a7\nThe collaboration agreement was extended to include the humanisation by Fusion of several of the NCI's existing camelid nanobodies;\n\u00a7\nReceipt of positive cells (\"\nhits\n\") from the NCI for the use of OptiMAL\u00ae;\n\u00a7\nThe Company reproduced the evaluation of the initial hits confirming their positive nature with regard to the OptiMAL\u00ae platform; and\n\u00a7\nThe resynthesis of OptiMAL\u00ae antibodies encoded by DNA from hit cells, which has shown positive binding in multiple established assay formats. Validation work is continuing.\n\u00b7\nEquity fundraise announced on 18 March 2025, raising approximately \u00a31.17m (before expenses) for additional research and development (\"\nR&D\n\") work primarily related to the validation of the hits from the studies with the NCI, general working capital and to invest into commercial activities, especially to support OptiMAL\u00ae should the validation prove successful.\n\u00b7\nCash position as at 31 March 2025 of \u00a30.4m* (31 March 2024: \u00a31.2m).\n*\u00a30.57 million of the 18 March 2025 placing proceeds, as well as the initial FMI grant payment, were received after the period end and are therefore not reflected in this figure.\nWhile the broader economic environment continued to present Fusion with headwinds in FY2025, the Company's new commercial strategy delivered a positive outcome with unaudited revenues for FY2025 of \u00a31.96m. This is broadly in line with consensus market expectations and represents a 71% increase on the previous financial year.\nThe significant growth seen in the Diagnostics sector was particularly pleasing, along with the increasing interest from early-stage smaller-scale prospects in the Veterinary sector, which suggests that there is potential for further growth in this sector. Moreover, the approval of the FMI grant is both positive in terms of non-dilutive cash income for the Company but is also an acknowledgement of our scientific experience being recognised independently as well as being viewed as strong and valuable.\nWhile we are very encouraged by the turnaround in revenue in FY2025, we must remain cognisant of recent challenging market conditions, most notably the downturn in venture capital investment into biotechnology companies that was seen in FY2024, which appears to now be easing slowly. This has continued to affect a significant proportion of the Company's prospective client base. This also affected their projects for therapeutic antibody development programmes which is Fusion's current primary customer type.\nThe Company has since taken steps to overcome the aforementioned challenges. For example, through focused business development activities targeting Diagnostics, Veterinary Medicine and Research Antibody markets, the Company has made the sales pipeline more resilient with less exposure to individual sectors.\nIn addition, scientific attrition, caused by the natural risk in the development of highly sophisticated targeted biological systems, also impacted the business with some pipeline projects yet to convert and other projects being received later than originally anticipated. In one instance, a project, details of which were announced on 6 February 2024, was paused part way through the project. Fusion understands that it has may now have been entirely stopped. Accordingly, the Company does not anticipate recognising all the project's full revenue potential, although US$293k has been recognised to date. This type of scientific attrition is an ever-present risk faced by Fusion's clients and in no way reflects poorly on t",
          "content_length": 13322
        },
        "ingested_at": "2026-01-21T02:20:26.431301Z"
      },
      {
        "event_id": "RNS-30th Apr 2025-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431314Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/total-voting-rights-jwy2rs7zay6olro.html",
          "rns_number": "RNS Number : 6813G",
          "full_content": "30 Apr 2025 17:00\nRNS Number : 6813G\nFusion Antibodies PLC\n30 April 2025\n30 April 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nTotal Voting Rights\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces\u00a0that the issued share capital of the Company at the date of this announcement comprises\u00a0113,318,140 ordinary shares of\u00a04 pence each with one voting right per share (\"Ordinary Shares\"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 113,318,140.\nThe above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nInvestor questions on this announcement\nInvestor hub\nWe encourage all investors to share questions\non this announcement via our investor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"\nCRO\n\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRBSGDSCSDDGUC",
          "content_length": 4084
        },
        "ingested_at": "2026-01-21T02:20:26.431326Z"
      },
      {
        "event_id": "RNS-24th Apr 2025-approval",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431339Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Approval of grant funding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/approval-of-grant-funding-6mwumxsc8345guz.html",
          "rns_number": "RNS Number : 9391F",
          "full_content": "24 Apr 2025 07:00\nRNS Number : 9391F\nFusion Antibodies PLC\n24 April 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n24 April 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nApproval of grant funding\nProject to develop a humanised therapeutic DR5 antibody to combat treatment-resistant cancers\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces\u00a0the approval of an InnovateUK Launchpad grant application (the \"Grant\") led by Fusion Antibodies plc in collaboration with Queens University Belfast (\"QUB\").\nHighlights:\n\u00b7\nFusion to receive up to \u00a3545K direct non-dilutive funding\n\u00b7\nGrant to run for 18 months\n\u00b7\nEligible costs include labour, overheads and materials\n\u00b7\nThe therapeutic anti-DR5 antibody asset will be owned by Fusion and QUB\n\u00b7\nProject will provide case study data for the marketing of Fusion's technologies\nThe total funding being made available under the Grant is over \u00a3808k, with up to \u00a3545k expected to be provided for Fusion over a period of approximately 18 months. Funds are being provided by UK Research & Innovation (\"UKRI\") and InvestNI. The primary purpose of the grant is to develop a humanised antibody targeting and activating the DR5 protein on cancer cells for the treatment of cancers which are resistant to other therapies, with a goal of having a clinic ready therapeutic asset at the end of the project that can be licenced to third party pharma companies or biotechs.\nA formal collaboration agreement has already been agreed and signed by Fusion and QUB setting out the work programme. Fusion's primary role will be the humanisation of the antibody and creation of a stable cell line. QUB will be conducting the\nin vivo\nefficacy studies of the antibody.\nThe Grant support to Fusion is to cover human resource needs, materials/consumables costs and overheads. The project is expected to start on 1 May 2025 and will provide case study data for the marketing of Fusion's technologies. The antibody asset generated under the Grant project will be jointly owned by Fusion and QUB although the ownership ratios are still to be determined.\nAdrian Kinkaid, CEO of Fusion, said:\n\"\nWe are delighted to receive this grant from UKRI and InvestNI. The project exemplifies the collaborative interactions we set out to achieve as part of the Future Medicines Institute and builds on the solid foundations that provides\n.\"\nRichard Buick, CSO of Fusion, said:\n\"This project will allow us to demonstrate some of our exceptional and world class scientific capabilities in the development of a novel DR5 agonist antibody. The target has attracted the interest of several of the best biotechnology companies pursuing novel cancer therapies.\"\nChistopher Scott, Dean of Research, QUB, said:\n\"\nI am delighted that QUB can partner with regional companies with such expertise to enhance development of home ground therapeutics - this builds on the successful establishment of the Future Medicines Institute aiming to bring the best of academic research, in this case the Patrick G Johnston Cancer Centre, together with industrial partners for the development of health and wealth benefits for Northern Ireland.\"\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0)20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0)207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nInvestor Hub\nWe encourage all investors to share questions on this announcement via our investor hub. You can view it here:\nhttps://investorhub.fusionantibodies.com/link/drLEQP\nTo view a video summary of today's news and pose questions, navigate to our Interactive Investor hub here:\nhttps://investorhub.fusionantibodies.com/\n. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequ",
          "content_length": 6953
        },
        "ingested_at": "2026-01-21T02:20:26.431352Z"
      },
      {
        "event_id": "RNS-11th Apr 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431365Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/holdings-in-company-n626ugmsi0l4e3q.html",
          "rns_number": "RNS Number : 7142E",
          "full_content": "11 Apr 2025 10:40\nRNS Number : 7142E\nFusion Antibodies PLC\n11 April 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nFUSION ANTIBODIES PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\"),\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nCANACCORD GENUITY GROUP INC\nCity and country of registered office (if applicable)\nVANCOUVER, CANADA\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nDISCRETIONARY CLIENTS\nCity and country of registered office (if applicable)\nAs above\n5. Date on which the threshold was crossed or reached\nvi\n:\n09 APRIL 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n10 APRIL 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.1182\n7.1182\n8,066,263\nPosition of previous notification (if\napplicable)\nN/A\nN/A\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BDQZGK16\n8,066,263\n7.1182\nSUBTOTAL 8. A\n8,066,263\n7.1182\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nCanaccord Genuity Group Inc.\n7.1182\n7.1182\nCanaccord Genuity Wealth Group Holdings Limited\n7.1182\n7.1182\nCanaccord Genuity Wealth Group Holdings (Jersey) Limited\n7.1182\n7.1182\nCanaccord Genuity Wealth Group Limited\n7.1182\n7.1182\nCanaccord Genuity Asset Management Limited\n7.1182\n7.1182\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nThe change in the percentage of shares held is due entirely to participation in the placing by Fusion Antibodies plc, the shares from which were admitted to trading on AIM on 09/04/2025.\nPlace of completion\nBLACKPOOL, ENGLAND\nDate of completion\n10 APRIL 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLGPURWCUPAUBG",
          "content_length": 4891
        },
        "ingested_at": "2026-01-21T02:20:26.431377Z"
      },
      {
        "event_id": "RNS-10th Apr 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431390Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/holdings-in-company-ltavdjlp6gh61qv.html",
          "rns_number": "RNS Number : 5495E",
          "full_content": "10 Apr 2025 12:47\nRNS Number : 5495E\nFusion Antibodies PLC\n10 April 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nFusion Antibodies plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nUnicorn Asset Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUnicorn AIM VCT plc\nCity and country of registered office (if applicable)\nNewton Abbot, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n09 April 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n10 April 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.65%\n5.65%\n6,397,290\nPosition of previous notification (if\napplicable)\n6.71%\n6.71%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nOrdinary shares\nGB00BDQZGK16\n6,397,290\n5.65%\nSUBTOTAL 8. A\n6,397,290\n5.65%\nB 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 113,318,140\nPlace of completion\nUnicorn Asset Management Limited, Preachers Court, Charterhouse, Chartehouse Square, London, EC1M 6AU\nDate of completion\n10 April 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLGPUQCCUPAGGU",
          "content_length": 4822
        },
        "ingested_at": "2026-01-21T02:20:26.431402Z"
      },
      {
        "event_id": "RNS-7th Apr 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431415Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/result-of-general-meeting-8lzf9cg5mg3xxem.html",
          "rns_number": "RNS Number : 9561D",
          "full_content": "7 Apr 2025 12:35\nRNS Number : 9561D\nFusion Antibodies PLC\n07 April 2025\n7 April 2025\nFusion Antibodies plc\n(\"\nFusion\n\" or the \"\nCompany\n\")\nResult of General Meeting\nand\nTotal voting Rights\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces\nthat\nat the general meeting of the Company, held earlier today, all resolutions were duly passed.\nFollowing the passing of the resolutions, the Company has raised a total of approximately \u00a31.17 million pursuant to the Placing, details of which were announced on 18 March 2025.\nApplication has been made for admission of the\n8,416,020\nSecond Tranche Placing Shares to trading on AIM (\"\nAdmission\n\"). It is currently anticipated that Admission will become effective and that dealings in the Second Tranche Placing Shares will commence on AIM at 8.00 a.m. on 9 April 2025.\nTotal voting rights\nOn Admission, the Company will have 113,318,140 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 113,318,140 and this figure may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\nUnless otherwise defined herein, the capitalised defined terms used in this announcement have the same meaning as those used in the Company's announcement on 18 March 2025.\nNavigate to our Interactive Investor hub here:\nhttps://investorhub.fusionantibodies.com/\n. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.\nEnquiries:\nInvestor questions on this announcement\nInvestor hub\nWe encourage all investors to share questions\non this announcement via our investor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"\nCRO\n\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nROMSSDFFWEISEDL",
          "content_length": 4961
        },
        "ingested_at": "2026-01-21T02:20:26.431427Z"
      },
      {
        "event_id": "RNS-31st Mar 2025-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431439Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/total-voting-rights-g47xfk411e0g629.html",
          "rns_number": "RNS Number : 5626C",
          "full_content": "31 Mar 2025 17:00\nRNS Number : 5626C\nFusion Antibodies PLC\n31 March 2025\n31 March 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nTotal Voting Rights\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces\u00a0that the issued share capital of the Company at the date of this announcement comprises\u00a0104,902,120 ordinary shares of\u00a04 pence each with one voting right per share (\"Ordinary Shares\"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 104,902,120.\nThe above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nInvestor questions on this announcement\nInvestor hub\nWe encourage all investors to share questions\non this announcement via our investor hub\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"\nCRO\n\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRBUGDXCGDDGUR",
          "content_length": 4084
        },
        "ingested_at": "2026-01-21T02:20:26.431452Z"
      },
      {
        "event_id": "RNS-24th Mar 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431464Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/holdings-in-company-9w7yqyuixpv31ai.html",
          "rns_number": "RNS Number : 9361B",
          "full_content": "24 Mar 2025 16:38\nRNS Number : 9361B\nFusion Antibodies PLC\n24 March 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BDQZGK16\nIssuer Name\nFUSION ANTIBODIES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nRathbones Investment Management Ltd\nCity of registered office (if applicable)\nLondon\nCountry of registered office (if applicable)\nUnited Kingdom\nName\nCity of registered office\nCountry of registered office\nInvestec Wealth & Investment Limited\nLondon\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nHero Nominees Limited\nSt Peter Port\nGuernsey\nFerlim Nominees Limited\nLondon\nUnited Kingdom\nRathbone Nominees Limited\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n21-Mar-2025\n6. Date on which Issuer notified\n24-Mar-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n7.118800\n0.000000\n7.118800\n7467753\nPosition of previous notification (if applicable)\n4.732400\n0.000000\n4.732400\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BDQZGK16\n7467753\n7.118800\nSub Total 8.A\n7467753\n7.118800%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nRathbones Group Plc\nRathbones Investment Management Limited\n7.107200\n7.107200%\nRathbones Group Plc\nInvestec Wealth & Investment Limited\n0.011600\n0.011600%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNone\n12. Date of Completion\n24-Mar-2025\n13. Place Of Completion\nPort of Liverpool Building, Liverpool L3 1NW\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLPPUQWWUPAGQC",
          "content_length": 4170
        },
        "ingested_at": "2026-01-21T02:20:26.431476Z"
      },
      {
        "event_id": "RNS-18th Mar 2025-placingt",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431490Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Placing to raise approximately \u00a31.17 million",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/placing-to-raise-approximately-163117-million-hf5f5ztc6wc4bvl.html",
          "rns_number": "RNS Number : 0125B",
          "full_content": "18 Mar 2025 07:00\nRNS Number : 0125B\nFusion Antibodies PLC\n18 March 2025\nTHIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED (\"EUWA\")) (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n18 March 2025\nFusion Antibodies plc\n(\"\nFusion\n\" or the \"\nCompany\n\")\nPlacing to raise approximately \u00a31.17 million\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces\nthat it has conditionally raised approximately \u00a31.17\nmillion (before expenses) by way of a placing (\nthe\n\"\nPlacing\n\") of\na total of\n17,365,228\nn\new\nordinary shares of 4 pence each in the\nCompany (\"\nOrdinary Shares\n\") at a\nprice of 6.75 pence per new Ordinary Share\n(the \"\nIssue Price\n\").\nAllenby Capital Limited (\"\nAllenby Capital\n\") and Shard Capital Partners LLP (\"\nShard\n\") are acting as the Company's joint brokers in connection with the Placing.\nKey highlights\n\u00b7\nPlacing to raise approximately \u00a3\n1.17 million\n(before expenses) through the issue of\n17,365,228\nnew Ordinary\nShares (the \"\nPlacing Shares\n\") at the Issue Price, of which\napproximately \u00a30.57\nmillion is conditional.\n\u00b7\nThe Issue Price is equal to the closing mid-market price of an Ordinary Share on\n17\nMarch 2025.\n\u00b7\nThe Placing will be conducted in two tranches as to: (i) 8,949,208 Placing Shares (the \"\nFirst Tranche Placing Shares\n\"), being referred to as the\n\"First Placing\"\n; and ii) 8,416,020 Placing Shares (the \"\nSecond Tranche Placing Shares\n\"), being referred to as the\n\"Second Placing\"\n.\no\nThe First Tranche Placing Shares will be allotted and issued utilising the Company's existing authorities granted at the annual general meeting of the Company held on 8 October 2024 (the \"\n2024 AGM\n\").\no\nThe issue and allotment of the Second Tranche Placing Shares is\u00a0conditional,\ninter alia\n, upon the passing of resolutions to authorise such issues and allotments and disapply pre-emption rights (the \"\nResolutions\n\") to be put to holders of Ordinary Shares (\"\nShareholders\n\") at a to be convened general meeting of the Company (the \"\nGeneral\nMeeting\n\").\n\u00b7\nThe General Meeting is to be\u00a0held at the offices of Fusion Antibodies at 1 Springbank Road, Springbank Industrial Estate,\u00a0Dunmurry, Belfast BT17 0QL at 10.00 a.m. on\u00a07 April\u00a02025 and a circular, including a notice of General Meeting, will be sent to Shareholders on\u00a0or before 19 March 2025.\n\u00b7\nThe Placing is not being underwritten by Allenby Capital or Shard.\nAdrian Kinkaid, Chief Executive Officer of Fusion Antibodies plc, commented:\n\"It is very pleasing to acknowledge the level of shareholder support for the Company that we currently enjoy. While we continue to work towards our goal of achieving cash flow neutrality, the Company is faced with some remarkable opportunities for growth which are worthy of additional investment. We are currently seeking to validate the OptiMAL\u00ae platform through our collaboration with the U.S. National Cancer Institute (\"\nNCI\n\") which has generated a significant number of worthy hits which we now intend to confirm. This requires additional research and development spending, which will be complemented by further investment in commercialisation activities. These exciting developments and opportunities, together with maximising the value of our grants, created the justification for the Placing, and I am delighted that our enthusiasm for the validation of our flagship platform has been matched by the participants in the Placing, and especially those from the institutional VCT funds with their inherent longer-term perspective.\"\nFurther details of the Placing are set out below.\nBackground to and reasons for the Placing and current trading\nThe Company has enjoyed a marked improvement in sales in the current financial year as a result of a significant increase in pipeline opportunities including in newly targeted sectors, such as diagnostics. This improvement has been achieved with reduced resources, following the cost cutting exercise that took place in 20",
          "content_length": 25071
        },
        "ingested_at": "2026-01-21T02:20:26.431503Z"
      },
      {
        "event_id": "RNS-27th Feb 2025-contract",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431516Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Contract win",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/contract-win-432um19bjkrdows.html",
          "rns_number": "RNS Number : 6084Y",
          "full_content": "27 Feb 2025 07:00\nRNS Number : 6084Y\nFusion Antibodies PLC\n27 February 2025\n27 February 2025\nFusion Antibodies plc\n(\"\nFusion\n\"\u00a0or the\n\"Company\n\")\nContract Win\nFusion Antibodies plc (AIM: FAB),\nspecialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces that it has been selected to proceed with a new stable Cell Line Development project\n(the \"\nCLD Project\n\") under a collaborative research and development agreement (the \"\nAgreement\n\") with a US based biotechnology company (the \"\nClient\n\").\nWork in relation to the CLD Project is expected to commence shortly and last six to nine months.\nThe Agreement is expected to result in Fusion generating revenues in the region\nof US\n$250,000 by the end of 2025.\nAdrian Kinkaid, CEO of Fusion, said:\n\"We are delighted to have been selected to generate the definitive cell line for the future production of this important therapeutic product. We look forward to continuing to work with our Client to bring better antibodies to the clinic more rapidly.\nThe CLD Project highlights the strong reputation that Fusion has for delivering high quality therapeutic antibodies and their associated cell lines\n: a part of our offering with excellent scope for growth.\n\"\nWhilst it is not anticipated that revenues from the new CLD Project will substantially impact revenues in the current financial year, it provides a valuable bedrock for the financial year ending 31 March 2026. We look forward to continuing to build on the excellent relationship with our Client and to repeating the success with more cell line development projects in the future\n.\"\nNavigate to our Interactive Investor hub here:\nhttps://investorhub.fusionantibodies.com/\n. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nCNTEAPAKAANSEFA",
          "content_length": 4827
        },
        "ingested_at": "2026-01-21T02:20:26.431529Z"
      },
      {
        "event_id": "RNS-31st Jan 2025-optimalr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431541Z",
        "source": "LSE_RNS",
        "data": {
          "title": "OptiMAL R&D Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/optimal-rd-update-w7gxs1o1h8qsm30.html",
          "rns_number": "RNS Number : 3633V",
          "full_content": "31 Jan 2025 07:00\nRNS Number : 3633V\nFusion Antibodies PLC\n31 January 2025\n31 January 2025\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nOptiMAL\n\u00ae\nR&D\nUpdate\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on the OptiMAL\u00ae validation project being performed under the collaboration agreement (the \"\nAgreement\n\") with the National Cancer Institute (\"\nNCI\n\").\nThe validation project is progressing as planned and, using Fusion's OptiMAL\u00ae Library, the NCI has identified a number of antibody expressing cells that positively bind to their targets of interest. Fusion will extract and sequence the DNA encoding for the antibodies from these cells for verification of binding and further analyses. This analysis will take several months. The Company has received the first batch of cells from the NCI that have been isolated from the OptiMAL\u00ae Library for this validation work and additional batches will be shipped subsequently. Fusion is undertaking this work on a goodwill basis to assist the validation of the OptiMAL\u00ae Library. The NCI will continue the process of identifying more positive cells against their various targets and the Company also anticipates assisting in the analysis of the antibodies produced from these cells.\nNCI, part of the US National Institutes of Health, is the US federal government's principal agency for cancer research and training. Pursuant to the Agreement, details of which were announced by the Company on 28 November 2023, Fusion has provided NCI with access to OptiMAL\u00ae for use in the discovery of novel antibodies against targets selected by NCI.\nRichard Buick, CSO of Fusion Antibodies plc, commented:\n\"We are excited by the prospect of analysing the antibodies from these OptiMAL\u00ae cells selected by Dr. Mitchell Ho's group at the NCI. The cells have shown positive binding activity to their target of interest and Fusion will now work on the validation of the antibody binding. We look forward to assisting the NCI in the validation of the OptiMAL\u00ae platform under the Agreement.\"\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS",
          "content_length": 5120
        },
        "ingested_at": "2026-01-21T02:20:26.431555Z"
      },
      {
        "event_id": "RNS-4th Dec 2024-approval",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431568Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Approval of Grant Funding Application",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/approval-of-grant-funding-application-krf71c8bmg7d561.html",
          "rns_number": "RNS Number : 8076O",
          "full_content": "4 Dec 2024 11:31\nRNS Number : 8076O\nFusion Antibodies PLC\n04 December 2024\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n4 December 2024\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nApproval of Grant Funding Application\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, is pleased to announce\u00a0the approval of a grant (the \"\nGrant\n\") to be provided to The Northern Ireland Precision Biomarkers and Therapeutics consortium (\"\nNIPBT\n\"), which includes Fusion.\nThe Grant provides Fusion with access to:\n\u00b7\napproximately \u00a31m of direct non-dilutive funding for research & development initiatives;\n\u00b7\nup to \u00a35m of capital equipment;\n\u00b7\napproximately 20 core staff, laboratories and offices spaces; and\n\u00b7\nnew PhD studentships.\nNIPBT is a partnership of Life and Health Science companies, Health Innovation Research Alliance Northern Ireland, Ulster University and Queen's University Belfast (\"\nQUB\n\") which is strategically aligned with the research and economic development strategies of the Departments of Health (\"\nDoH\n\") and Economy (\"\nDfE\n\") of the devolved government in Northern Ireland. Its mission is to galvanise Northern Ireland's strengths in digital health and pharmaceutical development through a shared strategic vision that will expand research capacity, drive innovation and maximise productivity\u200b resulting in the development of new technologies, diagnostics and therapeutics for the advancement of healthcare.\nThe Grant is being provided by UK Research and Innovation (\"\nUKRI\n\") as well as Invest Northern Ireland (\"\nInvest NI\n\") from the Strength in Places Fund. The primary purpose of the Grant is to enable the establishment of the Future Medicines Institute (\"\nFMI\"\n) at QUB, which will result in the creation of new facilities, laboratories and offices, core facility equipment as well as a cadre of approximately twenty FMI staff. Up to \u00a35 million is being provided for such equipment purchases under the terms of the Grant. In addition, the FMI will undertake the training of a further twenty PhD studentships covering areas of research central to the FMI and the consortium members' interests. All NIPBT members, including Fusion, will have access to the new facilities and staff at the FMI.\nIn addition, as a member of NIPBT, Fusion is entitled, subject to customary due diligence, to direct non-dilutive funding of approximately \u00a31 million from the Grant which can be claimed over the course of up to five years.\nFusion's role in the consortium will centre on the optimisation of antibody discovery and development processes, with resultant antibodies being intended as therapeutics or diagnostic agents. A formal collaboration agreement has already been signed by the Company.\nIt is intended that the non-dilutive funding available under the Grant will be used by Fusion to cover human resource needs, materials/consumables costs and capital investment. As such the bulk of the non-dilutive funding is likely to be claimed in the earlier period of the Grant and is expected to be paid quarterly in advance against an agreed project plan, which is a further distinct advantage to the consortium members including Fusion. The project is due to start on 1st January 2025.\nAdrian Kinkaid, CEO of Fusion, said:\n\"It is particularly gratifying to see the consortium gain approval for this substantial Grant which recognises Northern Ireland's excellence in life sciences, including therapeutics and diagnostics, and the significant role Fusion plays in the region's life sciences sector. We also acknowledge and applaud the foresight and determination of the lead applicants in securing the Grant. As the Grant provides non-dilutive funding, paid quarterlyin advance of incurring costs, to support further development of Fusion's core technologies, we can be highly confident that the economic impact will be very readily recognised. However, perhaps the most significant impact is likely to come from consequences of the research now achievable by Fusion through the Company's access to facilities, equipment, staff and expertise made available under the Grant.\"\nRichard Buick, CSO of Fusion, said:\n\"This Grant will support further development of our extensive discovery and engineering capabilities for both antibody-based therapeutics and diagnostics, especially in the areas of OptiPhageTM and Cell Line Development. There is also the opportunity for Fusion to work alongside academic and industry experts in the development of new technologies utilising Mass Spectrometry. We look forward to working together with the consortium partners to deploy these cutting-edge",
          "content_length": 8576
        },
        "ingested_at": "2026-01-21T02:20:26.431584Z"
      },
      {
        "event_id": "RNS-19th Nov 2024-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431597Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/half-year-report-ol9k04i93nau43k.html",
          "rns_number": "RNS Number : 6794M",
          "full_content": "19 Nov 2024 07:00\nRNS Number : 6794M\nFusion Antibodies PLC\n19 November 2024\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n19\nNovember 2024\nFusion Antibodies plc\n(\"\nFusion\n\"\nor the\n\"Company\n\")\nHalf year Report\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces its unaudited interim results for the six months ended 30 September 2024 (\"H1 FY2025\").\nFinancial highlights\n\u00b7\nRevenues of \u00a31.2 million (H1 FY2024: \u00a30.5 million)\n\u00b7\nExpenditure on R&D maintained at \u00a30.18 million (H1 FY2024: \u00a30.18 million)\n\u00b7\nLoss of \u00a30.76 million (H1 FY2024: \u00a31.4 million loss)\n\u00b7\nCash position in the bank at 30 September 2024 was \u00a30.4 million (31 March 2024: \u00a31.2 million) with a further \u00a3457k owed by existing debtors\nOperational highlights\n\u00b7\nFirst contract to develop a bespoke non-human antibody species\nOptiPhageTM library secured\n\u00b7\nContinued progress in development of the OptiMAL\u00ae library\n\u00b7\nCollaboration Agreement with the National Cancer Institute (\"NCI\") was expanded to include the humanisation of several of the NCI's existing camelid nanobodies\n\u00b7\nReceipt of Further orders from a leading diagnostics company under the master services agreement (\"MSA\") announced on 14 February 2024\nCommenting on the interim results, Adrian Kinkaid, CEO of Fusion Antibodies plc, said:\n\"\nThese interim figures bear witness to the significant improvements to the business and the more favourable market conditions we have deservedly enjoyed in the period. The Company is now well positioned, generating the financial evidence of a significant recovery and promising growth in the Company's prospects. Of particular note is the increase in margins complementing the more than doubling of revenues, which is testament to the Board's and the team's determination to move toward profitability.\nWe remain focused on meeting our stated goal of achieving cash flow breakeven without needing to raise additional funds.\"\nInvestor presentations\nFusion will host a presentation on the results open to all investors via the Investor Meet Company platform at 11.00am on Thursday,\n21 November 2024\n, delivered by Dr Adrian Kinkaid, CEO and Stephen Smyth, Interim CFO.\u00a0Adrian will also be presenting at the ShareSoc meeting on 12 December 2024.\nThe Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on these results.\nI\nnvestors can sign up to Investor Meet Company for free and add to meet Fusion Antibodies plc via the following link:\nhttps://www.investormeetcompany.com/fusion-antibodies-plc/register-investor\nFurther details on how to register for the ShareSoc meeting can be found via the following link:\nDiscovery Company Webinar 12 December 5:00pm - ShareSoc\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion Antibodies plc (\"Fusion Antibodies\", \"Fusion\" or the \"Company\") is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.\nThe range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM\u00a0platform and\u00a0cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 270 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nAt every stage, our client's vision is central to how we work in\ncombining the latest technological advances with cutting edge science.\nIn this work our world-class humanization and antibody ",
          "content_length": 24853
        },
        "ingested_at": "2026-01-21T02:20:26.431610Z"
      },
      {
        "event_id": "RNS-16th Oct 2024-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431623Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/directorpdmr-shareholding-uq9jchun4qtuyby.html",
          "rns_number": "RNS Number : 4668I",
          "full_content": "16 Oct 2024 13:23\nRNS Number : 4668I\nFusion Antibodies PLC\n16 October 2024\n16 October 2024\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nDirector/PDMR Shareholding\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that Adrian Kinkaid, Chief Executive Officer of Fusion, has\npurchased 83,728 ordinary\nshares of 4 pence each in the Company (\"\nOrdinary Shares\n\") at a price of 4.185 pence per Ordinary Share. Following this purchase, Adrian Kinkaid directly holds 750,000 Ordinary Shares, representing approximately 0.79 per cent. of the Company's issued share capital.\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nAdrian Kinkaid\n2\nReason for the notification\na)\nPosition/status\nChief Executive Officer\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nFusion Antibodies plc\nb)\nLEI\n213800KBAYRC9VOQ9V39\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nordinary shares of 4p each in Fusion Antibodies plc\nIdentification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16\nb)\nNature of the transaction\nPurchase of Ordinary Shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n4.185\np\n83,728\nd)\nAggregated information\n- Aggregated volume\n- Price\n- see above\n-\nsee above\ne)\nDate of the transaction\n16 October 2024\nf)\nPlace of the transaction\nXLON, London Stock Exchange\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your",
          "content_length": 5400
        },
        "ingested_at": "2026-01-21T02:20:26.431637Z"
      },
      {
        "event_id": "RNS-16th Oct 2024-issueofs",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431649Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of shares to non-executive directors",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/issue-of-shares-to-non-executive-directors-jb5yd5t1abzadpo.html",
          "rns_number": "RNS Number : 3209I",
          "full_content": "16 Oct 2024 07:00\nRNS Number : 3209I\nFusion Antibodies PLC\n16 October 2024\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n16 October 2024\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nIssue of shares to non-executive directors\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the\nissue of new ordinary shares of 4p each in the capital of the Company (\n\"Ordinary Shares\"\n) to certain non-executive directors of the Company in satisfaction of part of their salary and fees for the six-month period ended 30 September 2024.\nAs disclosed in the Company's annual report and accounts for the year ended 31 March 2024 (as announced on 5 September 2024), the Company's non-executive directors agreed to receive part of their salary in new Ordinary Shares until the end of the current financial year ending 31 March 2025 (\"\nFY25\n\"), in order to assist the Company as it continues to carefully control its cash flows.\nIn total, 587,348 new Ordinary Shares have been issued (the \"\nDirector Shares\n\") at a deemed issue price of 4.15p per Ordinary Share, being the closing mid-market price of an Ordinary Share on the date of grant,\nas follows:\nDirector\nAmount of salary/fees received in Director Shares\nNo. of Director Shares\nTotal holding of Ordinary Shares post issue\nPercentage of enlarged share capital\nSimon Douglas\n\u00a37,500\n180,722\n999,5871\n1.04%\nColin Walsh2\n\u00a313,500\n325,301\n2,887,8013\n3.01%\nMatthew Baker\n\u00a33,375\n81,325\n237,575\n0.25%\n1\nExcludes Ordinary Shares held by relatives of Simon Douglas.\n2\nHeld by Walsh Strategic Management Limited, a company controlled by Colin Walsh\n3\nIncludes 600,000 Ordinary Shares already held by Walsh Strategic Management Limited, a company controlled by Colin Walsh and 1,400,000 Ordinary Shares held by Hamniv (GP) Limited, a subsidiary of Crescent Capital NI Limited (\"Crescent Capital\"). Colin Walsh is the Chief Executive and founder of Crescent Capital.\nAdmission to trading on AIM\nApplication has been made to the London Stock Exchange plc for the Director Shares to be admitted to trading on AIM (\"\nAdmission\n\"). It is anticipated that Admission will become effective and that dealings in the Director Shares will commence on AIM at 8.00 a.m. on or around 22 October 2024.\nTotal voting rights\nOn Admission, the Company will have\n95,952,912\nOrdinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be\n95,952,912\nand this figure may be used by Shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global he",
          "content_length": 8026
        },
        "ingested_at": "2026-01-21T02:20:26.431663Z"
      },
      {
        "event_id": "RNS-8th Oct 2024-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431676Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/result-of-agm-8uxruzberqwznia.html",
          "rns_number": "RNS Number : 3947H",
          "full_content": "8 Oct 2024 12:32\nRNS Number : 3947H\nFusion Antibodies PLC\n08 October 2024\nFusion Antibodies plc\n(\"\nFusion\n\" or the \"\nCompany\n\")\nResult of AGM\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the annual general meeting (\"AGM\") held earlier today, all resolutions were duly passed.\nFull details of the voting results will be available on the Company's website\nhere\n.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGMPBBTMTJMBBI",
          "content_length": 3929
        },
        "ingested_at": "2026-01-21T02:20:26.431688Z"
      },
      {
        "event_id": "RNS-8th Oct 2024-agmstate",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431701Z",
        "source": "LSE_RNS",
        "data": {
          "title": "AGM statement and trading update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/agm-statement-and-trading-update-9ei9snossd3dsij.html",
          "rns_number": "RNS Number : 2408H",
          "full_content": "8 Oct 2024 07:00\nRNS Number : 2408H\nFusion Antibodies PLC\n08 October 2024\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n8 October 2024\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nAGM statement\nTrading update showing significant progress\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the Company's AGM, being held later today, Simon Douglas, Chairman, will provide the following update on trading for the first half of the current financial year ending 31 March 2025\n(\"HY25\"):\n\"I am pleased to update on the positive momentum the Company has achieved through HY25, with unaudited revenues for the period expected to be c. \u00a31.2m (HY24: \u00a3541k, FY24: \u00a31.14m). Unaudited gross margin for the period was 29%, compared to -16% in the first half of the prior year, showing significant progress against our targets. Cash as at 30 September 2024 was \u00a3464k and is tracking in line with management's expectations.\n\"During the period, the Company expanded its collaboration agreement with the National Cancer Institute (\"NCI\") to include the humanisation by Fusion of several of the NCI's existing camelid nanobodies. A new contract was secured to develop an antibody based therapeutic with a US based biotechnology company and we entered into a contract to develop a bespoke OptiPhageTM library. In addition, we have strengthened our investor and stakeholder engagement through launch of a new interactive investor hub at investorhub.fusionantibodies.com.\n\"Cash continues to be carefully controlled and, as set out in the Company's FY24 results announced on 5 September 2024, based on internal estimates the Company has a cash runway into the second half of FY26. The Company continues to seek to achieve cash neutrality during that timeframe and has no plans to raise cash through an equity placement. We remain on track and on plan with our strategic goals. The revised strategy has proven to be the correct one to ensure that Fusion is not only sustainable but also becomes the thriving business which it deserves to be.\"\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and mark",
          "content_length": 5888
        },
        "ingested_at": "2026-01-21T02:20:26.431715Z"
      },
      {
        "event_id": "RNS-2nd Oct 2024-blockadm",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431728Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block admission six monthly return",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/block-admission-six-monthly-return-5j5n5eermfq81p0.html",
          "rns_number": "RNS Number : 5237G",
          "full_content": "2 Oct 2024 07:00\nRNS Number : 5237G\nFusion Antibodies PLC\n02 October 2024\n2 October 2024\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nBlock admission six monthly return\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.\nAs of the date of this notification, 3,750 of the options over ordinary shares of 4 pence each in the Company\ncovered by the block admission announced by the Company on 27 September 2021 (the \"Block Admission\")\nremain outstanding\n. The Company has applied for the Block Admission to be cancelled, and accordingly the Block Admission will cease to exist with effect from 3 October 2024. The 3,750 options will remain outstanding.\nName of company:\nFusion Antibodies plc\nName of scheme:\nHistoric options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021\nPeriod of return:\nFrom 2 April 2024 to 1 October 2024\nNumber and class of securities not issued under the scheme at the beginning of the period:\n38,750 ordinary shares of 4 pence each in the Company (\"Ordinary Shares\")\nNumber of securities issued under the scheme during the period:\nNil\nNumber of options under the scheme that have lapsed during the period:\nOptions over\n35,000\nOrdinary Shares\nBalance under the scheme of securities not yet issued at the end of the period:\n3,750 Ordinary Shares\nNumber and class of securities originally admitted and the date of admission:\n917,083 Ordinary Shares on 27 September 2021\nContact name and telephone number:\nStephen Smyth, Interim CFO via Walbrook PR\n+44 (0)20 7933 8780\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an ano",
          "content_length": 5219
        },
        "ingested_at": "2026-01-21T02:20:26.431742Z"
      },
      {
        "event_id": "RNS-12th Sep 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431754Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/notice-of-agm-mv3vtvxp1jqf2yh.html",
          "rns_number": "RNS Number : 9549D",
          "full_content": "12 Sep 2024 09:54\nRNS Number : 9549D\nFusion Antibodies PLC\n12 September 2024\n12 September 2024\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nPosting of Annual Report & Notice of AGM\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces that the Annual Report and Accounts for the year ended 31 March 2024 and the Notice of the Company's Annual General Meeting (\"AGM\") is being posted to shareholders today.\nA copy of the 2024 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy will shortly be available to download from the Company website here:\nhttps://www.fusionantibodies-ir.com/\n.\nThe AGM will be held on Tuesday, 8 October 2024 at 11.00am at the offices of Fusion Antibodies,\n1 Springbank Road, Springbank Industrial Estate, Belfast\nBT17 0QL\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOALTMPTMTABMBI",
          "content_length": 4328
        },
        "ingested_at": "2026-01-21T02:20:26.431766Z"
      },
      {
        "event_id": "RNS-9th Sep 2024-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431779Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/directorpdmr-shareholding-vswa2xlvnr09wto.html",
          "rns_number": "RNS Number : 4570D",
          "full_content": "9 Sep 2024 12:35\nRNS Number : 4570D\nFusion Antibodies PLC\n09 September 2024\n9 September 2024\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nDirector/PDMR Shareholding\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that Richard Buick, Chief Scientific Officer of Fusion, has\npurchased\n94,825\nordinary\nshares of 4 pence each in the Company (\"\nOrdinary Shares\n\") at a price of 3.275 pence per Ordinary Share. Following this purchase, Richard Buick directly holds 1,000,000 Ordinary Shares, representing approximately 1.05 per cent. of the Company's issued share capital.\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nRichard Buick\n2\nReason for the notification\na)\nPosition/status\nChief Scientific Officer\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nFusion Antibodies plc\nb)\nLEI\n213800KBAYRC9VOQ9V39\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nordinary shares of 4p each in Fusion Antibodies plc\nIdentification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16\nb)\nNature of the transaction\nPurchase of Ordinary Shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n3.275\np\n94,825\nd)\nAggregated information\n- Aggregated volume\n- Price\n- see above\n-\nsee above\ne)\nDate of the transaction\n9 September 2024\nf)\nPlace of the transaction\nXLON, London Stock Exchange\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use ",
          "content_length": 5404
        },
        "ingested_at": "2026-01-21T02:20:26.431793Z"
      },
      {
        "event_id": "RNS-5th Sep 2024-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:20:26.431805Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/directorpdmr-shareholding-ewxv76s6h6s9wvf.html",
          "rns_number": "RNS Number : 1047D",
          "full_content": "5 Sep 2024 12:15\nRNS Number : 1047D\nFusion Antibodies PLC\n05 September 2024\n5 September 2024\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nDirector/PDMR Shareholding\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that Adrian Kinkaid, Chief Executive Officer of Fusion, has\npurchased 120,000 ordinary\nshares of 4 pence each in the Company (\"\nOrdinary Shares\n\") at a price of 3.17 pence per Ordinary Share. Following this purchase, Adrian Kinkaid directly holds 666,272 Ordinary Shares, representing approximately 0.70 per cent. of the Company's issued share capital.\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nAdrian Kinkaid\n2\nReason for the notification\na)\nPosition/status\nChief Executive Officer\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nFusion Antibodies plc\nb)\nLEI\n213800KBAYRC9VOQ9V39\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nordinary shares of 4p each in Fusion Antibodies plc\nIdentification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16\nb)\nNature of the transaction\nPurchase of Ordinary Shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n3.17p\n120,000\nd)\nAggregated information\n- Aggregated volume\n- Price\n- see above\n-\nsee above\ne)\nDate of the transaction\n5 September 2024\nf)\nPlace of the transaction\nXLON, London Stock Exchange\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx\u00a0TM\u00a0platform and\u00a0the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nThe Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.\nFusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.\nThe global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use yo",
          "content_length": 5402
        },
        "ingested_at": "2026-01-21T02:20:26.431819Z"
      },
      {
        "event_id": "SOCIAL-5Jan20260738-Bigjock3--8579690",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.321876",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bigjock36",
          "content": "STT1 you have failed to mention a very significant part of the cash flow equation. Aged debtors at the snapshot in time you mentioned were also \u00a3541k. This bolsters cash flow significantly! Here\u2019s the thing\u2026. That aged debtor figure is a SNAPSHOT. We can also assume they will have further debtors from that moment in time. Albeit costs will also be incurred, I feel safe in the knowledge that the Directors have a handle on the cash element of the business. Furthermore, you continuously slander the company yet you have just confirmed trading multiple times on the share. For myself sitting watching your continued drivel, you are nothing more than a hot air sadistic man who hopes the SP will drop on a few sells to buy back in as you know ultimately the businesses will be back above 20p+ long term.",
          "sentiment": 0.5,
          "engagement": "968",
          "price_at_post": "13.50",
          "thread_title": "RE: 2026 is the year of delivery",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D9CEEF08-772B-4611-ACBA-030106F711B9"
        },
        "ingested_at": "2026-01-22T21:37:31.332146+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260921-chrishut--4515397",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.321443",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "We will start to see the fruits of last years work come to harvest soon.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.00",
          "thread_title": "Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.332128+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260951-gtc1507-70770465",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.321024",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Let\u2019s hope so Chris! Lots of exciting stuff going on before the Christmas break, hopefully not long until some converts into orders",
          "sentiment": 0.5,
          "engagement": "1,141",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.332109+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261010-Bibzy7--7445337",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.320608",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Big contacts take time they ant giving this away for free",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.332082+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261035-Rocka-48793103",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.320199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Massive \u00a320k buy showing as unknown",
          "sentiment": 0.0,
          "engagement": "178",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.332065+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261044-evman27--3174723",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.319779",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Another \u00a310k buy too! Smart money loading up, we have also had a \u00a35k buyer most days for a few weeks too.",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.332047+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261046-Rocka-79837378",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.319359",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "It would be nice if we can stabilise at high teens /20p pre news then i think we can easily hit 40p thos month or next depending on news",
          "sentiment": 0.0,
          "engagement": "178",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.332029+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261049-evman27-29475950",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.318935",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "510k shares is 20p in IG, these shares will go like lightening on a good RNS. Lots of sticky hands here, tight float, the setup is fantastic when news arrives.",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.332011+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261240-Stan36--9138684",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.318512",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Nice to see this buying ahead of news about Optimal contracts & NCI. Risen 11% today to 15p & looking good.",
          "sentiment": 0.5,
          "engagement": "845",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.331993+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261240-Rocka-24684116",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.318104",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ask 15.5p\ud83d\ude80\ud83d\ude80\ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "178",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.331975+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261253-evman27--1774728",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.317686",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "She moves quick eh!",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.331956+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261349-chrishut-14550974",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.317272",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Long way up to go yet",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.331938+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261629-Bibzy7--5895417",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.316852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "100% correct",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.50",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-22T21:37:31.331920+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260721-gtc1507-22370224",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.316443",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://ascopost.com/news/october-2025/nci-issues-request-for-2027-budget/ NCI seeking an additional $4bn budget next yea. Maybe the purse strings are going to be loosened hence the \u201cscale of the proposal\u201d of the fab deal requiring NIH Approval. Exciting times, can\u2019t wait to see what they\u2019ve negotiated.",
          "sentiment": 0.5,
          "engagement": "1,141",
          "price_at_post": "14.50",
          "thread_title": "NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-22T21:37:31.331903+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260839-Gheko--8197869",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.316009",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Great find Gtc. We have the best in class platform  which is therefore hugely valuable not only to NCI but to big pharma sand smaller pharma alike. We know the size of deals in this industry\u2026.HUGE! So not only do I think the NCI will need/want a big deal with FAB but other pharmas will be circling. News anytime and no wonder the price is starting to creep up. The upside is mouthwatering. Good luck all.",
          "sentiment": 0.5,
          "engagement": "1,205",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-22T21:37:31.331885+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260840-Stan36--7127571",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.315582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Anticipation building. Only \u00a325,000 buys shifts the price up 1%. MMs short of stock, tightly held. Nice steady rise.",
          "sentiment": 0.5,
          "engagement": "845",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-22T21:37:31.331867+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260843-gtc1507--7540089",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.315169",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Especially when the new NCI director is also coming out and telling staff to fund gold standard cancer research. Optimal is best in class, first in classs according to fusion,  can\u2019t get more gold standard than that\u2026. https://x.com/thenci/status/1991594881232367638?s=46",
          "sentiment": 0.0,
          "engagement": "1,141",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-22T21:37:31.331849+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260843-evman27--4842717",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.314737",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes, this steady new year creep up bodes seriously well for holders. Whatever is going on in the background is seriously exciting. \ud83e\udd88",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "15.50",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-22T21:37:31.331831+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261207-cbeadle-54589210",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.314303",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right RNS FAB has the feel of a company whose share price could \ud83d\udca5 explode upwards. It\u2019s happened already with quite a few small pharma or biomedical companies in the past 12 months",
          "sentiment": 0.0,
          "engagement": "333",
          "price_at_post": "15.00",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-22T21:37:31.331813+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261354-gtc1507-34284570",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.313884",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Sorts of deals that Optimal could garner for Fusion maybe?? https://www.linkedin.com/posts/chabs-%E5%8D%8E%E4%BA%BA%E6%8A%97%E4%BD%93%E5%8D%8F%E4%BC%9A_earendil-labs-announces-strategic-collaboration-activity-7414297394865078272-X430?utm_source=share&utm_medium=member_ios&rcm=ACoAAAuyH_0BZuiiVe69ogYIdwe7HKyUbPvkmaA",
          "sentiment": 0.0,
          "engagement": "1,141",
          "price_at_post": "15.00",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-22T21:37:31.331795+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261554-NornIron--4867591",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.313455",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Hi folks I'm a relatively new investor here with FAB, but a lot of the research I done before investing was based on information, links, reports, etc, that some of you posted on here.  These gave me a starting point to do my own research. This post is just a thank you to you folks  who took the time to do this.  There certainly are some knowledgeable  posters on this page.  I'm including the rampers and derampers with my thanks too. You know who you are, lol, and your posts are also interesting  and informative for various reasons. Thanks for all your inputs and hopefully i can contribute to the posts in future here too.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "15.00",
          "thread_title": "Thanks folks !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=6655E900-946E-4D59-A610-FD833DD50AEB"
        },
        "ingested_at": "2026-01-22T21:37:31.331778+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261002-evman27-63799821",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.313023",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Fusion Antibodies presents at the Proactive One2One Investor Conference - January 11th 2024 https://www.youtube.com/watch?v=IAvbf90GgvQ I recommend everyone watches at least the Q&A of this one! A very jovial, excited and up beat Adrian at this presentation, this was a few months after the initial deal with the NCI was signed a few years ago. A gold mine of great quotes from Adrian I will share, \u201cNCI is a surrogate for big pharma, I\u2019d much rather do the first deal with NCI, when I might have to compromise things, rather than sell it cheaply to a blue chip\u201d \u201cWe approached NCI for sentiment around mammalian display on a scientist to scientist basis. We went directly to Dr Mitchell Ho saying what\u2019s the best way to do such and such, would you like to have a look at our technology. He liked it so much he didn\u2019t buy the company yet, we set up the agreement from his pulling it through, we may have positioned it to do that\u201d \u201cNo one has a platform like Optimal as far as I\u2019m concerned. I think that\u2019s one of the reasons why they really wanted us to come in\u201d \u201cThe NCI are taking it seriously, lots of people are going hang on this is worth another look, how far have they got. We went to the antibody engineering and therapeutics conference before Christmas 2023 in San Diego and came away with some very significant enquiries around that, it\u2019s really made people sit up\u201d \u201cI know antibodies are worth a lot of money so there is an example recently, Novartis bought a company called Calipso to get hold of one antibody called Cali002, $425m in order to do so, what you may not have known is we humanised that antibody\u201d \u201cWe certainly do not rule out such a big licensing deal, I think it\u2019s probably more likely and certainly looking at today\u2019s MCAP that a big pharma rather than licensing it for the amount it would be worth would just come in and buy us\u201d Follow up question to this, I can\u2019t understand why the valuation is probably less than kit in your laboratory plus the potential value of optimal already \u201cNope it confused me as well but that\u2019s one of the reasons why I work there, one of the reasons why I work for shares and it\u2019s one of the reasons why I bought shares\u201d GOLD. I haven\u2019t seen Adrian so bullish since the most recent presentation, you can watch that here, the Q&A at the end is particularly telling. https://investorhub.fusionantibodies.com/webinars/mPqXOr-optimal-r-launch-investor-q-a Compare both presentations, see where we are today and ask yourself, why am I not holding? Dyor",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.50",
          "thread_title": "Therapeutic Gold",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=8DB6EAD5-BA9B-4341-80E8-DEEA2E954E69"
        },
        "ingested_at": "2026-01-22T21:37:31.331760+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261023-chrishut-79841411",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.312520",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Managed 2 x 50k Thank you whoever wet the bed",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "I took some more",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BC2ABA98-B9D3-4F64-9839-C296923DF67A"
        },
        "ingested_at": "2026-01-22T21:37:31.331742+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20262046-gtc1507--3936536",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.312084",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a great post Evman. Thanks for reminding us of this. Much of the sentiment true even more so today",
          "sentiment": 0.0,
          "engagement": "1,141",
          "price_at_post": "14.50",
          "thread_title": "RE: Therapeutic Gold",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=8DB6EAD5-BA9B-4341-80E8-DEEA2E954E69"
        },
        "ingested_at": "2026-01-22T21:37:31.331724+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20262319-mmhater--6065054",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:31.311647",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Really enjoyed the banter the last couple of days\u2026 Hopefully STi will be about soon to tell us how the company is doomed and a dilution is imminent .",
          "sentiment": 0.0,
          "engagement": "651",
          "price_at_post": "15.00",
          "thread_title": "Banter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=3FD758A3-949D-40D2-9A70-A38BA90787BF"
        },
        "ingested_at": "2026-01-22T21:37:31.331706+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261920-Seancadm--3109214",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.765682",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "\u201c Negotiations regarding the expanded proposed programme are expected to continue into early 2026. Due to the scale of the proposal, formal approval processes at the US National Institutes of Health (of which the NCl is part) are likely to take several further months to complete. While discussions are progressing, there is no assurance that an extension to the Agreement will be reached, nor as to the timing or final terms of such an extension.\u201d The above extract from Fusions RNS regarding the NCI extension is very telling of how big this deal may be. The National institutes of health are only brought in to oversee deals that are greater than NCIs range, Fusions even stated in the RNS \u201cdue to the scale of the proposal\u201d. The proposal is large enough that it cannot be approved solely at NCI level.",
          "sentiment": 0.5,
          "engagement": "211",
          "price_at_post": "15.00",
          "thread_title": "NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-22T21:37:31.331688+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20262000-mariusz-86204335",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.765257",
        "source": "LSE_CHAT",
        "data": {
          "author": "mariusz",
          "content": "Currently at \u00a317m mcap\ud83e\udd2b",
          "sentiment": 0.0,
          "engagement": "356",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-22T21:37:31.331671+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20262127-gtc1507--4460748",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.764830",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Bargain basement right, question is who will realise first, retail herd, PIs, institutions or a competitor cro or potential client that wants to snap them up.",
          "sentiment": 0.0,
          "engagement": "1,141",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-22T21:37:31.331653+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260948-Cheapsha-20415916",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.764416",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Waiting game! NCI news shoud be big enough in it's own right plus we hopefully have some other new cotracts singed shortly!",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-22T21:37:31.331636+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261106-Stan36--4836249",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.763992",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Well I suppose there could also have been an approach to buy the business following the Optimal launch? The BOD are not obliged to RNS if this is confidential and ongoing and offer terms not clarified. E.g. informal approach: a company asks to enter into discussions about terms. GPT>> So what\u2019s the practical answer for FAB? \u2705 If FAB gets a quiet, informal approach and: it\u2019s confidential, there\u2019s no rumour, no unusual share price movement, and it\u2019s not yet inside information, \u27a1\ufe0f they are not obliged to put out an RNS. \u2757 But if any of the following occur: press/market chatter (\u201cFAB in talks\u201d), price/volume spikes that look \u201coffer related\u201d, confidentiality slips (more outsiders brought in), the approach becomes concrete enough to be inside info, \u27a1\ufe0f then yes \u2014 they\u2019d be pushed into an RNS (either because of UK MAR inside info disclosure or because the Takeover Panel requires a Rule 2 announcement).",
          "sentiment": 0.5,
          "engagement": "845",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-22T21:37:31.331618+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261114-Bibzy7-45223739",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.763528",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Just for talking sakes nci offer contract off 200 mil over nxt 4 years what does that do to the share price as it stands atm",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "15.00",
          "thread_title": "200 million",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=E421AF3B-BB86-44E4-89DC-E043088744F1"
        },
        "ingested_at": "2026-01-22T21:37:31.331601+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261236-Stan36-21388228",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.763125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Well just for the sake of fantasy figures & if you mean $50m/year for 4 years I'd go for a range of \u00a33-\u00a35 assuming the margin would be very high. No great additional overheads. That's an Mcap of \u00a3300m -\u00a3500m",
          "sentiment": 0.0,
          "engagement": "845",
          "price_at_post": "15.00",
          "thread_title": "RE: 200 million",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=E421AF3B-BB86-44E4-89DC-E043088744F1"
        },
        "ingested_at": "2026-01-22T21:37:31.331583+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261351-NornIron--7364560",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.762701",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I'm just thinking out loud here and coming from a different angle. Here's my thoughts :- - With NCI having the clout they have, Fusion needed them onboard using OptiMAL -  They got it 2 years ago when NCI starting using OptiMAL (November 2023). - They then needed NCI's seal of approval that OptiMAL does what it says on the tin - They got it when Optimal said they wanted to continue using it in late 2025 and negotiations  started with Fab for it's continued use. This approval from NCI now gives Fab and their OptiMAL product greater kudos, when having commercial conversations with other potential buyers of the product and licences  (or maybe even the company). As i see it, Fab have 2 potential buyers of the product / company / licences, these being NCI and big pharmas. Questions If Fab are selling to NCI, will they feel     'we need to look after these guys. They've gave us our product validation, we need to have gratitude for this, and to get a contract with them is additional kudos in the marketplace with other buyers' . . . and therefore do a financial deal that isn't as high as it could be ? Alternatively If Fab are selling to a big pharma (with the deep pockets they have), would it be better financially for us shareholders to sell to them, and let them negotiate with NCI on what NCI pay for it, if indeed they even let NCI have the product.  Big pharma won't have the same what could be regarded as moral obligation to give NCI favourable terms and could see this as an earner for them if they had full product control. You might say, and you could be right, that we need an NCI deal for validation of the product before selling to a big pharma.  The other argument is that we already have their validation with there desire for it's continued use. Could this discussion and waiting period that we 'see' with NCI negotiations be a board tactic in dangling the OptiMAL bait in front of a big pharma angler to take this before NCI take it ? To summarize my thoughts.   Does Fusion Antibodies want a deal with NCI  ?   . . . . My answer is,  I've absolutely no idea whatsoever if they do or not. Is it best to do a deal first with NCI before a deal with a big pharma ? . . . .  Same answer,  I've absolutely no idea if it is or not. Is this an exciting place to be as an investor at the minute with where this might go in the coming weeks / months ? YES, YES, YES is my answer to that. Good luck all.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "14.625",
          "thread_title": "Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-22T21:37:31.331565+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261618-Troutiso-38678653",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.762230",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Your suggestions assume some sort of exclusivity, with OptiMAL and Library that need not be the case. NCI can licence it for their work and several large Pharms can do so alongside that. The deals will be in terms of milestones and royalties later down the line as well as an up front licensing fee. I think there are plenty of options, but a complete buy out is just one small one given the roadmap we have been given. A bid cannot be ruled out, but that is just 'investors best option' for those who are more short term than others. An early bid while welcome will never be at the full price they could command in 12-24 months time.",
          "sentiment": 0.0,
          "engagement": "1,564",
          "price_at_post": "14.75",
          "thread_title": "RE: Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-22T21:37:31.331547+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261640-NornIron--3274676",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.761810",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I totally agree Trout. Exclusivity is something I wouldn't like to see personally, and although possible, i don't see it happening. As a shareholder (and planning to be a longer term one) i feel there's more value in this longer term not to sell out.  Ongoing revenues from this could be more lucrative and enhance a future company value . . . for selling out down the line if favourable. If there was an offer of 2 to 3 times the m/cap to buy us now, tempted as I'd be to sell, i can tell you i won't be selling. I think we could be a lot bigger than that multiple in a few years time. I've 22 holdings in my portfolio, most of these in predictable dividend producing household names. Of the 7 holdings i have in AIM stocks, Fab holds the biggest percentage of my assets and it's also the one i'm most excited, and least anxious about.   It's going to be very interesting how this OptiMAL story unfolds. . . . I must just say too though, if in the event this 10 folds overnight, I'm outta here, lol.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "14.75",
          "thread_title": "RE: Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-22T21:37:31.331529+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20260858-gtc1507-23221988",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.761374",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Their investor hub seems to be a really useful tool but anyone else noticed they\u2019re slower to respond on it recently?",
          "sentiment": 0.5,
          "engagement": "1,141",
          "price_at_post": "14.75",
          "thread_title": "Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-22T21:37:31.331511+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20260912-chrishut-30001970",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.760947",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Once we surpass and hold above 15 it should become a strong support level. We have been attempting it a lot so only a matter of time. Nice to have buys below support.",
          "sentiment": 0.5,
          "engagement": "17,379",
          "price_at_post": "14.75",
          "thread_title": "Breakout coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=63B466DE-B123-46EA-AE7B-9C82630737A7"
        },
        "ingested_at": "2026-01-22T21:37:31.331494+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20260926-cbeadle-83399733",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.760540",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I wonder if it\u2019s because they\u2019re really busy tying contracts/deals together- or else just overcoming the Christmas and New Year season \ud83d\ude1c",
          "sentiment": 0.0,
          "engagement": "333",
          "price_at_post": "15.00",
          "thread_title": "RE: Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-22T21:37:31.331476+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261429-Rich125--5529801",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.760114",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rich125",
          "content": "I wonder if they are being a bit cautious about what they say given contracts could be about to land or at least in deep discussions. Taking extra care to make sure they don\u2019t say something they shouldn\u2019t before it\u2019s officially announced",
          "sentiment": 0.5,
          "engagement": "281",
          "price_at_post": "15.00",
          "thread_title": "RE: Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-22T21:37:31.331458+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261457-mmhater-84950759",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.759690",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Frankly i think this share price is a disgrace. I\u2019m not sure who to blame but it should be multiples of where it is now. I\u2019ve seen it in numerous companies and think it is to do with the AIM markets. They need to be more like the american markets and people might want to invest more! It\u2019s not fair on the company if the true value of the company is not reflected in the share price.",
          "sentiment": 0.0,
          "engagement": "651",
          "price_at_post": "15.00",
          "thread_title": "Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-22T21:37:31.331440+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261520-Rich125--6211842",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.759283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rich125",
          "content": "I think we will rerate once that first contracts lands. It seems the market are waiting for that as validation that we have something worthwhile, despite NCI clearly valuing it and effectively validating it.",
          "sentiment": 0.5,
          "engagement": "281",
          "price_at_post": "15.00",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-22T21:37:31.331422+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261929-cbeadle-30721262",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.758864",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I agree it\u2019s absolutely crazy and I am hoping for a sudden violent rerate when the market eventually realises the potential of FAB",
          "sentiment": 0.0,
          "engagement": "333",
          "price_at_post": "15.00",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-22T21:37:31.331404+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261002-Troutiso-70567360",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.758460",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "It's just trying to catch out some weak hands, it's actually more expensive to buy now since the drop in SP, than it was yesterday afternoon...",
          "sentiment": 0.0,
          "engagement": "1,564",
          "price_at_post": "14.50",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-22T21:37:31.331386+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261049-chrishut-80704227",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.758036",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I figure news has to be close, they have been in discussions for ages, so I have been adding into any weakness.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331369+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261329-Cheapsha-20405580",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.757627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "I\u2019m expecting any news ftom Jan 19th - Feb 28th. That\u2019s a six weeks window that should get jam.",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331351+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261402-evman27--3722274",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.757204",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It is closer than a few months that is for sure. For now we are rangebound. Those who have been here a long time have no fear of this new range and will happily accumulate from weak hands with the clear and obvious upside that awaits.",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331333+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261448-chrishut--7017727",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.756658",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A few have suggested there may well be something this week.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331315+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261907-Seancadm--2437692",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.756239",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "The real value of OptiMal will be recognised from the NIH/NCI validation, yes, in turn Pharma will no doubt adopt the OptiMal platform but the key to unlocking these deals is the NIH/NCI validation. The icing on the cake would be an academic publication from NCI which may well be ongoing right now. I have no doubt that Fusion have played a blinder in gaining validation from the NCI it unlocks doors with big Pharma that previously would have been firmly closed and without the validation could have taken years to even get the notoriously sceptical scientists to agree to a meeting. The NCI have in essence de-risked OptiMal. Of course Pharma will still want to do their diligence but the timeline will shorten, NCI validation may not in its own close deals but it certainly opens doors! With validation, Pharma will be thinking, \u2018if NCI scientists used this and didn\u2019t abandon it, it probably works, let\u2019s see if it works for us.\u2019 Updates on negotiations should be interesting.",
          "sentiment": 0.5,
          "engagement": "211",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331297+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262019-chrishut-46490018",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.755776",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Causeway sensors, we  collaborated on this\u2026 https://www.linkedin.com/posts/uk-cpi_biologics-medicinesmanufacturing-scaleup-activity-7416841720232828929-mHTE?utm_medium=ios_app&rcm=ACoAADOfeHYBV7khqaq9UgJwAiGuFrEAYOcW22U&utm_source=social_share_send&utm_campaign=copy_link",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331280+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261121-Rocka-45677150",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:27.755330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Bought some more in the last few days. News can\u2019t be far. Bring on 50p plus",
          "sentiment": 0.0,
          "engagement": "178",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331262+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261348-Cheapsha-74351929",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.417952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "All sideways atm Patience will reap the rewards",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331244+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261501-Bibzy7-68427821",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.417537",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "All this waiting about to become absolutely minted is getting boring now. Can we please sign a mega million pound deal so we can all get rich and live in a sweet beach condo please I'm not asking much",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.50",
          "thread_title": "Boring",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=92D7FE6A-9EFC-42F4-A10C-EDA81D40EAC4"
        },
        "ingested_at": "2026-01-22T21:37:31.331226+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261314-evman27--4312194",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.417120",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It is so quiet, a huge number of items we could here about. Calm before the storm? \ud83e\udd88 \ud83e\udd88",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.00",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331208+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261727-gtc1507--8738155",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.416687",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Let\u2019s hope so, we\u2019re right in the early execution phase now. They\u2019ve done all the hard yards on r&d and launch, now the prooof is in the pudding. We just need to see the execution and proof that optimal actually is an attractive proposition. Judging by Adrian\u2019s commentary at the investor meet company on the prelaunch feedback, we should be in for some good uptake.",
          "sentiment": 0.0,
          "engagement": "1,141",
          "price_at_post": "14.00",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331190+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261034-chrishut--7611820",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.416267",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "We must be close to news",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-22T21:37:31.331172+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261334-mmhater-46973143",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.415847",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "There is very few trades and haven\u2019t been for a week now. Shares are in sticky hands and only small trades going through. That being said it\u2019s hard to sell and likely this will go down if company corporate is soon. This share price is ridiculous. Come on Adrian\u2026. update us on something",
          "sentiment": 0.0,
          "engagement": "651",
          "price_at_post": "13.75",
          "thread_title": "Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.331153+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261411-Rocka--8300739",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.415429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019m surprised there has been no  news since the  start of 2026.",
          "sentiment": 0.0,
          "engagement": "178",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.331135+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261540-Sanibel-42550738",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.415009",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Patience is the key hear. The sp movements dont worry me at all Deals take time and big ones a bit longerits not going to hapen in days or weeks. GL Sani",
          "sentiment": 0.0,
          "engagement": "4,561",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.331115+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261546-mmhater-56003686",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.414586",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Looks like someone is selling again with \u00a340k of sells today.",
          "sentiment": 0.0,
          "engagement": "651",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.331077+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261601-cbeadle-65343098",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.414169",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "We could do with one. Clearly a big seller atm depressing the share price",
          "sentiment": 0.0,
          "engagement": "333",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.331059+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261621-Laura202-79994028",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.413749",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Biotechs doing well today GDR TRLS I'm sure FAB and others  will follow",
          "sentiment": 0.0,
          "engagement": "15,164",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.331042+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261757-Cheapsha-86154243",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.413331",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.331024+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261812-gtc1507-62588026",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.412907",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,141",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.331006+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261821-formerly--8856636",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.412488",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,636",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.330989+00:00"
      },
      {
        "event_id": "SOCIAL-Today0810-formerly-22495698",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.412069",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Purchased 10,000 at 13.3 via HL this morning. Wait and See!",
          "sentiment": 0.0,
          "engagement": "1,636",
          "price_at_post": "13.25",
          "thread_title": "Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-22T21:37:31.330970+00:00"
      },
      {
        "event_id": "SOCIAL-Today1100-stan1234-16095725",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.411649",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "I am going to add today too. Just selling something else first.",
          "sentiment": 0.0,
          "engagement": "208",
          "price_at_post": "13.25",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-22T21:37:31.330952+00:00"
      },
      {
        "event_id": "SOCIAL-Today1310-gtc1507-68907262",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.411238",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Seems to be kicking into action again, some decent buys today. Investor relations seem to be answering questions on the hub too. Looks like the shareholder information has been updated too as of a few days ago, no sign of maven any more\u2026.. https://www.fusionantibodies-ir.com/content/investors/shareholder-information.asp",
          "sentiment": 0.5,
          "engagement": "1,141",
          "price_at_post": "13.50",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-22T21:37:31.330935+00:00"
      },
      {
        "event_id": "SOCIAL-Today1330-Antha-21307112",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.410806",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "Everyone is just waiting for the NCI contract and other pharma contracts to be signed, until then the sp will just drift up and down between the 12-16p range, just need to be patient.",
          "sentiment": 0.0,
          "engagement": "2,739",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.330917+00:00"
      },
      {
        "event_id": "SOCIAL-Today1338-mmhater-68231656",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.410394",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I got fed up of being patient so bought another \u00a316000 worth\u2026 Come on Fusion\u2026 give us a update",
          "sentiment": 0.0,
          "engagement": "651",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-22T21:37:31.330900+00:00"
      },
      {
        "event_id": "SOCIAL-Today1405-mmhater-22562827",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.409969",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "My 2 8k trades aren\u2019t showing. been a rise in trades past couple of days and i think this is going to pop soon. News is imminent. NCI have said they want to use optimal immediately so won\u2019t hang around doing deals for long\u2026",
          "sentiment": 0.0,
          "engagement": "651",
          "price_at_post": "13.50",
          "thread_title": "Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-22T21:37:31.330882+00:00"
      },
      {
        "event_id": "SOCIAL-Today1415-evman27--6664583",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.409558",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Nice buys, what a bargain price!",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-22T21:37:31.330864+00:00"
      },
      {
        "event_id": "SOCIAL-Today1456-Rocka--2885690",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.409137",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019d put more in to if i had available funds, topped up last week. Expecting \u00a310k early Feb, hopefully i can buy at todays price once funds clear.",
          "sentiment": 0.0,
          "engagement": "178",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-22T21:37:31.330845+00:00"
      },
      {
        "event_id": "SOCIAL-Today1512-CHEATED--1697430",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.408712",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "There should be a link-up with a large American antibody firm. Perhaps a partnership would be beneficial. Share price is in the doldrums and needs a boost of some kind. I cannot see the advantage  of the last addition of staff producing anything of great significance. Too many cooks spoil the broth. Try something new.",
          "sentiment": 0.0,
          "engagement": "678",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-22T21:37:31.330827+00:00"
      },
      {
        "event_id": "SOCIAL-Today1637-Darkryde--6995542",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.408289",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocks, I hope and think you\u2019ll only get 16,000 shares with your \u00a310k \ud83d\ude0a",
          "sentiment": 0.5,
          "engagement": "548",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-22T21:37:31.330808+00:00"
      },
      {
        "event_id": "SOCIAL-Today1641-Rocka--2935283",
        "event_type": "social_post",
        "date": "2026-01-22T21:37:24.407844",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Well if it goes that high that quick i\u2019ll be equally happy as i hold quite a few already",
          "sentiment": 0.0,
          "engagement": "178",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-22T21:37:31.330785+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250851-cbeadle-71702228",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.964001",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "At this price FAB at risk of a takeover offer lower than it should be reflective of Optimal technology",
          "sentiment": 0.0,
          "engagement": "330",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.983145+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250852-Cheapsha-19152685",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.963312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "And the Optimal revenue in 2026 should far exceed the revenue forecast from other businesses We are in for an outstanding 2026!",
          "sentiment": 0.5,
          "engagement": "2,669",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.983126+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250903-Laura202-28668560",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.962650",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks CSB Are you able to answer my question please ?, holders such as Troutisout1 were one of the top few shareholders if I recall Do you what their thoughts are on the recent  RNS (s).please M Tia",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.983089+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250908-Humpalum--1298887",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.961826",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Laura - we don't care that you and Trout hate eachother",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.983071+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250910-Laura202-73239241",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.961036",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "I dont hate anyone :) Always just wondered why he spent 95% of 2025 on another share Have a great Christmas",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.983052+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250913-chrishut-81101542",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.960230",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Trout please do Laura the same courtesy on Laura\u2019s board.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.983015+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250915-Laura202--2096568",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.959438",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Chris Have a wonderful Christmas Over on the other board we've had almost constant disruption for 12mths by Trout so your sentiments.are appreciated",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.982980+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250919-chrishut-15638435",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.958632",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "You too. Have a great Christmas and new year.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.982940+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250919-bobbust-35238659",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.957845",
        "source": "LSE_CHAT",
        "data": {
          "author": "bobbust",
          "content": "What is considered a large holding?",
          "sentiment": 0.0,
          "engagement": "2,471",
          "price_at_post": "13.00",
          "thread_title": "What is a large holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C25596D7-8D1E-42D9-8B1D-3CEA3B28C126"
        },
        "ingested_at": "2026-01-21T22:00:23.982905+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250920-Laura202-15821693",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.957035",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "2026 it is !! Continued wealth and happiness",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T22:00:23.982871+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250947-Troutiso-16772077",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.956261",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The former Jamaican cricketer Michael was quite large.",
          "sentiment": 0.0,
          "engagement": "1,560",
          "price_at_post": "13.00",
          "thread_title": "RE: What is a large holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C25596D7-8D1E-42D9-8B1D-3CEA3B28C126"
        },
        "ingested_at": "2026-01-21T22:00:23.982835+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251345-mmhater--7945148",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.955470",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Well we are up on the day of 10 trades\u2026. Would love to see a rns in morning stating the company has been contacted regarding negotiating purchasing the company\u2026. Would be worth holding some just for that day\u2026. Would send this to 50p in a second.",
          "sentiment": 0.0,
          "engagement": "649",
          "price_at_post": "13.25",
          "thread_title": "Tick up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AF234FD5-D2EB-4738-B574-721BE0F0056F"
        },
        "ingested_at": "2026-01-21T22:00:23.982800+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251534-druml-30218561",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.954872",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Living in lala land On the Christmas sauce too early !!",
          "sentiment": 0.0,
          "engagement": "23",
          "price_at_post": "13.75",
          "thread_title": "RE: Tick up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AF234FD5-D2EB-4738-B574-721BE0F0056F"
        },
        "ingested_at": "2026-01-21T22:00:23.982764+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251801-Stan36-21053447",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.954426",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "The support level seems a bit higher now: 13p to 14p rather than 12p. A measure of the new private investors on board minus the traders who sold down from recent 19p rise. I guess we're in a closed period as directors have inside information re the NCI deal, so no Director dealings. Looking forward to New Year when this will explode \ud83d\udca5 Thanks you for the stimulating debate and banter. Merry Christmas to all and good luck with your holdings.",
          "sentiment": 0.5,
          "engagement": "840",
          "price_at_post": "13.75",
          "thread_title": "RE: Tick up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AF234FD5-D2EB-4738-B574-721BE0F0056F"
        },
        "ingested_at": "2026-01-21T22:00:23.982731+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251826-gtc1507--7423172",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.953969",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Merry Christmas one and all!",
          "sentiment": 0.5,
          "engagement": "1,140",
          "price_at_post": "13.75",
          "thread_title": "RE: Tick up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AF234FD5-D2EB-4738-B574-721BE0F0056F"
        },
        "ingested_at": "2026-01-21T22:00:23.982695+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251907-bannside-64647795",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.953546",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "Merry Xmas mate",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "13.75",
          "thread_title": "RE: Tick up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AF234FD5-D2EB-4738-B574-721BE0F0056F"
        },
        "ingested_at": "2026-01-21T22:00:23.982661+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250044-chrishut-60517342",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.953061",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Let\u2019s lock the rampers out and see this boom",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "13.75",
          "thread_title": "Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982626+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250827-Gheko--4368363",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.952570",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Wonder if we feature in any new year tips in the media etc. should do for what is set up for a FAB year ahead. Happy Christmas all. Dreams of wealth but more importantly health and happiness.",
          "sentiment": 0.5,
          "engagement": "1,205",
          "price_at_post": "13.75",
          "thread_title": "New year tips",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=E2779072-C2BA-47ED-AB10-D65786ABE5B8"
        },
        "ingested_at": "2026-01-21T22:00:23.982605+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250840-chrishut--6224268",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.952093",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Morning",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "13.75",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982567+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250924-chrishut-79497238",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.951678",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I see we got a bit of free advertising in the fmi newsletter",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "13.75",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982531+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251003-bannside--7278214",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.951255",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "What it say",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "13.75",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982495+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251017-Rocka--8754229",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.950810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Rising nicely\ud83d\ude80\ud83d\ude80\ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "13.75",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982455+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251018-Rocka-74763641",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.950383",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "\ud83d\ude80\ud83d\ude80\ud83d\ude80here we go",
          "sentiment": 0.5,
          "engagement": "176",
          "price_at_post": "13.75",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982418+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251039-livinhop-71188217",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.949857",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Rocka, my screen is showing unchanged? Happy Christmas all and here\u2019s to a fantastic 2026.",
          "sentiment": 0.0,
          "engagement": "1,094",
          "price_at_post": "14.00",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982380+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251040-livinhop--4984433",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:23.949320",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Ha! Just moved to 13.50 on the Bid",
          "sentiment": 0.0,
          "engagement": "1,094",
          "price_at_post": "14.00",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982343+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251042-livinhop--5430386",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.134311",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Now we are moving \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "1,094",
          "price_at_post": "14.25",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982306+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251043-Rocka-42805584",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.133874",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "It will close blue, happy xmas and 2026 will  transformational.",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "13.75",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982271+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251044-Rocka--2419121",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.133455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Yep 14p to sell now.  I suspect it will rise further as wr approach close of play at 12:30",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "13.75",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982235+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251103-Rocka-84031831",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.133023",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "15p ask now!!",
          "sentiment": 0.5,
          "engagement": "176",
          "price_at_post": "14.25",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982200+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251123-Rocka--2212174",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.132605",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Wakey wakey peeps 15/15.5tight spread",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "15.25",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982164+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251124-Rocka--1930497",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.132164",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Can we hit 20\ud83d\ude80\ud83d\ude80\ud83d\ude80\ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "15.50",
          "thread_title": "16p now",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CDC06174-5EDA-473D-965E-9290AE873EEC"
        },
        "ingested_at": "2026-01-21T22:00:23.982129+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251133-Stan36--7208054",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.131723",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Maybe a leak - news of an approach? There was a very big buy earlier 134k shares above the ask at 0810 late reported",
          "sentiment": 0.5,
          "engagement": "840",
          "price_at_post": "15.50",
          "thread_title": "RE: 16p now",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CDC06174-5EDA-473D-965E-9290AE873EEC"
        },
        "ingested_at": "2026-01-21T22:00:23.982081+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251139-Rocka--5812290",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.131251",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Has to be as there has been no rns hopefully news out soon",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "15.50",
          "thread_title": "RE: 16p now",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CDC06174-5EDA-473D-965E-9290AE873EEC"
        },
        "ingested_at": "2026-01-21T22:00:23.982048+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251152-chrishut--2488010",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.130508",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This will fly soon enough",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "15.00",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.982013+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251204-Surfie19--3109270",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.129766",
        "source": "LSE_CHAT",
        "data": {
          "author": "Surfie1961",
          "content": "noooooo.... let's not start with there's been a leak *******s.",
          "sentiment": 0.0,
          "engagement": "2,051",
          "price_at_post": "15.00",
          "thread_title": "RE: 16p now",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CDC06174-5EDA-473D-965E-9290AE873EEC"
        },
        "ingested_at": "2026-01-21T22:00:23.981977+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251211-Alice-Wr-56467715",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.129027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alice-Wright",
          "content": "Tempted.",
          "sentiment": 0.0,
          "engagement": "120",
          "price_at_post": "15.00",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.981959+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250719-gtc1507-36038615",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.128322",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Let\u2019s hope so. The significance of the NCI rns will eventually set in. The fact they\u2019ve said that it\u2019s the scale of the proposal means that the deal to me is bigger than we are expecting. Very exciting times",
          "sentiment": 0.0,
          "engagement": "1,140",
          "price_at_post": "14.25",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.981940+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250758-Jollifan-77722991",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.127603",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jollifant",
          "content": "But the NCI deal is months away. They will need to announce new contracts to stop the sp drifting down.",
          "sentiment": 0.0,
          "engagement": "2,394",
          "price_at_post": "14.25",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.981913+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250808-mmhater-68343496",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.126871",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "From the last rns\u2026\u2026 The immediate needs of NCI are to support current and imminent screening projects using OptiMAL\u00ae. Immediate needs so i think things will move quickly\u2026",
          "sentiment": 0.0,
          "engagement": "649",
          "price_at_post": "14.25",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.981886+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250833-Troutiso-50324837",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.126154",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I think the NCI deal might be brokered in layers the biggest needing a future sign off from NIH. The fact they want to use it now, may result in an interim payment for FAB, before a bigger over-arching contract is signed with the NIH. Personally think any drops will get hoovered up and that we have lost a lot of the short term traders from the books for the moment. I am very excited for what is to come and believe we will hear of initial OptiMAL contracts soon, their value will be small to start but in relation to FAB's current revenues they will make a big difference!",
          "sentiment": 0.0,
          "engagement": "1,560",
          "price_at_post": "13.75",
          "thread_title": "RE: Best stock for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2B04A1A6-A3A6-49EC-B175-700FAA76F148"
        },
        "ingested_at": "2026-01-21T22:00:23.981861+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250929-Rocka-18771156",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.125428",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Topped up this morning. It\u2019s only a matter of time before this explodes. \ud83d\ude80\ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.25",
          "thread_title": "Topped up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=47A581BC-214D-4B31-804B-498F0C40DA20"
        },
        "ingested_at": "2026-01-21T22:00:23.981822+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251022-gtc1507-63898493",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.124713",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nona Biosciences\u2019 licensing deals illustrate how platform value can translate into material commercial outcomes: \u2022 In November 2025, Nona entered a non-exclusive strategic collaboration with Pfizer for its antibody discovery platform, designed to accelerate preclinical discovery with upfront fees, milestone payments, and potential royalties.  \ufffc \u2022 Earlier, Nona agreed a licensing arrangement with AstraZeneca worth up to $19m upfront, plus near-term milestones and up to $575m in further payments on development and commercial success.  \ufffc \u2022 In a separate deal, a global agreement with Pfizer (MSLN-targeted ADC) includes up to $53m upfront/near-term and up to $1.05bn in milestones plus royalties, showcasing how platform-driven antibody discovery rights can command significant value.  \ufffc Takeaway: These licensing / platform deals tend to be structured around upfront, milestone and royalties \u2014 and often assign hundreds of millions to low-billions of dollars of optionality. Fusion\u2019s OptiMAL\u00ae platform has the potential to command similar structures as it gains commercial traction beyond core services.",
          "sentiment": 0.5,
          "engagement": "1,140",
          "price_at_post": "14.50",
          "thread_title": "Optimal platform could unlock multimillion \u00a3/$ discovery deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=090390A9-3719-411D-A203-E48B1F4D89F3"
        },
        "ingested_at": "2026-01-21T22:00:23.981786+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251048-Seancadm--3789959",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.123949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "The collaboration with NCI matters a lot more than it first seems. This is not a routine CRO engagement. From a scientific credibility standpoint: NCI - Gold standard validation partner. Independent replication partner Meaning- NCIs researchers repeat a study performed by Fusion to see if they get the same results (which they have) which is crucial for scientific validity and future publications verifying the findings. The collaboration with NCI provides a non-commercial incentive structure. All of the above make any future publication or PATENT high impact for platform credibility.",
          "sentiment": 0.5,
          "engagement": "211",
          "price_at_post": "14.50",
          "thread_title": "This collaboration matters more than it looks.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=049EEE16-54E1-4AA4-9544-1A5496C0AF70"
        },
        "ingested_at": "2026-01-21T22:00:23.981756+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251934-Bibzy7-43751855",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.123182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "In last week's presentation Adrian almost laughed at the 100 mil question absolutely no chance they are doing all that work for a cheap sale",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.25",
          "thread_title": "RE: Optimal platform could unlock multimillion \u00a3/$ discovery deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=090390A9-3719-411D-A203-E48B1F4D89F3"
        },
        "ingested_at": "2026-01-21T22:00:23.981725+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20252359-stan1234--6702434",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.122461",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "This is the year the real move higher, happens, the board have implied that big moves in the business pipeline will happen.",
          "sentiment": 0.0,
          "engagement": "207",
          "price_at_post": "14.25",
          "thread_title": "This will be 30 to 50p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=71260EE8-8804-4482-B16A-4D69B3C416EC"
        },
        "ingested_at": "2026-01-21T22:00:23.981693+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20250009-Alice-Wr-14980298",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.121749",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alice-Wright",
          "content": "At most this will be 50p a share. Can\u2019t see more than that",
          "sentiment": 0.0,
          "engagement": "120",
          "price_at_post": "14.25",
          "thread_title": "RE: Optimal platform could unlock multimillion \u00a3/$ discovery deals",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=090390A9-3719-411D-A203-E48B1F4D89F3"
        },
        "ingested_at": "2026-01-21T22:00:23.981662+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20250841-Darkryde--8402085",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.121031",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "4p to 50p ! That's quite the gain Alice !",
          "sentiment": 0.0,
          "engagement": "547",
          "price_at_post": "14.25",
          "thread_title": "RE: This will be 30 to 50p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=71260EE8-8804-4482-B16A-4D69B3C416EC"
        },
        "ingested_at": "2026-01-21T22:00:23.981630+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251031-chrishut--8082540",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.120331",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Hopefully, we will  see some of the pipeline converting to contracts,  soon.",
          "sentiment": 0.5,
          "engagement": "17,379",
          "price_at_post": "14.25",
          "thread_title": "Blue month ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=30B64848-46D2-4321-8A28-CF0DB6CD01A0"
        },
        "ingested_at": "2026-01-21T22:00:23.981599+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251624-Laura202-82155495",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.119604",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "HNY Chris Sadly your plea to posters here fell on deaf ears for disruption elsewhere Such a shame that we cant all share the same moral compass Best wishes to you and your investments",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "14.25",
          "thread_title": "RE: Blue month ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=30B64848-46D2-4321-8A28-CF0DB6CD01A0"
        },
        "ingested_at": "2026-01-21T22:00:23.981567+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251006-gtc1507-75974141",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:21.118831",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Wouldn\u2019t it be lovely if we could all just be friendly and support with support or constructive challenges on our investment choices. Hopefully a nicer 2026",
          "sentiment": 0.0,
          "engagement": "1,140",
          "price_at_post": "14.25",
          "thread_title": "RE: Blue month ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=30B64848-46D2-4321-8A28-CF0DB6CD01A0"
        },
        "ingested_at": "2026-01-21T22:00:23.981536+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251007-chrishut--5260659",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.683093",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "And to you! Hopefully a very prosperous one ahead for us all.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.25",
          "thread_title": "RE: Blue month ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=30B64848-46D2-4321-8A28-CF0DB6CD01A0"
        },
        "ingested_at": "2026-01-21T22:00:23.981505+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251034-Laura202--5685595",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.682324",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Thanks ChrisHutch You enjoy",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "14.25",
          "thread_title": "RE: Blue month ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=30B64848-46D2-4321-8A28-CF0DB6CD01A0"
        },
        "ingested_at": "2026-01-21T22:00:23.981474+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260931-evman27-75908155",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.681636",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Happy new year to you all. 2026 is setting up to be the year of 'step changes' for Fusion. I'm looking forward to contracts pouring in for Optimal now it has been released, especially the NCI contract which is currently under approval from NIH, big time if you ask me! The company has been giving out quotes for many months now and these should start to materialise. A few quotes from Adrian at the last presentation the market may have missed. \u201cWe are now market leader, Optimal is best and first in class at what it does\u201d \u201cFusions platform is the best as evidenced by the data in this launch presentation\u201d \u201cIf that means we become more visible, I think it will and therefore more noticed by those considering acquiring companies like ours, well then so be it\u201d We are seriously undervalued and a serious target for acquisition, holding these shares is a bit like holding gold! DYOR GLA",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.00",
          "thread_title": "On the cusp of something big",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=71D37127-47EB-44B6-8388-D9DE3903E563"
        },
        "ingested_at": "2026-01-21T22:00:23.981442+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260937-chrishut-60079429",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.680976",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "100% agree, but sit back and make money, what could be easier",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.00",
          "thread_title": "RE: On the cusp of something big",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=71D37127-47EB-44B6-8388-D9DE3903E563"
        },
        "ingested_at": "2026-01-21T22:00:23.981410+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20260941-gtc1507-34962312",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.680549",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Also remember just landed 2 new hires and recruiting 2 more, the underlying business clearly strengthening as they\u2019re disciplined in cost control. The company is primed to continue its organic recovery plus what surprises might be in store with optimal or optiphage. I\u2019m excited for January to kick off.",
          "sentiment": 0.5,
          "engagement": "1,140",
          "price_at_post": "14.00",
          "thread_title": "RE: On the cusp of something big",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=71D37127-47EB-44B6-8388-D9DE3903E563"
        },
        "ingested_at": "2026-01-21T22:00:23.981379+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261140-chrishut--5459722",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.679802",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Got some more",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "13.75",
          "thread_title": "RE: On the cusp of something big",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=71D37127-47EB-44B6-8388-D9DE3903E563"
        },
        "ingested_at": "2026-01-21T22:00:23.981347+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261151-Rocka--4452198",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.679336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I noticed vik has stopped posting here , is he still in?",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "13.75",
          "thread_title": "RE: On the cusp of something big",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=71D37127-47EB-44B6-8388-D9DE3903E563"
        },
        "ingested_at": "2026-01-21T22:00:23.981315+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261625-VikR-77642100",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.678851",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "After a massive eventful year in 2025 this has now paved the way for a baseline to the upside. I neutralised my profits by buying higher up on the last run end of Q4 2025  but it bothers me not as I hold out for the long term. As and when I am ready to make some more sizeable buys I will keep you all updated. In the interim make no mistake when Dr Kinkaid drops the conclusion of the NCI sign off it will be a huge stepping stone. The tech is too good for NCI to walk away and the good thing there is no one else for them to approach Stay resolute, ignore the noise and watch the re rate unfold over the coming period.",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "14.00",
          "thread_title": "2026 is the year of delivery",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D9CEEF08-772B-4611-ACBA-030106F711B9"
        },
        "ingested_at": "2026-01-21T22:00:23.981284+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261835-Cheapsha-44609437",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.678426",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "I 100% with your sentiment Vic All the best to all FAB investors in 2026. This is our year",
          "sentiment": 0.5,
          "engagement": "2,669",
          "price_at_post": "13.50",
          "thread_title": "RE: 2026 is the year of delivery",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D9CEEF08-772B-4611-ACBA-030106F711B9"
        },
        "ingested_at": "2026-01-21T22:00:23.981253+00:00"
      },
      {
        "event_id": "SOCIAL-4Jan20262216-stt1-24780757",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.677968",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "GTC, \"Also remember just landed 2 new hires and recruiting 2 more, the underlying business clearly strengthening as they\u2019re disciplined in cost control. \" Those hires came out of the grant they received didn't they? It's nothing to do with their cash balance and cost control. That grant is limited. Unless they sign contracts they will need a placing.",
          "sentiment": 0.0,
          "engagement": "4,515",
          "price_at_post": "13.50",
          "thread_title": "RE: On the cusp of something big",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=71D37127-47EB-44B6-8388-D9DE3903E563"
        },
        "ingested_at": "2026-01-21T22:00:23.981221+00:00"
      },
      {
        "event_id": "SOCIAL-4Jan20262222-stt1-70190779",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.677501",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "VikR \"After a massive eventful year in 2025 this has now paved the way for a baseline to the upside.\" The shares were pumped and have now retreated back to around 12p-13p as I predicted they would. I traded these multiple times during 2025 and gained a profit by not listening to the pump/dump gang. The current sp of 13p doesn't mean there is a new baseline as that depends on cash, placing and contracts.  Contracts are NOT guaranteed. Cash would be declining. Placing is likely over coming months unless they gain contracts soon. Rampers were saying contract will be signed in December when the company had their demo. What happened?? As per my assertion, IF contracts are signed, it could take months. The company had only \u00a3250k as of Sept. That's not much cash to last them for this year. I expect a placing over the coming months.",
          "sentiment": 0.0,
          "engagement": "4,515",
          "price_at_post": "13.50",
          "thread_title": "RE: 2026 is the year of delivery",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D9CEEF08-772B-4611-ACBA-030106F711B9"
        },
        "ingested_at": "2026-01-21T22:00:23.981188+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260738-Bigjock3--2696465",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.676905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bigjock36",
          "content": "STT1 you have failed to mention a very significant part of the cash flow equation. Aged debtors at the snapshot in time you mentioned were also \u00a3541k. This bolsters cash flow significantly! Here\u2019s the thing\u2026. That aged debtor figure is a SNAPSHOT. We can also assume they will have further debtors from that moment in time. Albeit costs will also be incurred, I feel safe in the knowledge that the Directors have a handle on the cash element of the business. Furthermore, you continuously slander the company yet you have just confirmed trading multiple times on the share. For myself sitting watching your continued drivel, you are nothing more than a hot air sadistic man who hopes the SP will drop on a few sells to buy back in as you know ultimately the businesses will be back above 20p+ long term.",
          "sentiment": 0.5,
          "engagement": "968",
          "price_at_post": "13.50",
          "thread_title": "RE: 2026 is the year of delivery",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D9CEEF08-772B-4611-ACBA-030106F711B9"
        },
        "ingested_at": "2026-01-21T22:00:23.980973+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260921-chrishut-73696763",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.676438",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "We will start to see the fruits of last years work come to harvest soon.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.00",
          "thread_title": "Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980954+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260951-gtc1507-57928941",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.675983",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Let\u2019s hope so Chris! Lots of exciting stuff going on before the Christmas break, hopefully not long until some converts into orders",
          "sentiment": 0.5,
          "engagement": "1,140",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980936+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261010-Bibzy7-10893637",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.675557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Big contacts take time they ant giving this away for free",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980917+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261035-Rocka--6061514",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.675121",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Massive \u00a320k buy showing as unknown",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980899+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261044-evman27-53874709",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.674434",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Another \u00a310k buy too! Smart money loading up, we have also had a \u00a35k buyer most days for a few weeks too.",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980880+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261046-Rocka-88350712",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.673670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "It would be nice if we can stabilise at high teens /20p pre news then i think we can easily hit 40p thos month or next depending on news",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980860+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261049-evman27-66264431",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.672911",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "510k shares is 20p in IG, these shares will go like lightening on a good RNS. Lots of sticky hands here, tight float, the setup is fantastic when news arrives.",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980841+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261240-Stan36-26656635",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.672166",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Nice to see this buying ahead of news about Optimal contracts & NCI. Risen 11% today to 15p & looking good.",
          "sentiment": 0.5,
          "engagement": "840",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980822+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261240-Rocka--8092351",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.671410",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ask 15.5p\ud83d\ude80\ud83d\ude80\ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980804+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261253-evman27-55348600",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.670659",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "She moves quick eh!",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980786+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261349-chrishut--7038901",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.669880",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Long way up to go yet",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980768+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261629-Bibzy7--4603650",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.669133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "100% correct",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.50",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T22:00:23.980748+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260721-gtc1507-64928926",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:15.668647",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://ascopost.com/news/october-2025/nci-issues-request-for-2027-budget/ NCI seeking an additional $4bn budget next yea. Maybe the purse strings are going to be loosened hence the \u201cscale of the proposal\u201d of the fab deal requiring NIH Approval. Exciting times, can\u2019t wait to see what they\u2019ve negotiated.",
          "sentiment": 0.5,
          "engagement": "1,140",
          "price_at_post": "14.50",
          "thread_title": "NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T22:00:23.980714+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260839-Gheko--4681912",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.626839",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Great find Gtc. We have the best in class platform  which is therefore hugely valuable not only to NCI but to big pharma sand smaller pharma alike. We know the size of deals in this industry\u2026.HUGE! So not only do I think the NCI will need/want a big deal with FAB but other pharmas will be circling. News anytime and no wonder the price is starting to creep up. The upside is mouthwatering. Good luck all.",
          "sentiment": 0.5,
          "engagement": "1,205",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T22:00:23.980695+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260840-Stan36-38517366",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.626116",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Anticipation building. Only \u00a325,000 buys shifts the price up 1%. MMs short of stock, tightly held. Nice steady rise.",
          "sentiment": 0.5,
          "engagement": "840",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T22:00:23.980677+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260843-gtc1507--2399816",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.625419",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Especially when the new NCI director is also coming out and telling staff to fund gold standard cancer research. Optimal is best in class, first in classs according to fusion,  can\u2019t get more gold standard than that\u2026. https://x.com/thenci/status/1991594881232367638?s=46",
          "sentiment": 0.0,
          "engagement": "1,140",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T22:00:23.980658+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20260843-evman27--5823699",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.624679",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes, this steady new year creep up bodes seriously well for holders. Whatever is going on in the background is seriously exciting. \ud83e\udd88",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "15.50",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T22:00:23.980639+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261207-cbeadle--5928706",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.623922",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right RNS FAB has the feel of a company whose share price could \ud83d\udca5 explode upwards. It\u2019s happened already with quite a few small pharma or biomedical companies in the past 12 months",
          "sentiment": 0.0,
          "engagement": "330",
          "price_at_post": "15.00",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T22:00:23.980620+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261354-gtc1507--8787742",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.623217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Sorts of deals that Optimal could garner for Fusion maybe?? https://www.linkedin.com/posts/chabs-%E5%8D%8E%E4%BA%BA%E6%8A%97%E4%BD%93%E5%8D%8F%E4%BC%9A_earendil-labs-announces-strategic-collaboration-activity-7414297394865078272-X430?utm_source=share&utm_medium=member_ios&rcm=ACoAAAuyH_0BZuiiVe69ogYIdwe7HKyUbPvkmaA",
          "sentiment": 0.0,
          "engagement": "1,140",
          "price_at_post": "15.00",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T22:00:23.980593+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261554-NornIron--3386254",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.622480",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Hi folks I'm a relatively new investor here with FAB, but a lot of the research I done before investing was based on information, links, reports, etc, that some of you posted on here.  These gave me a starting point to do my own research. This post is just a thank you to you folks  who took the time to do this.  There certainly are some knowledgeable  posters on this page.  I'm including the rampers and derampers with my thanks too. You know who you are, lol, and your posts are also interesting  and informative for various reasons. Thanks for all your inputs and hopefully i can contribute to the posts in future here too.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "15.00",
          "thread_title": "Thanks folks !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=6655E900-946E-4D59-A610-FD833DD50AEB"
        },
        "ingested_at": "2026-01-21T22:00:23.980557+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261002-evman27--4969026",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.621740",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Fusion Antibodies presents at the Proactive One2One Investor Conference - January 11th 2024 https://www.youtube.com/watch?v=IAvbf90GgvQ I recommend everyone watches at least the Q&A of this one! A very jovial, excited and up beat Adrian at this presentation, this was a few months after the initial deal with the NCI was signed a few years ago. A gold mine of great quotes from Adrian I will share, \u201cNCI is a surrogate for big pharma, I\u2019d much rather do the first deal with NCI, when I might have to compromise things, rather than sell it cheaply to a blue chip\u201d \u201cWe approached NCI for sentiment around mammalian display on a scientist to scientist basis. We went directly to Dr Mitchell Ho saying what\u2019s the best way to do such and such, would you like to have a look at our technology. He liked it so much he didn\u2019t buy the company yet, we set up the agreement from his pulling it through, we may have positioned it to do that\u201d \u201cNo one has a platform like Optimal as far as I\u2019m concerned. I think that\u2019s one of the reasons why they really wanted us to come in\u201d \u201cThe NCI are taking it seriously, lots of people are going hang on this is worth another look, how far have they got. We went to the antibody engineering and therapeutics conference before Christmas 2023 in San Diego and came away with some very significant enquiries around that, it\u2019s really made people sit up\u201d \u201cI know antibodies are worth a lot of money so there is an example recently, Novartis bought a company called Calipso to get hold of one antibody called Cali002, $425m in order to do so, what you may not have known is we humanised that antibody\u201d \u201cWe certainly do not rule out such a big licensing deal, I think it\u2019s probably more likely and certainly looking at today\u2019s MCAP that a big pharma rather than licensing it for the amount it would be worth would just come in and buy us\u201d Follow up question to this, I can\u2019t understand why the valuation is probably less than kit in your laboratory plus the potential value of optimal already \u201cNope it confused me as well but that\u2019s one of the reasons why I work there, one of the reasons why I work for shares and it\u2019s one of the reasons why I bought shares\u201d GOLD. I haven\u2019t seen Adrian so bullish since the most recent presentation, you can watch that here, the Q&A at the end is particularly telling. https://investorhub.fusionantibodies.com/webinars/mPqXOr-optimal-r-launch-investor-q-a Compare both presentations, see where we are today and ask yourself, why am I not holding? Dyor",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.50",
          "thread_title": "Therapeutic Gold",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=8DB6EAD5-BA9B-4341-80E8-DEEA2E954E69"
        },
        "ingested_at": "2026-01-21T22:00:23.980522+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261023-chrishut-73343616",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.620862",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Managed 2 x 50k Thank you whoever wet the bed",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "I took some more",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BC2ABA98-B9D3-4F64-9839-C296923DF67A"
        },
        "ingested_at": "2026-01-21T22:00:23.980489+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20262046-gtc1507--5535361",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.620153",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a great post Evman. Thanks for reminding us of this. Much of the sentiment true even more so today",
          "sentiment": 0.0,
          "engagement": "1,140",
          "price_at_post": "14.50",
          "thread_title": "RE: Therapeutic Gold",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=8DB6EAD5-BA9B-4341-80E8-DEEA2E954E69"
        },
        "ingested_at": "2026-01-21T22:00:23.980457+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20262319-mmhater-32965306",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.619435",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Really enjoyed the banter the last couple of days\u2026 Hopefully STi will be about soon to tell us how the company is doomed and a dilution is imminent .",
          "sentiment": 0.0,
          "engagement": "649",
          "price_at_post": "15.00",
          "thread_title": "Banter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=3FD758A3-949D-40D2-9A70-A38BA90787BF"
        },
        "ingested_at": "2026-01-21T22:00:23.980425+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261920-Seancadm-34727085",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.618707",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "\u201c Negotiations regarding the expanded proposed programme are expected to continue into early 2026. Due to the scale of the proposal, formal approval processes at the US National Institutes of Health (of which the NCl is part) are likely to take several further months to complete. While discussions are progressing, there is no assurance that an extension to the Agreement will be reached, nor as to the timing or final terms of such an extension.\u201d The above extract from Fusions RNS regarding the NCI extension is very telling of how big this deal may be. The National institutes of health are only brought in to oversee deals that are greater than NCIs range, Fusions even stated in the RNS \u201cdue to the scale of the proposal\u201d. The proposal is large enough that it cannot be approved solely at NCI level.",
          "sentiment": 0.5,
          "engagement": "211",
          "price_at_post": "15.00",
          "thread_title": "NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T22:00:23.980392+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20262000-mariusz--8055073",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.617951",
        "source": "LSE_CHAT",
        "data": {
          "author": "mariusz",
          "content": "Currently at \u00a317m mcap\ud83e\udd2b",
          "sentiment": 0.0,
          "engagement": "356",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T22:00:23.980360+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20262127-gtc1507-21765037",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.617236",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Bargain basement right, question is who will realise first, retail herd, PIs, institutions or a competitor cro or potential client that wants to snap them up.",
          "sentiment": 0.0,
          "engagement": "1,140",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T22:00:23.980329+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260948-Cheapsha--1326040",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.616509",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Waiting game! NCI news shoud be big enough in it's own right plus we hopefully have some other new cotracts singed shortly!",
          "sentiment": 0.5,
          "engagement": "2,669",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T22:00:23.980296+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261106-Stan36--3680141",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.615793",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Well I suppose there could also have been an approach to buy the business following the Optimal launch? The BOD are not obliged to RNS if this is confidential and ongoing and offer terms not clarified. E.g. informal approach: a company asks to enter into discussions about terms. GPT>> So what\u2019s the practical answer for FAB? \u2705 If FAB gets a quiet, informal approach and: it\u2019s confidential, there\u2019s no rumour, no unusual share price movement, and it\u2019s not yet inside information, \u27a1\ufe0f they are not obliged to put out an RNS. \u2757 But if any of the following occur: press/market chatter (\u201cFAB in talks\u201d), price/volume spikes that look \u201coffer related\u201d, confidentiality slips (more outsiders brought in), the approach becomes concrete enough to be inside info, \u27a1\ufe0f then yes \u2014 they\u2019d be pushed into an RNS (either because of UK MAR inside info disclosure or because the Takeover Panel requires a Rule 2 announcement).",
          "sentiment": 0.5,
          "engagement": "840",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T22:00:23.980264+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261114-Bibzy7-74614742",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.614953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Just for talking sakes nci offer contract off 200 mil over nxt 4 years what does that do to the share price as it stands atm",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "15.00",
          "thread_title": "200 million",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=E421AF3B-BB86-44E4-89DC-E043088744F1"
        },
        "ingested_at": "2026-01-21T22:00:23.980232+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261236-Stan36--2986816",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.614260",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Well just for the sake of fantasy figures & if you mean $50m/year for 4 years I'd go for a range of \u00a33-\u00a35 assuming the margin would be very high. No great additional overheads. That's an Mcap of \u00a3300m -\u00a3500m",
          "sentiment": 0.0,
          "engagement": "840",
          "price_at_post": "15.00",
          "thread_title": "RE: 200 million",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=E421AF3B-BB86-44E4-89DC-E043088744F1"
        },
        "ingested_at": "2026-01-21T22:00:23.980200+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261351-NornIron-38466974",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.613520",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I'm just thinking out loud here and coming from a different angle. Here's my thoughts :- - With NCI having the clout they have, Fusion needed them onboard using OptiMAL -  They got it 2 years ago when NCI starting using OptiMAL (November 2023). - They then needed NCI's seal of approval that OptiMAL does what it says on the tin - They got it when Optimal said they wanted to continue using it in late 2025 and negotiations  started with Fab for it's continued use. This approval from NCI now gives Fab and their OptiMAL product greater kudos, when having commercial conversations with other potential buyers of the product and licences  (or maybe even the company). As i see it, Fab have 2 potential buyers of the product / company / licences, these being NCI and big pharmas. Questions If Fab are selling to NCI, will they feel     'we need to look after these guys. They've gave us our product validation, we need to have gratitude for this, and to get a contract with them is additional kudos in the marketplace with other buyers' . . . and therefore do a financial deal that isn't as high as it could be ? Alternatively If Fab are selling to a big pharma (with the deep pockets they have), would it be better financially for us shareholders to sell to them, and let them negotiate with NCI on what NCI pay for it, if indeed they even let NCI have the product.  Big pharma won't have the same what could be regarded as moral obligation to give NCI favourable terms and could see this as an earner for them if they had full product control. You might say, and you could be right, that we need an NCI deal for validation of the product before selling to a big pharma.  The other argument is that we already have their validation with there desire for it's continued use. Could this discussion and waiting period that we 'see' with NCI negotiations be a board tactic in dangling the OptiMAL bait in front of a big pharma angler to take this before NCI take it ? To summarize my thoughts.   Does Fusion Antibodies want a deal with NCI  ?   . . . . My answer is,  I've absolutely no idea whatsoever if they do or not. Is it best to do a deal first with NCI before a deal with a big pharma ? . . . .  Same answer,  I've absolutely no idea if it is or not. Is this an exciting place to be as an investor at the minute with where this might go in the coming weeks / months ? YES, YES, YES is my answer to that. Good luck all.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "14.625",
          "thread_title": "Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-21T22:00:23.980168+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261618-Troutiso--8410388",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.612677",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Your suggestions assume some sort of exclusivity, with OptiMAL and Library that need not be the case. NCI can licence it for their work and several large Pharms can do so alongside that. The deals will be in terms of milestones and royalties later down the line as well as an up front licensing fee. I think there are plenty of options, but a complete buy out is just one small one given the roadmap we have been given. A bid cannot be ruled out, but that is just 'investors best option' for those who are more short term than others. An early bid while welcome will never be at the full price they could command in 12-24 months time.",
          "sentiment": 0.0,
          "engagement": "1,560",
          "price_at_post": "14.75",
          "thread_title": "RE: Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-21T22:00:23.980135+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261640-NornIron-39353190",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.611956",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I totally agree Trout. Exclusivity is something I wouldn't like to see personally, and although possible, i don't see it happening. As a shareholder (and planning to be a longer term one) i feel there's more value in this longer term not to sell out.  Ongoing revenues from this could be more lucrative and enhance a future company value . . . for selling out down the line if favourable. If there was an offer of 2 to 3 times the m/cap to buy us now, tempted as I'd be to sell, i can tell you i won't be selling. I think we could be a lot bigger than that multiple in a few years time. I've 22 holdings in my portfolio, most of these in predictable dividend producing household names. Of the 7 holdings i have in AIM stocks, Fab holds the biggest percentage of my assets and it's also the one i'm most excited, and least anxious about.   It's going to be very interesting how this OptiMAL story unfolds. . . . I must just say too though, if in the event this 10 folds overnight, I'm outta here, lol.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "14.75",
          "thread_title": "RE: Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-21T22:00:23.980087+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20260858-gtc1507--3289426",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.611190",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Their investor hub seems to be a really useful tool but anyone else noticed they\u2019re slower to respond on it recently?",
          "sentiment": 0.5,
          "engagement": "1,140",
          "price_at_post": "14.75",
          "thread_title": "Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-21T22:00:23.980055+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20260912-chrishut--2184920",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.610459",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Once we surpass and hold above 15 it should become a strong support level. We have been attempting it a lot so only a matter of time. Nice to have buys below support.",
          "sentiment": 0.5,
          "engagement": "17,379",
          "price_at_post": "14.75",
          "thread_title": "Breakout coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=63B466DE-B123-46EA-AE7B-9C82630737A7"
        },
        "ingested_at": "2026-01-21T22:00:23.980023+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20260926-cbeadle-56616671",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.609735",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I wonder if it\u2019s because they\u2019re really busy tying contracts/deals together- or else just overcoming the Christmas and New Year season \ud83d\ude1c",
          "sentiment": 0.0,
          "engagement": "330",
          "price_at_post": "15.00",
          "thread_title": "RE: Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-21T22:00:23.979992+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261429-Rich125-14677814",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:10.608987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rich125",
          "content": "I wonder if they are being a bit cautious about what they say given contracts could be about to land or at least in deep discussions. Taking extra care to make sure they don\u2019t say something they shouldn\u2019t before it\u2019s officially announced",
          "sentiment": 0.5,
          "engagement": "281",
          "price_at_post": "15.00",
          "thread_title": "RE: Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-21T22:00:23.979960+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261457-mmhater-43088976",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.431456",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Frankly i think this share price is a disgrace. I\u2019m not sure who to blame but it should be multiples of where it is now. I\u2019ve seen it in numerous companies and think it is to do with the AIM markets. They need to be more like the american markets and people might want to invest more! It\u2019s not fair on the company if the true value of the company is not reflected in the share price.",
          "sentiment": 0.0,
          "engagement": "649",
          "price_at_post": "15.00",
          "thread_title": "Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-21T22:00:23.979929+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261520-Rich125--5420108",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.430975",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rich125",
          "content": "I think we will rerate once that first contracts lands. It seems the market are waiting for that as validation that we have something worthwhile, despite NCI clearly valuing it and effectively validating it.",
          "sentiment": 0.5,
          "engagement": "281",
          "price_at_post": "15.00",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-21T22:00:23.979898+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261929-cbeadle-51809558",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.430555",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I agree it\u2019s absolutely crazy and I am hoping for a sudden violent rerate when the market eventually realises the potential of FAB",
          "sentiment": 0.0,
          "engagement": "330",
          "price_at_post": "15.00",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-21T22:00:23.979869+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261002-Troutiso-85275680",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.430064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "It's just trying to catch out some weak hands, it's actually more expensive to buy now since the drop in SP, than it was yesterday afternoon...",
          "sentiment": 0.0,
          "engagement": "1,560",
          "price_at_post": "14.50",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-21T22:00:23.979833+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261049-chrishut-67159229",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.429609",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I figure news has to be close, they have been in discussions for ages, so I have been adding into any weakness.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979803+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261329-Cheapsha--6569847",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.429192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "I\u2019m expecting any news ftom Jan 19th - Feb 28th. That\u2019s a six weeks window that should get jam.",
          "sentiment": 0.5,
          "engagement": "2,669",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979772+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261402-evman27--1559978",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.428744",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It is closer than a few months that is for sure. For now we are rangebound. Those who have been here a long time have no fear of this new range and will happily accumulate from weak hands with the clear and obvious upside that awaits.",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979740+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261448-chrishut-54344983",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.428312",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A few have suggested there may well be something this week.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979708+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261907-Seancadm--5047663",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.427879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "The real value of OptiMal will be recognised from the NIH/NCI validation, yes, in turn Pharma will no doubt adopt the OptiMal platform but the key to unlocking these deals is the NIH/NCI validation. The icing on the cake would be an academic publication from NCI which may well be ongoing right now. I have no doubt that Fusion have played a blinder in gaining validation from the NCI it unlocks doors with big Pharma that previously would have been firmly closed and without the validation could have taken years to even get the notoriously sceptical scientists to agree to a meeting. The NCI have in essence de-risked OptiMal. Of course Pharma will still want to do their diligence but the timeline will shorten, NCI validation may not in its own close deals but it certainly opens doors! With validation, Pharma will be thinking, \u2018if NCI scientists used this and didn\u2019t abandon it, it probably works, let\u2019s see if it works for us.\u2019 Updates on negotiations should be interesting.",
          "sentiment": 0.5,
          "engagement": "211",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979676+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20262019-chrishut--1209253",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.427430",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Causeway sensors, we  collaborated on this\u2026 https://www.linkedin.com/posts/uk-cpi_biologics-medicinesmanufacturing-scaleup-activity-7416841720232828929-mHTE?utm_medium=ios_app&rcm=ACoAADOfeHYBV7khqaq9UgJwAiGuFrEAYOcW22U&utm_source=social_share_send&utm_campaign=copy_link",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979644+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261121-Rocka--6987475",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.426980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Bought some more in the last few days. News can\u2019t be far. Bring on 50p plus",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979612+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261348-Cheapsha-73638633",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.426545",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "All sideways atm Patience will reap the rewards",
          "sentiment": 0.5,
          "engagement": "2,669",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979581+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261501-Bibzy7--3182349",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.426056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "All this waiting about to become absolutely minted is getting boring now. Can we please sign a mega million pound deal so we can all get rich and live in a sweet beach condo please I'm not asking much",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.50",
          "thread_title": "Boring",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=92D7FE6A-9EFC-42F4-A10C-EDA81D40EAC4"
        },
        "ingested_at": "2026-01-21T22:00:23.979549+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261314-evman27-88102430",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.425623",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It is so quiet, a huge number of items we could here about. Calm before the storm? \ud83e\udd88 \ud83e\udd88",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.00",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979517+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261727-gtc1507--7172433",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.425011",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Let\u2019s hope so, we\u2019re right in the early execution phase now. They\u2019ve done all the hard yards on r&d and launch, now the prooof is in the pudding. We just need to see the execution and proof that optimal actually is an attractive proposition. Judging by Adrian\u2019s commentary at the investor meet company on the prelaunch feedback, we should be in for some good uptake.",
          "sentiment": 0.0,
          "engagement": "1,140",
          "price_at_post": "14.00",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979482+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261034-chrishut--3900375",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.424249",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "We must be close to news",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T22:00:23.979451+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261334-mmhater-72257837",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.423748",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "There is very few trades and haven\u2019t been for a week now. Shares are in sticky hands and only small trades going through. That being said it\u2019s hard to sell and likely this will go down if company corporate is soon. This share price is ridiculous. Come on Adrian\u2026. update us on something",
          "sentiment": 0.0,
          "engagement": "649",
          "price_at_post": "13.75",
          "thread_title": "Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979428+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261411-Rocka--6273632",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.423323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019m surprised there has been no  news since the  start of 2026.",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979409+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261540-Sanibel-47187907",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.422885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Patience is the key hear. The sp movements dont worry me at all Deals take time and big ones a bit longerits not going to hapen in days or weeks. GL Sani",
          "sentiment": 0.0,
          "engagement": "4,559",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979391+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261546-mmhater-69254269",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.422456",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Looks like someone is selling again with \u00a340k of sells today.",
          "sentiment": 0.0,
          "engagement": "649",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979373+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261601-cbeadle--8862120",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.422015",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "We could do with one. Clearly a big seller atm depressing the share price",
          "sentiment": 0.0,
          "engagement": "330",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979354+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261621-Laura202-69873560",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.421578",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Biotechs doing well today GDR TRLS I'm sure FAB and others  will follow",
          "sentiment": 0.0,
          "engagement": "15,149",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979335+00:00"
      },
      {
        "event_id": "SOCIAL-Today1757-Cheapsha-10162025",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.421131",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,669",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979315+00:00"
      },
      {
        "event_id": "SOCIAL-Today1812-gtc1507--7138104",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.420596",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,140",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979294+00:00"
      },
      {
        "event_id": "SOCIAL-Today1821-formerly--4275257",
        "event_type": "social_post",
        "date": "2026-01-21T22:00:06.420060",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,631",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T22:00:23.979265+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260738-Bigjock3--5520506",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.545255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bigjock36",
          "content": "STT1 you have failed to mention a very significant part of the cash flow equation. Aged debtors at the snapshot in time you mentioned were also \u00a3541k. This bolsters cash flow significantly! Here\u2019s the thing\u2026. That aged debtor figure is a SNAPSHOT. We can also assume they will have further debtors from that moment in time. Albeit costs will also be incurred, I feel safe in the knowledge that the Directors have a handle on the cash element of the business. Furthermore, you continuously slander the company yet you have just confirmed trading multiple times on the share. For myself sitting watching your continued drivel, you are nothing more than a hot air sadistic man who hopes the SP will drop on a few sells to buy back in as you know ultimately the businesses will be back above 20p+ long term.",
          "sentiment": 0.5,
          "engagement": "968",
          "price_at_post": "13.50",
          "thread_title": "RE: 2026 is the year of delivery",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D9CEEF08-772B-4611-ACBA-030106F711B9"
        },
        "ingested_at": "2026-01-21T02:20:47.400751Z"
      },
      {
        "event_id": "SOCIAL-5Jan20260921-chrishut--4449671",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.544810",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "We will start to see the fruits of last years work come to harvest soon.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.00",
          "thread_title": "Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400724Z"
      },
      {
        "event_id": "SOCIAL-5Jan20260951-gtc1507-71822049",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.544406",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Let\u2019s hope so Chris! Lots of exciting stuff going on before the Christmas break, hopefully not long until some converts into orders",
          "sentiment": 0.5,
          "engagement": "1,139",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400697Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261010-Bibzy7--1234072",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.543979",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Big contacts take time they ant giving this away for free",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400671Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261035-Rocka--2360313",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.543569",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Massive \u00a320k buy showing as unknown",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400644Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261044-evman27--1521982",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.543158",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Another \u00a310k buy too! Smart money loading up, we have also had a \u00a35k buyer most days for a few weeks too.",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400618Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261046-Rocka-20762916",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.542722",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "It would be nice if we can stabilise at high teens /20p pre news then i think we can easily hit 40p thos month or next depending on news",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400592Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261049-evman27-66055065",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.542308",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "510k shares is 20p in IG, these shares will go like lightening on a good RNS. Lots of sticky hands here, tight float, the setup is fantastic when news arrives.",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.25",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400565Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261240-Stan36--4305269",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.541877",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Nice to see this buying ahead of news about Optimal contracts & NCI. Risen 11% today to 15p & looking good.",
          "sentiment": 0.5,
          "engagement": "837",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400538Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261240-Rocka-20145129",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.541458",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ask 15.5p\ud83d\ude80\ud83d\ude80\ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400512Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261253-evman27--4851922",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:38.541008",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "She moves quick eh!",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "15.00",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400485Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261349-chrishut-47220472",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.794085",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Long way up to go yet",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400458Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261629-Bibzy7-73323454",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.793676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "100% correct",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.50",
          "thread_title": "RE: Fabulous move coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=9D02C4BE-AD9C-473C-9945-F3D29D8EE670"
        },
        "ingested_at": "2026-01-21T02:20:47.400432Z"
      },
      {
        "event_id": "SOCIAL-6Jan20260721-gtc1507--4162580",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.793270",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://ascopost.com/news/october-2025/nci-issues-request-for-2027-budget/ NCI seeking an additional $4bn budget next yea. Maybe the purse strings are going to be loosened hence the \u201cscale of the proposal\u201d of the fab deal requiring NIH Approval. Exciting times, can\u2019t wait to see what they\u2019ve negotiated.",
          "sentiment": 0.5,
          "engagement": "1,139",
          "price_at_post": "14.50",
          "thread_title": "NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T02:20:47.400405Z"
      },
      {
        "event_id": "SOCIAL-6Jan20260839-Gheko-30402902",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.792835",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Great find Gtc. We have the best in class platform  which is therefore hugely valuable not only to NCI but to big pharma sand smaller pharma alike. We know the size of deals in this industry\u2026.HUGE! So not only do I think the NCI will need/want a big deal with FAB but other pharmas will be circling. News anytime and no wonder the price is starting to creep up. The upside is mouthwatering. Good luck all.",
          "sentiment": 0.5,
          "engagement": "1,205",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T02:20:47.400378Z"
      },
      {
        "event_id": "SOCIAL-6Jan20260840-Stan36--3952114",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.792414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Anticipation building. Only \u00a325,000 buys shifts the price up 1%. MMs short of stock, tightly held. Nice steady rise.",
          "sentiment": 0.5,
          "engagement": "837",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T02:20:47.400352Z"
      },
      {
        "event_id": "SOCIAL-6Jan20260843-gtc1507-72999846",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.791992",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Especially when the new NCI director is also coming out and telling staff to fund gold standard cancer research. Optimal is best in class, first in classs according to fusion,  can\u2019t get more gold standard than that\u2026. https://x.com/thenci/status/1991594881232367638?s=46",
          "sentiment": 0.0,
          "engagement": "1,139",
          "price_at_post": "15.25",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T02:20:47.400326Z"
      },
      {
        "event_id": "SOCIAL-6Jan20260843-evman27-31911867",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.791571",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes, this steady new year creep up bodes seriously well for holders. Whatever is going on in the background is seriously exciting. \ud83e\udd88",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "15.50",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T02:20:47.400299Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261207-cbeadle-35222472",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.791144",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right RNS FAB has the feel of a company whose share price could \ud83d\udca5 explode upwards. It\u2019s happened already with quite a few small pharma or biomedical companies in the past 12 months",
          "sentiment": 0.0,
          "engagement": "329",
          "price_at_post": "15.00",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T02:20:47.400272Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261354-gtc1507--8261848",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.790722",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Sorts of deals that Optimal could garner for Fusion maybe?? https://www.linkedin.com/posts/chabs-%E5%8D%8E%E4%BA%BA%E6%8A%97%E4%BD%93%E5%8D%8F%E4%BC%9A_earendil-labs-announces-strategic-collaboration-activity-7414297394865078272-X430?utm_source=share&utm_medium=member_ios&rcm=ACoAAAuyH_0BZuiiVe69ogYIdwe7HKyUbPvkmaA",
          "sentiment": 0.0,
          "engagement": "1,139",
          "price_at_post": "15.00",
          "thread_title": "RE: NCI deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=539F1E4C-B84B-43B6-B2C7-20E0FBCEC523"
        },
        "ingested_at": "2026-01-21T02:20:47.400246Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261554-NornIron-50894876",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.790300",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Hi folks I'm a relatively new investor here with FAB, but a lot of the research I done before investing was based on information, links, reports, etc, that some of you posted on here.  These gave me a starting point to do my own research. This post is just a thank you to you folks  who took the time to do this.  There certainly are some knowledgeable  posters on this page.  I'm including the rampers and derampers with my thanks too. You know who you are, lol, and your posts are also interesting  and informative for various reasons. Thanks for all your inputs and hopefully i can contribute to the posts in future here too.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "15.00",
          "thread_title": "Thanks folks !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=6655E900-946E-4D59-A610-FD833DD50AEB"
        },
        "ingested_at": "2026-01-21T02:20:47.400219Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261002-evman27--7727325",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.789868",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Fusion Antibodies presents at the Proactive One2One Investor Conference - January 11th 2024 https://www.youtube.com/watch?v=IAvbf90GgvQ I recommend everyone watches at least the Q&A of this one! A very jovial, excited and up beat Adrian at this presentation, this was a few months after the initial deal with the NCI was signed a few years ago. A gold mine of great quotes from Adrian I will share, \u201cNCI is a surrogate for big pharma, I\u2019d much rather do the first deal with NCI, when I might have to compromise things, rather than sell it cheaply to a blue chip\u201d \u201cWe approached NCI for sentiment around mammalian display on a scientist to scientist basis. We went directly to Dr Mitchell Ho saying what\u2019s the best way to do such and such, would you like to have a look at our technology. He liked it so much he didn\u2019t buy the company yet, we set up the agreement from his pulling it through, we may have positioned it to do that\u201d \u201cNo one has a platform like Optimal as far as I\u2019m concerned. I think that\u2019s one of the reasons why they really wanted us to come in\u201d \u201cThe NCI are taking it seriously, lots of people are going hang on this is worth another look, how far have they got. We went to the antibody engineering and therapeutics conference before Christmas 2023 in San Diego and came away with some very significant enquiries around that, it\u2019s really made people sit up\u201d \u201cI know antibodies are worth a lot of money so there is an example recently, Novartis bought a company called Calipso to get hold of one antibody called Cali002, $425m in order to do so, what you may not have known is we humanised that antibody\u201d \u201cWe certainly do not rule out such a big licensing deal, I think it\u2019s probably more likely and certainly looking at today\u2019s MCAP that a big pharma rather than licensing it for the amount it would be worth would just come in and buy us\u201d Follow up question to this, I can\u2019t understand why the valuation is probably less than kit in your laboratory plus the potential value of optimal already \u201cNope it confused me as well but that\u2019s one of the reasons why I work there, one of the reasons why I work for shares and it\u2019s one of the reasons why I bought shares\u201d GOLD. I haven\u2019t seen Adrian so bullish since the most recent presentation, you can watch that here, the Q&A at the end is particularly telling. https://investorhub.fusionantibodies.com/webinars/mPqXOr-optimal-r-launch-investor-q-a Compare both presentations, see where we are today and ask yourself, why am I not holding? Dyor",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.50",
          "thread_title": "Therapeutic Gold",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=8DB6EAD5-BA9B-4341-80E8-DEEA2E954E69"
        },
        "ingested_at": "2026-01-21T02:20:47.400192Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261023-chrishut-49120726",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.789374",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Managed 2 x 50k Thank you whoever wet the bed",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "I took some more",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BC2ABA98-B9D3-4F64-9839-C296923DF67A"
        },
        "ingested_at": "2026-01-21T02:20:47.400166Z"
      },
      {
        "event_id": "SOCIAL-7Jan20262046-gtc1507-45989919",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.788947",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a great post Evman. Thanks for reminding us of this. Much of the sentiment true even more so today",
          "sentiment": 0.0,
          "engagement": "1,139",
          "price_at_post": "14.50",
          "thread_title": "RE: Therapeutic Gold",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=8DB6EAD5-BA9B-4341-80E8-DEEA2E954E69"
        },
        "ingested_at": "2026-01-21T02:20:47.400140Z"
      },
      {
        "event_id": "SOCIAL-9Jan20262319-mmhater-82803620",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.788534",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Really enjoyed the banter the last couple of days\u2026 Hopefully STi will be about soon to tell us how the company is doomed and a dilution is imminent .",
          "sentiment": 0.0,
          "engagement": "648",
          "price_at_post": "15.00",
          "thread_title": "Banter",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=3FD758A3-949D-40D2-9A70-A38BA90787BF"
        },
        "ingested_at": "2026-01-21T02:20:47.400112Z"
      },
      {
        "event_id": "SOCIAL-11Jan20261920-Seancadm--1188241",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.788119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "\u201c Negotiations regarding the expanded proposed programme are expected to continue into early 2026. Due to the scale of the proposal, formal approval processes at the US National Institutes of Health (of which the NCl is part) are likely to take several further months to complete. While discussions are progressing, there is no assurance that an extension to the Agreement will be reached, nor as to the timing or final terms of such an extension.\u201d The above extract from Fusions RNS regarding the NCI extension is very telling of how big this deal may be. The National institutes of health are only brought in to oversee deals that are greater than NCIs range, Fusions even stated in the RNS \u201cdue to the scale of the proposal\u201d. The proposal is large enough that it cannot be approved solely at NCI level.",
          "sentiment": 0.5,
          "engagement": "211",
          "price_at_post": "15.00",
          "thread_title": "NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T02:20:47.400076Z"
      },
      {
        "event_id": "SOCIAL-11Jan20262000-mariusz-53748344",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.787683",
        "source": "LSE_CHAT",
        "data": {
          "author": "mariusz",
          "content": "Currently at \u00a317m mcap\ud83e\udd2b",
          "sentiment": 0.0,
          "engagement": "354",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T02:20:47.400050Z"
      },
      {
        "event_id": "SOCIAL-11Jan20262127-gtc1507-59850767",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.787270",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Bargain basement right, question is who will realise first, retail herd, PIs, institutions or a competitor cro or potential client that wants to snap them up.",
          "sentiment": 0.0,
          "engagement": "1,139",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T02:20:47.400024Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260948-Cheapsha--8256196",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.786845",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Waiting game! NCI news shoud be big enough in it's own right plus we hopefully have some other new cotracts singed shortly!",
          "sentiment": 0.5,
          "engagement": "2,665",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T02:20:47.399997Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261106-Stan36-49881213",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.786434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Well I suppose there could also have been an approach to buy the business following the Optimal launch? The BOD are not obliged to RNS if this is confidential and ongoing and offer terms not clarified. E.g. informal approach: a company asks to enter into discussions about terms. GPT>> So what\u2019s the practical answer for FAB? \u2705 If FAB gets a quiet, informal approach and: it\u2019s confidential, there\u2019s no rumour, no unusual share price movement, and it\u2019s not yet inside information, \u27a1\ufe0f they are not obliged to put out an RNS. \u2757 But if any of the following occur: press/market chatter (\u201cFAB in talks\u201d), price/volume spikes that look \u201coffer related\u201d, confidentiality slips (more outsiders brought in), the approach becomes concrete enough to be inside info, \u27a1\ufe0f then yes \u2014 they\u2019d be pushed into an RNS (either because of UK MAR inside info disclosure or because the Takeover Panel requires a Rule 2 announcement).",
          "sentiment": 0.5,
          "engagement": "837",
          "price_at_post": "15.00",
          "thread_title": "RE: NIH involvement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=A49FC7E6-C448-48CD-AF07-C638719E97F8"
        },
        "ingested_at": "2026-01-21T02:20:47.399971Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261114-Bibzy7-35449976",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.785954",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Just for talking sakes nci offer contract off 200 mil over nxt 4 years what does that do to the share price as it stands atm",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "15.00",
          "thread_title": "200 million",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=E421AF3B-BB86-44E4-89DC-E043088744F1"
        },
        "ingested_at": "2026-01-21T02:20:47.399945Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261236-Stan36--8628124",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.785539",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Well just for the sake of fantasy figures & if you mean $50m/year for 4 years I'd go for a range of \u00a33-\u00a35 assuming the margin would be very high. No great additional overheads. That's an Mcap of \u00a3300m -\u00a3500m",
          "sentiment": 0.0,
          "engagement": "837",
          "price_at_post": "15.00",
          "thread_title": "RE: 200 million",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=E421AF3B-BB86-44E4-89DC-E043088744F1"
        },
        "ingested_at": "2026-01-21T02:20:47.399919Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261351-NornIron--1900754",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.785116",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I'm just thinking out loud here and coming from a different angle. Here's my thoughts :- - With NCI having the clout they have, Fusion needed them onboard using OptiMAL -  They got it 2 years ago when NCI starting using OptiMAL (November 2023). - They then needed NCI's seal of approval that OptiMAL does what it says on the tin - They got it when Optimal said they wanted to continue using it in late 2025 and negotiations  started with Fab for it's continued use. This approval from NCI now gives Fab and their OptiMAL product greater kudos, when having commercial conversations with other potential buyers of the product and licences  (or maybe even the company). As i see it, Fab have 2 potential buyers of the product / company / licences, these being NCI and big pharmas. Questions If Fab are selling to NCI, will they feel     'we need to look after these guys. They've gave us our product validation, we need to have gratitude for this, and to get a contract with them is additional kudos in the marketplace with other buyers' . . . and therefore do a financial deal that isn't as high as it could be ? Alternatively If Fab are selling to a big pharma (with the deep pockets they have), would it be better financially for us shareholders to sell to them, and let them negotiate with NCI on what NCI pay for it, if indeed they even let NCI have the product.  Big pharma won't have the same what could be regarded as moral obligation to give NCI favourable terms and could see this as an earner for them if they had full product control. You might say, and you could be right, that we need an NCI deal for validation of the product before selling to a big pharma.  The other argument is that we already have their validation with there desire for it's continued use. Could this discussion and waiting period that we 'see' with NCI negotiations be a board tactic in dangling the OptiMAL bait in front of a big pharma angler to take this before NCI take it ? To summarize my thoughts.   Does Fusion Antibodies want a deal with NCI  ?   . . . . My answer is,  I've absolutely no idea whatsoever if they do or not. Is it best to do a deal first with NCI before a deal with a big pharma ? . . . .  Same answer,  I've absolutely no idea if it is or not. Is this an exciting place to be as an investor at the minute with where this might go in the coming weeks / months ? YES, YES, YES is my answer to that. Good luck all.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "14.625",
          "thread_title": "Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-21T02:20:47.399892Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261618-Troutiso-16764155",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.784635",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Your suggestions assume some sort of exclusivity, with OptiMAL and Library that need not be the case. NCI can licence it for their work and several large Pharms can do so alongside that. The deals will be in terms of milestones and royalties later down the line as well as an up front licensing fee. I think there are plenty of options, but a complete buy out is just one small one given the roadmap we have been given. A bid cannot be ruled out, but that is just 'investors best option' for those who are more short term than others. An early bid while welcome will never be at the full price they could command in 12-24 months time.",
          "sentiment": 0.0,
          "engagement": "1,554",
          "price_at_post": "14.75",
          "thread_title": "RE: Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-21T02:20:47.399866Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261640-NornIron-45535765",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.784215",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I totally agree Trout. Exclusivity is something I wouldn't like to see personally, and although possible, i don't see it happening. As a shareholder (and planning to be a longer term one) i feel there's more value in this longer term not to sell out.  Ongoing revenues from this could be more lucrative and enhance a future company value . . . for selling out down the line if favourable. If there was an offer of 2 to 3 times the m/cap to buy us now, tempted as I'd be to sell, i can tell you i won't be selling. I think we could be a lot bigger than that multiple in a few years time. I've 22 holdings in my portfolio, most of these in predictable dividend producing household names. Of the 7 holdings i have in AIM stocks, Fab holds the biggest percentage of my assets and it's also the one i'm most excited, and least anxious about.   It's going to be very interesting how this OptiMAL story unfolds. . . . I must just say too though, if in the event this 10 folds overnight, I'm outta here, lol.",
          "sentiment": 0.0,
          "engagement": "456",
          "price_at_post": "14.75",
          "thread_title": "RE: Is it possible that Fab don't want an NCI deal ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=AA7DE79C-28AF-4033-BF0C-8BC814171654"
        },
        "ingested_at": "2026-01-21T02:20:47.399839Z"
      },
      {
        "event_id": "SOCIAL-13Jan20260858-gtc1507-68175232",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:33.783742",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Their investor hub seems to be a really useful tool but anyone else noticed they\u2019re slower to respond on it recently?",
          "sentiment": 0.5,
          "engagement": "1,139",
          "price_at_post": "14.75",
          "thread_title": "Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-21T02:20:47.399813Z"
      },
      {
        "event_id": "SOCIAL-13Jan20260912-chrishut-32908921",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.609516",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Once we surpass and hold above 15 it should become a strong support level. We have been attempting it a lot so only a matter of time. Nice to have buys below support.",
          "sentiment": 0.5,
          "engagement": "17,379",
          "price_at_post": "14.75",
          "thread_title": "Breakout coming",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=63B466DE-B123-46EA-AE7B-9C82630737A7"
        },
        "ingested_at": "2026-01-21T02:20:47.399786Z"
      },
      {
        "event_id": "SOCIAL-13Jan20260926-cbeadle--8898860",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.609109",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I wonder if it\u2019s because they\u2019re really busy tying contracts/deals together- or else just overcoming the Christmas and New Year season \ud83d\ude1c",
          "sentiment": 0.0,
          "engagement": "329",
          "price_at_post": "15.00",
          "thread_title": "RE: Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-21T02:20:47.399760Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261429-Rich125--3829201",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.608688",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rich125",
          "content": "I wonder if they are being a bit cautious about what they say given contracts could be about to land or at least in deep discussions. Taking extra care to make sure they don\u2019t say something they shouldn\u2019t before it\u2019s officially announced",
          "sentiment": 0.5,
          "engagement": "281",
          "price_at_post": "15.00",
          "thread_title": "RE: Investor hub",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=880652D2-F677-4B24-AC57-DD28B81EAC16"
        },
        "ingested_at": "2026-01-21T02:20:47.399734Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261457-mmhater--1407412",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.608278",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Frankly i think this share price is a disgrace. I\u2019m not sure who to blame but it should be multiples of where it is now. I\u2019ve seen it in numerous companies and think it is to do with the AIM markets. They need to be more like the american markets and people might want to invest more! It\u2019s not fair on the company if the true value of the company is not reflected in the share price.",
          "sentiment": 0.0,
          "engagement": "648",
          "price_at_post": "15.00",
          "thread_title": "Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-21T02:20:47.399708Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261520-Rich125--4951093",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.607860",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rich125",
          "content": "I think we will rerate once that first contracts lands. It seems the market are waiting for that as validation that we have something worthwhile, despite NCI clearly valuing it and effectively validating it.",
          "sentiment": 0.5,
          "engagement": "281",
          "price_at_post": "15.00",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-21T02:20:47.399682Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261929-cbeadle--5562605",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.607449",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I agree it\u2019s absolutely crazy and I am hoping for a sudden violent rerate when the market eventually realises the potential of FAB",
          "sentiment": 0.0,
          "engagement": "329",
          "price_at_post": "15.00",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-21T02:20:47.399655Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261002-Troutiso-80679593",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.607030",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "It's just trying to catch out some weak hands, it's actually more expensive to buy now since the drop in SP, than it was yesterday afternoon...",
          "sentiment": 0.0,
          "engagement": "1,554",
          "price_at_post": "14.50",
          "thread_title": "RE: Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=285ACBC8-7F42-4308-B389-E6B2E53EA5E7"
        },
        "ingested_at": "2026-01-21T02:20:47.399629Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261049-chrishut-21246952",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.606621",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I figure news has to be close, they have been in discussions for ages, so I have been adding into any weakness.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399603Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261329-Cheapsha-28318575",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.606215",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "I\u2019m expecting any news ftom Jan 19th - Feb 28th. That\u2019s a six weeks window that should get jam.",
          "sentiment": 0.5,
          "engagement": "2,665",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399577Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261402-evman27-86581424",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.605781",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It is closer than a few months that is for sure. For now we are rangebound. Those who have been here a long time have no fear of this new range and will happily accumulate from weak hands with the clear and obvious upside that awaits.",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399550Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261448-chrishut--2899939",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.605360",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A few have suggested there may well be something this week.",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399523Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261907-Seancadm-19134325",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.604938",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "The real value of OptiMal will be recognised from the NIH/NCI validation, yes, in turn Pharma will no doubt adopt the OptiMal platform but the key to unlocking these deals is the NIH/NCI validation. The icing on the cake would be an academic publication from NCI which may well be ongoing right now. I have no doubt that Fusion have played a blinder in gaining validation from the NCI it unlocks doors with big Pharma that previously would have been firmly closed and without the validation could have taken years to even get the notoriously sceptical scientists to agree to a meeting. The NCI have in essence de-risked OptiMal. Of course Pharma will still want to do their diligence but the timeline will shorten, NCI validation may not in its own close deals but it certainly opens doors! With validation, Pharma will be thinking, \u2018if NCI scientists used this and didn\u2019t abandon it, it probably works, let\u2019s see if it works for us.\u2019 Updates on negotiations should be interesting.",
          "sentiment": 0.5,
          "engagement": "211",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399497Z"
      },
      {
        "event_id": "SOCIAL-14Jan20262019-chrishut--7012463",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.604505",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Causeway sensors, we  collaborated on this\u2026 https://www.linkedin.com/posts/uk-cpi_biologics-medicinesmanufacturing-scaleup-activity-7416841720232828929-mHTE?utm_medium=ios_app&rcm=ACoAADOfeHYBV7khqaq9UgJwAiGuFrEAYOcW22U&utm_source=social_share_send&utm_campaign=copy_link",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399470Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261121-Rocka--2577091",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.604075",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Bought some more in the last few days. News can\u2019t be far. Bring on 50p plus",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399444Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261348-Cheapsha-53818301",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.603669",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "All sideways atm Patience will reap the rewards",
          "sentiment": 0.5,
          "engagement": "2,665",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399418Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261501-Bibzy7--5807476",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.603253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "All this waiting about to become absolutely minted is getting boring now. Can we please sign a mega million pound deal so we can all get rich and live in a sweet beach condo please I'm not asking much",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "14.50",
          "thread_title": "Boring",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=92D7FE6A-9EFC-42F4-A10C-EDA81D40EAC4"
        },
        "ingested_at": "2026-01-21T02:20:47.399391Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261314-evman27-59007386",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.602837",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It is so quiet, a huge number of items we could here about. Calm before the storm? \ud83e\udd88 \ud83e\udd88",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "14.00",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399365Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261727-gtc1507-14416839",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.602413",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Let\u2019s hope so, we\u2019re right in the early execution phase now. They\u2019ve done all the hard yards on r&d and launch, now the prooof is in the pudding. We just need to see the execution and proof that optimal actually is an attractive proposition. Judging by Adrian\u2019s commentary at the investor meet company on the prelaunch feedback, we should be in for some good uptake.",
          "sentiment": 0.0,
          "engagement": "1,139",
          "price_at_post": "14.00",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399338Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261034-chrishut--4047091",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.601985",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "We must be close to news",
          "sentiment": 0.0,
          "engagement": "17,379",
          "price_at_post": "14.50",
          "thread_title": "RE: News soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=5D97454B-CFEB-4578-9571-BA2DC4D61C3C"
        },
        "ingested_at": "2026-01-21T02:20:47.399312Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261334-mmhater-47641688",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.601580",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "There is very few trades and haven\u2019t been for a week now. Shares are in sticky hands and only small trades going through. That being said it\u2019s hard to sell and likely this will go down if company corporate is soon. This share price is ridiculous. Come on Adrian\u2026. update us on something",
          "sentiment": 0.0,
          "engagement": "648",
          "price_at_post": "13.75",
          "thread_title": "Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T02:20:47.399285Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261411-Rocka--4436237",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.601157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019m surprised there has been no  news since the  start of 2026.",
          "sentiment": 0.0,
          "engagement": "176",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T02:20:47.399258Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261540-Sanibel--4056546",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.600733",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Patience is the key hear. The sp movements dont worry me at all Deals take time and big ones a bit longerits not going to hapen in days or weeks. GL Sani",
          "sentiment": 0.0,
          "engagement": "4,558",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T02:20:47.399232Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261546-mmhater--2970459",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.600311",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Looks like someone is selling again with \u00a340k of sells today.",
          "sentiment": 0.0,
          "engagement": "648",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T02:20:47.399204Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261601-cbeadle-23366813",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.599884",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "We could do with one. Clearly a big seller atm depressing the share price",
          "sentiment": 0.0,
          "engagement": "329",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T02:20:47.399177Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261621-Laura202--6568976",
        "event_type": "social_post",
        "date": "2026-01-21T02:20:29.599455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Biotechs doing well today GDR TRLS I'm sure FAB and others  will follow",
          "sentiment": 0.0,
          "engagement": "15,139",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-21T02:20:47.399145Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251119-saxman30--8556272",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.956633",
        "source": "LSE_CHAT",
        "data": {
          "author": "saxman303",
          "content": "Nobody was robbed of they shares they were fools they sold out cheaply",
          "sentiment": 0.0,
          "engagement": "692",
          "price_at_post": "13.75",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403421Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251134-Laura202--5932080",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.956229",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "If any large holders like Troutisout1 will offer their thoughts?",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "13.75",
          "thread_title": "Wonder",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=3DD26B6B-A78F-4578-A911-C9DA96375635"
        },
        "ingested_at": "2026-01-21T02:20:47.403394Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251231-Humpalum-29137844",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.955815",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "My thought is we finish blue \ud83d\udc4d this was a bullish RNS not a negative one lol - just standard aim lettuce hands see something isn't happening in a couple of days and try to chase rainbows",
          "sentiment": 0.5,
          "engagement": "1,592",
          "price_at_post": "13.75",
          "thread_title": "RE: Wonder",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=3DD26B6B-A78F-4578-A911-C9DA96375635"
        },
        "ingested_at": "2026-01-21T02:20:47.403367Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251235-gerihatr-37018855",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.955413",
        "source": "LSE_CHAT",
        "data": {
          "author": "gerihatrick",
          "content": "Would a 50,:50 deal with the NCI be fair and reasonable.... Like a marriage made in heaven!?",
          "sentiment": 0.0,
          "engagement": "123",
          "price_at_post": "13.75",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403341Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251245-Humpalum--4426610",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.954995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Just a 1% royalty with NCI on antibodies discovered with optimal would be worth multiples of our current mkt cap lol",
          "sentiment": 0.5,
          "engagement": "1,592",
          "price_at_post": "13.75",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403314Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251258-Stan36--4399431",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.954590",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "The U.S. National Cancer Institute (NCI) can earn royalty income from antibodies (or other inventions) it discovers, but it cannot commercialise them like a private company or keep profits in the usual sense. How it works in practice 1. Discovery & patents If NCI scientists discover an antibody (or a target, platform, method, etc.), The invention is typically patented by the U.S. government (not by NCI as a \u201ccompany\u201d). 2. Licensing to industry Through NIH/NCI Technology Transfer Offices, the government can: Grant exclusive or non-exclusive licences to biotech or pharma companies Allow those companies to develop, manufacture, and sell the antibody as a drug 3. Royalties & licence fees Licensed companies usually pay: Up-front licence fees Milestone payments Running royalties on sales 4. Where the money goes Royalties do not become \u201cprofit\u201d for NCI They are: Returned to the U.S. Treasury and NIH Partially shared with the inventing scientists (by law) Reinvested into further government research This system is governed by U.S. federal law (notably the Bayh\u2013Dole Act). What NCI cannot do \u274c It cannot manufacture and sell antibodies itself \u274c It cannot operate like a commercial biotech \u274c It cannot distribute profits to shareholders (there are none)",
          "sentiment": 0.5,
          "engagement": "815",
          "price_at_post": "13.75",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403288Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251302-Stan36-46879019",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.954082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "If NCI uses Optimal: Worst case: paid service revenue + validation Base case: tech licence income when antibody is commercialised Best case: recurring royalty stream tied to government-originated blockbuster drugs The upside comes from IP entanglement, not antibody ownership. What investors should look for in FAB disclosures When reading FAB RNS / reports, the gold signals are: \ud83d\udd0d Language clues \u201cPlatform licence\u201d \u201cBackground IP\u201d \u201cEnabling technology\u201d \u201cFreedom to operate\u201d \u201cCannot be readily designed around\u201d \ud83d\udd0d Counterparties NIH....NCI...NIAID....DoD labs These are credibility multipliers, even if revenue is small initially.",
          "sentiment": 0.5,
          "engagement": "815",
          "price_at_post": "13.75",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403262Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251320-Sanibel-33736639",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.953616",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Its not all about NCI that is the the great thing. Who else wants to get their hands on this cutting edge technology Could be very very big indeed but negotiations and contracts take time. We are in Aim as well so thats a consideration.",
          "sentiment": 0.0,
          "engagement": "4,556",
          "price_at_post": "13.75",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403236Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251326-Humpalum-63928662",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.953201",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "And then the second piece of who wouldn't want optimal? It stops the need for animal testing which saves 6 months and loads of costs + the fact the fda are trying to stop animal testing where possible - is just a matter of patience here and the contracts will come imo",
          "sentiment": 0.5,
          "engagement": "1,592",
          "price_at_post": "13.75",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403210Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251335-saxman30--2367859",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.952783",
        "source": "LSE_CHAT",
        "data": {
          "author": "saxman303",
          "content": "I wonder how many sold at a loss today anybody want to own upto it",
          "sentiment": 0.0,
          "engagement": "692",
          "price_at_post": "13.75",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403183Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251412-Sanibel-14486610",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.952378",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "I can see this moving up again very soon.",
          "sentiment": 0.0,
          "engagement": "4,556",
          "price_at_post": "14.00",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403156Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251429-saxman30-72903762",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.951960",
        "source": "LSE_CHAT",
        "data": {
          "author": "saxman303",
          "content": "Really",
          "sentiment": 0.0,
          "engagement": "692",
          "price_at_post": "14.00",
          "thread_title": "RE: Enhanced ownership for Fusion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=EAB4AE99-DFEE-4D01-8B49-792AC0EF8C00"
        },
        "ingested_at": "2026-01-21T02:20:47.403129Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251459-stan1234--4191051",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.951555",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "Would be nice for us all.",
          "sentiment": 0.5,
          "engagement": "207",
          "price_at_post": "14.00",
          "thread_title": "Blue close",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=6A6359DD-B063-486D-A36D-A8C66886A3F0"
        },
        "ingested_at": "2026-01-21T02:20:47.403094Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251505-Eurobuil--3034291",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.951156",
        "source": "LSE_CHAT",
        "data": {
          "author": "Eurobuild1",
          "content": "The price seems to be stuck in treacle, it will take some stirring and and a different mindset from the mm to shift it upwards",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "14.00",
          "thread_title": "RE: Blue close",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=6A6359DD-B063-486D-A36D-A8C66886A3F0"
        },
        "ingested_at": "2026-01-21T02:20:47.403068Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251550-Antha-75734212",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.950739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "It seems obvious to me that FAB are now looking at a far more substantial contract with the NCI than the original one first envisaged hence the delay of a few months or could it be that the US National Institutes of Health are looking at buying FAB outright, it's going to be a very interesting Q1 2026.",
          "sentiment": 0.0,
          "engagement": "2,735",
          "price_at_post": "14.00",
          "thread_title": "RE: RNS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5E867739-2BFA-45DB-9EF9-A62A12836706"
        },
        "ingested_at": "2026-01-21T02:20:47.403041Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251556-DP64-26141390",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.950337",
        "source": "LSE_CHAT",
        "data": {
          "author": "DP64",
          "content": "Antha, I agree with your assessment.  I think FAB is now in a very good bargaining position rather than just sign whatever NCI wants.  This is definitely a very good sign.",
          "sentiment": 0.5,
          "engagement": "820",
          "price_at_post": "14.00",
          "thread_title": "RE: RNS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5E867739-2BFA-45DB-9EF9-A62A12836706"
        },
        "ingested_at": "2026-01-21T02:20:47.403014Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251558-Rocka--1284304",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.949914",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Don\u2019t think they are allowed to buy them out. Its a a federal agency.",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "14.00",
          "thread_title": "RE: RNS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5E867739-2BFA-45DB-9EF9-A62A12836706"
        },
        "ingested_at": "2026-01-21T02:20:47.402988Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251604-Humpalum-54154472",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.949510",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Potentially Antha, doing the contract at the org above NCI will defo open doors to the other 26 institutions underneath it several of which deal with antibodies such as NIAID",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "14.00",
          "thread_title": "RE: RNS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5E867739-2BFA-45DB-9EF9-A62A12836706"
        },
        "ingested_at": "2026-01-21T02:20:47.402962Z"
      },
      {
        "event_id": "SOCIAL-19Dec20251734-Antha-51597458",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.949091",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "I said last week that this week was going to be crazy, never in a million years did I think it would drop over 27% on validation news but I guess that's AIM for you. If I had any spare money I would literally put it all in here whilst the sp is so low and then simply wait for the upgraded NCI contract to land in a few months time, hold for gold as they say.",
          "sentiment": 0.0,
          "engagement": "2,735",
          "price_at_post": "14.00",
          "thread_title": "Crazy week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0B2A7116-2ACF-4558-BF67-8EE3DD161CD7"
        },
        "ingested_at": "2026-01-21T02:20:47.402935Z"
      },
      {
        "event_id": "SOCIAL-20Dec20250836-Seancadm-36483939",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.948682",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This line taken from yesterday\u2019s RNS. \u201c The NCI has expressed an interest in continuing to use OptiMAL\u00ae as a frontline human antibody discovery platform for a range of targets.\u201d My understanding of the term \u201cfrontline\u201d means that OptiMal will be the NCIs platform of choice for antibody discovery, the \u201cgo to\u201d method because it is better than all the rest! So if the most respected organisation in the field describes OptiMal as \u201cfrontline\u201d Fusion now have the best they could have hoped for in terms of validation for OptiMal. This is a huge milestone for the company.",
          "sentiment": 0.5,
          "engagement": "209",
          "price_at_post": "14.00",
          "thread_title": "RE: RNS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5E867739-2BFA-45DB-9EF9-A62A12836706"
        },
        "ingested_at": "2026-01-21T02:20:47.402909Z"
      },
      {
        "event_id": "SOCIAL-20Dec20251022-Rocka-70036026",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.948250",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Potential is huge but we do need some short term catalysts and killer rns\u2019s shorterm to stop this dropping any further. Hopefully 2026 will be a transformational year.",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "14.00",
          "thread_title": "RE: RNS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5E867739-2BFA-45DB-9EF9-A62A12836706"
        },
        "ingested_at": "2026-01-21T02:20:47.402883Z"
      },
      {
        "event_id": "SOCIAL-20Dec20251318-druml-18846972",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.947818",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "The fact that nih are involved in the optimal deal is significantly important. This can open up the other us institutions such as centre of disease control. CDC and other. Fusion has a track record of working with these bodies in the past. We can also be assured that Roche are talking to Fusion as there is a long positive relationship there. These will all bear fruit in 2026.",
          "sentiment": 0.5,
          "engagement": "23",
          "price_at_post": "14.00",
          "thread_title": "Nci nih",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1BC51F7D-B610-4C79-A94C-ADACC27FA759"
        },
        "ingested_at": "2026-01-21T02:20:47.402856Z"
      },
      {
        "event_id": "SOCIAL-20Dec20251637-jaari888-33785293",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.947383",
        "source": "LSE_CHAT",
        "data": {
          "author": "jaari888",
          "content": "Good point about the validation and use of the term frontline from seancadman Very confident in FABs ability to negotiate a contract with NCI which balances goals of achieving formal public validation as well as commercial value for shareholders",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "14.00",
          "thread_title": "RE: RNS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5E867739-2BFA-45DB-9EF9-A62A12836706"
        },
        "ingested_at": "2026-01-21T02:20:47.402830Z"
      },
      {
        "event_id": "SOCIAL-21Dec20252313-gtc1507-44519262",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.946945",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The share price dropped on the rns but this is my View on Why It\u2019s Still a Positive Development: Despite the price dip, the NCI\u2019s interest is largely good news for Fusion\u2019s long-term prospects. It validates the OptiMAL platform\u2019s efficacy on real-world targets and could lead to a materially expanded partnership. The proposal would allow NCI to screen multiple additional targets via OptiMAL, which, if formalized, likely not only increases Fusion\u2019s service revenue potential but also might involve Fusion sharing in the intellectual property or downstream value (\u201cenhanced ownership\u201d) of resulting antibody candidates. Such a scenario could be transformative \u2013 e.g. royalties or license fees if NCI-discovered antibodies progress to therapeutics. In sum, the market\u2019s short-term reaction seems cautious due to uncertainty and timing, but fundamentally the update reinforces Fusion\u2019s technology validation at the highest level and opens the door to deeper collaboration with a premier cancer research institute.",
          "sentiment": 0.5,
          "engagement": "1,136",
          "price_at_post": "14.00",
          "thread_title": "Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402804Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250811-Saintsmi--5280225",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:20.946481",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "The deal will come with the NCI but they are not our only customer. There are plenty of huge big name pharmaceuticals who spend a lot of money developing antibodies , who all want to bring them to market as quickly , safe and accurately as possible . Big money to be made through royalties and access to FAB \u2018s huge antibody library . Our tech is patented and the NCI have validated it and want to continue using optimal as it is the best and largest in the world . It will just take time for the huge orders to come rolling in now after the launch in San Diego . Patience is all that is required now .",
          "sentiment": 0.0,
          "engagement": "2,134",
          "price_at_post": "14.25",
          "thread_title": "RE: Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402778Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250818-bannside-80393763",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.269193",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "Where\u2019s your proof for these large orders",
          "sentiment": 0.0,
          "engagement": "169",
          "price_at_post": "14.00",
          "thread_title": "RE: Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402751Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250918-gtc1507-15258683",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.268779",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Referring to the \u00a31m in the optimal sales pipeline before the launch had even happened maybe?",
          "sentiment": 0.0,
          "engagement": "1,136",
          "price_at_post": "14.00",
          "thread_title": "RE: Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402725Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251012-Rocka-28508215",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.268367",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Great price for a topup",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "13.00",
          "thread_title": "RE: Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402699Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251337-stt1--5245041",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.267953",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "There you go, fell back, as predicted. Was great to trade again, whilst maintaining that they need funding and were pumped/dumped.",
          "sentiment": 0.0,
          "engagement": "4,512",
          "price_at_post": "13.50",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-01-21T02:20:47.402673Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251341-stt1-80389729",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.267538",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "MMHater \"Sti must feel a right idiot and loser today. \" you posted this when the sp was 19p.... Have you looked in the mirror???...",
          "sentiment": 0.0,
          "engagement": "4,512",
          "price_at_post": "13.50",
          "thread_title": "RE: Ha ha ha. sti sold a couple days ago",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=16F2F8FD-FC78-4AF1-834F-BFF85ACDD8C8"
        },
        "ingested_at": "2026-01-21T02:20:47.402647Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251344-stt1-60570137",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.267116",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc \"\u00a31m in the optimal sales pipeline \" \u00a31m sales pipeline by when and over what period of time? How much profit, cash generation, given they are short of cash?",
          "sentiment": 0.0,
          "engagement": "4,512",
          "price_at_post": "13.50",
          "thread_title": "RE: Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402620Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251351-Humpalum-20284389",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.266689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "They have a cash runway til FY27 which as has been confirmed on the investor hub didn't include NCI in the calculation so they're fine for cash And profit again as has been stated optimal license agreements are as close to 100% margin as you can get as there is little to no outlay on them - this was in one of the recent presenations",
          "sentiment": 0.5,
          "engagement": "1,592",
          "price_at_post": "13.50",
          "thread_title": "RE: Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402594Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251400-Rocka-12741008",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.266279",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Guys please, please, ignore it. I have him on filter, he\u2019s a loser, don\u2019t feed the troll.",
          "sentiment": 0.0,
          "engagement": "174",
          "price_at_post": "13.50",
          "thread_title": "RE: Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402568Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251654-evman27-35291697",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.265859",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Merry Christmas STI, Try to stay merry.",
          "sentiment": 0.0,
          "engagement": "173",
          "price_at_post": "13.00",
          "thread_title": "RE: Hidden gem",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=C29BBB4E-B47C-4904-A16D-F898BF70D85B"
        },
        "ingested_at": "2026-01-21T02:20:47.402542Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251745-Cheapsha--1947663",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.265444",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Buy and hold. I\u2019m probably gonna hit the long button too tomorrow Still have all my shares. Not selling anytime soon.",
          "sentiment": 0.5,
          "engagement": "2,643",
          "price_at_post": "13.00",
          "thread_title": "Bargain",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B857BAC3-8659-444F-B513-C1D88C0575CF"
        },
        "ingested_at": "2026-01-21T02:20:47.402515Z"
      },
      {
        "event_id": "SOCIAL-22Dec20252115-JRjnr-49481856",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.265020",
        "source": "LSE_CHAT",
        "data": {
          "author": "JRjnr",
          "content": "Suspect this will rally back fast in Jan\u2026 contract news and NCI deal are on the menu\u2026 and if sharks are circling this could move even quicker\u2026Adrian looked like the cat that had got the cream at the conference\u2026 more to come I suspect very shortly",
          "sentiment": 0.0,
          "engagement": "4,861",
          "price_at_post": "13.00",
          "thread_title": "RE: Bargain",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B857BAC3-8659-444F-B513-C1D88C0575CF"
        },
        "ingested_at": "2026-01-21T02:20:47.402489Z"
      },
      {
        "event_id": "SOCIAL-23Dec20250728-mmhater--6681959",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.264614",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "How this is at 13p a share with a world leading technology is beyond me. AIM has a lot to answer for on how it manipulates the value of companies. This will  have to re rate at some point to a sensible level. It\u2019s no wonder so many companies leave the market to realise true value.",
          "sentiment": 0.0,
          "engagement": "645",
          "price_at_post": "13.00",
          "thread_title": "Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T02:20:47.402463Z"
      },
      {
        "event_id": "SOCIAL-23Dec20250741-Laura202--6283657",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.264209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Does anyone know if the top holders like Troutisout1 have commented yet on the recent RNS and also the drop in revenues mentioned in recent results Would be re assuring to hear thier views before I invest The Directors note that there is inherent uncertainty in any cash flow forecast, however this is further exacerbated given the nature of the Company's trade and the industry in which it operates. Due to the risk that revenues and the related conversion of revenue to cash inflows may not be achieved as forecast over the going concern period, the Directors believe that there exists a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern without raising additional funds and it may be unable to realise its assets and discharge its liabilities in the normal course of business.",
          "sentiment": 0.0,
          "engagement": "14,915",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T02:20:47.402436Z"
      },
      {
        "event_id": "SOCIAL-23Dec20250850-Cheapsha-86646394",
        "event_type": "social_post",
        "date": "2026-01-10T04:06:17.263785",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "There is a large NCI on the way plus many other deals to come. You could also do well to read the Allenby note along with the RNS contents; Allenby note is significantly more positive that what we chatting here: \u201c Fusion Antibodies\u2019 (FAB.L) interim results highlight impressive progress, given its limited resources and the difficult trading environment in the reporting period (April-September). The receipt of two grant awards has allowed Fusion to offset some overhead costs, increase R&D spend and lease some capital items ahead of the planned commercial launch of OptiMAL next month. The results themselves were in line with the trading statement last month and our FY26 forecasts are broadly unchanged. We continue to see a significant recovery with revenue in H2 (to \u00a31.4m, +86%) with trading helped by the improving environment in biotech. With improvements in gross margin and tight cost control/working capital management, our model indicates Fusion has a cash runway into FY27. We tentatively indicate revenues for FY27 to be c. \u00a33m without assuming any material contribution from OptiMAL",
          "sentiment": 0.5,
          "engagement": "2,643",
          "price_at_post": "13.00",
          "thread_title": "RE: Ridiculous share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=887A2F3C-11F4-41DF-BDB7-90F8C954D3EB"
        },
        "ingested_at": "2026-01-21T02:20:47.402409Z"
      },
      {
        "event_id": "SOCIAL-23Jan20261516-gtc1507--1336363",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721015",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Still sitting 4 v 3 here. The l2 book Hasn\u2019t moved since open strangely despite some chunky buys",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738033+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261512-mmhater-86582872",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721463",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Has anyone got level 2? i imagine it will be getting stronger all the time. A tick up would be nice to see.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738069+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-chrishut-55389220",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721890",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A couple in the telegram group bought more today Great prices on offer",
          "sentiment": 0.0,
          "engagement": "17,380",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738116+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261215-mmhater-55200953",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722312",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I\u2019ve got far to many already\u2026. This is AIM at the end of the day and you never know when you are going to get screwed over. Expect the unexpected! On that note i don\u2019t expect 50p anytime soon.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738152+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261208-Rocka-19350896",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ideally i\u2019d like this at 20p pre news then i think we\u2019ll easily easily hit 40p min short term",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738171+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261207-Rocka-87585795",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723144",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "No ramping intended but if i had \u00a38k now i\u2019d put it all in FAB, topped up last week and expecting \u00a310k early Feb and i\u2019ll put it all in fab. This is a no brainer tbh especially at this price",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738190+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-gtc1507--4439549",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723563",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My gut says we will hear something next week",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738209+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261159-mmhater--6983926",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723976",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I did my little bit yesterday\u2026. I do have another 8k i\u2019m tempted to put in but haven\u2019t decided yet\u2026. Time is ticking and i\u2019m expecting news very soon. NCI wanted to carry on using optimal immediately so must need a deal soon??? Are FAB just letting them use it in the interim?? I still think this is getting bought out. Adrian\u2026 give us an update.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738227+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261138-evman27--7462992",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724413",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "250k is 14.6 Then 260k jumps to 20p!! Float disappearing fast, news will send this crazy, or if someone wants to do the honours now?!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738245+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261059-CHEATED-19101826",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724821",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "I suggest a new field of research that might be rewarding. The lack of mobility and the balance problems of stroke victims. You may have a winner here.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738263+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262332-cbeadle-86501107",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725238",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Something could happen very quickly with FAB",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738281+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261641-Rocka-59844814",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Well if it goes that high that quick i\u2019ll be equally happy as i hold quite a few already",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738298+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261637-Darkryde--8335706",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocks, I hope and think you\u2019ll only get 16,000 shares with your \u00a310k \ud83d\ude0a",
          "sentiment": 0.5,
          "engagement": "548",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738316+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261512-CHEATED-12162084",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726484",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "There should be a link-up with a large American antibody firm. Perhaps a partnership would be beneficial. Share price is in the doldrums and needs a boost of some kind. I cannot see the advantage  of the last addition of staff producing anything of great significance. Too many cooks spoil the broth. Try something new.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738334+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261456-Rocka--9565758",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019d put more in to if i had available funds, topped up last week. Expecting \u00a310k early Feb, hopefully i can buy at todays price once funds clear.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738351+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261415-evman27--8401130",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727321",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Nice buys, what a bargain price!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738369+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261405-mmhater-29292706",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727732",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "My 2 8k trades aren\u2019t showing. been a rise in trades past couple of days and i think this is going to pop soon. News is imminent. NCI have said they want to use optimal immediately so won\u2019t hang around doing deals for long\u2026",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-24T02:20:38.738387+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261338-mmhater-14976989",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728151",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I got fed up of being patient so bought another \u00a316000 worth\u2026 Come on Fusion\u2026 give us a update",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-24T02:20:38.738405+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261330-Antha-18891591",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "Everyone is just waiting for the NCI contract and other pharma contracts to be signed, until then the sp will just drift up and down between the 12-16p range, just need to be patient.",
          "sentiment": 0.0,
          "engagement": "2,740",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-24T02:20:38.738423+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261310-gtc1507-29248969",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728989",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Seems to be kicking into action again, some decent buys today. Investor relations seem to be answering questions on the hub too. Looks like the shareholder information has been updated too as of a few days ago, no sign of maven any more\u2026.. https://www.fusionantibodies-ir.com/content/investors/shareholder-information.asp",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-24T02:20:38.738441+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261100-stan1234-91474138",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729412",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "I am going to add today too. Just selling something else first.",
          "sentiment": 0.0,
          "engagement": "208",
          "price_at_post": "13.25",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-24T02:20:38.738459+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260810-formerly-37870701",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729827",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Purchased 10,000 at 13.3 via HL this morning. Wait and See!",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-24T02:20:38.738478+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261821-formerly--7537756",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730246",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-24T02:20:38.738496+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261812-gtc1507--7261822",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730660",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-24T02:20:38.738513+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261757-Cheapsha--7256516",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.731071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-24T02:20:38.738531+00:00"
      },
      {
        "event_id": "RNS-27th Jan 2026-issueofd",
        "event_type": "rns_announcement",
        "date": "2026-01-29T12:04:53.950403+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of Director Shares",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/issue-of-director-shares-uvzxm19lnyhbh5q.html",
          "rns_number": "RNS Number : 4327Q",
          "full_content": "27 Jan 2026 07:05\nRNS Number : 4327Q\nFusion Antibodies PLC\n27 January 2026\n27 January 2026\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nIssue of Director Shares\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces, further to the notification of the conditional placing and subscription to raise approximately \u00a31.4 million (before expenses) (the \"\nFundraise\n\") released earlier today (the \"\nFundraise Announcement\n\"), the Company has issued 308,720 new ordinary shares of 4p each in the share capital of the Company (\"\nOrdinary Shares\n\") to certain\nexecutive Directors at a deemed subscription price equal to the Fundraise issue price of 13 pence per new Ordinary Share (the \"\nIssue Price\n\") in satisfaction of a portion of their bonuses for the year ended 31 March 2025 (the \"\nDirector\nShares\n\").\nAs disclosed in the Company's annual report and accounts for the year ended 31 March 2025 (as announced on 4 September 2025), the remuneration committee recommended, and the board of directors of Fusion (the \"\nBoard\n\" or the \"\nDirectors\n\") accepted, a bonus award for Adrian Kinkaid (CEO) and Richard Buick (CSO) each of 20% of their gross salary, against their maximum contractual bonus of 45% and 40% respectively. In recognition that the Company is still controlling costs tightly and cognisant of the cash position, it was agreed that the bonus award be split into two components: 40% cash and the remainder to be satisfied via the issue of new Ordinary Shares once the Company was in an open period.\nAs separately indicated in Fundraise Announcement, the Board has now resolved to issue and allot, in aggregate,\n308,720\nnew Ordinary Shares to Adrian Kinkaid (CEO) and Richard Buick (CSO) at a deemed issue price equal to the Issue Price and pursuant to the authorities previously granted at the\nCompany's annual general meeting held on 16 October 2025,\nas follows:\nDirector\nAmount of bonus award to be received in Director Shares\nNo. of Director Shares issued\nTotal holding of Ordinary Shares post issue\nPercentage of enlarged issued share capital1\nAdrian Kinkaid\n\u00a323,846.94\n183,438\n1,033,438\n0.83%\nRichard Buick\n\u00a316,286.66\n125,282\n1,125,282\n0.90%\n1\nBased on the enlarged issued share capital of the Company following the issue of the Director Shares, the Placing Shares and the Subscription Shares, as defined in the Fundraise Announcement.\nAdmission to trading on AIM\nApplication has been made to the London Stock Exchange plc for the New Ordinary Shares to be admitted to trading on AIM (\"\nAdmission\n\"). It is currently anticipated that Admission will become effective and that dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on or around\n30\nJanuary 2026.\nTotal voting rights\nOn Admission, the Company will have 125,021,878 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 125,021,878 and this figure may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\nDefined terms in this announcement shall have the same meaning as defined in the Fundraise Announcement, unless otherwise defined herein.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nDirector/PDMR UK MAR disclosures\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\n1.\nAdrian Kinkaid\n2.\nRichard Buick\n2\nReason for the notification\na)\nPosition/status\n1. Chief Executive Officer\n2.\nChief Scientific Officer\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nFusion Antibodies plc\nb)\nLEI\n213800KBAYRC9VOQ9V39\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary sh",
          "content_length": 9019
        },
        "ingested_at": "2026-01-29T12:04:53.950447+00:00"
      },
      {
        "event_id": "RNS-27th Jan 2026-placinga",
        "event_type": "rns_announcement",
        "date": "2026-01-29T12:04:53.950471+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Placing and Subscription to raise approx \u00a31.4m",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/placing-and-subscription-to-raise-approx-16314m-8cdlhlss8h1m7m8.html",
          "rns_number": "RNS Number : 4325Q",
          "full_content": "27 Jan 2026 07:00\nRNS Number : 4325Q\nFusion Antibodies PLC\n27 January 2026\nTHIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED (\"EUWA\")) (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n27 January 2026\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nPlacing and Subscription to raise approximately \u00a31.4 million\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,\nannounces\nthat it has conditionally raised approximately \u00a31.4\nmillion (before expenses)\nthrough the issue of\n11,056,905\nnew ordinary shares of 4 pence each in the\nCompany (\"\nOrdinary Shares\n\") at a\nprice of 13 pence per new Ordinary Share\n(the \"\nIssue Price\n\"), as follows:\n\u00b7\napproximately \u00a31.4 million (before expenses) has been raised by way of a placing of a total of 10,904,121 new Ordinary Shares (the \"\nPlacing Shares\n\") at the Issue Price with new investors and existing shareholders (the \"\nPlacing\n\"); and\n\u00b7\nColin Walsh, Non-Executive Director, has directly subscribed with the Company for\n152,784\nnew Ordinary Shares (the \"\nSubscription Shares\n\") at the Issue Price (the \"\nSubscription\n\", and together with the Placing, the \"\nFundraise\n\"), raising \u00a319,861.92 (before expenses).\nAllenby Capital Limited (\"\nAllenby Capital\n\") and Shard Capital Partners LLP (\"\nShard\n\") are acting as the Company's joint brokers in connection with the Placing.\nKey highlights\n\u00b7\nPlacing and Subscription to raise approximately \u00a3\n1.4 million\n(before expenses) through the issue of\n11,056,905 new Ordinary\nShares at the Issue Price.\n\u00b7\nThe Issue Price is equal to the closing bid price of an Ordinary Share on\n26\nJanuary 2026.\n\u00b7\nThe Fundraise is being conducted utilising all of the existing share authorities available to the Board to issue shares for cash on a non-pre-emptive basis, as approved at the Company's annual general meeting held on 16 October 2025 (the \"\n2025 AGM\n\").\n\u00b7\nShortly following the publication of this announcement, the Company intends to issue 308,720 new Ordinary Shares (the \"\nDirector Shares\n\") to certain executive directors at a deemed subscription price equal to the Issue Price in satisfaction of a portion of their bonuses for the year ended 31 March 2025, further details of which are outlined below.\n\u00b7\nThe Placing is not being underwritten by Allenby Capital or Shard.\nAdrian Kinkaid, Chief Executive Officer of Fusion Antibodies plc, commented:\n\"\nThe successful validation and formal launch of our OptiMAL\u00ae platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time.\n\"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders.\"\nFurther details of the Fundraise are set out below.\nBackground to and reasons for the\nFundraise\nThrough the successful collaboration with the National Cancer Institute (\"\nNCI\n\") in the United Sates, the directors of the Company (the \"\nDirectors\n\" or together, the \"\nBoard\n\") believe that the Company has now validated the OptiMAL\u00ae platform with the platform performing in line with and in certain instances exceeding target performance parameters laid out by the Company.\nThe formal launch of the OptiMAL\u00ae platform took place on 15 December 2025 at the Antibody Engineering and Therapeutics conference in San Diego, an established conference which attracts a wide range of technical experts in the antibody discovery field. Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae p",
          "content_length": 26001
        },
        "ingested_at": "2026-01-29T12:04:53.950488+00:00"
      },
      {
        "event_id": "SOCIAL-Today1107-chrishut--4217801",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.749919",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316210+00:00"
      },
      {
        "event_id": "SOCIAL-Today1057-gtc1507-11882159",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.750538",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316253+00:00"
      },
      {
        "event_id": "SOCIAL-Today1042-Troutiso-75096381",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316292+00:00"
      },
      {
        "event_id": "SOCIAL-Today1035-Troutiso-30361428",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751618",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316331+00:00"
      },
      {
        "event_id": "SOCIAL-Today1033-Gheko--8978530",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-01-29T12:05:06.316370+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Rocka-43976055",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752748",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316408+00:00"
      },
      {
        "event_id": "SOCIAL-Today0846-Troutiso--4331020",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753371",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316448+00:00"
      },
      {
        "event_id": "SOCIAL-Today0842-Troutiso--6664516",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753974",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316487+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-gtc1507-83214893",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.754578",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316524+00:00"
      },
      {
        "event_id": "SOCIAL-Today0820-gtc1507--5185848",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755194",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316562+00:00"
      },
      {
        "event_id": "SOCIAL-Today0811-Rocka-39488401",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755779",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316599+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Seancadm-33150718",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316637+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Darkryde--1456013",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316674+00:00"
      },
      {
        "event_id": "SOCIAL-Today0754-gtc1507-40109793",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.757590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316712+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-Saintsmi--8834128",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316751+00:00"
      },
      {
        "event_id": "SOCIAL-Today0709-Darkryde--3295301",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316790+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262241-mmhater--1288868",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759247",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "So i\u2019ve been a big investor of FAB for the past year and am well in profit. I currently own over 1.3 million shares but this latest placement has left me sat on the fence\u2026.. I\u2019m a little fed up of the company telling us they are financially stable till time X but still keep raising money\u2026 The latest raise for 1.4 million is at a great price but i wonder if 1.4m was necessary? If deals are incoming surely  0.5m would have done\u2026.. My next thought is if the industry is worth so may billion a year why are we struggling to get a million pound of deals? surely we should be getting at least 5 percent of the market if we are best in the field. I\u2019m starting to lose faith Adrian\u2026. nearly put another 10k in here but your latest actions have made me dubious.",
          "sentiment": 0.0,
          "engagement": "656",
          "price_at_post": "13.125",
          "thread_title": "Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-29T12:05:06.316829+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262110-cbeadle-74968655",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759663",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I would do , but FAB my largest holding and I am very into mining stocks which are generally doing well.",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.125",
          "thread_title": "Buy More?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=9B999AB7-3C0D-4F49-942F-FD2729833E45"
        },
        "ingested_at": "2026-01-29T12:05:06.316867+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262033-gtc1507-84328210",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760077",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "That\u2019s some conviction Chris good to see. Hopefully a floor here. Looking forward to seeing the tr1s to see which institutions came in",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316906+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261838-chrishut--2886926",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760509",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I took 175k today and still had orders in, that didn\u2019t fill.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316944+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261805-gtc1507--7463943",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761183",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "ORDEEERRRR",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.316981+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261744-Troutiso--8931998",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I count at least 200k of buys been put in the sell column,  150k were mine and the other looks to be a 50k buy just as the offer rose this morning. So the buys have it, the buys have it...",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.317021+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261540-Troutiso--3332690",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.762581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Just sniped another 50k at the placing price",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.317058+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261342-chrishut-85119862",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763155",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I added quite a few more today too, it is a no brainer now, cashed up and contracts likely to be a lot more frequent",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.317096+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261341-chrishut--5702831",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763701",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nicely played trout",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.317156+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261209-Troutiso-70993323",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.516994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There seems to be a few PI sellers, getting out at below the placing price. I think these may be short term investors looking at other grass is greener stocks. I have used the opportunity to add at the placing price for the moment, I believe that the shares will have gone to long term investors and as such think that in a few days this realisation will be apparent and others will start to add again. Looks like a few delayed 50k buys coming through now. MMs are playing around with this, but not enough conviction from buyers to get this moving upwards, hopefully start to see something next week, would be good now they have got this out of the way to get an update from the Company.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.317196+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261037-gtc1507--8880900",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.517590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Positive mention in a research note yesterday on SP angel, healthcare conditions note/ https://www.spangel.co.uk/research/",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "12.875",
          "thread_title": "Research note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=574BB89D-C932-496A-80A3-2E9C64DACF5C"
        },
        "ingested_at": "2026-01-29T12:05:06.317235+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-Troutiso--5278302",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes me too, limits down to 10k now, well on the way to filling the headroom back up to 2.99%",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "12.875",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.317276+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260930-chrishut--8532886",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518658",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Took another 75k",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.00",
          "thread_title": "I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-29T12:05:06.317315+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260733-Eurobuil--3337211",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Eurobuild1",
          "content": "Don\u2019t come gloating on here , keep your opinions to yourself if your giving it the big told you so",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "13.25",
          "thread_title": "RE: Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-01-29T12:05:06.317354+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262144-stt1-78413744",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519750",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "From the placing rns: \"The net proceeds of the fundraise, being approximately \u00a31.3m, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL platform, to invest in the company's commercial activities and for general working capital purposes.\" https://www.insidermedia.com/news/ireland/fusion-antibodies-raises-1.4m-to-drive-growth-plans From the grant rns, which they received less than a year ago: \"The Grant support to Fusion is to cover human resource needs, materials/consumables costs and overheads.\" https://www.londonstockexchange.com/news-article/FAB/approval-of-grant-funding/17002681 That suggests to me they have utilised all of the grant money to date and so needed more.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-01-29T12:05:06.317394+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262128-stt1--5151971",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520299",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Well done Alice for predicting a placing. I see you got a lot of abuse. I wouldn't wait for an apology from these clueless rampers.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: If Fusion places 100M share",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BCF5D778-E9D7-439C-990A-6D28AB648781"
        },
        "ingested_at": "2026-01-29T12:05:06.317431+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262117-stt1-90854469",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520864",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Humpalumps \"Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually\" Oh dear, can't handle the truth. My 1st post on FAB was a year ago, Jan 2025, after HVO pump and dumpers moved across to here. HVO crashed from c30p to c5p today on company newsflow, red flags I'd been warning about. https://www.lse.co.uk/profiles/stt1/?page=16 I can understand your frustration at being completely wrong and loading up c30p.. my posting history is there for all to see your lies about my posts... There's always one who's totally stupidity and incapable of reading the company newsflow. This from your post just a month ago....22nd Dec 13.51 \"They have a cash runway til FY27 which as has been confirmed on the investor hub didn't include NCI in the calculation so they're fine for cash\" https://www.lse.co.uk/profiles/humpalumps/ You need to read and understand company newsflow as it'll help you stop making those stupid mistakes.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-01-29T12:05:06.317469+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261929-Humpalum--2481890",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Jokes \ud83e\udd23 are we actually being lectured by the guy who told everyone to buy TLY that went bust while simultaneously warning people off FAB at circa 4p \ud83e\udd23\ud83e\udd23 Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually And finally this placing isn't a bad thing it sets a floor at the current price, was at 0 discount and will probably be last one this company will ever need Also I won't be replying to any of the crap you respond with because you're a terrible investor for point 1 in this comment \ud83c\udf1d",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-01-29T12:05:06.317506+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261816-stt1-25413012",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521921",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Antha, I'm glad I traded these and not held on, like you, at 30p.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Ha ha ha. sti sold a couple days ago",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=16F2F8FD-FC78-4AF1-834F-BFF85ACDD8C8"
        },
        "ingested_at": "2026-01-29T12:05:06.317544+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261804-stt1-36590785",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.522484",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Rocka, \"Sti so is now almost 20p , you are making yourself look very silly.\" I see there's a placing. Who's making themselves look very silly. I traded or you who was ramping at 20-30p. You should learn to read and understand company newsflow. The sp has fallen back exactly as predicted. Where's the clueless Humpalumps? he needs to learn and understand company newsflow. He was clueless as well, ramping these at 30p!!!",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-01-29T12:05:06.317581+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261757-stt1-25520524",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523018",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "There you go, exactly as predicted. Placing. Who was gullible enough to believe the clueless rampers!!!! Back to the same sp as before the previous pump/dump. Newsflow was exactly as expected.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Cash is low, so placing likely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=56D85761-47EE-47AB-BE35-44485A6673DC"
        },
        "ingested_at": "2026-01-29T12:05:06.317617+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261308-gtc1507--3061183",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523551",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes you\u2019re right! Sorry thought you were talking about smaller optimal screens. But yes the sliced bread analogy was a good one. We\u2019re already seeing the ITAS approach being mention in the RNS which is good. That last big pharma one Was referred to as an ITAS one so hopefully means we can retain them for more business",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317655+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261258-Troutiso--2284434",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524059",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Gtc, You are talking about full screens and AK did state that some companies may want smaller more focussed screens (if they had already developed some targets), He also stated that a full ITAS contract would be over \u00a31m, but some might want to take a more modular approach and contract to do some phases of the ITAS with FAB and that those companies will choose how many phases they would want to do with Fusion. These would likely not be RNSed due to their smaller size, piecemeal approach.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317692+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261248-Rocka--5889914",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Actually i said if there isn\u2019t any news, there has been today! Today\u2019s RNS isn\u2019t great but it\u2019s not bad news that will see the sp tank 50% as i\u2019ve been in such stocks.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317731+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261238-Troutiso-80608647",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Literally 23 hours ago you posted that if no news soon you would consider selling up.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317770+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261222-Rocka-80051011",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout, not a gambler at all. I\u2019ve been here for quite some time . I still believe in the longterm future here but the proof is in the pudding and this is what we will find out in the coming months( hopefully) Not planning on selling just considering whether i should buy more to bring my average down.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317808+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261215-gtc1507-40872822",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526095",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a good assessment, although, just to correct one piece. Adrian was clear they wouldn\u2019t get smaller contracts at the start as Optimal was designed to do full large scale screens. He said they may structure the deals differently to begin so that some of the client risk is reduced, potentially by reducing up fronts but including  success based milestone payments I.e when the screen delivers what fusion know it should then fritter payments will trigger. Slightly nuanced but still the overall value shouldn\u2019t change and the scale of the challenges will still be big but the point on the journey that fusion and the client risk profile is set and payments set may be adjusted to begin to incentivise early adopters. Adrian also said this will only be available for a limited period.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317846+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261209-Troutiso--6689292",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526590",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Realistic timeframes, valuations, etc.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317884+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261208-Troutiso--2407418",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Can I suggest having read back through your recent posts, that you are waving in the wind and seem to be very short term/big demands type of gambler. An investor wouldn't change their mind in a matter of days, unless there is a material change. You have been bemoaning news and after your post yesterday I nearly replied be careful what you wish for as a placing had entered my mind here. This is a medical CRO and they work in a field which takes a long time to get anyone to sign anything, rigorous checking and re-checking of the science, followed by rigorous checking and re-checking of the product before anyone is prepared to commit, it takes time. However, FAB has now launched OptiMAL and that is being assessed by prospective clients, this will take time but has been ongoing for some time. The Company have stated they are likely to get smaller OptiMAL use contracts to start, before some clients may come back for the chunkier full development contracts. That is the way of this particular industry. So whether or not you spend another \u00a310k here or you sell up or you spend \u00a310k elsewhere, my advice to you is to develop some patience (and that sometimes is very long term patience), while you are sitting there holding one company, others always look like they are doing better, but in reality that is not the case most of the time. Good Luck with whatever you do, but remember PIs and those on these BBs will always be ahead of reality, as they want short term gratification, when it always takes longer, costs more and can fail, invest and be patient and look at",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317923+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-Humpalum-39279262",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527465",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Personally I think there is a strong chance this will be the last placing this company ever needs - I can't really see a world where this company isn't profitable in the next 12-16 months which would be the kind of timeframe this money would last them without profitability",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.317960+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-evman27--2585174",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527915",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It's always frustrating to see a placing happen but I believe this will be the last one fusion ever has. Back when the company was struggling they raised at 80% discount, the raise last year and today was at no discount, that counts for something. As many have said it puts us in a strong negotiating position, hard to get good deals when everyone knows your cash situation is tight. Since the raise last year the company has moved leaps and bounds, raised at 6.75p and SP hit 20p not long after, I suspect we will see similar here, we should be entering a news rich period too having commercially released Optimal. It is clear there is a lot of background interest in Fusion and Optimal, at least the buyout offer when it comes won't reflect a struggling company, it puts us in a stronger position to refuse a cheap offer. I'm still happy with my money here and have been since September 2024, the value on show here today is immense.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318000+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261144-Rocka--6817296",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.528425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I have \u00a310k funds clearing next week, i\u2019m tempted , i\u2019ll have to think about whether i\u2019ll buy more. Let\u2019s  just hope we start generating some serious income without needing to resort to more placings.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318039+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261139-Rocka-30872704",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Not the RNS i was expecting, also i don\u2019t believe the BOD should get any bonuses until the company is generating a profit but hey ho it is what it is. Let\u2019s just hope we see some contracts and/or news on NCI. We need a catalyst to propel the sp.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318077+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261115-gtc1507-44122620",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529652",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Shares admitted on Friday 30th, suspect we\u2019ll see tr1s shortly after - be interesting to see who went for it",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318127+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260941-druml-76618822",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.278271",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Prudent decision by the board. Give the headroom for getting the deals in. Good to see director support.",
          "sentiment": 0.5,
          "engagement": "24",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318165+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260940-gtc1507--8019659",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279131",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "What does \u201cinvest in strategic partnerships\u201d mean do we think? \u201cThe successful validation and formal launch of our OptiMAL\u00ae platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time. \"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders.\"",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-01-29T12:05:06.318204+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260934-gtc1507--8543491",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279952",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - I took comfort there was no indication in the rns about weakness in the trading position also which I assume means they remain on track to achieve the 80% growth in h2. This was strong from the launch conference \u201c Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time\u201d.",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-01-29T12:05:06.318242+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260930-Cheapsha-73940213",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.280743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "After the raise and director shares the share count is bang on 125M share still very low. The bonus shares also issued at 13p. Market cap just under \u00a317M with this issue. To get to 50M cap we need about 40p share price very reasonable- actually that would still be cheap very cheap. But we do need some contracts signed should be here soon!",
          "sentiment": 0.5,
          "engagement": "2,671",
          "price_at_post": "13.375",
          "thread_title": "Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-01-29T12:05:06.318281+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-Bibzy7--1676443",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.281547",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Is this just the last chance for the ones in the know to get the cheap shares before this goes crazy Half full maybe outlook",
          "sentiment": 0.0,
          "engagement": "321",
          "price_at_post": "13.50",
          "thread_title": "Cheap",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34F59233-C112-41AC-AA13-18CE6878B383"
        },
        "ingested_at": "2026-01-29T12:05:06.318318+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-David195-34847731",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.282359",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "This is no surprise and positions FAB to move forward more quickly.  Potential customers need to be reassured the company is in good shape financially when due diligence is carried out.  A raise at current SP is excellent in current market conditions.  The discussions with NCI are crucial and FAB are able to conduct them from a stronger position. Getting the first contracts and renewing the agreement with NCI in the coming months is now more likely.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318356+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260824-Troutiso-45664413",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283156",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Both the bid and offer price rising within the wide quoted spread. I have a little more headroom to fill now, so have started with 50k.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318395+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260815-gtc1507-29030677",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The said they had runway to FY27 which is April. Good they have topped up the cash balance. Should help with due diligence for contracts. Buried line in the rns: \u201cMany of the organizations approached in the pre-launch phase have expressed an interest in the OptiMAL\u00ae platform including disclosure of target details under non-disclosure agreements\u201c Companies willing to share their target data with fusion is strong endorsement for their capability and expertise . This provides a very strong foundation to move forward in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318433+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Aldebara--2556712",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.284672",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Barely any discount. Seems ok to me",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318471+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Troutiso-90310550",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.285377",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Had a feeling this was coming, very quiet, lack of real trading and the timing were all tell tales, as was the tight lipped rumours. Last week SML another I have a large holding in (and seems to have been mirroring FAB prices albeit at a tenth of FAB) did a placing at 1.3p for \u00a34m they too have lots going on and are using the funds to accelerate drilling towards an earlier PFS. That was at 1.3p at no discount. The market although PIs were telling each other it had enough money has responded very positively and it closed yesterday at 1.9p. I felt it was possible that FAB would do the same and am pleased they have done so, this will accelerate OptiMAL rollout and was probably needed for some of the bigger new clients to sign any deal (they will not want to have contracts with companies who don't have a robust financial situation. I think the company have explained themselves well and don't see this as negative, if, and a big if, the shares have gone to long term IIs as the last one did. I have no reason to believe it hasn't as if this was a vulture driven firesale placing the SP would have been hammered and there would have been a 30%+ discount. I believe this is more to do with large investors wanting to add more, but not wanting to buy in the market and happy to do so in a placing at no or little discount. Overall happy with this and if the market reacts like it did last time we will soon be up at recent highs. This is nearly double the price they raised at last year, that is a sign of good progress!!! Stan it was 13.4p to buy yesterday so below mid anyway....",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318508+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260751-Seancadm--4558303",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "They had stated they had cash runway into \u201827 (financial year 27, which is from April \u201826 ). So in order to avoid a raise they would have needed contracts to drop in the next month and even then they couldn\u2019t have been certain to have money in the bank by then. So they are now fully funded, with, from the details in the RNS strong indications of OptiMal take up. This is good for the company putting a strong cash foundation under what could well become a company making year!",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318546+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260743-U_time-27551444",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286990",
        "source": "LSE_CHAT",
        "data": {
          "author": "U_time",
          "content": "Hard not to be negative about this placing. Comes at a time where we thought no placing was needed as the company was good financially and had enough contracts to manage day to day cash without a raise. Strange. Seems to suggest people are q'ing up for the 'best in class'. NCI deal now becomes even more crucial hopefully they can get it over the line otherwise FAB just becomes another one of those AIM companies that wants to keep raising funds on share holders dime until eventually they decide to delist... Hopefully wont come to that but its game time now.",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318585+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260727-bannside--8074103",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.287780",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "Tells me there no contracts ready to be signed",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318623+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260725-rp6577-90839308",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.288565",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Not the RNS I wanted to see. However, at least it is at the market price. Hopefully this now gives them the fire power to accelerate growth and really kick into gear",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318661+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260723-Stan36--8070836",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.289358",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Cheadle it is discounted from the mid price. And from the ask price ordinary investors would have to pay. So a discount of 3.8 to 7.6% NED participation during contract negotiation with NCI tells us he's not party to the details?",
          "sentiment": 0.0,
          "engagement": "863",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318698+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260710-rubarbru-54996517",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290150",
        "source": "LSE_CHAT",
        "data": {
          "author": "rubarbrubarb",
          "content": "And director involvement",
          "sentiment": 0.0,
          "engagement": "60",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318737+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260708-cbeadle--7270407",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290933",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Quite encouraging it\u2019s at the market price and not discounted at all",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318774+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260705-cbeadle--8719058",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.291707",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right news 50p to \u00a31 could happen really fast",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-01-29T12:05:06.318811+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260703-Laura202-16079226",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.292433",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Out",
          "sentiment": 0.0,
          "engagement": "15,342",
          "price_at_post": "13.50",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-29T12:05:06.318848+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262352-Clachair--2241529",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293116",
        "source": "LSE_CHAT",
        "data": {
          "author": "Clachair10",
          "content": "Hi, I have been in since near the very beginning. I need to see \u00a31/share to get my money back. Not sure that will ever happen? Could have made a killing when they floated but wasn\u2019t able to realise it. May have to bale when and if it hits 50p a share. Have been watching this for so many years waiting for the upside! C.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-01-29T12:05:06.318886+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262314-rp6577-58656556",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293774",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "My view is that they have something which is better that what their competitors have. Things can take time to get traction. However, if you are fundamentally better, then it is difficult not to see significant success down the road. Just got to sit tight and if you don\u2019t have your full position yet, add during these quiet times",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-29T12:05:06.318924+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262105-evman27--9137941",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.294509",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes I was there too, still holding and have added to my position since then on dips. It's clear Optimal and Fusion are dangerously undervalued and I feel very relaxed with my money here.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-29T12:05:06.318960+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-Seancadm--5058111",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.295238",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Anyone who is concerned about any lack of news since the launch (which to be fair was only a few weeks ago) should google how long diligence on a new platform takes, these things take time and there is certainly no need for concern at the moment. The NCI deal is progressing and as GTC says could well be bigger than anticipated due to NIH involvement. I agree though an update on progress so far would go a long way to calming investors.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-29T12:05:06.318997+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-NornIron-10255178",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296005",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Many thanks for that GTC.",
          "sentiment": 0.0,
          "engagement": "458",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-29T12:05:06.319035+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261616-gtc1507--2830158",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296852",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I\u2019m still here and was at the AGM. They were very positive about the future potential of the Optimal platform and as have said throughout all their engagements , it will take time to convince people to come onboard but they said it had the potential to be transformational for drug discovery. The brokers are predicting growth of 80% in h2 without any optimal contribution. they have historically not published every single contract they win as their view is their clients don\u2019t always enable that and it could be commercially damaging. All I know is we\u2019ve had nothing from the company to indicate anything materially different to their forecasts either up or down and all we can do is wait for news. They were hiring just before Christmas for 3 new roles so they must be confident about prospects given their cautious cash management approach. They have the grants from the FMI to help them balance those. We\u2019re just in that phase at the moment where we need to see the proof in the execution. I take comfort in the fact the NCI deal is of such a scale it requires NIH approval - that sort of deal will turn the heads of big pharma. They already have big pharma on the books as notified by the two rns at the end of summer autumn so they\u2019ll likely be engaging them about the benefits of optimal. We just need to give them time. They confirmed their cash runway into FY27 was not dependent on an NCI deal so they are. If the company are reading this tho I think investors would welcome something of an update though, silence on the hub, silence to emails, nothing on LinkedIn - all very quiet does feel like something may be bubbling behind the scenes in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-29T12:05:06.319072+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261516-gtc1507-49253803",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721015",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Still sitting 4 v 3 here. The l2 book Hasn\u2019t moved since open strangely despite some chunky buys",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319122+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261512-mmhater-25903951",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721463",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Has anyone got level 2? i imagine it will be getting stronger all the time. A tick up would be nice to see.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319162+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-chrishut-85378595",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721890",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A couple in the telegram group bought more today Great prices on offer",
          "sentiment": 0.0,
          "engagement": "17,380",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319200+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261215-mmhater-44364998",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722312",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I\u2019ve got far to many already\u2026. This is AIM at the end of the day and you never know when you are going to get screwed over. Expect the unexpected! On that note i don\u2019t expect 50p anytime soon.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319238+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261208-Rocka--8644495",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ideally i\u2019d like this at 20p pre news then i think we\u2019ll easily easily hit 40p min short term",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319276+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261207-Rocka-71877872",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723144",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "No ramping intended but if i had \u00a38k now i\u2019d put it all in FAB, topped up last week and expecting \u00a310k early Feb and i\u2019ll put it all in fab. This is a no brainer tbh especially at this price",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319318+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-gtc1507--6398405",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723563",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My gut says we will hear something next week",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319356+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261159-mmhater--7175301",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723976",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I did my little bit yesterday\u2026. I do have another 8k i\u2019m tempted to put in but haven\u2019t decided yet\u2026. Time is ticking and i\u2019m expecting news very soon. NCI wanted to carry on using optimal immediately so must need a deal soon??? Are FAB just letting them use it in the interim?? I still think this is getting bought out. Adrian\u2026 give us an update.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319394+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261138-evman27--4399426",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724413",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "250k is 14.6 Then 260k jumps to 20p!! Float disappearing fast, news will send this crazy, or if someone wants to do the honours now?!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319433+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261059-CHEATED-45081157",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724821",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "I suggest a new field of research that might be rewarding. The lack of mobility and the balance problems of stroke victims. You may have a winner here.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319471+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262332-cbeadle-78051715",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725238",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Something could happen very quickly with FAB",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319511+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261641-Rocka--7462687",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Well if it goes that high that quick i\u2019ll be equally happy as i hold quite a few already",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319549+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261637-Darkryde--6470331",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocks, I hope and think you\u2019ll only get 16,000 shares with your \u00a310k \ud83d\ude0a",
          "sentiment": 0.5,
          "engagement": "548",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319587+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261512-CHEATED-58875206",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726484",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "There should be a link-up with a large American antibody firm. Perhaps a partnership would be beneficial. Share price is in the doldrums and needs a boost of some kind. I cannot see the advantage  of the last addition of staff producing anything of great significance. Too many cooks spoil the broth. Try something new.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319625+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261456-Rocka--8630820",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019d put more in to if i had available funds, topped up last week. Expecting \u00a310k early Feb, hopefully i can buy at todays price once funds clear.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319664+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261415-evman27-62088959",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727321",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Nice buys, what a bargain price!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319702+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261405-mmhater--7314766",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727732",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "My 2 8k trades aren\u2019t showing. been a rise in trades past couple of days and i think this is going to pop soon. News is imminent. NCI have said they want to use optimal immediately so won\u2019t hang around doing deals for long\u2026",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-29T12:05:06.319739+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261338-mmhater--3948694",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728151",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I got fed up of being patient so bought another \u00a316000 worth\u2026 Come on Fusion\u2026 give us a update",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-29T12:05:06.319778+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261330-Antha--7899926",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "Everyone is just waiting for the NCI contract and other pharma contracts to be signed, until then the sp will just drift up and down between the 12-16p range, just need to be patient.",
          "sentiment": 0.0,
          "engagement": "2,740",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-29T12:05:06.319816+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261310-gtc1507-72970330",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728989",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Seems to be kicking into action again, some decent buys today. Investor relations seem to be answering questions on the hub too. Looks like the shareholder information has been updated too as of a few days ago, no sign of maven any more\u2026.. https://www.fusionantibodies-ir.com/content/investors/shareholder-information.asp",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-29T12:05:06.319855+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261100-stan1234-17385992",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729412",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "I am going to add today too. Just selling something else first.",
          "sentiment": 0.0,
          "engagement": "208",
          "price_at_post": "13.25",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-29T12:05:06.319894+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260810-formerly--4810974",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729827",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Purchased 10,000 at 13.3 via HL this morning. Wait and See!",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-29T12:05:06.319932+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261821-formerly-15015239",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730246",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-29T12:05:06.319970+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261812-gtc1507--5359273",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730660",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-29T12:05:06.320008+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261757-Cheapsha-13382063",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.731071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-29T12:05:06.320047+00:00"
      },
      {
        "event_id": "RNS-30th Jan 2026-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-30T23:46:41.996742+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/total-voting-rights-nzs8pi4mxm02lfq.html",
          "rns_number": "RNS Number : 1535R",
          "full_content": "Today 17:00\nRNS Number : 1535R\nFusion Antibodies PLC\n30 January 2026\n30 January 2026\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nTotal Voting Rights\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces\u00a0that the issued share capital of the Company at the date of this announcement comprises\n125,021,878\nordinary shares of\u00a04 pence each with one voting right per share (\"Ordinary Shares\"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is\n125,021,878\n.\nThe above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.\nThe range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM\u00a0platform and\u00a0cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nAt every stage, our client's vision is central to how we work in\ncombining the latest technological advances with cutting edge science.\nIn this work our world-class discovery (\nOptiMAL\u00ae\nand OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)\nto\nensure the best molecule goes to the clinic.\nFusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our\nIntegrated Therapeutic Antibody Services (\"ITA\") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.\nFusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.\nFusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.\nWhile therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and th",
          "content_length": 5113
        },
        "ingested_at": "2026-01-30T23:46:41.996775+00:00"
      },
      {
        "event_id": "SOCIAL-Today2232-mmhater-35432713",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472383",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Sorry guys i sound like Sti!! Just a little frustrated and disappointed at the moment",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "RE: This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-01-30T23:46:51.786287+00:00"
      },
      {
        "event_id": "SOCIAL-Today2230-mmhater-38336988",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472835",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023. Why can\u2019t fusion even make a couple of million!!!! Thought we were best in world!!",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-01-30T23:46:51.786309+00:00"
      },
      {
        "event_id": "SOCIAL-Today2116-chrishut-84417813",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473268",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Don\u2019t miss the opportunity to get some stock before the big news comes.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786328+00:00"
      },
      {
        "event_id": "SOCIAL-Today2008-stt1--6338890",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473705",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc \"Once we start to see those contracts \" Another month gone. Nearly 2 months gone since Optimal Launch, where are all these millions of pounds of contracts that were ready and waiting and were supposed to announced when Optimal Launched?? There you go, exactly as expected, newsflow continues as expected.",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786347+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507--5454927",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474138",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Indeed - the fact that they said it\u2019s of sufficient scale to warrant NIH approval over NCI is encouraging. I think that they might be able to pull off some significant down stream entitlements like royalties and milestone payments if/when NCI licence those assets out to biotech/pharma.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786364+00:00"
      },
      {
        "event_id": "SOCIAL-Today1335-David195-53582240",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474551",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "The big unknown factor is the continuation with NCI and if renewed what the contract value will be.  It could be a few million $ pa.",
          "sentiment": 0.0,
          "engagement": "875",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786383+00:00"
      },
      {
        "event_id": "SOCIAL-Today1324-Laura202-75531716",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474965",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "I added at 13.5p this morning Good afternoon",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786401+00:00"
      },
      {
        "event_id": "SOCIAL-Today1254-chrishut-85820832",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475395",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "It has to go up, and up and up. Just patience needed and we will be laughing",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786419+00:00"
      },
      {
        "event_id": "SOCIAL-Today1227-gtc1507-77641179",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475809",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "It feels like everyone is holding back on forecasting the unknown of what the optimal contribution may be. Once we start to see those contracts and how quickly they come in once the first adopters take it on I suspect we\u2019ll see quick revisions upwards.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786436+00:00"
      },
      {
        "event_id": "SOCIAL-Today1223-rp6577-64221539",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476238",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "The Allenby note is much better than Shard\u2019s, with more forward looking comments.  My only niggle is that I felt the 2027 revenue estimate was a little underwhelming. Hopefully that is a prudent number and that Optimal contribution could kick into gear with the increased BD. Also I presume that it doesn\u2019t factor in any payment that could arise under the NCI agreement (or any other potential agreements for that matter). I would have liked to have seen break even early than 2028 but perhaps that is reflective of them investing more in spending now to get the revenue growth.",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786454+00:00"
      },
      {
        "event_id": "SOCIAL-Today1120-chrishut-27240380",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476643",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nice",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-01-30T23:46:51.786472+00:00"
      },
      {
        "event_id": "SOCIAL-Today1053-gtc1507--2571277",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477058",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://x.com/hybridanllp/status/2017171235352781200?s=46",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-01-30T23:46:51.786489+00:00"
      },
      {
        "event_id": "SOCIAL-Today0947-gtc1507--5128113",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477484",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "good coverage here too https://*********************/research/hybridan/friday-take-away-30-january-2026/14_922a0adc-24fc-4af3-83ed-fa76e67f06e7",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-01-30T23:46:51.786507+00:00"
      },
      {
        "event_id": "SOCIAL-Today0921-gtc1507-21355192",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477919",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some very interesting insight in here: At least 400k going into new kit to optimise optimal. Plus infrastructure IT upgrades - think this was the website upgrade Adrian mentioned before. Also new BD executives in USA and Asia planned. Allenby holding firm on the growth forecasts for h2 so should be fairly nailed on for that. Optimal pricing interesting insight there too with indications that projects could start around 200k but generate value up to \u00a32m each if they take the whole service. Indication that clients are already considering this. Talk of aiming to return base revenues to \u00a34m and that the new platforms could match and exceed that so over \u00a38m revenues aimed for medium term. Very exciting and interesting note",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-01-30T23:46:51.786524+00:00"
      },
      {
        "event_id": "SOCIAL-Today0828-gtc1507-58089810",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478348",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2026/01/20260130-Allenby-Capital-Fusion-Antibodies-plc-FAB.L-Update-1.pdf?c5187=on&_gl=1 *6ojkea*_ga*MTUzMjEwNjY0MC4xNzY5NTAxODU0*_ga_MZVZ4CNQ86*czE3Njk3NjEzMzYkbzExJGcxJHQxNzY5NzYxMzM5JGo1NyRsMCRoMA..",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-01-30T23:46:51.786542+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-gtc1507-52397734",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478764",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/live/donald-trump-news-updates-1-29-2026 Looking positive",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "Shutdown looks to be avoided! Roll on NCI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=3F614C0C-E9AC-4A45-8698-61C9AD6D520E"
        },
        "ingested_at": "2026-01-30T23:46:51.786560+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262124-Troutiso-79011230",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "31% up with a close of 13.25p , would suggest a price a year ago just north of 10p. It actually closed on 29th Jan at 8.75p and at 8.1p on the 30th Jan, so depending on where you would like the 12 months to start, either over 50% or for the 365 day version just over 60%. But that's nit-picking, it is up substantially on a year ago!",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-01-30T23:46:51.786578+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262123-gtc1507--7715712",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479606",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Guess depends what day shard wrote the note!",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-01-30T23:46:51.786596+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262052-Surfie19-87327598",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480016",
        "source": "LSE_CHAT",
        "data": {
          "author": "Surfie1961",
          "content": "\"But the momentum is building with the share price up nearly 60% over the last 12 months\". Er.... NO Ithink you will find it more like 31%.",
          "sentiment": 0.0,
          "engagement": "2,062",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-01-30T23:46:51.786614+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261951-stt1-75847893",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480486",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc, \"The raise matters\" A lot of hindsight views. After months of claiming they don't need to raise money, they have cash runway into 2027 etc etc, you're now agreeing with me that they DID needed a raise. Great to see you've changed your opinion and agree with me. Read and understand the company/sector newsflow. Your posts: https://www.lse.co.uk/profiles/gtc1507/?page=4 My post 9th Dec, 22.46 to Vikr: \"I believe they will use this higher sp to raise cash, as they need it to fund their project plans.\" https://www.lse.co.uk/profiles/stt1/?page=3 That's exactly what they have done. The company newsflow continues as expected. The rest of your posts are all ifs, coulds, buts and potential, which isn't surprising given you've been here years and holding since the sp was over 100p and so need investors to buy in..",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-01-30T23:46:51.786632+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261910-gtc1507-19631357",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480915",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Sorry thought I\u2019d copied it in: https://shardcapital.com/capital-markets/corporate-broking/research-portal/ Top note or filter for fab",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-01-30T23:46:51.786649+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261906-rp6577--3439291",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481335",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Are you able to share a link? Whenever I read their notes I always wish they would stick their neck out and state what they consider a fair market value of the company would be in their opinion",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-01-30T23:46:51.786667+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261607-gtc1507-36523708",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481756",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Investment case. In our assessment, Fusion is significantly undervalued relative to its peers. Its current market capitalisation of \u00a314m does not adequately reflect the investments made or the underlying technology. We believe the market has yet to fully recognise the ongoing recovery in sales and order book, as well as the potential of Fusion's novel proprietary platforms (OptiMAL\u00ae, OptiPhage\u2122, and AI/ML-Ab\u2122). But the momentum is building with the share price up nearly 60% over the last 12 months.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-01-30T23:46:51.786685+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261443-Laura202-37309907",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Be nice also if one person here would end their 14mth disruption of another share after your previous gracious plea fell on deaf ears 2mths ago Is that wishful thiking ?...who knows FAB hopefully rewards all concerned Best wishes all",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786703+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261440-druml-85785985",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482597",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Be rude not to buy some more. Been in for the penny looking for the \u00a3\u00a3\u00a3",
          "sentiment": 0.5,
          "engagement": "25",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786720+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261438-Laura202--5154404",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Chris I have taken that view also , it was clear with the drop in revenues H1 and slightly delayed launch they MAY needed funds for growth... I have bought today at 13.3p a few lots",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786738+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261335-gtc1507-70013887",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497848",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I expect we\u2019ll see a few tr1s for existing vc or II taking more as well as potentially new investors as indicated in the rns",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-01-30T23:46:51.786756+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261315-Troutiso--4998368",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Well there are 68k of buys in the sell column and a delayed buy just under 100k going through, so buying well outweighs sells here, the price is climbing within the quoted spread and I see another tick or two this afternoon if this continues. Realisation will come tomorrow (with the issue of placing shares) and next week, if the placing shares have gone to sticky IIs as the last did, then people will jump on board from the sidelines",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-01-30T23:46:51.786775+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261306-livinhop--2975034",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498703",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Excellent gtc, thank you!",
          "sentiment": 0.0,
          "engagement": "1,095",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-01-30T23:46:51.786793+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261303-gtc1507-10787483",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499226",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My reflections post raise\u2026..FAB now appears to be entering a very different phase with the launch of its world-first OptiMAL platform. 1) The raise matters \u2014 and it was done from strength The placing was completed at 13p with no discount to the prior bid. That\u2019s unusual on AIM. It removes near-term funding risk just as the company moves into commercial execution, allowing Fusion to accelerate growth rather than constrain it through cost control. 2) What OptiMAL is \u2014 and why it matters OptiMAL is a new antibody discovery platform designed to find brand-new, fully human antibodies faster and with lower risk. Management describes it as first- and best-in-class, targeting the most valuable part of the drug pipeline: discovery. Discovery work is higher margin than Fusion\u2019s traditional services and keeps clients engaged for longer. Crucially, they have updated that multiple clients are already engaging under NDA to discuss OptiMAL. Clients won\u2019t engage like this unless they are serious discussions. These are premium, additive services that materially improve earnings quality. 3) Validation, commercialisation \u2014 and IP protection OptiMAL has been validated by the US National Cancer Institute, delivering single-digit nanomolar hits directly from screening. NCI now wants to move to a commercial agreement to use OptiMAL across multiple targets and years. Fusion has said the proposed deal is large enough to require NIH approval \u2014 a powerful external endorsement. This may take time to get through but it is powerful none the less at this stage. The platform is also patent-protected, with US coverage secured and further decisions pending in Europe, China, and Japan. Strong IP underpins pricing power, licensing potential, and long-term strategic value. 4) Growth was already forecast before the raise Brokers were already modelling strong H2 growth (often cited around ~80% vs H1) and ~\u00a33m revenues by FY27 before the placing. The raise de-risks delivery and broker forecasts still exclude any OptiMAL contribution. 5) Cash burn is supported, not stressed Fusion also benefits from \u00a31m of non-dilutive Future Medicines Institute funding over five years, plus shared capital equipment \u2014 lowering burn while supporting scale-up. They also have the \u00a3545k Dr5 grant. Potential near-term catalysts: \u2022 OptiMAL NDAs converting to contracts \u2022 updates on Progress on an NIH-approved NCI deal \u2022 potentially Patent decisions in major jurisdictions \u2022 Outcome of the OptiPhage licence evaluation \u2022 Hiring momentum as the company scales \u2022 A potentially strong FY26 trading update This is Not advice. DYOR \u2014 but IMO this is the clearest setup Fusion has had in years: funded, validated, IP-protected, and launching higher-margin services.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-01-30T23:46:51.786811+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261107-chrishut--7843736",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499637",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786829+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261057-gtc1507-47523559",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500057",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786846+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261042-Troutiso--1557511",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786865+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261035-Troutiso-53038441",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786882+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261033-Gheko-66478204",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-01-30T23:46:51.786901+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261012-Rocka-82185221",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786919+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260846-Troutiso--6968173",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.786938+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260842-Troutiso-59939041",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.786956+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260824-gtc1507--9088554",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502979",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.786974+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260820-gtc1507-46805197",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503409",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.786992+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260811-Rocka-72702134",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787010+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Seancadm-46231785",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787028+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Darkryde--3447664",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504671",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787046+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260754-gtc1507-30902764",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505088",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787068+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260745-Saintsmi-85060920",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505507",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787087+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260709-Darkryde-71096357",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787116+00:00"
      },
      {
        "event_id": "SOCIAL-Today1107-chrishut--7843736",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.749919",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787136+00:00"
      },
      {
        "event_id": "SOCIAL-Today1057-gtc1507-47523559",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.750538",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787155+00:00"
      },
      {
        "event_id": "SOCIAL-Today1042-Troutiso--1557511",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787173+00:00"
      },
      {
        "event_id": "SOCIAL-Today1035-Troutiso-53038441",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751618",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787191+00:00"
      },
      {
        "event_id": "SOCIAL-Today1033-Gheko-66478204",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-01-30T23:46:51.787209+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Rocka-82185221",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752748",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787227+00:00"
      },
      {
        "event_id": "SOCIAL-Today0846-Troutiso--6968173",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753371",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787245+00:00"
      },
      {
        "event_id": "SOCIAL-Today0842-Troutiso-59939041",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753974",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787264+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-gtc1507--9088554",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.754578",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787282+00:00"
      },
      {
        "event_id": "SOCIAL-Today0820-gtc1507-46805197",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755194",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787301+00:00"
      },
      {
        "event_id": "SOCIAL-Today0811-Rocka-72702134",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755779",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787319+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Seancadm-46231785",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787337+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Darkryde--3447664",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787355+00:00"
      },
      {
        "event_id": "SOCIAL-Today0754-gtc1507-30902764",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.757590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787372+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-Saintsmi-85060920",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787391+00:00"
      },
      {
        "event_id": "SOCIAL-Today0709-Darkryde-71096357",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787408+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262241-mmhater-78349976",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759247",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "So i\u2019ve been a big investor of FAB for the past year and am well in profit. I currently own over 1.3 million shares but this latest placement has left me sat on the fence\u2026.. I\u2019m a little fed up of the company telling us they are financially stable till time X but still keep raising money\u2026 The latest raise for 1.4 million is at a great price but i wonder if 1.4m was necessary? If deals are incoming surely  0.5m would have done\u2026.. My next thought is if the industry is worth so may billion a year why are we struggling to get a million pound of deals? surely we should be getting at least 5 percent of the market if we are best in the field. I\u2019m starting to lose faith Adrian\u2026. nearly put another 10k in here but your latest actions have made me dubious.",
          "sentiment": 0.0,
          "engagement": "656",
          "price_at_post": "13.125",
          "thread_title": "Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-01-30T23:46:51.787427+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262110-cbeadle--7326095",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759663",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I would do , but FAB my largest holding and I am very into mining stocks which are generally doing well.",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.125",
          "thread_title": "Buy More?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=9B999AB7-3C0D-4F49-942F-FD2729833E45"
        },
        "ingested_at": "2026-01-30T23:46:51.787445+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262033-gtc1507-80610129",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760077",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "That\u2019s some conviction Chris good to see. Hopefully a floor here. Looking forward to seeing the tr1s to see which institutions came in",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787463+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261838-chrishut--6329681",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760509",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I took 175k today and still had orders in, that didn\u2019t fill.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787481+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261805-gtc1507--7154703",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761183",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "ORDEEERRRR",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787499+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261744-Troutiso-67273864",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I count at least 200k of buys been put in the sell column,  150k were mine and the other looks to be a 50k buy just as the offer rose this morning. So the buys have it, the buys have it...",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787518+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261540-Troutiso--9368442",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.762581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Just sniped another 50k at the placing price",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787537+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261342-chrishut-46723730",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763155",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I added quite a few more today too, it is a no brainer now, cashed up and contracts likely to be a lot more frequent",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787555+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261341-chrishut-37825126",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763701",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nicely played trout",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787574+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261209-Troutiso--8453675",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.516994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There seems to be a few PI sellers, getting out at below the placing price. I think these may be short term investors looking at other grass is greener stocks. I have used the opportunity to add at the placing price for the moment, I believe that the shares will have gone to long term investors and as such think that in a few days this realisation will be apparent and others will start to add again. Looks like a few delayed 50k buys coming through now. MMs are playing around with this, but not enough conviction from buyers to get this moving upwards, hopefully start to see something next week, would be good now they have got this out of the way to get an update from the Company.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787592+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261037-gtc1507-31104322",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.517590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Positive mention in a research note yesterday on SP angel, healthcare conditions note/ https://www.spangel.co.uk/research/",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "12.875",
          "thread_title": "Research note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=574BB89D-C932-496A-80A3-2E9C64DACF5C"
        },
        "ingested_at": "2026-01-30T23:46:51.787610+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-Troutiso-88996918",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes me too, limits down to 10k now, well on the way to filling the headroom back up to 2.99%",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "12.875",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787629+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260930-chrishut-81479939",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518658",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Took another 75k",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.00",
          "thread_title": "I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-01-30T23:46:51.787647+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260733-Eurobuil--6237530",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Eurobuild1",
          "content": "Don\u2019t come gloating on here , keep your opinions to yourself if your giving it the big told you so",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "13.25",
          "thread_title": "RE: Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-01-30T23:46:51.787665+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262144-stt1--2242785",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519750",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "From the placing rns: \"The net proceeds of the fundraise, being approximately \u00a31.3m, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL platform, to invest in the company's commercial activities and for general working capital purposes.\" https://www.insidermedia.com/news/ireland/fusion-antibodies-raises-1.4m-to-drive-growth-plans From the grant rns, which they received less than a year ago: \"The Grant support to Fusion is to cover human resource needs, materials/consumables costs and overheads.\" https://www.londonstockexchange.com/news-article/FAB/approval-of-grant-funding/17002681 That suggests to me they have utilised all of the grant money to date and so needed more.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-01-30T23:46:51.787684+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262128-stt1--1664987",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520299",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Well done Alice for predicting a placing. I see you got a lot of abuse. I wouldn't wait for an apology from these clueless rampers.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: If Fusion places 100M share",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BCF5D778-E9D7-439C-990A-6D28AB648781"
        },
        "ingested_at": "2026-01-30T23:46:51.787702+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262117-stt1-48606336",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520864",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Humpalumps \"Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually\" Oh dear, can't handle the truth. My 1st post on FAB was a year ago, Jan 2025, after HVO pump and dumpers moved across to here. HVO crashed from c30p to c5p today on company newsflow, red flags I'd been warning about. https://www.lse.co.uk/profiles/stt1/?page=16 I can understand your frustration at being completely wrong and loading up c30p.. my posting history is there for all to see your lies about my posts... There's always one who's totally stupidity and incapable of reading the company newsflow. This from your post just a month ago....22nd Dec 13.51 \"They have a cash runway til FY27 which as has been confirmed on the investor hub didn't include NCI in the calculation so they're fine for cash\" https://www.lse.co.uk/profiles/humpalumps/ You need to read and understand company newsflow as it'll help you stop making those stupid mistakes.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-01-30T23:46:51.787720+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261929-Humpalum-64019550",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Jokes \ud83e\udd23 are we actually being lectured by the guy who told everyone to buy TLY that went bust while simultaneously warning people off FAB at circa 4p \ud83e\udd23\ud83e\udd23 Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually And finally this placing isn't a bad thing it sets a floor at the current price, was at 0 discount and will probably be last one this company will ever need Also I won't be replying to any of the crap you respond with because you're a terrible investor for point 1 in this comment \ud83c\udf1d",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-01-30T23:46:51.787738+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261816-stt1--5362150",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521921",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Antha, I'm glad I traded these and not held on, like you, at 30p.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Ha ha ha. sti sold a couple days ago",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=16F2F8FD-FC78-4AF1-834F-BFF85ACDD8C8"
        },
        "ingested_at": "2026-01-30T23:46:51.787756+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261804-stt1-75559378",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.522484",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Rocka, \"Sti so is now almost 20p , you are making yourself look very silly.\" I see there's a placing. Who's making themselves look very silly. I traded or you who was ramping at 20-30p. You should learn to read and understand company newsflow. The sp has fallen back exactly as predicted. Where's the clueless Humpalumps? he needs to learn and understand company newsflow. He was clueless as well, ramping these at 30p!!!",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-01-30T23:46:51.787774+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261757-stt1--3772450",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523018",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "There you go, exactly as predicted. Placing. Who was gullible enough to believe the clueless rampers!!!! Back to the same sp as before the previous pump/dump. Newsflow was exactly as expected.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Cash is low, so placing likely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=56D85761-47EE-47AB-BE35-44485A6673DC"
        },
        "ingested_at": "2026-01-30T23:46:51.787793+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261308-gtc1507--5681566",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523551",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes you\u2019re right! Sorry thought you were talking about smaller optimal screens. But yes the sliced bread analogy was a good one. We\u2019re already seeing the ITAS approach being mention in the RNS which is good. That last big pharma one Was referred to as an ITAS one so hopefully means we can retain them for more business",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787811+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261258-Troutiso-25533679",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524059",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Gtc, You are talking about full screens and AK did state that some companies may want smaller more focussed screens (if they had already developed some targets), He also stated that a full ITAS contract would be over \u00a31m, but some might want to take a more modular approach and contract to do some phases of the ITAS with FAB and that those companies will choose how many phases they would want to do with Fusion. These would likely not be RNSed due to their smaller size, piecemeal approach.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787829+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261248-Rocka--3865208",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Actually i said if there isn\u2019t any news, there has been today! Today\u2019s RNS isn\u2019t great but it\u2019s not bad news that will see the sp tank 50% as i\u2019ve been in such stocks.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787848+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261238-Troutiso-56070933",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Literally 23 hours ago you posted that if no news soon you would consider selling up.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787866+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261222-Rocka-20801403",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout, not a gambler at all. I\u2019ve been here for quite some time . I still believe in the longterm future here but the proof is in the pudding and this is what we will find out in the coming months( hopefully) Not planning on selling just considering whether i should buy more to bring my average down.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787884+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261215-gtc1507-17846555",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526095",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a good assessment, although, just to correct one piece. Adrian was clear they wouldn\u2019t get smaller contracts at the start as Optimal was designed to do full large scale screens. He said they may structure the deals differently to begin so that some of the client risk is reduced, potentially by reducing up fronts but including  success based milestone payments I.e when the screen delivers what fusion know it should then fritter payments will trigger. Slightly nuanced but still the overall value shouldn\u2019t change and the scale of the challenges will still be big but the point on the journey that fusion and the client risk profile is set and payments set may be adjusted to begin to incentivise early adopters. Adrian also said this will only be available for a limited period.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787902+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261209-Troutiso--4485071",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526590",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Realistic timeframes, valuations, etc.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787920+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261208-Troutiso-80867338",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Can I suggest having read back through your recent posts, that you are waving in the wind and seem to be very short term/big demands type of gambler. An investor wouldn't change their mind in a matter of days, unless there is a material change. You have been bemoaning news and after your post yesterday I nearly replied be careful what you wish for as a placing had entered my mind here. This is a medical CRO and they work in a field which takes a long time to get anyone to sign anything, rigorous checking and re-checking of the science, followed by rigorous checking and re-checking of the product before anyone is prepared to commit, it takes time. However, FAB has now launched OptiMAL and that is being assessed by prospective clients, this will take time but has been ongoing for some time. The Company have stated they are likely to get smaller OptiMAL use contracts to start, before some clients may come back for the chunkier full development contracts. That is the way of this particular industry. So whether or not you spend another \u00a310k here or you sell up or you spend \u00a310k elsewhere, my advice to you is to develop some patience (and that sometimes is very long term patience), while you are sitting there holding one company, others always look like they are doing better, but in reality that is not the case most of the time. Good Luck with whatever you do, but remember PIs and those on these BBs will always be ahead of reality, as they want short term gratification, when it always takes longer, costs more and can fail, invest and be patient and look at",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787938+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-Humpalum-12891071",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527465",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Personally I think there is a strong chance this will be the last placing this company ever needs - I can't really see a world where this company isn't profitable in the next 12-16 months which would be the kind of timeframe this money would last them without profitability",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787956+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-evman27--1085027",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527915",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It's always frustrating to see a placing happen but I believe this will be the last one fusion ever has. Back when the company was struggling they raised at 80% discount, the raise last year and today was at no discount, that counts for something. As many have said it puts us in a strong negotiating position, hard to get good deals when everyone knows your cash situation is tight. Since the raise last year the company has moved leaps and bounds, raised at 6.75p and SP hit 20p not long after, I suspect we will see similar here, we should be entering a news rich period too having commercially released Optimal. It is clear there is a lot of background interest in Fusion and Optimal, at least the buyout offer when it comes won't reflect a struggling company, it puts us in a stronger position to refuse a cheap offer. I'm still happy with my money here and have been since September 2024, the value on show here today is immense.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787975+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261144-Rocka-81999409",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.528425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I have \u00a310k funds clearing next week, i\u2019m tempted , i\u2019ll have to think about whether i\u2019ll buy more. Let\u2019s  just hope we start generating some serious income without needing to resort to more placings.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.787993+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261139-Rocka--2228602",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Not the RNS i was expecting, also i don\u2019t believe the BOD should get any bonuses until the company is generating a profit but hey ho it is what it is. Let\u2019s just hope we see some contracts and/or news on NCI. We need a catalyst to propel the sp.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788011+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261115-gtc1507--2483874",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529652",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Shares admitted on Friday 30th, suspect we\u2019ll see tr1s shortly after - be interesting to see who went for it",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788029+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260941-druml--4137982",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.278271",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Prudent decision by the board. Give the headroom for getting the deals in. Good to see director support.",
          "sentiment": 0.5,
          "engagement": "24",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788047+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260940-gtc1507-87091430",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279131",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "What does \u201cinvest in strategic partnerships\u201d mean do we think? \u201cThe successful validation and formal launch of our OptiMAL\u00ae platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time. \"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders.\"",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-01-30T23:46:51.788066+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260934-gtc1507-15864449",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279952",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - I took comfort there was no indication in the rns about weakness in the trading position also which I assume means they remain on track to achieve the 80% growth in h2. This was strong from the launch conference \u201c Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time\u201d.",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-01-30T23:46:51.788084+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260930-Cheapsha--4737536",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.280743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "After the raise and director shares the share count is bang on 125M share still very low. The bonus shares also issued at 13p. Market cap just under \u00a317M with this issue. To get to 50M cap we need about 40p share price very reasonable- actually that would still be cheap very cheap. But we do need some contracts signed should be here soon!",
          "sentiment": 0.5,
          "engagement": "2,671",
          "price_at_post": "13.375",
          "thread_title": "Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-01-30T23:46:51.788110+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-Bibzy7-74095579",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.281547",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Is this just the last chance for the ones in the know to get the cheap shares before this goes crazy Half full maybe outlook",
          "sentiment": 0.0,
          "engagement": "321",
          "price_at_post": "13.50",
          "thread_title": "Cheap",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34F59233-C112-41AC-AA13-18CE6878B383"
        },
        "ingested_at": "2026-01-30T23:46:51.788129+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-David195--1426054",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.282359",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "This is no surprise and positions FAB to move forward more quickly.  Potential customers need to be reassured the company is in good shape financially when due diligence is carried out.  A raise at current SP is excellent in current market conditions.  The discussions with NCI are crucial and FAB are able to conduct them from a stronger position. Getting the first contracts and renewing the agreement with NCI in the coming months is now more likely.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788148+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260824-Troutiso-65408116",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283156",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Both the bid and offer price rising within the wide quoted spread. I have a little more headroom to fill now, so have started with 50k.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788166+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260815-gtc1507--2974452",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The said they had runway to FY27 which is April. Good they have topped up the cash balance. Should help with due diligence for contracts. Buried line in the rns: \u201cMany of the organizations approached in the pre-launch phase have expressed an interest in the OptiMAL\u00ae platform including disclosure of target details under non-disclosure agreements\u201c Companies willing to share their target data with fusion is strong endorsement for their capability and expertise . This provides a very strong foundation to move forward in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788184+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Aldebara-23665158",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.284672",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Barely any discount. Seems ok to me",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788202+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Troutiso-40053341",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.285377",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Had a feeling this was coming, very quiet, lack of real trading and the timing were all tell tales, as was the tight lipped rumours. Last week SML another I have a large holding in (and seems to have been mirroring FAB prices albeit at a tenth of FAB) did a placing at 1.3p for \u00a34m they too have lots going on and are using the funds to accelerate drilling towards an earlier PFS. That was at 1.3p at no discount. The market although PIs were telling each other it had enough money has responded very positively and it closed yesterday at 1.9p. I felt it was possible that FAB would do the same and am pleased they have done so, this will accelerate OptiMAL rollout and was probably needed for some of the bigger new clients to sign any deal (they will not want to have contracts with companies who don't have a robust financial situation. I think the company have explained themselves well and don't see this as negative, if, and a big if, the shares have gone to long term IIs as the last one did. I have no reason to believe it hasn't as if this was a vulture driven firesale placing the SP would have been hammered and there would have been a 30%+ discount. I believe this is more to do with large investors wanting to add more, but not wanting to buy in the market and happy to do so in a placing at no or little discount. Overall happy with this and if the market reacts like it did last time we will soon be up at recent highs. This is nearly double the price they raised at last year, that is a sign of good progress!!! Stan it was 13.4p to buy yesterday so below mid anyway....",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788220+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260751-Seancadm--9075361",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "They had stated they had cash runway into \u201827 (financial year 27, which is from April \u201826 ). So in order to avoid a raise they would have needed contracts to drop in the next month and even then they couldn\u2019t have been certain to have money in the bank by then. So they are now fully funded, with, from the details in the RNS strong indications of OptiMal take up. This is good for the company putting a strong cash foundation under what could well become a company making year!",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788238+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260743-U_time-44435318",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286990",
        "source": "LSE_CHAT",
        "data": {
          "author": "U_time",
          "content": "Hard not to be negative about this placing. Comes at a time where we thought no placing was needed as the company was good financially and had enough contracts to manage day to day cash without a raise. Strange. Seems to suggest people are q'ing up for the 'best in class'. NCI deal now becomes even more crucial hopefully they can get it over the line otherwise FAB just becomes another one of those AIM companies that wants to keep raising funds on share holders dime until eventually they decide to delist... Hopefully wont come to that but its game time now.",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788256+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260727-bannside-15094960",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.287780",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "Tells me there no contracts ready to be signed",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788275+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260725-rp6577-21797236",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.288565",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Not the RNS I wanted to see. However, at least it is at the market price. Hopefully this now gives them the fire power to accelerate growth and really kick into gear",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788293+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260723-Stan36-24007545",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.289358",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Cheadle it is discounted from the mid price. And from the ask price ordinary investors would have to pay. So a discount of 3.8 to 7.6% NED participation during contract negotiation with NCI tells us he's not party to the details?",
          "sentiment": 0.0,
          "engagement": "863",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788311+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260710-rubarbru--9010224",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290150",
        "source": "LSE_CHAT",
        "data": {
          "author": "rubarbrubarb",
          "content": "And director involvement",
          "sentiment": 0.0,
          "engagement": "60",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788329+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260708-cbeadle--5832055",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290933",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Quite encouraging it\u2019s at the market price and not discounted at all",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788346+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260705-cbeadle--4386919",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.291707",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right news 50p to \u00a31 could happen really fast",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-01-30T23:46:51.788364+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260703-Laura202-13184897",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.292433",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Out",
          "sentiment": 0.0,
          "engagement": "15,342",
          "price_at_post": "13.50",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-01-30T23:46:51.788382+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262352-Clachair-27467035",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293116",
        "source": "LSE_CHAT",
        "data": {
          "author": "Clachair10",
          "content": "Hi, I have been in since near the very beginning. I need to see \u00a31/share to get my money back. Not sure that will ever happen? Could have made a killing when they floated but wasn\u2019t able to realise it. May have to bale when and if it hits 50p a share. Have been watching this for so many years waiting for the upside! C.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-01-30T23:46:51.788403+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262314-rp6577--7701376",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293774",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "My view is that they have something which is better that what their competitors have. Things can take time to get traction. However, if you are fundamentally better, then it is difficult not to see significant success down the road. Just got to sit tight and if you don\u2019t have your full position yet, add during these quiet times",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-30T23:46:51.788421+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262105-evman27-18784696",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.294509",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes I was there too, still holding and have added to my position since then on dips. It's clear Optimal and Fusion are dangerously undervalued and I feel very relaxed with my money here.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-30T23:46:51.788439+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-Seancadm--3226449",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.295238",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Anyone who is concerned about any lack of news since the launch (which to be fair was only a few weeks ago) should google how long diligence on a new platform takes, these things take time and there is certainly no need for concern at the moment. The NCI deal is progressing and as GTC says could well be bigger than anticipated due to NIH involvement. I agree though an update on progress so far would go a long way to calming investors.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-30T23:46:51.788456+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-NornIron-10331909",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296005",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Many thanks for that GTC.",
          "sentiment": 0.0,
          "engagement": "458",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-30T23:46:51.788474+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261616-gtc1507--7958806",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296852",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I\u2019m still here and was at the AGM. They were very positive about the future potential of the Optimal platform and as have said throughout all their engagements , it will take time to convince people to come onboard but they said it had the potential to be transformational for drug discovery. The brokers are predicting growth of 80% in h2 without any optimal contribution. they have historically not published every single contract they win as their view is their clients don\u2019t always enable that and it could be commercially damaging. All I know is we\u2019ve had nothing from the company to indicate anything materially different to their forecasts either up or down and all we can do is wait for news. They were hiring just before Christmas for 3 new roles so they must be confident about prospects given their cautious cash management approach. They have the grants from the FMI to help them balance those. We\u2019re just in that phase at the moment where we need to see the proof in the execution. I take comfort in the fact the NCI deal is of such a scale it requires NIH approval - that sort of deal will turn the heads of big pharma. They already have big pharma on the books as notified by the two rns at the end of summer autumn so they\u2019ll likely be engaging them about the benefits of optimal. We just need to give them time. They confirmed their cash runway into FY27 was not dependent on an NCI deal so they are. If the company are reading this tho I think investors would welcome something of an update though, silence on the hub, silence to emails, nothing on LinkedIn - all very quiet does feel like something may be bubbling behind the scenes in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-01-30T23:46:51.788492+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261516-gtc1507-88909723",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721015",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Still sitting 4 v 3 here. The l2 book Hasn\u2019t moved since open strangely despite some chunky buys",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788510+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261512-mmhater--4260074",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721463",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Has anyone got level 2? i imagine it will be getting stronger all the time. A tick up would be nice to see.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788528+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-chrishut--4448003",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721890",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A couple in the telegram group bought more today Great prices on offer",
          "sentiment": 0.0,
          "engagement": "17,380",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788546+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261215-mmhater-66678644",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722312",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I\u2019ve got far to many already\u2026. This is AIM at the end of the day and you never know when you are going to get screwed over. Expect the unexpected! On that note i don\u2019t expect 50p anytime soon.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788564+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261208-Rocka--2295440",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ideally i\u2019d like this at 20p pre news then i think we\u2019ll easily easily hit 40p min short term",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788582+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261207-Rocka--5257046",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723144",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "No ramping intended but if i had \u00a38k now i\u2019d put it all in FAB, topped up last week and expecting \u00a310k early Feb and i\u2019ll put it all in fab. This is a no brainer tbh especially at this price",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788600+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-gtc1507--1720904",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723563",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My gut says we will hear something next week",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788618+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261159-mmhater--7419970",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723976",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I did my little bit yesterday\u2026. I do have another 8k i\u2019m tempted to put in but haven\u2019t decided yet\u2026. Time is ticking and i\u2019m expecting news very soon. NCI wanted to carry on using optimal immediately so must need a deal soon??? Are FAB just letting them use it in the interim?? I still think this is getting bought out. Adrian\u2026 give us an update.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788636+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261138-evman27--4572730",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724413",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "250k is 14.6 Then 260k jumps to 20p!! Float disappearing fast, news will send this crazy, or if someone wants to do the honours now?!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788654+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261059-CHEATED-26743392",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724821",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "I suggest a new field of research that might be rewarding. The lack of mobility and the balance problems of stroke victims. You may have a winner here.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788672+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262332-cbeadle--4373415",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725238",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Something could happen very quickly with FAB",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788690+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261641-Rocka--3678026",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Well if it goes that high that quick i\u2019ll be equally happy as i hold quite a few already",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788708+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261637-Darkryde--8478901",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocks, I hope and think you\u2019ll only get 16,000 shares with your \u00a310k \ud83d\ude0a",
          "sentiment": 0.5,
          "engagement": "548",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788727+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261512-CHEATED--8365605",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726484",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "There should be a link-up with a large American antibody firm. Perhaps a partnership would be beneficial. Share price is in the doldrums and needs a boost of some kind. I cannot see the advantage  of the last addition of staff producing anything of great significance. Too many cooks spoil the broth. Try something new.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788746+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261456-Rocka-64282433",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019d put more in to if i had available funds, topped up last week. Expecting \u00a310k early Feb, hopefully i can buy at todays price once funds clear.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788763+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261415-evman27--3088325",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727321",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Nice buys, what a bargain price!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788781+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261405-mmhater--9230934",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727732",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "My 2 8k trades aren\u2019t showing. been a rise in trades past couple of days and i think this is going to pop soon. News is imminent. NCI have said they want to use optimal immediately so won\u2019t hang around doing deals for long\u2026",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-01-30T23:46:51.788799+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261338-mmhater--5180175",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728151",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I got fed up of being patient so bought another \u00a316000 worth\u2026 Come on Fusion\u2026 give us a update",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-30T23:46:51.788817+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261330-Antha--7171008",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "Everyone is just waiting for the NCI contract and other pharma contracts to be signed, until then the sp will just drift up and down between the 12-16p range, just need to be patient.",
          "sentiment": 0.0,
          "engagement": "2,740",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-30T23:46:51.788834+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261310-gtc1507--7436649",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728989",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Seems to be kicking into action again, some decent buys today. Investor relations seem to be answering questions on the hub too. Looks like the shareholder information has been updated too as of a few days ago, no sign of maven any more\u2026.. https://www.fusionantibodies-ir.com/content/investors/shareholder-information.asp",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-30T23:46:51.788852+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261100-stan1234-71636628",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729412",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "I am going to add today too. Just selling something else first.",
          "sentiment": 0.0,
          "engagement": "208",
          "price_at_post": "13.25",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-30T23:46:51.788870+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260810-formerly-11034980",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729827",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Purchased 10,000 at 13.3 via HL this morning. Wait and See!",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-01-30T23:46:51.788888+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261821-formerly-66813706",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730246",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-30T23:46:51.788906+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261812-gtc1507--4761716",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730660",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-30T23:46:51.788923+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261757-Cheapsha-59614932",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.731071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-01-30T23:46:51.788941+00:00"
      },
      {
        "event_id": "RNS-4th Feb 2026-holding(",
        "event_type": "rns_announcement",
        "date": "2026-02-06T23:52:50.271547+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/holdings-in-company-j8zzi1qhry9er5k.html",
          "rns_number": "RNS Number : 7532R",
          "full_content": "4 Feb 2026 15:27\nRNS Number : 7532R\nFusion Antibodies PLC\n04 February 2026\n4 February 2026\nFusion Antibodies plc\n(\"Fusion\"\nor the\n\"Company\")\nHolding(s) in Company\nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, was informed today that Rathbones Investment Management Ltd (ultimately controlled by Rathbones Group Plc) now holds 9,679,837 ordinary shares of 4 pence each in the Company, representing approximately 7.74 per cent. of the Company's issued share capital. These shares are registered in the name of Rathbones Nominees Limited.\nEnquiries:\nFusion Antibodies plc\nwww.fusionantibodies.com\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\nVia Walbrook PR\nFusion Antibodies interactive investor hub\nhttps://investorhub.fusionantibodies.com/\nAllenby Capital Limited\nTel: +44 (0) 20 3328 5656\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\nShard Capital Partners LLP\nDamon Heath (Joint Broker)\nTel: +44 (0) 207 186 9952\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\u00a0fusion@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nAbout Fusion Antibodies plc\nFusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.\nThe range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM\u00a0platform and\u00a0cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,\u00a0the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.\nAt every stage, our client's vision is central to how we work in\ncombining the latest technological advances with cutting edge science.\nIn this work our world-class discovery (\nOptiMAL\u00ae\nand OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)\nto\nensure the best molecule goes to the clinic.\nFusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our\nIntegrated Therapeutic Antibody Services (\"ITA\") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.\nFusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.\nFusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.\nWhile therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUAPPUPQGAC",
          "content_length": 4790
        },
        "ingested_at": "2026-02-06T23:52:50.271586+00:00"
      },
      {
        "event_id": "RNS-2nd Feb 2026-holding(",
        "event_type": "rns_announcement",
        "date": "2026-02-06T23:52:50.271609+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/FAB/holdings-in-company-bqgzizo7xs5apwg.html",
          "rns_number": "RNS Number : 3413R",
          "full_content": "2 Feb 2026 11:33\nRNS Number : 3413R\nFusion Antibodies PLC\n02 February 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nFusion Antibodies plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nUnicorn Asset Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUnicorn AIM VCT plc\nCity and country of registered office (if applicable)\nTeignmouth, Devon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n30 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n02 February 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n6.66%\n6.66%\n8,320,366\nPosition of previous notification (if\napplicable)\n5.65%\n5.65%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nOrdinary shares\nGB00BDQZGK16\n8,320,366\n6.66%\nSUBTOTAL 8. A\n8,320,366\n6.66%\nB 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 125,021,878\nPlace of completion\nUnicorn Asset Management Limited, Preachers Court, Charterhouse, Chartehouse Square, London, EC1M 6AU\nDate of completion\n02 February 2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUGWPUPQGGP",
          "content_length": 4839
        },
        "ingested_at": "2026-02-06T23:52:50.271626+00:00"
      },
      {
        "event_id": "SOCIAL-Today1359-Sanibel--4671042",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.729743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Some nice buys Nothing is certain but this has to be a worthwhile investment for those who have researched. A big contract or a number of would be transformational here with \u00a31 or more easily achievable Im holding tight GL Sani",
          "sentiment": 0.0,
          "engagement": "4,569",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123045+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507--6557988",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.730217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Looks like someone took 260k in the space of 15 mins earlier one this morn, must be confident",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123083+00:00"
      },
      {
        "event_id": "SOCIAL-Today1256-gtc1507--7714933",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.730651",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice to see some chunky delayed buys coming through today. Is somone accumulating or are many people realising just wha the potential is here",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123135+00:00"
      },
      {
        "event_id": "SOCIAL-Today1211-gtc1507-37670821",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731073",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "A close at these or near levels will be very strong weekly setup. Bodes well for next week",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123175+00:00"
      },
      {
        "event_id": "SOCIAL-Today1008-Seancadm-44351322",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731511",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I'm not expecting fireworks overnight, but with NCI validation, institutions increasing, and funding risk reduced, the setup looks better than it did a few months ago. Now it's about waiting for the first OptiMAL commercial foothold. Even a small evaluation or platform-access agreement would change how the market values Fusion.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123197+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261902-Troutiso-62207312",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I think apart from the initial 60k trade which was a buy, all the rest of the delayed trades over 50k look to be sells. Not a problem they got a good price and those shares will be bought up by others.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.25",
          "thread_title": "RE: Big trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=D96A8918-A1B6-42AA-B090-11B604330C21"
        },
        "ingested_at": "2026-02-06T23:53:04.123218+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261853-Troutiso--7534035",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.732355",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "A little different last year as they issued some shares and the others after a GM. However Canaccord Genuity Group Inc did announce their TR1 last of the three, probably as they are based in Vancouver. Their holding and the dilution mean they could add nearly 1.94m shares and not need to TR1 as still within the 7% band.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123241+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261851-mmhater--7003196",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.732769",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Well there has been a lot of big trades today. hard to tell if buys or sells but i think are delayed buys. Market makers have played the price sneakily dropping nothing. i expect a large rise tomorrow to counter the false drop.",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "15.25",
          "thread_title": "Big trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=D96A8918-A1B6-42AA-B090-11B604330C21"
        },
        "ingested_at": "2026-02-06T23:53:04.123273+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261319-gtc1507--7124090",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.733200",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes they are already holders - they took 7% at last years placing. Think the rns this time talked about existing and new investors demonstrating confidence. There is a possibility cannacord took more but we might have seen an rns by now perhaps",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123292+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261315-Cheapsha--1401661",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.733614",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Who is the 3rd institution, we seen 2 x RNSs Is that Cannacord?",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "15.75",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123310+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261149-Sanibel-71534989",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734033",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "All looking very good here. All thats needed is patience. Gl all Sani",
          "sentiment": 0.0,
          "engagement": "4,569",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123329+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260902-chrishut--5826414",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734466",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Was going to edit that but the word is funny so leaving it ha",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123347+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260901-chrishut-38688783",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734875",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Will we see a cancrod rns today?",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123365+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260838-gtc1507--5567385",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.735327",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Also I\u2019m glad to see stt has bought in. I think deep down we\u2019re on the same page, about the strength of fab.  the company said they would always consider raise for growth if they thought was right thing and that\u2019s what happened. They also said they were on track for breakeven without a raise but chose to take the brakes off and raise to accelerate growth. They are credible enough to convince big funds like these that the prospects are materially good enough to justify at market price investment. They\u2019ve filled the war chest now let the battle for market share with their new discovery tools commence!",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123395+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260809-gtc1507-26952172",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.735821",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "You\u2019re totally right Sean. It\u2019s kudos to them that they were able to secure that investment at zero discount from funds lik that",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123420+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260749-Seancadm--4549097",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.736277",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Most AIM companies can't attract this level of institutional capital, they don't just buy on 'hope. They Perform due diligence Speak directly to management Stress test the story. Fusion must have gained a hell of a lot of credibility! Having the backing of 3 institutional funds means the company has passed enough internal filters for serious capital to stay involved and even increase. I'm confident people are going to take notice of this backing over the coming weeks and jump on board.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123438+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262117-mmhater--4905268",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.736682",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Just waiting for a tie for tat rely a lowlife would do\u2026.. standing by.",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123456+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262047-stt1-79869252",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737139",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Buying in the placing or post placing made sense. It's hardly surprising....I also added after the placing and before today's rns, as per my assertion that they needed a placing. I've said the company needed another placing to advance their projects and that's what they have done. Rampers were claiming the company doesn't need a placing, they have cash runway until 2027. The rampers also claimed the company would be winning contracts as soon as they launch their platform. It's now 2 months and still no contracts. Newsflow has been as expected. I'll look to trade as and when as the company still face hurdles...",
          "sentiment": 0.0,
          "engagement": "4,531",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123475+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262013-steven49--5199249",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737548",
        "source": "LSE_CHAT",
        "data": {
          "author": "steven49",
          "content": "From placing",
          "sentiment": 0.0,
          "engagement": "13,711",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123494+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261941-Rocka--4958188",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737956",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Could well hit 20p this week and move on to 30-50p on contract rns",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123520+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261925-evman27--8900814",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.738402",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Great post GTC and as far as I am aware that is all correct. Things are turning here now, there are so many reasons to be invested here and I'm expecting the highly geared returns to start taking shape this year. The future is FAB!",
          "sentiment": 0.0,
          "engagement": "182",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123551+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261856-gtc1507--6883133",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.738823",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "\u2026.Counters the case that now is their time to shine? DYOR and fact check me but I think we\u2019re in for an exciting time",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123570+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261855-gtc1507-55091544",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.739377",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some substantial delayed trades printed after hours. Feels like then market is finally waking up to the positive potential here. Cashed up with large volumes going at discount to sticky institutions all while\u2026. \u2022 OptiMAL now LIVE \u2013 world-first antibody discovery platform, with multiple customers already engaging under NDA \u2022 OptiMAL deal economics step-change \u2013 programmes identified by Allenby potentially at \u00a3200k\u2013\u00a32m per deal, depending on scope, versus current revenue guidance of ~\u00a32.25m for FY26 \u2022 Clear headroom vs history \u2013 revenues were close to \u00a35m pre-downturn, highlighting recovery plus upside potential \u2022 Platform shift underway \u2013 moving from services \u2192 scalable discovery platform, structurally improving margins \u2022 Lean, cost-efficient operation \u2013 capital disciplined, with strong operating leverage as revenues scale \u2022 Margin recovery underway \u2013 mix shifting toward higher-value discovery work, reversing historic pressure \u2022 National Cancer Institute fully open \u2013 boosted FY budget and active negotiations on a multi-target collaboration \u2022 Potential peer-reviewed publications \u2013 NCI work could translate into high-impact journals, boosting credibility \u2022 Sales momentum building \u2013 brokers guiding to >80% revenue growth in h2, before any premium discovery revenues \u2022 potential for Longer, stickier client engagements \u2013 discovery work keeps clients involved earlier and for longer \u2022 Cashed up and confident \u2013 recent raise removes funding risk and unlocks growth ambition \u2022 OptiPhage licence decision pending \u2013 asymmetric upside if converted to an exclusive deal \u2022 US patent secured \u2013 strengthens IP moat in the most important biotech market \u2022 IP footprint expanding \u2013 additional patents progressing in key jurisdictions \u2022 Prestige access via Future Medicines Institute \u2013 world-class ecosystem, talent pipeline, plus \u00a31m grant and \u00a35m capital access \u2022 Local ecosystem strengthening \u2013 academia\u2013biotech\u2013industry collaboration deeper than ever in Northern Ireland \u2022 Client funding conditions improving \u2013 biotech risk appetite back, with SPDR S&P Biotech ETF at multi-year highs \u2022 Hiring from strength \u2013 attracting staff from big-name competitors \u2022 Clear geographic growth plans \u2013 expansion targeted in US and Asia \u2022 AI-enabled discovery play \u2013 OptiMAL sits squarely in the AI drug discovery sweet spot \u2022 Legacy royalties & milestones still live \u2013 historic deals mean unexpected upside remains possible \u2022 DR5 time asset nearing conclusion \u2013 project due to complete this year with licensing potential \u2022 Strategic antibody partnership with Finn therapeutics\u2013 leveraging patented antibody asset \u2022 Collaboration with Eurofins Discovery \u2013 validation and access to a global pharma client base Valuation angle: Is FAB still trading closer to a cash-backed services multiple, despite OptiMAL-sized deals that could move revenues with only a handful of wins? Genuine question: Am I missing anything that meaningfully co",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123588+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261707-Stan36--5138346",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.739787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "@Troutisout1 I'm in with 202k shares average 13.95p. Wasn't tempted to sell at 19p. Happy to wait. Good to see these tr1 confirmations and the 9.4% rise today.",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "15.75",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123607+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261706-Laura202-46804027",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.740199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Buys in the 13s looking very healthy",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "15.75",
          "thread_title": "Great day",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C6467160-466B-42CC-A9F0-BEED146D848D"
        },
        "ingested_at": "2026-02-06T23:53:04.123625+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261658-Cheapsha-16408462",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.784626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Good news overall big guns adding Hopefully soon 20p before some contracts hit the RNS Then got a better base and higher base to jump from",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123652+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261652-Troutiso--2559311",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.785367",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes their last Holdings RNS was a little confusing naming at least 5 different entities, but it is another 2,212,084 shares they have purchased for \u00a3287.6k, There's another \u00a3862k out there, so still room for another TR1, but I reckon more likely to have gone to new IIs at under 3%. Cannacord though, could still update.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123683+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261641-Dw198--8891755",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.786053",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dw198",
          "content": "Ignore, it is  Rathbones Investment Management Ltd who is the owner of the nominee account :-). Great news",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123702+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261637-Dw198--5526916",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.786745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dw198",
          "content": "It\u2019s a nominee account isn\u2019t it? So it is not Rathbones who made the investment decision, it would be the holder of the nominee account, whoever that may be",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123721+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261630-Troutiso--6796886",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.787475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Stan, I bought 200k at 13p on the 28th Jan, so others could have done so too, it wasn't just the placees. Great to see another holder from last year's placing increase again on this one, do we think we might see something from Cannacord as well? That would be great, but the realisation will now dawn that the placing shares are tightly held for the second year running.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123740+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261619-rp6577-89866440",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.788164",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Looking solid. Setting us up very nicely for news to blast us through 20p",
          "sentiment": 0.0,
          "engagement": "899",
          "price_at_post": "16.00",
          "thread_title": "RE: Another tr1",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34E599B3-B512-45C9-AF92-5E920C8E28AF"
        },
        "ingested_at": "2026-02-06T23:53:04.123758+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261603-Stan36-51514067",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.788816",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "And those investors who paid 13p in the placing are already 23% up. Where's Alice? She did predict a placing bless her \ud83d\udc8b\ud83e\udd20",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123784+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261600-NornIron-14855091",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.789509",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Go Rathbones ! Although investors like myself and many of you guys here will do our own research before investing in any share, the comprehensiveness and depth of any research most of us do will obviously never touch that of the big institutions. Buck eejits like my myself maybe think we do research at times, but the reality is we'll never get access to the info or individuals where 'real' info can be gained to make an informed buy or sell decision on any holding/s. Companies like Rathbones can do !   Although it's still heads or tails for them whether a share goes up or down going forward, they're making the investment decision knowing more than we PI's will ever know. This is a BIGGIE with Rathbones buying more  ! !",
          "sentiment": 0.0,
          "engagement": "461",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123816+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261548-chrishut--7499251",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.790197",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Boom Up we go",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-06T23:53:04.123835+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261536-AnnaRobi--4702497",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.790856",
        "source": "LSE_CHAT",
        "data": {
          "author": "AnnaRobinson",
          "content": "They didn\u2019t have that before so assuming they grossed up in the placing?",
          "sentiment": 0.0,
          "engagement": "322",
          "price_at_post": "15.25",
          "thread_title": "Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-06T23:53:04.123853+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261533-gtc1507--3630395",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.791541",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Ratbones took another 2m shares",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "15.00",
          "thread_title": "Another tr1",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34E599B3-B512-45C9-AF92-5E920C8E28AF"
        },
        "ingested_at": "2026-02-06T23:53:04.123872+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261533-Humpalum--3914704",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.792213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Rathbones increased holding too \ud83d\udc4d",
          "sentiment": 0.5,
          "engagement": "1,595",
          "price_at_post": "15.25",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=68BAB7F0-F1B4-4AD2-9D69-A66FF8564B72"
        },
        "ingested_at": "2026-02-06T23:53:04.123891+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261514-gtc1507--2724496",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.792886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some serious chunks being bought up these past few days. Someone building a big position perhaps",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-06T23:53:04.123914+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261425-gtc1507--7028733",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.793593",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I asked chat gpt to do some technical analysis last night, this is what I got; Barring any unforeseen negative developments, bullish momentum is slowly shifting in on all timeframes \u2013 implying that the balance of risks for the next few days to months is tilted toward a continuation upward or at least stabilization, rather than a return to sustained bearishness. The technical setup thus points to a greater likelihood of bullish scenarios (momentum accelerating upward) ahead, with the caveat that the market must confirm this by clearing the remaining resistance zones. If those confirmations occur, Fusion Antibodies could very well be at the start of a significant bullish momentum shift after months of decline, with upside targets in the coming weeks and months substantially above today\u2019s closing 14.625p price.",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-06T23:53:04.123947+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261419-NornIron--5664922",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.794267",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I've just done a small top up there now of 29,889 for around 4.6k.  I got them at 15.39 and happy at that. Obviously prices can rise and fall, but i feel there are too many positives going for Fab not to take a chance with a few quid more. We could see this move up very very soon.",
          "sentiment": 0.0,
          "engagement": "461",
          "price_at_post": "15.25",
          "thread_title": "Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-06T23:53:04.123966+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261121-stan1234-88060147",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.794908",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "This will just keep going up",
          "sentiment": 0.0,
          "engagement": "210",
          "price_at_post": "15.25",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-06T23:53:04.123984+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261109-mmhater-58904403",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.795568",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Market makers allowing this to slowly climb now on the quiet. Some nice buys amongst tiny sells. Brakes are slowly coming off ready for a nice rns hopefully imminently which will send this nicely into the 20s or maybe 30s. Need to remember this was 50-60p and spikes to \u00a32 a few years ago on nothing compared to where we were now",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "15.25",
          "thread_title": "RE: Going well",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1A2E7CD6-748A-4AB7-A8D9-A6D8EB0D755E"
        },
        "ingested_at": "2026-02-06T23:53:04.124003+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260958-Laura202--8303977",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.796239",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected once 14p went",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "15.125",
          "thread_title": "Going well",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1A2E7CD6-748A-4AB7-A8D9-A6D8EB0D755E"
        },
        "ingested_at": "2026-02-06T23:53:04.124021+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260954-Troutiso--7551373",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.796904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There will be delayed trades behind that SP move.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.125",
          "thread_title": "RE: Sensitivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0268C929-5B5A-4561-A591-6FD2897DA7B1"
        },
        "ingested_at": "2026-02-06T23:53:04.124039+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260933-Stan36--4897528",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.797577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Net buys 44,000 shares today. Net value of buys \u00a36,600 and market cap increases by \u00a3700,000 100:1 factor.",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "14.75",
          "thread_title": "Sensitivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0268C929-5B5A-4561-A591-6FD2897DA7B1"
        },
        "ingested_at": "2026-02-06T23:53:04.124073+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260932-chrishut-88629925",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.798249",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This is heading higher",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-06T23:53:04.124093+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260927-Stan36-55915801",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.798904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Up 15% to 15p since the 13p placing. That shows investor confidence. And has happened with low volume. Any positive news and this will burst forth \ud83d\udca5",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-06T23:53:04.124125+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260926-gtc1507-56635102",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.799723",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The decision by the National Cancer Institute (NCI) to move forward with Fusion Antibodies\u2019 OptiMAL platform is highly significant. NCI is the largest single funder of cancer research in the world, with an annual budget measured in tens of billions of dollars and a mandate to apply exceptionally rigorous scientific, technical, and commercial scrutiny. US federal procurement frameworks are specifically designed to promote competition and multi-provider tenders. Progressing instead with a single-provider approach strongly suggests that OptiMAL is not merely competitive, but meaningfully differentiated. In that context, the decision itself lends real weight to management\u2019s description of OptiMAL as first-in-class and best-in-class, claims that are rarely validated so early by an institution of this calibre. Fusion has described this as the best deal the company has ever made strategically as much as financially. Within months, this collaboration could be showcased globally, with one of the world\u2019s most prestigious cancer research bodies actively deploying OptiMAL in live discovery programmes. That level of external validation is exceptionally rare and extremely hard to replicate.",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "15.125",
          "thread_title": "NCI significance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B5214597-2A26-4A40-8D06-C710908586C7"
        },
        "ingested_at": "2026-02-06T23:53:04.124148+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260900-Troutiso-68980314",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.800425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes looking good, just very low volume again, when that picks up this will motor...",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-06T23:53:04.124166+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260847-gtc1507-40093357",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.801005",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is looking strong - no shares available instantly here, feels like it\u2019s primed for a continuation of the move up today",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-06T23:53:04.124185+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260809-gtc1507--6919997",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.083149",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Multiple clients are under NDA for Optima discussions and just reading the update from Allenby they say that they understand a number of clients are evaluating proposals from fusion. That to me fees like the tail end of the business development cycle and we could be seeing some contract awards soon enough if things move positively! Will be exciting  to see just how effectively they can convert the potential of optimal to contracts.",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.75",
          "thread_title": "Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-06T23:53:04.124217+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261950-gtc1507-22597632",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.083682",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/article/government-shutdown-ice-funding-471e55ba4c3247051739ee1b50b2857a",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.625",
          "thread_title": "RE: Serious buying",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B732929B-3433-4DD4-A746-BD075AADC17D"
        },
        "ingested_at": "2026-02-06T23:53:04.124239+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261501-livinhop--3983094",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.084215",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Another 50k delayed shares purchase - serious buying going on at the moment, has to be a good sign....I hope!! L2  currently 2v2",
          "sentiment": 0.0,
          "engagement": "1,096",
          "price_at_post": "14.50",
          "thread_title": "Serious buying",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B732929B-3433-4DD4-A746-BD075AADC17D"
        },
        "ingested_at": "2026-02-06T23:53:04.124258+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261434-Troutiso-45986578",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.084715",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Vewry shortly I reckon.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: 15.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=79D1BEB9-25D7-49E1-B410-CBAED6C59387"
        },
        "ingested_at": "2026-02-06T23:53:04.124276+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261430-mmhater-70755462",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.085225",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Tick up on its way by end of play i guess",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "14.50",
          "thread_title": "15.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=79D1BEB9-25D7-49E1-B410-CBAED6C59387"
        },
        "ingested_at": "2026-02-06T23:53:04.124294+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261350-Troutiso--7798899",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.085701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Volume is very small at the moment but positive with buys regularly outweighing sells by some margin.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-06T23:53:04.124312+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261338-gtc1507-85013612",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.086217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - new investor would need to take just short of \u00a3500k to reach tr1 / more likely we\u2019ll see the others taking more. Not to say that\u2019s not impossible - cannacord came in cold with 500k last year",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124339+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261314-Troutiso--8642244",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.086728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, I very much doubt any of the placing went to bucket shops, the twitter brigade or PIs, the clue is always in the discount. This was a well organised funding round, allowing IIs a chance to add to their holdings at a fair price.  These placings tend to see the SP react favourably, but often need a news catalyst to really ignite the SP rise. I hope to see some more TR1s but I am happy if there aren't more, there will be many IIs in here at less than 3% and probably won't move for more until the FAB valuation allows. We saw Maven sell out due to a change in Management of their fund and a different direction, many Fund Managers will be looking but not able to purchase through their fund due to investing criteria. I have now bought up all my headroom, so happy to sit back and enjoy the ride. I can see Rathbone or Cannacord adding enough for a TR1, maybe not a new investor though.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124367+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261208-chrishut-88060147",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.087238",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This will just keep going up",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124385+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261146-Rocka--4063024",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.087727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Hope you\u2019re right but i would still like to see more tr1 rns\u2019s.",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124403+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261122-Seancadm-23360261",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.088210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I think there is a good chance that a large proportion of the raise has been taken up by institutional investors, as we found out yesterday with Unicorn adding, I also don\u2019t think we have to worry about smaller investors flipping, in the RNS Adrian said, \u2018supported by a number of our longstanding shareholders\u2019, sounds like sticky hands to me.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124422+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261038-Rocka-66445504",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.088705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "We do need more tr1\u2019s , if most of the placing has been taken up by pi\u2019s then there will be flipping. I hope most of it has been taken by institutions.",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124440+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260903-gtc1507-39654633",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.089223",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice \u00a310k buy on the bell just printed!",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124461+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260837-Troutiso-29995652",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.089724",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "This is just getting us back to the price of a month ago, the placing will have weighed on that during January and now that pressure has been removed we are able to move back to previous levels. Another TR1 would show the market the placing was taken by sticky hands as last year's one was and that will encourage more to jump aboard. I see this back in the high teens soon and then it's all about newsflow to get this into the 20p's.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124493+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260808-rp6577-12033606",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.090219",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Picking up\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "899",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-06T23:53:04.124512+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260752-gtc1507-74456094",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.090732",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "In amongst the noise about the us shutdown which looks to end shortly is this positive news:...NIH getting funding increase of $415m and NCI $128m in this financial year \ud83d\udc40 https://www.science.org/content/article/final-funding-bill-nih-pushes-back-against-trump-cuts",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "NCI budget increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=12E05045-67EF-4EEF-8C99-AC4E30F34994"
        },
        "ingested_at": "2026-02-06T23:53:04.124530+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260748-gtc1507--6631571",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.091246",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Certainly did! Might we see another TR1 today to catalyse the continuation upwards?",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-06T23:53:04.124548+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260653-Laura202-74334240",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.091737",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Well yesterday certainly looked like the start of the breakout",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-06T23:53:04.124567+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262341-Cheapsha-90019409",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.092242",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Penny has dropped well that\u2019s good news After 5p and 10p what comes? 20p then 50p Easy! \ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124584+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262127-gtc1507--2221661",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.092729",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The penny will start to drop\u2026.crushed a few of the key moving averages today, starting to look very positively setup",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124616+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261404-Rocka--7753009",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.093234",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "If we get more institutional investor rns\u2019s who taken the fill placing then i think we will be in the twenties pre contract news",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124637+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261358-Rocka-71523551",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.093725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Dark, never said i was selling 100%. I was frustrated with lack of news. I was considering wether to topup and i have topped up only \u00a35k not the full \u00a310k , i used the other \u00a35k to topup some bitcoin",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124654+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261314-Laura202-40883323",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.094204",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Excellent news",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "14.00",
          "thread_title": "Institutions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=80932BC0-29D6-499F-82C1-ABEFC7DCE7F1"
        },
        "ingested_at": "2026-02-06T23:53:04.124672+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261305-Darkryde--6402806",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.094697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocka, thought you were selling and moving on to pastures new? \ud83e\udd14 \ud83d\udea7\ud83d\udfe2",
          "sentiment": 0.5,
          "engagement": "554",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124690+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261228-gtc1507--8806360",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.095205",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Should be very attractive here, cash derisked all the other positives in play",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "13.75",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-06T23:53:04.124708+00:00"
      },
      {
        "event_id": "SOCIAL-Today2232-mmhater--9179189",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472383",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Sorry guys i sound like Sti!! Just a little frustrated and disappointed at the moment",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "RE: This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-02-06T23:53:04.124731+00:00"
      },
      {
        "event_id": "SOCIAL-Today2230-mmhater-55229244",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472835",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023. Why can\u2019t fusion even make a couple of million!!!! Thought we were best in world!!",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-02-06T23:53:04.124762+00:00"
      },
      {
        "event_id": "SOCIAL-Today2116-chrishut-73120347",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473268",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Don\u2019t miss the opportunity to get some stock before the big news comes.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124782+00:00"
      },
      {
        "event_id": "SOCIAL-Today2008-stt1-21506476",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473705",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc \"Once we start to see those contracts \" Another month gone. Nearly 2 months gone since Optimal Launch, where are all these millions of pounds of contracts that were ready and waiting and were supposed to announced when Optimal Launched?? There you go, exactly as expected, newsflow continues as expected.",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124801+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507-23343399",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474138",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Indeed - the fact that they said it\u2019s of sufficient scale to warrant NIH approval over NCI is encouraging. I think that they might be able to pull off some significant down stream entitlements like royalties and milestone payments if/when NCI licence those assets out to biotech/pharma.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124819+00:00"
      },
      {
        "event_id": "SOCIAL-Today1335-David195--8629963",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474551",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "The big unknown factor is the continuation with NCI and if renewed what the contract value will be.  It could be a few million $ pa.",
          "sentiment": 0.0,
          "engagement": "875",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124838+00:00"
      },
      {
        "event_id": "SOCIAL-Today1324-Laura202--5518974",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474965",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "I added at 13.5p this morning Good afternoon",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124857+00:00"
      },
      {
        "event_id": "SOCIAL-Today1254-chrishut-80918649",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475395",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "It has to go up, and up and up. Just patience needed and we will be laughing",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124892+00:00"
      },
      {
        "event_id": "SOCIAL-Today1227-gtc1507--3663474",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475809",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "It feels like everyone is holding back on forecasting the unknown of what the optimal contribution may be. Once we start to see those contracts and how quickly they come in once the first adopters take it on I suspect we\u2019ll see quick revisions upwards.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124911+00:00"
      },
      {
        "event_id": "SOCIAL-Today1223-rp6577-69166830",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476238",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "The Allenby note is much better than Shard\u2019s, with more forward looking comments.  My only niggle is that I felt the 2027 revenue estimate was a little underwhelming. Hopefully that is a prudent number and that Optimal contribution could kick into gear with the increased BD. Also I presume that it doesn\u2019t factor in any payment that could arise under the NCI agreement (or any other potential agreements for that matter). I would have liked to have seen break even early than 2028 but perhaps that is reflective of them investing more in spending now to get the revenue growth.",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124930+00:00"
      },
      {
        "event_id": "SOCIAL-Today1120-chrishut--4119520",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476643",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nice",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-06T23:53:04.124948+00:00"
      },
      {
        "event_id": "SOCIAL-Today1053-gtc1507-31689391",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477058",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://x.com/hybridanllp/status/2017171235352781200?s=46",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-02-06T23:53:04.124966+00:00"
      },
      {
        "event_id": "SOCIAL-Today0947-gtc1507--8025019",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477484",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "good coverage here too https://*********************/research/hybridan/friday-take-away-30-january-2026/14_922a0adc-24fc-4af3-83ed-fa76e67f06e7",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-02-06T23:53:04.124984+00:00"
      },
      {
        "event_id": "SOCIAL-Today0921-gtc1507-20271123",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477919",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some very interesting insight in here: At least 400k going into new kit to optimise optimal. Plus infrastructure IT upgrades - think this was the website upgrade Adrian mentioned before. Also new BD executives in USA and Asia planned. Allenby holding firm on the growth forecasts for h2 so should be fairly nailed on for that. Optimal pricing interesting insight there too with indications that projects could start around 200k but generate value up to \u00a32m each if they take the whole service. Indication that clients are already considering this. Talk of aiming to return base revenues to \u00a34m and that the new platforms could match and exceed that so over \u00a38m revenues aimed for medium term. Very exciting and interesting note",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-02-06T23:53:04.125015+00:00"
      },
      {
        "event_id": "SOCIAL-Today0828-gtc1507--5211038",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478348",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2026/01/20260130-Allenby-Capital-Fusion-Antibodies-plc-FAB.L-Update-1.pdf?c5187=on&_gl=1 *6ojkea*_ga*MTUzMjEwNjY0MC4xNzY5NTAxODU0*_ga_MZVZ4CNQ86*czE3Njk3NjEzMzYkbzExJGcxJHQxNzY5NzYxMzM5JGo1NyRsMCRoMA..",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-02-06T23:53:04.125037+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-gtc1507-81354800",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478764",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/live/donald-trump-news-updates-1-29-2026 Looking positive",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "Shutdown looks to be avoided! Roll on NCI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=3F614C0C-E9AC-4A45-8698-61C9AD6D520E"
        },
        "ingested_at": "2026-02-06T23:53:04.125055+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262124-Troutiso-84377222",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "31% up with a close of 13.25p , would suggest a price a year ago just north of 10p. It actually closed on 29th Jan at 8.75p and at 8.1p on the 30th Jan, so depending on where you would like the 12 months to start, either over 50% or for the 365 day version just over 60%. But that's nit-picking, it is up substantially on a year ago!",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-06T23:53:04.125074+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262123-gtc1507-77609814",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479606",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Guess depends what day shard wrote the note!",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-06T23:53:04.125093+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262052-Surfie19-60280310",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480016",
        "source": "LSE_CHAT",
        "data": {
          "author": "Surfie1961",
          "content": "\"But the momentum is building with the share price up nearly 60% over the last 12 months\". Er.... NO Ithink you will find it more like 31%.",
          "sentiment": 0.0,
          "engagement": "2,062",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-06T23:53:04.125124+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261951-stt1-10901227",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480486",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc, \"The raise matters\" A lot of hindsight views. After months of claiming they don't need to raise money, they have cash runway into 2027 etc etc, you're now agreeing with me that they DID needed a raise. Great to see you've changed your opinion and agree with me. Read and understand the company/sector newsflow. Your posts: https://www.lse.co.uk/profiles/gtc1507/?page=4 My post 9th Dec, 22.46 to Vikr: \"I believe they will use this higher sp to raise cash, as they need it to fund their project plans.\" https://www.lse.co.uk/profiles/stt1/?page=3 That's exactly what they have done. The company newsflow continues as expected. The rest of your posts are all ifs, coulds, buts and potential, which isn't surprising given you've been here years and holding since the sp was over 100p and so need investors to buy in..",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-06T23:53:04.125150+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261910-gtc1507--2671584",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480915",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Sorry thought I\u2019d copied it in: https://shardcapital.com/capital-markets/corporate-broking/research-portal/ Top note or filter for fab",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-06T23:53:04.125178+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261906-rp6577-32172745",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481335",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Are you able to share a link? Whenever I read their notes I always wish they would stick their neck out and state what they consider a fair market value of the company would be in their opinion",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-06T23:53:04.125197+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261607-gtc1507-74596859",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481756",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Investment case. In our assessment, Fusion is significantly undervalued relative to its peers. Its current market capitalisation of \u00a314m does not adequately reflect the investments made or the underlying technology. We believe the market has yet to fully recognise the ongoing recovery in sales and order book, as well as the potential of Fusion's novel proprietary platforms (OptiMAL\u00ae, OptiPhage\u2122, and AI/ML-Ab\u2122). But the momentum is building with the share price up nearly 60% over the last 12 months.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-06T23:53:04.125215+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261443-Laura202-49238390",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Be nice also if one person here would end their 14mth disruption of another share after your previous gracious plea fell on deaf ears 2mths ago Is that wishful thiking ?...who knows FAB hopefully rewards all concerned Best wishes all",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125234+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261440-druml-56110448",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482597",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Be rude not to buy some more. Been in for the penny looking for the \u00a3\u00a3\u00a3",
          "sentiment": 0.5,
          "engagement": "25",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125252+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261438-Laura202--7401274",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Chris I have taken that view also , it was clear with the drop in revenues H1 and slightly delayed launch they MAY needed funds for growth... I have bought today at 13.3p a few lots",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125271+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261335-gtc1507--5003800",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497848",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I expect we\u2019ll see a few tr1s for existing vc or II taking more as well as potentially new investors as indicated in the rns",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-06T23:53:04.125306+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261315-Troutiso--1714620",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Well there are 68k of buys in the sell column and a delayed buy just under 100k going through, so buying well outweighs sells here, the price is climbing within the quoted spread and I see another tick or two this afternoon if this continues. Realisation will come tomorrow (with the issue of placing shares) and next week, if the placing shares have gone to sticky IIs as the last did, then people will jump on board from the sidelines",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-06T23:53:04.125325+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261306-livinhop--3568900",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498703",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Excellent gtc, thank you!",
          "sentiment": 0.0,
          "engagement": "1,095",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-06T23:53:04.125343+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261303-gtc1507--8046995",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499226",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My reflections post raise\u2026..FAB now appears to be entering a very different phase with the launch of its world-first OptiMAL platform. 1) The raise matters \u2014 and it was done from strength The placing was completed at 13p with no discount to the prior bid. That\u2019s unusual on AIM. It removes near-term funding risk just as the company moves into commercial execution, allowing Fusion to accelerate growth rather than constrain it through cost control. 2) What OptiMAL is \u2014 and why it matters OptiMAL is a new antibody discovery platform designed to find brand-new, fully human antibodies faster and with lower risk. Management describes it as first- and best-in-class, targeting the most valuable part of the drug pipeline: discovery. Discovery work is higher margin than Fusion\u2019s traditional services and keeps clients engaged for longer. Crucially, they have updated that multiple clients are already engaging under NDA to discuss OptiMAL. Clients won\u2019t engage like this unless they are serious discussions. These are premium, additive services that materially improve earnings quality. 3) Validation, commercialisation \u2014 and IP protection OptiMAL has been validated by the US National Cancer Institute, delivering single-digit nanomolar hits directly from screening. NCI now wants to move to a commercial agreement to use OptiMAL across multiple targets and years. Fusion has said the proposed deal is large enough to require NIH approval \u2014 a powerful external endorsement. This may take time to get through but it is powerful none the less at this stage. The platform is also patent-protected, with US coverage secured and further decisions pending in Europe, China, and Japan. Strong IP underpins pricing power, licensing potential, and long-term strategic value. 4) Growth was already forecast before the raise Brokers were already modelling strong H2 growth (often cited around ~80% vs H1) and ~\u00a33m revenues by FY27 before the placing. The raise de-risks delivery and broker forecasts still exclude any OptiMAL contribution. 5) Cash burn is supported, not stressed Fusion also benefits from \u00a31m of non-dilutive Future Medicines Institute funding over five years, plus shared capital equipment \u2014 lowering burn while supporting scale-up. They also have the \u00a3545k Dr5 grant. Potential near-term catalysts: \u2022 OptiMAL NDAs converting to contracts \u2022 updates on Progress on an NIH-approved NCI deal \u2022 potentially Patent decisions in major jurisdictions \u2022 Outcome of the OptiPhage licence evaluation \u2022 Hiring momentum as the company scales \u2022 A potentially strong FY26 trading update This is Not advice. DYOR \u2014 but IMO this is the clearest setup Fusion has had in years: funded, validated, IP-protected, and launching higher-margin services.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-06T23:53:04.125362+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261107-chrishut--5446697",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499637",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125380+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261057-gtc1507-52497191",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500057",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125399+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261042-Troutiso--3710178",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125432+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261035-Troutiso-31137393",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125453+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261033-Gheko-77874002",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-02-06T23:53:04.125471+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261012-Rocka-34875188",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125489+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260846-Troutiso--1460759",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125508+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260842-Troutiso--3751093",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125526+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260824-gtc1507-38999466",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502979",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125553+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260820-gtc1507-21319169",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503409",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125579+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260811-Rocka--4300073",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125597+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Seancadm-67497207",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125616+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Darkryde-64996087",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504671",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125634+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260754-gtc1507-48413554",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505088",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125652+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260745-Saintsmi--4115657",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505507",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125671+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260709-Darkryde--8487847",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.125705+00:00"
      },
      {
        "event_id": "SOCIAL-Today1107-chrishut--5446697",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.749919",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125725+00:00"
      },
      {
        "event_id": "SOCIAL-Today1057-gtc1507-52497191",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.750538",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125743+00:00"
      },
      {
        "event_id": "SOCIAL-Today1042-Troutiso--3710178",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125762+00:00"
      },
      {
        "event_id": "SOCIAL-Today1035-Troutiso-31137393",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751618",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.125780+00:00"
      },
      {
        "event_id": "SOCIAL-Today1033-Gheko-77874002",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-02-06T23:53:04.125969+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Rocka-34875188",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752748",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126004+00:00"
      },
      {
        "event_id": "SOCIAL-Today0846-Troutiso--1460759",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753371",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126024+00:00"
      },
      {
        "event_id": "SOCIAL-Today0842-Troutiso--3751093",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753974",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126043+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-gtc1507-38999466",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.754578",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126062+00:00"
      },
      {
        "event_id": "SOCIAL-Today0820-gtc1507-21319169",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755194",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126080+00:00"
      },
      {
        "event_id": "SOCIAL-Today0811-Rocka--4300073",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755779",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126107+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Seancadm-67497207",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126141+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Darkryde-64996087",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126166+00:00"
      },
      {
        "event_id": "SOCIAL-Today0754-gtc1507-48413554",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.757590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126184+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-Saintsmi--4115657",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126205+00:00"
      },
      {
        "event_id": "SOCIAL-Today0709-Darkryde--8487847",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126223+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262241-mmhater-16404647",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759247",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "So i\u2019ve been a big investor of FAB for the past year and am well in profit. I currently own over 1.3 million shares but this latest placement has left me sat on the fence\u2026.. I\u2019m a little fed up of the company telling us they are financially stable till time X but still keep raising money\u2026 The latest raise for 1.4 million is at a great price but i wonder if 1.4m was necessary? If deals are incoming surely  0.5m would have done\u2026.. My next thought is if the industry is worth so may billion a year why are we struggling to get a million pound of deals? surely we should be getting at least 5 percent of the market if we are best in the field. I\u2019m starting to lose faith Adrian\u2026. nearly put another 10k in here but your latest actions have made me dubious.",
          "sentiment": 0.0,
          "engagement": "656",
          "price_at_post": "13.125",
          "thread_title": "Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-06T23:53:04.126242+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262110-cbeadle-62402589",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759663",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I would do , but FAB my largest holding and I am very into mining stocks which are generally doing well.",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.125",
          "thread_title": "Buy More?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=9B999AB7-3C0D-4F49-942F-FD2729833E45"
        },
        "ingested_at": "2026-02-06T23:53:04.126265+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262033-gtc1507-10672708",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760077",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "That\u2019s some conviction Chris good to see. Hopefully a floor here. Looking forward to seeing the tr1s to see which institutions came in",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126296+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261838-chrishut--4071724",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760509",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I took 175k today and still had orders in, that didn\u2019t fill.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126315+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261805-gtc1507-23699693",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761183",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "ORDEEERRRR",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126333+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261744-Troutiso-14039071",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I count at least 200k of buys been put in the sell column,  150k were mine and the other looks to be a 50k buy just as the offer rose this morning. So the buys have it, the buys have it...",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126352+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261540-Troutiso-90952057",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.762581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Just sniped another 50k at the placing price",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126370+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261342-chrishut-67068560",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763155",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I added quite a few more today too, it is a no brainer now, cashed up and contracts likely to be a lot more frequent",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126399+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261341-chrishut-79379923",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763701",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nicely played trout",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126429+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261209-Troutiso--2318822",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.516994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There seems to be a few PI sellers, getting out at below the placing price. I think these may be short term investors looking at other grass is greener stocks. I have used the opportunity to add at the placing price for the moment, I believe that the shares will have gone to long term investors and as such think that in a few days this realisation will be apparent and others will start to add again. Looks like a few delayed 50k buys coming through now. MMs are playing around with this, but not enough conviction from buyers to get this moving upwards, hopefully start to see something next week, would be good now they have got this out of the way to get an update from the Company.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126465+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261037-gtc1507-40089131",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.517590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Positive mention in a research note yesterday on SP angel, healthcare conditions note/ https://www.spangel.co.uk/research/",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "12.875",
          "thread_title": "Research note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=574BB89D-C932-496A-80A3-2E9C64DACF5C"
        },
        "ingested_at": "2026-02-06T23:53:04.126495+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-Troutiso--2523115",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes me too, limits down to 10k now, well on the way to filling the headroom back up to 2.99%",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "12.875",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126514+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260930-chrishut--6931768",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518658",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Took another 75k",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.00",
          "thread_title": "I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-06T23:53:04.126533+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260733-Eurobuil-33120965",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Eurobuild1",
          "content": "Don\u2019t come gloating on here , keep your opinions to yourself if your giving it the big told you so",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "13.25",
          "thread_title": "RE: Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-02-06T23:53:04.126551+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262144-stt1-15843747",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519750",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "From the placing rns: \"The net proceeds of the fundraise, being approximately \u00a31.3m, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL platform, to invest in the company's commercial activities and for general working capital purposes.\" https://www.insidermedia.com/news/ireland/fusion-antibodies-raises-1.4m-to-drive-growth-plans From the grant rns, which they received less than a year ago: \"The Grant support to Fusion is to cover human resource needs, materials/consumables costs and overheads.\" https://www.londonstockexchange.com/news-article/FAB/approval-of-grant-funding/17002681 That suggests to me they have utilised all of the grant money to date and so needed more.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-02-06T23:53:04.126576+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262128-stt1-89928773",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520299",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Well done Alice for predicting a placing. I see you got a lot of abuse. I wouldn't wait for an apology from these clueless rampers.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: If Fusion places 100M share",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BCF5D778-E9D7-439C-990A-6D28AB648781"
        },
        "ingested_at": "2026-02-06T23:53:04.126606+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262117-stt1-63109806",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520864",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Humpalumps \"Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually\" Oh dear, can't handle the truth. My 1st post on FAB was a year ago, Jan 2025, after HVO pump and dumpers moved across to here. HVO crashed from c30p to c5p today on company newsflow, red flags I'd been warning about. https://www.lse.co.uk/profiles/stt1/?page=16 I can understand your frustration at being completely wrong and loading up c30p.. my posting history is there for all to see your lies about my posts... There's always one who's totally stupidity and incapable of reading the company newsflow. This from your post just a month ago....22nd Dec 13.51 \"They have a cash runway til FY27 which as has been confirmed on the investor hub didn't include NCI in the calculation so they're fine for cash\" https://www.lse.co.uk/profiles/humpalumps/ You need to read and understand company newsflow as it'll help you stop making those stupid mistakes.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-06T23:53:04.126625+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261929-Humpalum--4052257",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Jokes \ud83e\udd23 are we actually being lectured by the guy who told everyone to buy TLY that went bust while simultaneously warning people off FAB at circa 4p \ud83e\udd23\ud83e\udd23 Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually And finally this placing isn't a bad thing it sets a floor at the current price, was at 0 discount and will probably be last one this company will ever need Also I won't be replying to any of the crap you respond with because you're a terrible investor for point 1 in this comment \ud83c\udf1d",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-06T23:53:04.126643+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261816-stt1--2269367",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521921",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Antha, I'm glad I traded these and not held on, like you, at 30p.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Ha ha ha. sti sold a couple days ago",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=16F2F8FD-FC78-4AF1-834F-BFF85ACDD8C8"
        },
        "ingested_at": "2026-02-06T23:53:04.126661+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261804-stt1-24194758",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.522484",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Rocka, \"Sti so is now almost 20p , you are making yourself look very silly.\" I see there's a placing. Who's making themselves look very silly. I traded or you who was ramping at 20-30p. You should learn to read and understand company newsflow. The sp has fallen back exactly as predicted. Where's the clueless Humpalumps? he needs to learn and understand company newsflow. He was clueless as well, ramping these at 30p!!!",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-06T23:53:04.126680+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261757-stt1-90570667",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523018",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "There you go, exactly as predicted. Placing. Who was gullible enough to believe the clueless rampers!!!! Back to the same sp as before the previous pump/dump. Newsflow was exactly as expected.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Cash is low, so placing likely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=56D85761-47EE-47AB-BE35-44485A6673DC"
        },
        "ingested_at": "2026-02-06T23:53:04.126699+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261308-gtc1507--2280945",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523551",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes you\u2019re right! Sorry thought you were talking about smaller optimal screens. But yes the sliced bread analogy was a good one. We\u2019re already seeing the ITAS approach being mention in the RNS which is good. That last big pharma one Was referred to as an ITAS one so hopefully means we can retain them for more business",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126733+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261258-Troutiso-65788881",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524059",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Gtc, You are talking about full screens and AK did state that some companies may want smaller more focussed screens (if they had already developed some targets), He also stated that a full ITAS contract would be over \u00a31m, but some might want to take a more modular approach and contract to do some phases of the ITAS with FAB and that those companies will choose how many phases they would want to do with Fusion. These would likely not be RNSed due to their smaller size, piecemeal approach.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126754+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261248-Rocka-49024304",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Actually i said if there isn\u2019t any news, there has been today! Today\u2019s RNS isn\u2019t great but it\u2019s not bad news that will see the sp tank 50% as i\u2019ve been in such stocks.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126772+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261238-Troutiso-69793422",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Literally 23 hours ago you posted that if no news soon you would consider selling up.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126791+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261222-Rocka-81146266",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout, not a gambler at all. I\u2019ve been here for quite some time . I still believe in the longterm future here but the proof is in the pudding and this is what we will find out in the coming months( hopefully) Not planning on selling just considering whether i should buy more to bring my average down.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126809+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261215-gtc1507--6741775",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526095",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a good assessment, although, just to correct one piece. Adrian was clear they wouldn\u2019t get smaller contracts at the start as Optimal was designed to do full large scale screens. He said they may structure the deals differently to begin so that some of the client risk is reduced, potentially by reducing up fronts but including  success based milestone payments I.e when the screen delivers what fusion know it should then fritter payments will trigger. Slightly nuanced but still the overall value shouldn\u2019t change and the scale of the challenges will still be big but the point on the journey that fusion and the client risk profile is set and payments set may be adjusted to begin to incentivise early adopters. Adrian also said this will only be available for a limited period.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126827+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261209-Troutiso-30455262",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526590",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Realistic timeframes, valuations, etc.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126861+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261208-Troutiso--5497678",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Can I suggest having read back through your recent posts, that you are waving in the wind and seem to be very short term/big demands type of gambler. An investor wouldn't change their mind in a matter of days, unless there is a material change. You have been bemoaning news and after your post yesterday I nearly replied be careful what you wish for as a placing had entered my mind here. This is a medical CRO and they work in a field which takes a long time to get anyone to sign anything, rigorous checking and re-checking of the science, followed by rigorous checking and re-checking of the product before anyone is prepared to commit, it takes time. However, FAB has now launched OptiMAL and that is being assessed by prospective clients, this will take time but has been ongoing for some time. The Company have stated they are likely to get smaller OptiMAL use contracts to start, before some clients may come back for the chunkier full development contracts. That is the way of this particular industry. So whether or not you spend another \u00a310k here or you sell up or you spend \u00a310k elsewhere, my advice to you is to develop some patience (and that sometimes is very long term patience), while you are sitting there holding one company, others always look like they are doing better, but in reality that is not the case most of the time. Good Luck with whatever you do, but remember PIs and those on these BBs will always be ahead of reality, as they want short term gratification, when it always takes longer, costs more and can fail, invest and be patient and look at",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126881+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-Humpalum--8079398",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527465",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Personally I think there is a strong chance this will be the last placing this company ever needs - I can't really see a world where this company isn't profitable in the next 12-16 months which would be the kind of timeframe this money would last them without profitability",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126899+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-evman27--1764556",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527915",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It's always frustrating to see a placing happen but I believe this will be the last one fusion ever has. Back when the company was struggling they raised at 80% discount, the raise last year and today was at no discount, that counts for something. As many have said it puts us in a strong negotiating position, hard to get good deals when everyone knows your cash situation is tight. Since the raise last year the company has moved leaps and bounds, raised at 6.75p and SP hit 20p not long after, I suspect we will see similar here, we should be entering a news rich period too having commercially released Optimal. It is clear there is a lot of background interest in Fusion and Optimal, at least the buyout offer when it comes won't reflect a struggling company, it puts us in a stronger position to refuse a cheap offer. I'm still happy with my money here and have been since September 2024, the value on show here today is immense.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126918+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261144-Rocka--4900313",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.528425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I have \u00a310k funds clearing next week, i\u2019m tempted , i\u2019ll have to think about whether i\u2019ll buy more. Let\u2019s  just hope we start generating some serious income without needing to resort to more placings.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126936+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261139-Rocka--7364191",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Not the RNS i was expecting, also i don\u2019t believe the BOD should get any bonuses until the company is generating a profit but hey ho it is what it is. Let\u2019s just hope we see some contracts and/or news on NCI. We need a catalyst to propel the sp.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126954+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261115-gtc1507-49103772",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529652",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Shares admitted on Friday 30th, suspect we\u2019ll see tr1s shortly after - be interesting to see who went for it",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.126980+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260941-druml-27383668",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.278271",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Prudent decision by the board. Give the headroom for getting the deals in. Good to see director support.",
          "sentiment": 0.5,
          "engagement": "24",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127008+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260940-gtc1507-91382813",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279131",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "What does \u201cinvest in strategic partnerships\u201d mean do we think? \u201cThe successful validation and formal launch of our OptiMAL\u00ae platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time. \"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders.\"",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-06T23:53:04.127027+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260934-gtc1507--2239441",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279952",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - I took comfort there was no indication in the rns about weakness in the trading position also which I assume means they remain on track to achieve the 80% growth in h2. This was strong from the launch conference \u201c Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time\u201d.",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-06T23:53:04.127045+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260930-Cheapsha-53512652",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.280743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "After the raise and director shares the share count is bang on 125M share still very low. The bonus shares also issued at 13p. Market cap just under \u00a317M with this issue. To get to 50M cap we need about 40p share price very reasonable- actually that would still be cheap very cheap. But we do need some contracts signed should be here soon!",
          "sentiment": 0.5,
          "engagement": "2,671",
          "price_at_post": "13.375",
          "thread_title": "Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-06T23:53:04.127064+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-Bibzy7--6416478",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.281547",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Is this just the last chance for the ones in the know to get the cheap shares before this goes crazy Half full maybe outlook",
          "sentiment": 0.0,
          "engagement": "321",
          "price_at_post": "13.50",
          "thread_title": "Cheap",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34F59233-C112-41AC-AA13-18CE6878B383"
        },
        "ingested_at": "2026-02-06T23:53:04.127082+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-David195-17435728",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.282359",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "This is no surprise and positions FAB to move forward more quickly.  Potential customers need to be reassured the company is in good shape financially when due diligence is carried out.  A raise at current SP is excellent in current market conditions.  The discussions with NCI are crucial and FAB are able to conduct them from a stronger position. Getting the first contracts and renewing the agreement with NCI in the coming months is now more likely.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127118+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260824-Troutiso-12696818",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283156",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Both the bid and offer price rising within the wide quoted spread. I have a little more headroom to fill now, so have started with 50k.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127145+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260815-gtc1507--9124346",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The said they had runway to FY27 which is April. Good they have topped up the cash balance. Should help with due diligence for contracts. Buried line in the rns: \u201cMany of the organizations approached in the pre-launch phase have expressed an interest in the OptiMAL\u00ae platform including disclosure of target details under non-disclosure agreements\u201c Companies willing to share their target data with fusion is strong endorsement for their capability and expertise . This provides a very strong foundation to move forward in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127164+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Aldebara-31465529",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.284672",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Barely any discount. Seems ok to me",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127182+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Troutiso--8208793",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.285377",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Had a feeling this was coming, very quiet, lack of real trading and the timing were all tell tales, as was the tight lipped rumours. Last week SML another I have a large holding in (and seems to have been mirroring FAB prices albeit at a tenth of FAB) did a placing at 1.3p for \u00a34m they too have lots going on and are using the funds to accelerate drilling towards an earlier PFS. That was at 1.3p at no discount. The market although PIs were telling each other it had enough money has responded very positively and it closed yesterday at 1.9p. I felt it was possible that FAB would do the same and am pleased they have done so, this will accelerate OptiMAL rollout and was probably needed for some of the bigger new clients to sign any deal (they will not want to have contracts with companies who don't have a robust financial situation. I think the company have explained themselves well and don't see this as negative, if, and a big if, the shares have gone to long term IIs as the last one did. I have no reason to believe it hasn't as if this was a vulture driven firesale placing the SP would have been hammered and there would have been a 30%+ discount. I believe this is more to do with large investors wanting to add more, but not wanting to buy in the market and happy to do so in a placing at no or little discount. Overall happy with this and if the market reacts like it did last time we will soon be up at recent highs. This is nearly double the price they raised at last year, that is a sign of good progress!!! Stan it was 13.4p to buy yesterday so below mid anyway....",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127200+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260751-Seancadm-12643705",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "They had stated they had cash runway into \u201827 (financial year 27, which is from April \u201826 ). So in order to avoid a raise they would have needed contracts to drop in the next month and even then they couldn\u2019t have been certain to have money in the bank by then. So they are now fully funded, with, from the details in the RNS strong indications of OptiMal take up. This is good for the company putting a strong cash foundation under what could well become a company making year!",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127219+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260743-U_time-27033223",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286990",
        "source": "LSE_CHAT",
        "data": {
          "author": "U_time",
          "content": "Hard not to be negative about this placing. Comes at a time where we thought no placing was needed as the company was good financially and had enough contracts to manage day to day cash without a raise. Strange. Seems to suggest people are q'ing up for the 'best in class'. NCI deal now becomes even more crucial hopefully they can get it over the line otherwise FAB just becomes another one of those AIM companies that wants to keep raising funds on share holders dime until eventually they decide to delist... Hopefully wont come to that but its game time now.",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127237+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260727-bannside--5114072",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.287780",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "Tells me there no contracts ready to be signed",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127262+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260725-rp6577-58526126",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.288565",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Not the RNS I wanted to see. However, at least it is at the market price. Hopefully this now gives them the fire power to accelerate growth and really kick into gear",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127291+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260723-Stan36--6956598",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.289358",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Cheadle it is discounted from the mid price. And from the ask price ordinary investors would have to pay. So a discount of 3.8 to 7.6% NED participation during contract negotiation with NCI tells us he's not party to the details?",
          "sentiment": 0.0,
          "engagement": "863",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127310+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260710-rubarbru--7633452",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290150",
        "source": "LSE_CHAT",
        "data": {
          "author": "rubarbrubarb",
          "content": "And director involvement",
          "sentiment": 0.0,
          "engagement": "60",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127329+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260708-cbeadle--5773575",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290933",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Quite encouraging it\u2019s at the market price and not discounted at all",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127347+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260705-cbeadle--5173364",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.291707",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right news 50p to \u00a31 could happen really fast",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-02-06T23:53:04.127366+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260703-Laura202--2670705",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.292433",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Out",
          "sentiment": 0.0,
          "engagement": "15,342",
          "price_at_post": "13.50",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-06T23:53:04.127385+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262352-Clachair-43803621",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293116",
        "source": "LSE_CHAT",
        "data": {
          "author": "Clachair10",
          "content": "Hi, I have been in since near the very beginning. I need to see \u00a31/share to get my money back. Not sure that will ever happen? Could have made a killing when they floated but wasn\u2019t able to realise it. May have to bale when and if it hits 50p a share. Have been watching this for so many years waiting for the upside! C.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-02-06T23:53:04.127418+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262314-rp6577-56922619",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293774",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "My view is that they have something which is better that what their competitors have. Things can take time to get traction. However, if you are fundamentally better, then it is difficult not to see significant success down the road. Just got to sit tight and if you don\u2019t have your full position yet, add during these quiet times",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-06T23:53:04.127437+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262105-evman27--9169635",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.294509",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes I was there too, still holding and have added to my position since then on dips. It's clear Optimal and Fusion are dangerously undervalued and I feel very relaxed with my money here.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-06T23:53:04.127456+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-Seancadm--4447161",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.295238",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Anyone who is concerned about any lack of news since the launch (which to be fair was only a few weeks ago) should google how long diligence on a new platform takes, these things take time and there is certainly no need for concern at the moment. The NCI deal is progressing and as GTC says could well be bigger than anticipated due to NIH involvement. I agree though an update on progress so far would go a long way to calming investors.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-06T23:53:04.127474+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-NornIron--7487212",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296005",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Many thanks for that GTC.",
          "sentiment": 0.0,
          "engagement": "458",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-06T23:53:04.127492+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261616-gtc1507--4461602",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296852",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I\u2019m still here and was at the AGM. They were very positive about the future potential of the Optimal platform and as have said throughout all their engagements , it will take time to convince people to come onboard but they said it had the potential to be transformational for drug discovery. The brokers are predicting growth of 80% in h2 without any optimal contribution. they have historically not published every single contract they win as their view is their clients don\u2019t always enable that and it could be commercially damaging. All I know is we\u2019ve had nothing from the company to indicate anything materially different to their forecasts either up or down and all we can do is wait for news. They were hiring just before Christmas for 3 new roles so they must be confident about prospects given their cautious cash management approach. They have the grants from the FMI to help them balance those. We\u2019re just in that phase at the moment where we need to see the proof in the execution. I take comfort in the fact the NCI deal is of such a scale it requires NIH approval - that sort of deal will turn the heads of big pharma. They already have big pharma on the books as notified by the two rns at the end of summer autumn so they\u2019ll likely be engaging them about the benefits of optimal. We just need to give them time. They confirmed their cash runway into FY27 was not dependent on an NCI deal so they are. If the company are reading this tho I think investors would welcome something of an update though, silence on the hub, silence to emails, nothing on LinkedIn - all very quiet does feel like something may be bubbling behind the scenes in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-06T23:53:04.127510+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261516-gtc1507--6346925",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721015",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Still sitting 4 v 3 here. The l2 book Hasn\u2019t moved since open strangely despite some chunky buys",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127542+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261512-mmhater--1245789",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721463",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Has anyone got level 2? i imagine it will be getting stronger all the time. A tick up would be nice to see.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127564+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-chrishut-20609118",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721890",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A couple in the telegram group bought more today Great prices on offer",
          "sentiment": 0.0,
          "engagement": "17,380",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127582+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261215-mmhater-64059203",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722312",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I\u2019ve got far to many already\u2026. This is AIM at the end of the day and you never know when you are going to get screwed over. Expect the unexpected! On that note i don\u2019t expect 50p anytime soon.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127601+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261208-Rocka-25718219",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ideally i\u2019d like this at 20p pre news then i think we\u2019ll easily easily hit 40p min short term",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127619+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261207-Rocka--7773144",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723144",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "No ramping intended but if i had \u00a38k now i\u2019d put it all in FAB, topped up last week and expecting \u00a310k early Feb and i\u2019ll put it all in fab. This is a no brainer tbh especially at this price",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127637+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-gtc1507-66478254",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723563",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My gut says we will hear something next week",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127664+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261159-mmhater-67450973",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723976",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I did my little bit yesterday\u2026. I do have another 8k i\u2019m tempted to put in but haven\u2019t decided yet\u2026. Time is ticking and i\u2019m expecting news very soon. NCI wanted to carry on using optimal immediately so must need a deal soon??? Are FAB just letting them use it in the interim?? I still think this is getting bought out. Adrian\u2026 give us an update.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127691+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261138-evman27-43250900",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724413",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "250k is 14.6 Then 260k jumps to 20p!! Float disappearing fast, news will send this crazy, or if someone wants to do the honours now?!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127710+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261059-CHEATED-96115584",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724821",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "I suggest a new field of research that might be rewarding. The lack of mobility and the balance problems of stroke victims. You may have a winner here.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127728+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262332-cbeadle--5836075",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725238",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Something could happen very quickly with FAB",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127747+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261641-Rocka--1834105",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Well if it goes that high that quick i\u2019ll be equally happy as i hold quite a few already",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127765+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261637-Darkryde--7519445",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocks, I hope and think you\u2019ll only get 16,000 shares with your \u00a310k \ud83d\ude0a",
          "sentiment": 0.5,
          "engagement": "548",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127787+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261512-CHEATED-23281116",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726484",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "There should be a link-up with a large American antibody firm. Perhaps a partnership would be beneficial. Share price is in the doldrums and needs a boost of some kind. I cannot see the advantage  of the last addition of staff producing anything of great significance. Too many cooks spoil the broth. Try something new.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127817+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261456-Rocka--7817556",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019d put more in to if i had available funds, topped up last week. Expecting \u00a310k early Feb, hopefully i can buy at todays price once funds clear.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127836+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261415-evman27--5458439",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727321",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Nice buys, what a bargain price!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127855+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261405-mmhater--2364815",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727732",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "My 2 8k trades aren\u2019t showing. been a rise in trades past couple of days and i think this is going to pop soon. News is imminent. NCI have said they want to use optimal immediately so won\u2019t hang around doing deals for long\u2026",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-06T23:53:04.127873+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261338-mmhater--8412193",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728151",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I got fed up of being patient so bought another \u00a316000 worth\u2026 Come on Fusion\u2026 give us a update",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-06T23:53:04.127891+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261330-Antha-69231353",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "Everyone is just waiting for the NCI contract and other pharma contracts to be signed, until then the sp will just drift up and down between the 12-16p range, just need to be patient.",
          "sentiment": 0.0,
          "engagement": "2,740",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-06T23:53:04.127909+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261310-gtc1507--8332502",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728989",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Seems to be kicking into action again, some decent buys today. Investor relations seem to be answering questions on the hub too. Looks like the shareholder information has been updated too as of a few days ago, no sign of maven any more\u2026.. https://www.fusionantibodies-ir.com/content/investors/shareholder-information.asp",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-06T23:53:04.127943+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261100-stan1234--3641712",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729412",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "I am going to add today too. Just selling something else first.",
          "sentiment": 0.0,
          "engagement": "208",
          "price_at_post": "13.25",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-06T23:53:04.127977+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260810-formerly--1090785",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729827",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Purchased 10,000 at 13.3 via HL this morning. Wait and See!",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-06T23:53:04.128010+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261821-formerly--5156581",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730246",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-06T23:53:04.128042+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261812-gtc1507--5761649",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730660",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-06T23:53:04.128075+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261757-Cheapsha-41358281",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.731071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-06T23:53:04.128121+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261800-Cheapsha-34249105",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.682514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Oooh bless you Alice $$$ Year of the Fusion- jump in!",
          "sentiment": 0.5,
          "engagement": "2,677",
          "price_at_post": "16.00",
          "thread_title": "RE: Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-10T00:34:15.583681+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261619-Rocka-45200466",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.683225",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Alice, at best 130p plus add a zero to 13p.",
          "sentiment": 0.0,
          "engagement": "198",
          "price_at_post": "16.00",
          "thread_title": "RE: Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-10T00:34:15.583722+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261610-Seancadm-18779404",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.683905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Don\u2019t think you\u2019ll get your buy in price this time Alice! I\u2019ll focus on the funded balance sheet and validated tech rather than short term price guesses.",
          "sentiment": 0.0,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-10T00:34:15.583743+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261550-Alice-Wr--6078299",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.684583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alice-Wright",
          "content": "At worst.",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "16.00",
          "thread_title": "Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-10T00:34:15.583763+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261103-gtc1507-15561942",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.685263",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some decent delayed prints continuing today. Feels like someone accumulating",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-10T00:34:15.583782+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260848-Seancadm--3937420",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.685925",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "NCI/NIH better funded, Fusion fully funded, OptiMAL already validated and in continued use discussions... feels like all the pieces are lining up.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-10T00:34:15.583801+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-gtc1507-47447547",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.686647",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "\u201cNIH and NCI Receive Funding Increases The FY26 bill provides $47.2 billion for the National Institutes of Health (NIH) and $7.4 billion for the National Cancer Institute (NCI), representing increases over current funding levels. At the same time, the measure maintains flat funding of $1.5 billion for the Advanced Research Projects Agency for Health (ARPA-H). Together, these appropriations reinforce federal support for the cancer research pipeline, including discovery science, translational research, clinical trials infrastructure, and efforts to improve prevention and outcomes across diverse populations.\u201d Good to see discovery science specifically mentioned\u2026. https://oncodaily.com/public-health/nih-fy26",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-10T00:34:15.583819+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261827-gtc1507--6530147",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.687448",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I think it\u2019s good to reflect back on what the company have actually told us about Optimal and why it\u2019s supposed to be a game changer. Based on Fusion\u2019s own published data and comparisons reported in the scientific literature, OptiMAL appears to be materially more effective than competing antibody discovery platforms. The most important metric is efficiency. Fusion reports that OptiMAL achieves over 70% gene integration, meaning most cells produce a working antibody. Published data for competing mammalian display systems typically show efficiencies of only 1\u201310%. In plain terms, OptiMAL seems to waste far less effort and deliver far more usable output. That efficiency advantage apparently allows OptiMAL to do something competitors generally cannot: screen more than one billion functional antibodies. Fusion states that OptiMAL can generate functional libraries greater than 10\u2079 antibodies, whereas most competing platforms are limited to millions. Antibody discovery is a numbers game, and searching a much larger, fully functional library should significantly increases the chances of finding a high-quality drug candidate, particularly for difficult targets. Importantly, the data suggests this is about quality as well as scale. Fusion has shown antibodies from OptiMAL with nanomolar binding strength, which aligns with the standards needed for real drug development. This indicates the platform can deliver clinically relevant candidates, not just early-stage research hits. They say OptiMAL is also designed to closely mimic real human antibodies. Using human antibodies should reduce the risk of antibodies failing later due to safety or manufacturing issues, which would be a major cost for drug developers. For investors, the implication is straightforward. Platforms that improve success rates and reduce risk should command higher fees and if truly different should mean they can generate more and more repeat business Based on the published performance gap versus competitors, my investment thesis is therefore that OptiMAL appears to offer Fusion a defensible edge that should hopefully support stronger commercial traction and long-term value. If they can get in early with clients, be valuable partners then they have a better chance of getting royalty and milestone entitlements. If they found the next Keytruda for example and had even 0.1% royalty on future sales that could add up to $31.7 million per year for fusion. If we start to see contracts coming through, which with clients under NDA looks likely, then it would appear to me they have genuinely found a market gap and if they can scale should generate good returns for us. DYOR and best of luck!",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T00:34:15.583836+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261750-Seancadm--2881175",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.688107",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "NCI-validated tech, big conference buzz, partners circling, pipeline building... feels like Fusion could be sitting on something seriously interesting here.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T00:34:15.583854+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261731-Rocka-50912445",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.688764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Feeling very positive here, locked and loaded, bring on 20p pre contract news and we\u2019ll be at 40p in a flash post news imo.",
          "sentiment": 0.0,
          "engagement": "198",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T00:34:15.583872+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261234-gtc1507-96460659",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.689434",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The company also said they want to \u201cinvest in strategic partnerships\u201d in the placing RNS. What sorts of tie ups might we see!",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T00:34:15.583891+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261106-evman27--5447099",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.690131",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "I like the theory Sean. We've seen that in this industry there are lot of NDAs so we can never know the whole picture no matter how positive it looks from the outside. Fusion do set themselves up to be a partner for big pharma, after all they have worked with 8/10 of the worlds biggest pharma companies in the past! When I was at the AGM, I got a tour of the labs, the scientists working in there told me they were doing work for the NCI, highlighting that 'partner' approach.",
          "sentiment": 0.0,
          "engagement": "184",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T00:34:15.583909+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261047-Seancadm-76917511",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.690831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time. The above from the recent RNS. I am interested in why Fusion included 'and the company' in the above. It suggests that interest isn't limited to a single product, does this suggest that Pharma see Fusion as a partner organisation rather than just a vendor selling one product. In other words, the opportunity is bigger than just one product. Does this mean that Fusion is being viewed as a credible antibody discovery company with multiple valuable assets? I know people are eager for news but there are clues in recent RNSs that suggest Fusion is doing a lot behind the scenes.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T00:34:15.583927+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261035-gtc1507--1047776",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.691506",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "#FAB looks strong for a move this week, risen nicely after placing at 13p, sitting well above key moving averages and weekly slingshot now in play. 200ma on the weekly is 19.49, with 52 week high of 21p. With potential catalyst news coming in short to medium term, cash in the bank and technicals all lining up the next move could be pretty impressive",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T00:34:15.583945+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261303-gtc1507-31664755",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.692178",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I suspect we\u2019lll soon see evidence that Optimal is attractive to their clients. At that point it\u2019s just a case of seeing how big this can scale. If they\u2019re to be believed it will be game changing for the company and the drug discovery industry",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.583969+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261144-evman27--4652650",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.692876",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Incase you all need a reminder of what Adrian said at the last presentation \u201cWe are now market leader, Optimal is best and first in class at what it does\u201d \u201cFusions platform is the best as evidenced by the data in this launch presentation\u201d \u201cIf that means we become more visible, I think it will and therefore more noticed by those considering acquiring companies like ours, well then so be it\u201d Happy holding!!",
          "sentiment": 0.0,
          "engagement": "184",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.583987+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261359-Sanibel--4901865",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.693583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Some nice buys Nothing is certain but this has to be a worthwhile investment for those who have researched. A big contract or a number of would be transformational here with \u00a31 or more easily achievable Im holding tight GL Sani",
          "sentiment": 0.0,
          "engagement": "4,570",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584005+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261342-gtc1507--3337960",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.694262",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Looks like someone took 260k in the space of 15 mins earlier one this morn, must be confident",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584022+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261256-gtc1507--3663617",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.694929",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice to see some chunky delayed buys coming through today. Is somone accumulating or are many people realising just wha the potential is here",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584040+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261211-gtc1507-72669325",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.695604",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "A close at these or near levels will be very strong weekly setup. Bodes well for next week",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584058+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Seancadm--7284591",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.696280",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I'm not expecting fireworks overnight, but with NCI validation, institutions increasing, and funding risk reduced, the setup looks better than it did a few months ago. Now it's about waiting for the first OptiMAL commercial foothold. Even a small evaluation or platform-access agreement would change how the market values Fusion.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584076+00:00"
      },
      {
        "event_id": "SOCIAL-Today1359-Sanibel--4901865",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.729743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Some nice buys Nothing is certain but this has to be a worthwhile investment for those who have researched. A big contract or a number of would be transformational here with \u00a31 or more easily achievable Im holding tight GL Sani",
          "sentiment": 0.0,
          "engagement": "4,569",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584095+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507--3337960",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.730217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Looks like someone took 260k in the space of 15 mins earlier one this morn, must be confident",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584138+00:00"
      },
      {
        "event_id": "SOCIAL-Today1256-gtc1507--3663617",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.730651",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice to see some chunky delayed buys coming through today. Is somone accumulating or are many people realising just wha the potential is here",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584157+00:00"
      },
      {
        "event_id": "SOCIAL-Today1211-gtc1507-72669325",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731073",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "A close at these or near levels will be very strong weekly setup. Bodes well for next week",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584176+00:00"
      },
      {
        "event_id": "SOCIAL-Today1008-Seancadm--7284591",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731511",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I'm not expecting fireworks overnight, but with NCI validation, institutions increasing, and funding risk reduced, the setup looks better than it did a few months ago. Now it's about waiting for the first OptiMAL commercial foothold. Even a small evaluation or platform-access agreement would change how the market values Fusion.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584193+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261902-Troutiso-29195584",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I think apart from the initial 60k trade which was a buy, all the rest of the delayed trades over 50k look to be sells. Not a problem they got a good price and those shares will be bought up by others.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.25",
          "thread_title": "RE: Big trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=D96A8918-A1B6-42AA-B090-11B604330C21"
        },
        "ingested_at": "2026-02-10T00:34:15.584212+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261853-Troutiso--7075012",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.732355",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "A little different last year as they issued some shares and the others after a GM. However Canaccord Genuity Group Inc did announce their TR1 last of the three, probably as they are based in Vancouver. Their holding and the dilution mean they could add nearly 1.94m shares and not need to TR1 as still within the 7% band.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584239+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261851-mmhater--4733081",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.732769",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Well there has been a lot of big trades today. hard to tell if buys or sells but i think are delayed buys. Market makers have played the price sneakily dropping nothing. i expect a large rise tomorrow to counter the false drop.",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "15.25",
          "thread_title": "Big trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=D96A8918-A1B6-42AA-B090-11B604330C21"
        },
        "ingested_at": "2026-02-10T00:34:15.584271+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261319-gtc1507--3968064",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.733200",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes they are already holders - they took 7% at last years placing. Think the rns this time talked about existing and new investors demonstrating confidence. There is a possibility cannacord took more but we might have seen an rns by now perhaps",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584303+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261315-Cheapsha-91673144",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.733614",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Who is the 3rd institution, we seen 2 x RNSs Is that Cannacord?",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "15.75",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584338+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261149-Sanibel-81620072",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734033",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "All looking very good here. All thats needed is patience. Gl all Sani",
          "sentiment": 0.0,
          "engagement": "4,569",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584376+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260902-chrishut--2455806",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734466",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Was going to edit that but the word is funny so leaving it ha",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584412+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260901-chrishut-50538738",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734875",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Will we see a cancrod rns today?",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584434+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260838-gtc1507--7785508",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.735327",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Also I\u2019m glad to see stt has bought in. I think deep down we\u2019re on the same page, about the strength of fab.  the company said they would always consider raise for growth if they thought was right thing and that\u2019s what happened. They also said they were on track for breakeven without a raise but chose to take the brakes off and raise to accelerate growth. They are credible enough to convince big funds like these that the prospects are materially good enough to justify at market price investment. They\u2019ve filled the war chest now let the battle for market share with their new discovery tools commence!",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584452+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260809-gtc1507-34643067",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.735821",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "You\u2019re totally right Sean. It\u2019s kudos to them that they were able to secure that investment at zero discount from funds lik that",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584470+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260749-Seancadm-76098880",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.736277",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Most AIM companies can't attract this level of institutional capital, they don't just buy on 'hope. They Perform due diligence Speak directly to management Stress test the story. Fusion must have gained a hell of a lot of credibility! Having the backing of 3 institutional funds means the company has passed enough internal filters for serious capital to stay involved and even increase. I'm confident people are going to take notice of this backing over the coming weeks and jump on board.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584488+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262117-mmhater--9174320",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.736682",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Just waiting for a tie for tat rely a lowlife would do\u2026.. standing by.",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584506+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262047-stt1--5678249",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737139",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Buying in the placing or post placing made sense. It's hardly surprising....I also added after the placing and before today's rns, as per my assertion that they needed a placing. I've said the company needed another placing to advance their projects and that's what they have done. Rampers were claiming the company doesn't need a placing, they have cash runway until 2027. The rampers also claimed the company would be winning contracts as soon as they launch their platform. It's now 2 months and still no contracts. Newsflow has been as expected. I'll look to trade as and when as the company still face hurdles...",
          "sentiment": 0.0,
          "engagement": "4,531",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584524+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262013-steven49--1605985",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737548",
        "source": "LSE_CHAT",
        "data": {
          "author": "steven49",
          "content": "From placing",
          "sentiment": 0.0,
          "engagement": "13,711",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584543+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261941-Rocka--2367449",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737956",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Could well hit 20p this week and move on to 30-50p on contract rns",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584562+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261925-evman27-10760549",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.738402",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Great post GTC and as far as I am aware that is all correct. Things are turning here now, there are so many reasons to be invested here and I'm expecting the highly geared returns to start taking shape this year. The future is FAB!",
          "sentiment": 0.0,
          "engagement": "182",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584581+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261856-gtc1507--2551384",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.738823",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "\u2026.Counters the case that now is their time to shine? DYOR and fact check me but I think we\u2019re in for an exciting time",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584599+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261855-gtc1507--1583912",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.739377",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some substantial delayed trades printed after hours. Feels like then market is finally waking up to the positive potential here. Cashed up with large volumes going at discount to sticky institutions all while\u2026. \u2022 OptiMAL now LIVE \u2013 world-first antibody discovery platform, with multiple customers already engaging under NDA \u2022 OptiMAL deal economics step-change \u2013 programmes identified by Allenby potentially at \u00a3200k\u2013\u00a32m per deal, depending on scope, versus current revenue guidance of ~\u00a32.25m for FY26 \u2022 Clear headroom vs history \u2013 revenues were close to \u00a35m pre-downturn, highlighting recovery plus upside potential \u2022 Platform shift underway \u2013 moving from services \u2192 scalable discovery platform, structurally improving margins \u2022 Lean, cost-efficient operation \u2013 capital disciplined, with strong operating leverage as revenues scale \u2022 Margin recovery underway \u2013 mix shifting toward higher-value discovery work, reversing historic pressure \u2022 National Cancer Institute fully open \u2013 boosted FY budget and active negotiations on a multi-target collaboration \u2022 Potential peer-reviewed publications \u2013 NCI work could translate into high-impact journals, boosting credibility \u2022 Sales momentum building \u2013 brokers guiding to >80% revenue growth in h2, before any premium discovery revenues \u2022 potential for Longer, stickier client engagements \u2013 discovery work keeps clients involved earlier and for longer \u2022 Cashed up and confident \u2013 recent raise removes funding risk and unlocks growth ambition \u2022 OptiPhage licence decision pending \u2013 asymmetric upside if converted to an exclusive deal \u2022 US patent secured \u2013 strengthens IP moat in the most important biotech market \u2022 IP footprint expanding \u2013 additional patents progressing in key jurisdictions \u2022 Prestige access via Future Medicines Institute \u2013 world-class ecosystem, talent pipeline, plus \u00a31m grant and \u00a35m capital access \u2022 Local ecosystem strengthening \u2013 academia\u2013biotech\u2013industry collaboration deeper than ever in Northern Ireland \u2022 Client funding conditions improving \u2013 biotech risk appetite back, with SPDR S&P Biotech ETF at multi-year highs \u2022 Hiring from strength \u2013 attracting staff from big-name competitors \u2022 Clear geographic growth plans \u2013 expansion targeted in US and Asia \u2022 AI-enabled discovery play \u2013 OptiMAL sits squarely in the AI drug discovery sweet spot \u2022 Legacy royalties & milestones still live \u2013 historic deals mean unexpected upside remains possible \u2022 DR5 time asset nearing conclusion \u2013 project due to complete this year with licensing potential \u2022 Strategic antibody partnership with Finn therapeutics\u2013 leveraging patented antibody asset \u2022 Collaboration with Eurofins Discovery \u2013 validation and access to a global pharma client base Valuation angle: Is FAB still trading closer to a cash-backed services multiple, despite OptiMAL-sized deals that could move revenues with only a handful of wins? Genuine question: Am I missing anything that meaningfully co",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584618+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261707-Stan36--5378632",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.739787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "@Troutisout1 I'm in with 202k shares average 13.95p. Wasn't tempted to sell at 19p. Happy to wait. Good to see these tr1 confirmations and the 9.4% rise today.",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "15.75",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584636+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261706-Laura202-37002860",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.740199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Buys in the 13s looking very healthy",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "15.75",
          "thread_title": "Great day",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C6467160-466B-42CC-A9F0-BEED146D848D"
        },
        "ingested_at": "2026-02-10T00:34:15.584655+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261658-Cheapsha--2425795",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.784626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Good news overall big guns adding Hopefully soon 20p before some contracts hit the RNS Then got a better base and higher base to jump from",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584673+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261652-Troutiso--2754149",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.785367",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes their last Holdings RNS was a little confusing naming at least 5 different entities, but it is another 2,212,084 shares they have purchased for \u00a3287.6k, There's another \u00a3862k out there, so still room for another TR1, but I reckon more likely to have gone to new IIs at under 3%. Cannacord though, could still update.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584692+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261641-Dw198-48523296",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.786053",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dw198",
          "content": "Ignore, it is  Rathbones Investment Management Ltd who is the owner of the nominee account :-). Great news",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584711+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261637-Dw198--3247261",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.786745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dw198",
          "content": "It\u2019s a nominee account isn\u2019t it? So it is not Rathbones who made the investment decision, it would be the holder of the nominee account, whoever that may be",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584729+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261630-Troutiso-62467868",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.787475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Stan, I bought 200k at 13p on the 28th Jan, so others could have done so too, it wasn't just the placees. Great to see another holder from last year's placing increase again on this one, do we think we might see something from Cannacord as well? That would be great, but the realisation will now dawn that the placing shares are tightly held for the second year running.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584747+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261619-rp6577--3961762",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.788164",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Looking solid. Setting us up very nicely for news to blast us through 20p",
          "sentiment": 0.0,
          "engagement": "899",
          "price_at_post": "16.00",
          "thread_title": "RE: Another tr1",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34E599B3-B512-45C9-AF92-5E920C8E28AF"
        },
        "ingested_at": "2026-02-10T00:34:15.584766+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261603-Stan36-43377384",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.788816",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "And those investors who paid 13p in the placing are already 23% up. Where's Alice? She did predict a placing bless her \ud83d\udc8b\ud83e\udd20",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584784+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261600-NornIron-67714827",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.789509",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Go Rathbones ! Although investors like myself and many of you guys here will do our own research before investing in any share, the comprehensiveness and depth of any research most of us do will obviously never touch that of the big institutions. Buck eejits like my myself maybe think we do research at times, but the reality is we'll never get access to the info or individuals where 'real' info can be gained to make an informed buy or sell decision on any holding/s. Companies like Rathbones can do !   Although it's still heads or tails for them whether a share goes up or down going forward, they're making the investment decision knowing more than we PI's will ever know. This is a BIGGIE with Rathbones buying more  ! !",
          "sentiment": 0.0,
          "engagement": "461",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584803+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261548-chrishut-36969378",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.790197",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Boom Up we go",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-10T00:34:15.584820+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261536-AnnaRobi-14919578",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.790856",
        "source": "LSE_CHAT",
        "data": {
          "author": "AnnaRobinson",
          "content": "They didn\u2019t have that before so assuming they grossed up in the placing?",
          "sentiment": 0.0,
          "engagement": "322",
          "price_at_post": "15.25",
          "thread_title": "Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T00:34:15.584838+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261533-gtc1507--5125476",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.791541",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Ratbones took another 2m shares",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "15.00",
          "thread_title": "Another tr1",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34E599B3-B512-45C9-AF92-5E920C8E28AF"
        },
        "ingested_at": "2026-02-10T00:34:15.584856+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261533-Humpalum--2210927",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.792213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Rathbones increased holding too \ud83d\udc4d",
          "sentiment": 0.5,
          "engagement": "1,595",
          "price_at_post": "15.25",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=68BAB7F0-F1B4-4AD2-9D69-A66FF8564B72"
        },
        "ingested_at": "2026-02-10T00:34:15.584874+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261514-gtc1507-23680838",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.792886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some serious chunks being bought up these past few days. Someone building a big position perhaps",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-10T00:34:15.584892+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261425-gtc1507-78164152",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.793593",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I asked chat gpt to do some technical analysis last night, this is what I got; Barring any unforeseen negative developments, bullish momentum is slowly shifting in on all timeframes \u2013 implying that the balance of risks for the next few days to months is tilted toward a continuation upward or at least stabilization, rather than a return to sustained bearishness. The technical setup thus points to a greater likelihood of bullish scenarios (momentum accelerating upward) ahead, with the caveat that the market must confirm this by clearing the remaining resistance zones. If those confirmations occur, Fusion Antibodies could very well be at the start of a significant bullish momentum shift after months of decline, with upside targets in the coming weeks and months substantially above today\u2019s closing 14.625p price.",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-10T00:34:15.584910+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261419-NornIron--5888394",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.794267",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I've just done a small top up there now of 29,889 for around 4.6k.  I got them at 15.39 and happy at that. Obviously prices can rise and fall, but i feel there are too many positives going for Fab not to take a chance with a few quid more. We could see this move up very very soon.",
          "sentiment": 0.0,
          "engagement": "461",
          "price_at_post": "15.25",
          "thread_title": "Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-10T00:34:15.584928+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261121-stan1234-65520159",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.794908",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "This will just keep going up",
          "sentiment": 0.0,
          "engagement": "210",
          "price_at_post": "15.25",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T00:34:15.584946+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261109-mmhater--5960208",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.795568",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Market makers allowing this to slowly climb now on the quiet. Some nice buys amongst tiny sells. Brakes are slowly coming off ready for a nice rns hopefully imminently which will send this nicely into the 20s or maybe 30s. Need to remember this was 50-60p and spikes to \u00a32 a few years ago on nothing compared to where we were now",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "15.25",
          "thread_title": "RE: Going well",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1A2E7CD6-748A-4AB7-A8D9-A6D8EB0D755E"
        },
        "ingested_at": "2026-02-10T00:34:15.584964+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260958-Laura202-38152776",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.796239",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected once 14p went",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "15.125",
          "thread_title": "Going well",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1A2E7CD6-748A-4AB7-A8D9-A6D8EB0D755E"
        },
        "ingested_at": "2026-02-10T00:34:15.584983+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260954-Troutiso-74222862",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.796904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There will be delayed trades behind that SP move.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.125",
          "thread_title": "RE: Sensitivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0268C929-5B5A-4561-A591-6FD2897DA7B1"
        },
        "ingested_at": "2026-02-10T00:34:15.585001+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260933-Stan36--7808259",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.797577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Net buys 44,000 shares today. Net value of buys \u00a36,600 and market cap increases by \u00a3700,000 100:1 factor.",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "14.75",
          "thread_title": "Sensitivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0268C929-5B5A-4561-A591-6FD2897DA7B1"
        },
        "ingested_at": "2026-02-10T00:34:15.585019+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260932-chrishut-81314988",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.798249",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This is heading higher",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T00:34:15.585037+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260927-Stan36--1469826",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.798904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Up 15% to 15p since the 13p placing. That shows investor confidence. And has happened with low volume. Any positive news and this will burst forth \ud83d\udca5",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T00:34:15.585055+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260926-gtc1507--5626820",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.799723",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The decision by the National Cancer Institute (NCI) to move forward with Fusion Antibodies\u2019 OptiMAL platform is highly significant. NCI is the largest single funder of cancer research in the world, with an annual budget measured in tens of billions of dollars and a mandate to apply exceptionally rigorous scientific, technical, and commercial scrutiny. US federal procurement frameworks are specifically designed to promote competition and multi-provider tenders. Progressing instead with a single-provider approach strongly suggests that OptiMAL is not merely competitive, but meaningfully differentiated. In that context, the decision itself lends real weight to management\u2019s description of OptiMAL as first-in-class and best-in-class, claims that are rarely validated so early by an institution of this calibre. Fusion has described this as the best deal the company has ever made strategically as much as financially. Within months, this collaboration could be showcased globally, with one of the world\u2019s most prestigious cancer research bodies actively deploying OptiMAL in live discovery programmes. That level of external validation is exceptionally rare and extremely hard to replicate.",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "15.125",
          "thread_title": "NCI significance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B5214597-2A26-4A40-8D06-C710908586C7"
        },
        "ingested_at": "2026-02-10T00:34:15.585073+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260900-Troutiso--4412512",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.800425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes looking good, just very low volume again, when that picks up this will motor...",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T00:34:15.585091+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260847-gtc1507-91774470",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.801005",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is looking strong - no shares available instantly here, feels like it\u2019s primed for a continuation of the move up today",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T00:34:15.585130+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260809-gtc1507--2995910",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.083149",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Multiple clients are under NDA for Optima discussions and just reading the update from Allenby they say that they understand a number of clients are evaluating proposals from fusion. That to me fees like the tail end of the business development cycle and we could be seeing some contract awards soon enough if things move positively! Will be exciting  to see just how effectively they can convert the potential of optimal to contracts.",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.75",
          "thread_title": "Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T00:34:15.585149+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261950-gtc1507-46175804",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.083682",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/article/government-shutdown-ice-funding-471e55ba4c3247051739ee1b50b2857a",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.625",
          "thread_title": "RE: Serious buying",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B732929B-3433-4DD4-A746-BD075AADC17D"
        },
        "ingested_at": "2026-02-10T00:34:15.585166+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261501-livinhop-57852706",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.084215",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Another 50k delayed shares purchase - serious buying going on at the moment, has to be a good sign....I hope!! L2  currently 2v2",
          "sentiment": 0.0,
          "engagement": "1,096",
          "price_at_post": "14.50",
          "thread_title": "Serious buying",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B732929B-3433-4DD4-A746-BD075AADC17D"
        },
        "ingested_at": "2026-02-10T00:34:15.585185+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261434-Troutiso-51370902",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.084715",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Vewry shortly I reckon.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: 15.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=79D1BEB9-25D7-49E1-B410-CBAED6C59387"
        },
        "ingested_at": "2026-02-10T00:34:15.585203+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261430-mmhater-75247011",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.085225",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Tick up on its way by end of play i guess",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "14.50",
          "thread_title": "15.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=79D1BEB9-25D7-49E1-B410-CBAED6C59387"
        },
        "ingested_at": "2026-02-10T00:34:15.585221+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261350-Troutiso--5480235",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.085701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Volume is very small at the moment but positive with buys regularly outweighing sells by some margin.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-10T00:34:15.585240+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261338-gtc1507-41275020",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.086217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - new investor would need to take just short of \u00a3500k to reach tr1 / more likely we\u2019ll see the others taking more. Not to say that\u2019s not impossible - cannacord came in cold with 500k last year",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585258+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261314-Troutiso-36467871",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.086728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, I very much doubt any of the placing went to bucket shops, the twitter brigade or PIs, the clue is always in the discount. This was a well organised funding round, allowing IIs a chance to add to their holdings at a fair price.  These placings tend to see the SP react favourably, but often need a news catalyst to really ignite the SP rise. I hope to see some more TR1s but I am happy if there aren't more, there will be many IIs in here at less than 3% and probably won't move for more until the FAB valuation allows. We saw Maven sell out due to a change in Management of their fund and a different direction, many Fund Managers will be looking but not able to purchase through their fund due to investing criteria. I have now bought up all my headroom, so happy to sit back and enjoy the ride. I can see Rathbone or Cannacord adding enough for a TR1, maybe not a new investor though.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585276+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261208-chrishut-65520159",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.087238",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This will just keep going up",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585295+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261146-Rocka-34911975",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.087727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Hope you\u2019re right but i would still like to see more tr1 rns\u2019s.",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585313+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261122-Seancadm-72128688",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.088210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I think there is a good chance that a large proportion of the raise has been taken up by institutional investors, as we found out yesterday with Unicorn adding, I also don\u2019t think we have to worry about smaller investors flipping, in the RNS Adrian said, \u2018supported by a number of our longstanding shareholders\u2019, sounds like sticky hands to me.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585331+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261038-Rocka-32704040",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.088705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "We do need more tr1\u2019s , if most of the placing has been taken up by pi\u2019s then there will be flipping. I hope most of it has been taken by institutions.",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585349+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260903-gtc1507-19429973",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.089223",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice \u00a310k buy on the bell just printed!",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585367+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260837-Troutiso--6068517",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.089724",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "This is just getting us back to the price of a month ago, the placing will have weighed on that during January and now that pressure has been removed we are able to move back to previous levels. Another TR1 would show the market the placing was taken by sticky hands as last year's one was and that will encourage more to jump aboard. I see this back in the high teens soon and then it's all about newsflow to get this into the 20p's.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585385+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260808-rp6577-28811575",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.090219",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Picking up\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "899",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-10T00:34:15.585403+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260752-gtc1507--1545679",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.090732",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "In amongst the noise about the us shutdown which looks to end shortly is this positive news:...NIH getting funding increase of $415m and NCI $128m in this financial year \ud83d\udc40 https://www.science.org/content/article/final-funding-bill-nih-pushes-back-against-trump-cuts",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "NCI budget increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=12E05045-67EF-4EEF-8C99-AC4E30F34994"
        },
        "ingested_at": "2026-02-10T00:34:15.585422+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260748-gtc1507--4968518",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.091246",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Certainly did! Might we see another TR1 today to catalyse the continuation upwards?",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-10T00:34:15.585440+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260653-Laura202-18464193",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.091737",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Well yesterday certainly looked like the start of the breakout",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-10T00:34:15.585458+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262341-Cheapsha-63966951",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.092242",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Penny has dropped well that\u2019s good news After 5p and 10p what comes? 20p then 50p Easy! \ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585476+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262127-gtc1507-85692356",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.092729",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The penny will start to drop\u2026.crushed a few of the key moving averages today, starting to look very positively setup",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585494+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261404-Rocka-50129466",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.093234",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "If we get more institutional investor rns\u2019s who taken the fill placing then i think we will be in the twenties pre contract news",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585512+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261358-Rocka-75129844",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.093725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Dark, never said i was selling 100%. I was frustrated with lack of news. I was considering wether to topup and i have topped up only \u00a35k not the full \u00a310k , i used the other \u00a35k to topup some bitcoin",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585530+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261314-Laura202--8461566",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.094204",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Excellent news",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "14.00",
          "thread_title": "Institutions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=80932BC0-29D6-499F-82C1-ABEFC7DCE7F1"
        },
        "ingested_at": "2026-02-10T00:34:15.585549+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261305-Darkryde--1428131",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.094697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocka, thought you were selling and moving on to pastures new? \ud83e\udd14 \ud83d\udea7\ud83d\udfe2",
          "sentiment": 0.5,
          "engagement": "554",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585567+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261228-gtc1507--4270660",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.095205",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Should be very attractive here, cash derisked all the other positives in play",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "13.75",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T00:34:15.585585+00:00"
      },
      {
        "event_id": "SOCIAL-Today2232-mmhater--2162760",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472383",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Sorry guys i sound like Sti!! Just a little frustrated and disappointed at the moment",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "RE: This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-02-10T00:34:15.585603+00:00"
      },
      {
        "event_id": "SOCIAL-Today2230-mmhater--5246052",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472835",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023. Why can\u2019t fusion even make a couple of million!!!! Thought we were best in world!!",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-02-10T00:34:15.585621+00:00"
      },
      {
        "event_id": "SOCIAL-Today2116-chrishut-26238586",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473268",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Don\u2019t miss the opportunity to get some stock before the big news comes.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585640+00:00"
      },
      {
        "event_id": "SOCIAL-Today2008-stt1--4016858",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473705",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc \"Once we start to see those contracts \" Another month gone. Nearly 2 months gone since Optimal Launch, where are all these millions of pounds of contracts that were ready and waiting and were supposed to announced when Optimal Launched?? There you go, exactly as expected, newsflow continues as expected.",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585658+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507--7960800",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474138",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Indeed - the fact that they said it\u2019s of sufficient scale to warrant NIH approval over NCI is encouraging. I think that they might be able to pull off some significant down stream entitlements like royalties and milestone payments if/when NCI licence those assets out to biotech/pharma.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585676+00:00"
      },
      {
        "event_id": "SOCIAL-Today1335-David195--2440125",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474551",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "The big unknown factor is the continuation with NCI and if renewed what the contract value will be.  It could be a few million $ pa.",
          "sentiment": 0.0,
          "engagement": "875",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585693+00:00"
      },
      {
        "event_id": "SOCIAL-Today1324-Laura202--6426860",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474965",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "I added at 13.5p this morning Good afternoon",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585711+00:00"
      },
      {
        "event_id": "SOCIAL-Today1254-chrishut-43555331",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475395",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "It has to go up, and up and up. Just patience needed and we will be laughing",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585730+00:00"
      },
      {
        "event_id": "SOCIAL-Today1227-gtc1507-62783374",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475809",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "It feels like everyone is holding back on forecasting the unknown of what the optimal contribution may be. Once we start to see those contracts and how quickly they come in once the first adopters take it on I suspect we\u2019ll see quick revisions upwards.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585748+00:00"
      },
      {
        "event_id": "SOCIAL-Today1223-rp6577--2718407",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476238",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "The Allenby note is much better than Shard\u2019s, with more forward looking comments.  My only niggle is that I felt the 2027 revenue estimate was a little underwhelming. Hopefully that is a prudent number and that Optimal contribution could kick into gear with the increased BD. Also I presume that it doesn\u2019t factor in any payment that could arise under the NCI agreement (or any other potential agreements for that matter). I would have liked to have seen break even early than 2028 but perhaps that is reflective of them investing more in spending now to get the revenue growth.",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585765+00:00"
      },
      {
        "event_id": "SOCIAL-Today1120-chrishut--8069580",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476643",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nice",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T00:34:15.585784+00:00"
      },
      {
        "event_id": "SOCIAL-Today1053-gtc1507--2565224",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477058",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://x.com/hybridanllp/status/2017171235352781200?s=46",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-02-10T00:34:15.585802+00:00"
      },
      {
        "event_id": "SOCIAL-Today0947-gtc1507-66260334",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477484",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "good coverage here too https://*********************/research/hybridan/friday-take-away-30-january-2026/14_922a0adc-24fc-4af3-83ed-fa76e67f06e7",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-02-10T00:34:15.585820+00:00"
      },
      {
        "event_id": "SOCIAL-Today0921-gtc1507-83682703",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477919",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some very interesting insight in here: At least 400k going into new kit to optimise optimal. Plus infrastructure IT upgrades - think this was the website upgrade Adrian mentioned before. Also new BD executives in USA and Asia planned. Allenby holding firm on the growth forecasts for h2 so should be fairly nailed on for that. Optimal pricing interesting insight there too with indications that projects could start around 200k but generate value up to \u00a32m each if they take the whole service. Indication that clients are already considering this. Talk of aiming to return base revenues to \u00a34m and that the new platforms could match and exceed that so over \u00a38m revenues aimed for medium term. Very exciting and interesting note",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-02-10T00:34:15.585838+00:00"
      },
      {
        "event_id": "SOCIAL-Today0828-gtc1507--7802334",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478348",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2026/01/20260130-Allenby-Capital-Fusion-Antibodies-plc-FAB.L-Update-1.pdf?c5187=on&_gl=1 *6ojkea*_ga*MTUzMjEwNjY0MC4xNzY5NTAxODU0*_ga_MZVZ4CNQ86*czE3Njk3NjEzMzYkbzExJGcxJHQxNzY5NzYxMzM5JGo1NyRsMCRoMA..",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-02-10T00:34:15.585855+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-gtc1507--5493495",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478764",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/live/donald-trump-news-updates-1-29-2026 Looking positive",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "Shutdown looks to be avoided! Roll on NCI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=3F614C0C-E9AC-4A45-8698-61C9AD6D520E"
        },
        "ingested_at": "2026-02-10T00:34:15.585874+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262124-Troutiso-23644315",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "31% up with a close of 13.25p , would suggest a price a year ago just north of 10p. It actually closed on 29th Jan at 8.75p and at 8.1p on the 30th Jan, so depending on where you would like the 12 months to start, either over 50% or for the 365 day version just over 60%. But that's nit-picking, it is up substantially on a year ago!",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T00:34:15.585892+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262123-gtc1507-81894822",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479606",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Guess depends what day shard wrote the note!",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T00:34:15.585910+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262052-Surfie19--4732792",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480016",
        "source": "LSE_CHAT",
        "data": {
          "author": "Surfie1961",
          "content": "\"But the momentum is building with the share price up nearly 60% over the last 12 months\". Er.... NO Ithink you will find it more like 31%.",
          "sentiment": 0.0,
          "engagement": "2,062",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T00:34:15.585929+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261951-stt1--2186859",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480486",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc, \"The raise matters\" A lot of hindsight views. After months of claiming they don't need to raise money, they have cash runway into 2027 etc etc, you're now agreeing with me that they DID needed a raise. Great to see you've changed your opinion and agree with me. Read and understand the company/sector newsflow. Your posts: https://www.lse.co.uk/profiles/gtc1507/?page=4 My post 9th Dec, 22.46 to Vikr: \"I believe they will use this higher sp to raise cash, as they need it to fund their project plans.\" https://www.lse.co.uk/profiles/stt1/?page=3 That's exactly what they have done. The company newsflow continues as expected. The rest of your posts are all ifs, coulds, buts and potential, which isn't surprising given you've been here years and holding since the sp was over 100p and so need investors to buy in..",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T00:34:15.585947+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261910-gtc1507--3862796",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480915",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Sorry thought I\u2019d copied it in: https://shardcapital.com/capital-markets/corporate-broking/research-portal/ Top note or filter for fab",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T00:34:15.585965+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261906-rp6577-33327240",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481335",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Are you able to share a link? Whenever I read their notes I always wish they would stick their neck out and state what they consider a fair market value of the company would be in their opinion",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T00:34:15.585983+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261607-gtc1507-45280031",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481756",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Investment case. In our assessment, Fusion is significantly undervalued relative to its peers. Its current market capitalisation of \u00a314m does not adequately reflect the investments made or the underlying technology. We believe the market has yet to fully recognise the ongoing recovery in sales and order book, as well as the potential of Fusion's novel proprietary platforms (OptiMAL\u00ae, OptiPhage\u2122, and AI/ML-Ab\u2122). But the momentum is building with the share price up nearly 60% over the last 12 months.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T00:34:15.586001+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261443-Laura202-71931164",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Be nice also if one person here would end their 14mth disruption of another share after your previous gracious plea fell on deaf ears 2mths ago Is that wishful thiking ?...who knows FAB hopefully rewards all concerned Best wishes all",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586019+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261440-druml-50159858",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482597",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Be rude not to buy some more. Been in for the penny looking for the \u00a3\u00a3\u00a3",
          "sentiment": 0.5,
          "engagement": "25",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586037+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261438-Laura202--2308782",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Chris I have taken that view also , it was clear with the drop in revenues H1 and slightly delayed launch they MAY needed funds for growth... I have bought today at 13.3p a few lots",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586054+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261335-gtc1507--6276493",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497848",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I expect we\u2019ll see a few tr1s for existing vc or II taking more as well as potentially new investors as indicated in the rns",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T00:34:15.586072+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261315-Troutiso--3836410",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Well there are 68k of buys in the sell column and a delayed buy just under 100k going through, so buying well outweighs sells here, the price is climbing within the quoted spread and I see another tick or two this afternoon if this continues. Realisation will come tomorrow (with the issue of placing shares) and next week, if the placing shares have gone to sticky IIs as the last did, then people will jump on board from the sidelines",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T00:34:15.586090+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261306-livinhop-50856584",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498703",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Excellent gtc, thank you!",
          "sentiment": 0.0,
          "engagement": "1,095",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T00:34:15.586128+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261303-gtc1507-59259316",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499226",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My reflections post raise\u2026..FAB now appears to be entering a very different phase with the launch of its world-first OptiMAL platform. 1) The raise matters \u2014 and it was done from strength The placing was completed at 13p with no discount to the prior bid. That\u2019s unusual on AIM. It removes near-term funding risk just as the company moves into commercial execution, allowing Fusion to accelerate growth rather than constrain it through cost control. 2) What OptiMAL is \u2014 and why it matters OptiMAL is a new antibody discovery platform designed to find brand-new, fully human antibodies faster and with lower risk. Management describes it as first- and best-in-class, targeting the most valuable part of the drug pipeline: discovery. Discovery work is higher margin than Fusion\u2019s traditional services and keeps clients engaged for longer. Crucially, they have updated that multiple clients are already engaging under NDA to discuss OptiMAL. Clients won\u2019t engage like this unless they are serious discussions. These are premium, additive services that materially improve earnings quality. 3) Validation, commercialisation \u2014 and IP protection OptiMAL has been validated by the US National Cancer Institute, delivering single-digit nanomolar hits directly from screening. NCI now wants to move to a commercial agreement to use OptiMAL across multiple targets and years. Fusion has said the proposed deal is large enough to require NIH approval \u2014 a powerful external endorsement. This may take time to get through but it is powerful none the less at this stage. The platform is also patent-protected, with US coverage secured and further decisions pending in Europe, China, and Japan. Strong IP underpins pricing power, licensing potential, and long-term strategic value. 4) Growth was already forecast before the raise Brokers were already modelling strong H2 growth (often cited around ~80% vs H1) and ~\u00a33m revenues by FY27 before the placing. The raise de-risks delivery and broker forecasts still exclude any OptiMAL contribution. 5) Cash burn is supported, not stressed Fusion also benefits from \u00a31m of non-dilutive Future Medicines Institute funding over five years, plus shared capital equipment \u2014 lowering burn while supporting scale-up. They also have the \u00a3545k Dr5 grant. Potential near-term catalysts: \u2022 OptiMAL NDAs converting to contracts \u2022 updates on Progress on an NIH-approved NCI deal \u2022 potentially Patent decisions in major jurisdictions \u2022 Outcome of the OptiPhage licence evaluation \u2022 Hiring momentum as the company scales \u2022 A potentially strong FY26 trading update This is Not advice. DYOR \u2014 but IMO this is the clearest setup Fusion has had in years: funded, validated, IP-protected, and launching higher-margin services.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T00:34:15.586146+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261107-chrishut-71167604",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499637",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586170+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261057-gtc1507-31243571",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500057",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586189+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261042-Troutiso-36906515",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586208+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261035-Troutiso--4579500",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586226+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261033-Gheko--3752186",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-02-10T00:34:15.586244+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261012-Rocka-57240411",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586262+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260846-Troutiso-86202706",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586281+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260842-Troutiso--5945468",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586299+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260824-gtc1507-69584131",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502979",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586317+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260820-gtc1507-46742561",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503409",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586336+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260811-Rocka-84937898",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586354+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Seancadm-40265888",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586373+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Darkryde-19711435",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504671",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586390+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260754-gtc1507-64928899",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505088",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586408+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260745-Saintsmi--3273546",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505507",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586426+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260709-Darkryde-73424473",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586444+00:00"
      },
      {
        "event_id": "SOCIAL-Today1107-chrishut-71167604",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.749919",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586462+00:00"
      },
      {
        "event_id": "SOCIAL-Today1057-gtc1507-31243571",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.750538",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586480+00:00"
      },
      {
        "event_id": "SOCIAL-Today1042-Troutiso-36906515",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586498+00:00"
      },
      {
        "event_id": "SOCIAL-Today1035-Troutiso--4579500",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751618",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586516+00:00"
      },
      {
        "event_id": "SOCIAL-Today1033-Gheko--3752186",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-02-10T00:34:15.586534+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Rocka-57240411",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752748",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586552+00:00"
      },
      {
        "event_id": "SOCIAL-Today0846-Troutiso-86202706",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753371",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586570+00:00"
      },
      {
        "event_id": "SOCIAL-Today0842-Troutiso--5945468",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753974",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586588+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-gtc1507-69584131",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.754578",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586606+00:00"
      },
      {
        "event_id": "SOCIAL-Today0820-gtc1507-46742561",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755194",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586624+00:00"
      },
      {
        "event_id": "SOCIAL-Today0811-Rocka-84937898",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755779",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586642+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Seancadm-40265888",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586659+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Darkryde-19711435",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586677+00:00"
      },
      {
        "event_id": "SOCIAL-Today0754-gtc1507-64928899",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.757590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586694+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-Saintsmi--3273546",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586711+00:00"
      },
      {
        "event_id": "SOCIAL-Today0709-Darkryde-73424473",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586730+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262241-mmhater-68035184",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759247",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "So i\u2019ve been a big investor of FAB for the past year and am well in profit. I currently own over 1.3 million shares but this latest placement has left me sat on the fence\u2026.. I\u2019m a little fed up of the company telling us they are financially stable till time X but still keep raising money\u2026 The latest raise for 1.4 million is at a great price but i wonder if 1.4m was necessary? If deals are incoming surely  0.5m would have done\u2026.. My next thought is if the industry is worth so may billion a year why are we struggling to get a million pound of deals? surely we should be getting at least 5 percent of the market if we are best in the field. I\u2019m starting to lose faith Adrian\u2026. nearly put another 10k in here but your latest actions have made me dubious.",
          "sentiment": 0.0,
          "engagement": "656",
          "price_at_post": "13.125",
          "thread_title": "Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T00:34:15.586748+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262110-cbeadle-44053739",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759663",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I would do , but FAB my largest holding and I am very into mining stocks which are generally doing well.",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.125",
          "thread_title": "Buy More?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=9B999AB7-3C0D-4F49-942F-FD2729833E45"
        },
        "ingested_at": "2026-02-10T00:34:15.586767+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262033-gtc1507-36999347",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760077",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "That\u2019s some conviction Chris good to see. Hopefully a floor here. Looking forward to seeing the tr1s to see which institutions came in",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586785+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261838-chrishut-78415304",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760509",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I took 175k today and still had orders in, that didn\u2019t fill.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586803+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261805-gtc1507--8500009",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761183",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "ORDEEERRRR",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586821+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261744-Troutiso--1615632",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I count at least 200k of buys been put in the sell column,  150k were mine and the other looks to be a 50k buy just as the offer rose this morning. So the buys have it, the buys have it...",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586840+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261540-Troutiso-56979383",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.762581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Just sniped another 50k at the placing price",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586859+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261342-chrishut--2456650",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763155",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I added quite a few more today too, it is a no brainer now, cashed up and contracts likely to be a lot more frequent",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586877+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261341-chrishut--1785757",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763701",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nicely played trout",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586896+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261209-Troutiso-32392865",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.516994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There seems to be a few PI sellers, getting out at below the placing price. I think these may be short term investors looking at other grass is greener stocks. I have used the opportunity to add at the placing price for the moment, I believe that the shares will have gone to long term investors and as such think that in a few days this realisation will be apparent and others will start to add again. Looks like a few delayed 50k buys coming through now. MMs are playing around with this, but not enough conviction from buyers to get this moving upwards, hopefully start to see something next week, would be good now they have got this out of the way to get an update from the Company.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586914+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261037-gtc1507--1819364",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.517590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Positive mention in a research note yesterday on SP angel, healthcare conditions note/ https://www.spangel.co.uk/research/",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "12.875",
          "thread_title": "Research note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=574BB89D-C932-496A-80A3-2E9C64DACF5C"
        },
        "ingested_at": "2026-02-10T00:34:15.586932+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-Troutiso-75317134",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes me too, limits down to 10k now, well on the way to filling the headroom back up to 2.99%",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "12.875",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586959+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260930-chrishut-66158909",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518658",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Took another 75k",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.00",
          "thread_title": "I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T00:34:15.586977+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260733-Eurobuil--7080295",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Eurobuild1",
          "content": "Don\u2019t come gloating on here , keep your opinions to yourself if your giving it the big told you so",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "13.25",
          "thread_title": "RE: Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-02-10T00:34:15.586996+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262144-stt1-45360586",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519750",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "From the placing rns: \"The net proceeds of the fundraise, being approximately \u00a31.3m, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL platform, to invest in the company's commercial activities and for general working capital purposes.\" https://www.insidermedia.com/news/ireland/fusion-antibodies-raises-1.4m-to-drive-growth-plans From the grant rns, which they received less than a year ago: \"The Grant support to Fusion is to cover human resource needs, materials/consumables costs and overheads.\" https://www.londonstockexchange.com/news-article/FAB/approval-of-grant-funding/17002681 That suggests to me they have utilised all of the grant money to date and so needed more.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-02-10T00:34:15.587015+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262128-stt1--4186021",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520299",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Well done Alice for predicting a placing. I see you got a lot of abuse. I wouldn't wait for an apology from these clueless rampers.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: If Fusion places 100M share",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BCF5D778-E9D7-439C-990A-6D28AB648781"
        },
        "ingested_at": "2026-02-10T00:34:15.587033+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262117-stt1--3760707",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520864",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Humpalumps \"Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually\" Oh dear, can't handle the truth. My 1st post on FAB was a year ago, Jan 2025, after HVO pump and dumpers moved across to here. HVO crashed from c30p to c5p today on company newsflow, red flags I'd been warning about. https://www.lse.co.uk/profiles/stt1/?page=16 I can understand your frustration at being completely wrong and loading up c30p.. my posting history is there for all to see your lies about my posts... There's always one who's totally stupidity and incapable of reading the company newsflow. This from your post just a month ago....22nd Dec 13.51 \"They have a cash runway til FY27 which as has been confirmed on the investor hub didn't include NCI in the calculation so they're fine for cash\" https://www.lse.co.uk/profiles/humpalumps/ You need to read and understand company newsflow as it'll help you stop making those stupid mistakes.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-10T00:34:15.587051+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261929-Humpalum-35778035",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Jokes \ud83e\udd23 are we actually being lectured by the guy who told everyone to buy TLY that went bust while simultaneously warning people off FAB at circa 4p \ud83e\udd23\ud83e\udd23 Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually And finally this placing isn't a bad thing it sets a floor at the current price, was at 0 discount and will probably be last one this company will ever need Also I won't be replying to any of the crap you respond with because you're a terrible investor for point 1 in this comment \ud83c\udf1d",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-10T00:34:15.587068+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261816-stt1-83732244",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521921",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Antha, I'm glad I traded these and not held on, like you, at 30p.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Ha ha ha. sti sold a couple days ago",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=16F2F8FD-FC78-4AF1-834F-BFF85ACDD8C8"
        },
        "ingested_at": "2026-02-10T00:34:15.587087+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261804-stt1--2676872",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.522484",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Rocka, \"Sti so is now almost 20p , you are making yourself look very silly.\" I see there's a placing. Who's making themselves look very silly. I traded or you who was ramping at 20-30p. You should learn to read and understand company newsflow. The sp has fallen back exactly as predicted. Where's the clueless Humpalumps? he needs to learn and understand company newsflow. He was clueless as well, ramping these at 30p!!!",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-10T00:34:15.587125+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261757-stt1--6936638",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523018",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "There you go, exactly as predicted. Placing. Who was gullible enough to believe the clueless rampers!!!! Back to the same sp as before the previous pump/dump. Newsflow was exactly as expected.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Cash is low, so placing likely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=56D85761-47EE-47AB-BE35-44485A6673DC"
        },
        "ingested_at": "2026-02-10T00:34:15.587155+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261308-gtc1507-60577163",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523551",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes you\u2019re right! Sorry thought you were talking about smaller optimal screens. But yes the sliced bread analogy was a good one. We\u2019re already seeing the ITAS approach being mention in the RNS which is good. That last big pharma one Was referred to as an ITAS one so hopefully means we can retain them for more business",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587173+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261258-Troutiso-47248992",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524059",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Gtc, You are talking about full screens and AK did state that some companies may want smaller more focussed screens (if they had already developed some targets), He also stated that a full ITAS contract would be over \u00a31m, but some might want to take a more modular approach and contract to do some phases of the ITAS with FAB and that those companies will choose how many phases they would want to do with Fusion. These would likely not be RNSed due to their smaller size, piecemeal approach.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587192+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261248-Rocka-88338169",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Actually i said if there isn\u2019t any news, there has been today! Today\u2019s RNS isn\u2019t great but it\u2019s not bad news that will see the sp tank 50% as i\u2019ve been in such stocks.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587210+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261238-Troutiso--7920212",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Literally 23 hours ago you posted that if no news soon you would consider selling up.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587228+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261222-Rocka-80294940",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout, not a gambler at all. I\u2019ve been here for quite some time . I still believe in the longterm future here but the proof is in the pudding and this is what we will find out in the coming months( hopefully) Not planning on selling just considering whether i should buy more to bring my average down.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587246+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261215-gtc1507--2927020",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526095",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a good assessment, although, just to correct one piece. Adrian was clear they wouldn\u2019t get smaller contracts at the start as Optimal was designed to do full large scale screens. He said they may structure the deals differently to begin so that some of the client risk is reduced, potentially by reducing up fronts but including  success based milestone payments I.e when the screen delivers what fusion know it should then fritter payments will trigger. Slightly nuanced but still the overall value shouldn\u2019t change and the scale of the challenges will still be big but the point on the journey that fusion and the client risk profile is set and payments set may be adjusted to begin to incentivise early adopters. Adrian also said this will only be available for a limited period.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587264+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261209-Troutiso-55426281",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526590",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Realistic timeframes, valuations, etc.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587282+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261208-Troutiso-12824700",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Can I suggest having read back through your recent posts, that you are waving in the wind and seem to be very short term/big demands type of gambler. An investor wouldn't change their mind in a matter of days, unless there is a material change. You have been bemoaning news and after your post yesterday I nearly replied be careful what you wish for as a placing had entered my mind here. This is a medical CRO and they work in a field which takes a long time to get anyone to sign anything, rigorous checking and re-checking of the science, followed by rigorous checking and re-checking of the product before anyone is prepared to commit, it takes time. However, FAB has now launched OptiMAL and that is being assessed by prospective clients, this will take time but has been ongoing for some time. The Company have stated they are likely to get smaller OptiMAL use contracts to start, before some clients may come back for the chunkier full development contracts. That is the way of this particular industry. So whether or not you spend another \u00a310k here or you sell up or you spend \u00a310k elsewhere, my advice to you is to develop some patience (and that sometimes is very long term patience), while you are sitting there holding one company, others always look like they are doing better, but in reality that is not the case most of the time. Good Luck with whatever you do, but remember PIs and those on these BBs will always be ahead of reality, as they want short term gratification, when it always takes longer, costs more and can fail, invest and be patient and look at",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587300+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-Humpalum--5021514",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527465",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Personally I think there is a strong chance this will be the last placing this company ever needs - I can't really see a world where this company isn't profitable in the next 12-16 months which would be the kind of timeframe this money would last them without profitability",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587318+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-evman27--5345099",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527915",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It's always frustrating to see a placing happen but I believe this will be the last one fusion ever has. Back when the company was struggling they raised at 80% discount, the raise last year and today was at no discount, that counts for something. As many have said it puts us in a strong negotiating position, hard to get good deals when everyone knows your cash situation is tight. Since the raise last year the company has moved leaps and bounds, raised at 6.75p and SP hit 20p not long after, I suspect we will see similar here, we should be entering a news rich period too having commercially released Optimal. It is clear there is a lot of background interest in Fusion and Optimal, at least the buyout offer when it comes won't reflect a struggling company, it puts us in a stronger position to refuse a cheap offer. I'm still happy with my money here and have been since September 2024, the value on show here today is immense.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587336+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261144-Rocka--4005431",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.528425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I have \u00a310k funds clearing next week, i\u2019m tempted , i\u2019ll have to think about whether i\u2019ll buy more. Let\u2019s  just hope we start generating some serious income without needing to resort to more placings.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587354+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261139-Rocka-83525548",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Not the RNS i was expecting, also i don\u2019t believe the BOD should get any bonuses until the company is generating a profit but hey ho it is what it is. Let\u2019s just hope we see some contracts and/or news on NCI. We need a catalyst to propel the sp.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587372+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261115-gtc1507-84483039",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529652",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Shares admitted on Friday 30th, suspect we\u2019ll see tr1s shortly after - be interesting to see who went for it",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587390+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260941-druml--2454094",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.278271",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Prudent decision by the board. Give the headroom for getting the deals in. Good to see director support.",
          "sentiment": 0.5,
          "engagement": "24",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587408+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260940-gtc1507--7937117",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279131",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "What does \u201cinvest in strategic partnerships\u201d mean do we think? \u201cThe successful validation and formal launch of our OptiMAL\u00ae platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time. \"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders.\"",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-10T00:34:15.587426+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260934-gtc1507-69052410",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279952",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - I took comfort there was no indication in the rns about weakness in the trading position also which I assume means they remain on track to achieve the 80% growth in h2. This was strong from the launch conference \u201c Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time\u201d.",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-10T00:34:15.587444+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260930-Cheapsha-74397244",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.280743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "After the raise and director shares the share count is bang on 125M share still very low. The bonus shares also issued at 13p. Market cap just under \u00a317M with this issue. To get to 50M cap we need about 40p share price very reasonable- actually that would still be cheap very cheap. But we do need some contracts signed should be here soon!",
          "sentiment": 0.5,
          "engagement": "2,671",
          "price_at_post": "13.375",
          "thread_title": "Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-10T00:34:15.587462+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-Bibzy7--3389800",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.281547",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Is this just the last chance for the ones in the know to get the cheap shares before this goes crazy Half full maybe outlook",
          "sentiment": 0.0,
          "engagement": "321",
          "price_at_post": "13.50",
          "thread_title": "Cheap",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34F59233-C112-41AC-AA13-18CE6878B383"
        },
        "ingested_at": "2026-02-10T00:34:15.587480+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-David195--9205248",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.282359",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "This is no surprise and positions FAB to move forward more quickly.  Potential customers need to be reassured the company is in good shape financially when due diligence is carried out.  A raise at current SP is excellent in current market conditions.  The discussions with NCI are crucial and FAB are able to conduct them from a stronger position. Getting the first contracts and renewing the agreement with NCI in the coming months is now more likely.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587498+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260824-Troutiso--1892012",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283156",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Both the bid and offer price rising within the wide quoted spread. I have a little more headroom to fill now, so have started with 50k.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587516+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260815-gtc1507-37209455",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The said they had runway to FY27 which is April. Good they have topped up the cash balance. Should help with due diligence for contracts. Buried line in the rns: \u201cMany of the organizations approached in the pre-launch phase have expressed an interest in the OptiMAL\u00ae platform including disclosure of target details under non-disclosure agreements\u201c Companies willing to share their target data with fusion is strong endorsement for their capability and expertise . This provides a very strong foundation to move forward in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587534+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Aldebara-55645073",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.284672",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Barely any discount. Seems ok to me",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587551+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Troutiso--9058116",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.285377",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Had a feeling this was coming, very quiet, lack of real trading and the timing were all tell tales, as was the tight lipped rumours. Last week SML another I have a large holding in (and seems to have been mirroring FAB prices albeit at a tenth of FAB) did a placing at 1.3p for \u00a34m they too have lots going on and are using the funds to accelerate drilling towards an earlier PFS. That was at 1.3p at no discount. The market although PIs were telling each other it had enough money has responded very positively and it closed yesterday at 1.9p. I felt it was possible that FAB would do the same and am pleased they have done so, this will accelerate OptiMAL rollout and was probably needed for some of the bigger new clients to sign any deal (they will not want to have contracts with companies who don't have a robust financial situation. I think the company have explained themselves well and don't see this as negative, if, and a big if, the shares have gone to long term IIs as the last one did. I have no reason to believe it hasn't as if this was a vulture driven firesale placing the SP would have been hammered and there would have been a 30%+ discount. I believe this is more to do with large investors wanting to add more, but not wanting to buy in the market and happy to do so in a placing at no or little discount. Overall happy with this and if the market reacts like it did last time we will soon be up at recent highs. This is nearly double the price they raised at last year, that is a sign of good progress!!! Stan it was 13.4p to buy yesterday so below mid anyway....",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587569+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260751-Seancadm-24969770",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "They had stated they had cash runway into \u201827 (financial year 27, which is from April \u201826 ). So in order to avoid a raise they would have needed contracts to drop in the next month and even then they couldn\u2019t have been certain to have money in the bank by then. So they are now fully funded, with, from the details in the RNS strong indications of OptiMal take up. This is good for the company putting a strong cash foundation under what could well become a company making year!",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587587+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260743-U_time--6688535",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286990",
        "source": "LSE_CHAT",
        "data": {
          "author": "U_time",
          "content": "Hard not to be negative about this placing. Comes at a time where we thought no placing was needed as the company was good financially and had enough contracts to manage day to day cash without a raise. Strange. Seems to suggest people are q'ing up for the 'best in class'. NCI deal now becomes even more crucial hopefully they can get it over the line otherwise FAB just becomes another one of those AIM companies that wants to keep raising funds on share holders dime until eventually they decide to delist... Hopefully wont come to that but its game time now.",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587605+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260727-bannside--5539958",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.287780",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "Tells me there no contracts ready to be signed",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587624+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260725-rp6577--4659045",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.288565",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Not the RNS I wanted to see. However, at least it is at the market price. Hopefully this now gives them the fire power to accelerate growth and really kick into gear",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587641+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260723-Stan36-54355210",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.289358",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Cheadle it is discounted from the mid price. And from the ask price ordinary investors would have to pay. So a discount of 3.8 to 7.6% NED participation during contract negotiation with NCI tells us he's not party to the details?",
          "sentiment": 0.0,
          "engagement": "863",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587659+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260710-rubarbru--2434047",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290150",
        "source": "LSE_CHAT",
        "data": {
          "author": "rubarbrubarb",
          "content": "And director involvement",
          "sentiment": 0.0,
          "engagement": "60",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587677+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260708-cbeadle--3814765",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290933",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Quite encouraging it\u2019s at the market price and not discounted at all",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587695+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260705-cbeadle--8977632",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.291707",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right news 50p to \u00a31 could happen really fast",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-02-10T00:34:15.587713+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260703-Laura202-48565110",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.292433",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Out",
          "sentiment": 0.0,
          "engagement": "15,342",
          "price_at_post": "13.50",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T00:34:15.587731+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262352-Clachair-22633001",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293116",
        "source": "LSE_CHAT",
        "data": {
          "author": "Clachair10",
          "content": "Hi, I have been in since near the very beginning. I need to see \u00a31/share to get my money back. Not sure that will ever happen? Could have made a killing when they floated but wasn\u2019t able to realise it. May have to bale when and if it hits 50p a share. Have been watching this for so many years waiting for the upside! C.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-02-10T00:34:15.587755+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262314-rp6577--5687367",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293774",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "My view is that they have something which is better that what their competitors have. Things can take time to get traction. However, if you are fundamentally better, then it is difficult not to see significant success down the road. Just got to sit tight and if you don\u2019t have your full position yet, add during these quiet times",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T00:34:15.587774+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262105-evman27--6037703",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.294509",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes I was there too, still holding and have added to my position since then on dips. It's clear Optimal and Fusion are dangerously undervalued and I feel very relaxed with my money here.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T00:34:15.587791+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-Seancadm-34194486",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.295238",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Anyone who is concerned about any lack of news since the launch (which to be fair was only a few weeks ago) should google how long diligence on a new platform takes, these things take time and there is certainly no need for concern at the moment. The NCI deal is progressing and as GTC says could well be bigger than anticipated due to NIH involvement. I agree though an update on progress so far would go a long way to calming investors.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T00:34:15.587810+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-NornIron-45860746",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296005",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Many thanks for that GTC.",
          "sentiment": 0.0,
          "engagement": "458",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T00:34:15.587828+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261616-gtc1507-74766247",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296852",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I\u2019m still here and was at the AGM. They were very positive about the future potential of the Optimal platform and as have said throughout all their engagements , it will take time to convince people to come onboard but they said it had the potential to be transformational for drug discovery. The brokers are predicting growth of 80% in h2 without any optimal contribution. they have historically not published every single contract they win as their view is their clients don\u2019t always enable that and it could be commercially damaging. All I know is we\u2019ve had nothing from the company to indicate anything materially different to their forecasts either up or down and all we can do is wait for news. They were hiring just before Christmas for 3 new roles so they must be confident about prospects given their cautious cash management approach. They have the grants from the FMI to help them balance those. We\u2019re just in that phase at the moment where we need to see the proof in the execution. I take comfort in the fact the NCI deal is of such a scale it requires NIH approval - that sort of deal will turn the heads of big pharma. They already have big pharma on the books as notified by the two rns at the end of summer autumn so they\u2019ll likely be engaging them about the benefits of optimal. We just need to give them time. They confirmed their cash runway into FY27 was not dependent on an NCI deal so they are. If the company are reading this tho I think investors would welcome something of an update though, silence on the hub, silence to emails, nothing on LinkedIn - all very quiet does feel like something may be bubbling behind the scenes in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T00:34:15.587846+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261516-gtc1507--1748879",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721015",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Still sitting 4 v 3 here. The l2 book Hasn\u2019t moved since open strangely despite some chunky buys",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.587864+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261512-mmhater--5923633",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721463",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Has anyone got level 2? i imagine it will be getting stronger all the time. A tick up would be nice to see.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.587882+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-chrishut-37900149",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721890",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A couple in the telegram group bought more today Great prices on offer",
          "sentiment": 0.0,
          "engagement": "17,380",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.587901+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261215-mmhater-82661531",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722312",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I\u2019ve got far to many already\u2026. This is AIM at the end of the day and you never know when you are going to get screwed over. Expect the unexpected! On that note i don\u2019t expect 50p anytime soon.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.587919+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261208-Rocka-69728753",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ideally i\u2019d like this at 20p pre news then i think we\u2019ll easily easily hit 40p min short term",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.587938+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261207-Rocka--5058491",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723144",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "No ramping intended but if i had \u00a38k now i\u2019d put it all in FAB, topped up last week and expecting \u00a310k early Feb and i\u2019ll put it all in fab. This is a no brainer tbh especially at this price",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.587956+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-gtc1507--1033529",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723563",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My gut says we will hear something next week",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.587974+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261159-mmhater--8734178",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723976",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I did my little bit yesterday\u2026. I do have another 8k i\u2019m tempted to put in but haven\u2019t decided yet\u2026. Time is ticking and i\u2019m expecting news very soon. NCI wanted to carry on using optimal immediately so must need a deal soon??? Are FAB just letting them use it in the interim?? I still think this is getting bought out. Adrian\u2026 give us an update.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.587992+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261138-evman27--8426644",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724413",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "250k is 14.6 Then 260k jumps to 20p!! Float disappearing fast, news will send this crazy, or if someone wants to do the honours now?!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588010+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261059-CHEATED-93966656",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724821",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "I suggest a new field of research that might be rewarding. The lack of mobility and the balance problems of stroke victims. You may have a winner here.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588028+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262332-cbeadle--2183943",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725238",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Something could happen very quickly with FAB",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588046+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261641-Rocka--5601595",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Well if it goes that high that quick i\u2019ll be equally happy as i hold quite a few already",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588064+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261637-Darkryde--8561935",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocks, I hope and think you\u2019ll only get 16,000 shares with your \u00a310k \ud83d\ude0a",
          "sentiment": 0.5,
          "engagement": "548",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588091+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261512-CHEATED-82781544",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726484",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "There should be a link-up with a large American antibody firm. Perhaps a partnership would be beneficial. Share price is in the doldrums and needs a boost of some kind. I cannot see the advantage  of the last addition of staff producing anything of great significance. Too many cooks spoil the broth. Try something new.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588136+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261456-Rocka--6228820",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019d put more in to if i had available funds, topped up last week. Expecting \u00a310k early Feb, hopefully i can buy at todays price once funds clear.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588155+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261415-evman27-14556917",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727321",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Nice buys, what a bargain price!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588173+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261405-mmhater--7640007",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727732",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "My 2 8k trades aren\u2019t showing. been a rise in trades past couple of days and i think this is going to pop soon. News is imminent. NCI have said they want to use optimal immediately so won\u2019t hang around doing deals for long\u2026",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T00:34:15.588190+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261338-mmhater-51877364",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728151",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I got fed up of being patient so bought another \u00a316000 worth\u2026 Come on Fusion\u2026 give us a update",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T00:34:15.588208+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261330-Antha--8017817",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "Everyone is just waiting for the NCI contract and other pharma contracts to be signed, until then the sp will just drift up and down between the 12-16p range, just need to be patient.",
          "sentiment": 0.0,
          "engagement": "2,740",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T00:34:15.588226+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261310-gtc1507--7153200",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728989",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Seems to be kicking into action again, some decent buys today. Investor relations seem to be answering questions on the hub too. Looks like the shareholder information has been updated too as of a few days ago, no sign of maven any more\u2026.. https://www.fusionantibodies-ir.com/content/investors/shareholder-information.asp",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-10T00:34:15.588244+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261100-stan1234--7603655",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729412",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "I am going to add today too. Just selling something else first.",
          "sentiment": 0.0,
          "engagement": "208",
          "price_at_post": "13.25",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-10T00:34:15.588262+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260810-formerly--3075232",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729827",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Purchased 10,000 at 13.3 via HL this morning. Wait and See!",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-10T00:34:15.588281+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261821-formerly-88276707",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730246",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T00:34:15.588299+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261812-gtc1507-63600579",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730660",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T00:34:15.588317+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261757-Cheapsha--1612706",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.731071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T00:34:15.588335+00:00"
      },
      {
        "event_id": "SOCIAL-Today1746-Cheapsha-23023373",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.939863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "I recon Feb 19th we get some juice. If I am wrong just feel free to poke fun at me. That's just my crystal ball",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718207+00:00"
      },
      {
        "event_id": "SOCIAL-Today1633-evman27-85941989",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.940401",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Loving the quotes today guys! If no news, let's do poetry wednesdays tomorrow.",
          "sentiment": 0.0,
          "engagement": "186",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718252+00:00"
      },
      {
        "event_id": "SOCIAL-Today1541-rp6577--7509701",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.940895",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "I just focus on the fact that if we are offering something that is better than the competition and in a massive market, then the results should surely follow. It might not be a straight line or quick, but you should eventually succeed",
          "sentiment": 0.0,
          "engagement": "900",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718289+00:00"
      },
      {
        "event_id": "SOCIAL-Today1538-Cheapsha--3494245",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.941413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Quite from Mr Google clarify: \u201cContext: Buffett uses this phrase to emphasize that patience, discipline, and a long-term perspective are the true keys to building wealth, rather than trying to time the market.\u201d",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718311+00:00"
      },
      {
        "event_id": "SOCIAL-Today1534-Cheapsha--1161847",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.941924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "News gonna come soon It\u2019s just a little patience that most people do not have Remember W Buffet \u201cStock market is a mechanism of transferring wealth from the impatient to the patient\u201d Obviously this applies to well run companies not losers; but FAB is very well run with a platform that the best players do want\u2026so\u2026",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718329+00:00"
      },
      {
        "event_id": "SOCIAL-Today1229-Rocka-51970572",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.942434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Nice quote\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718347+00:00"
      },
      {
        "event_id": "SOCIAL-Today1220-Seancadm--2977121",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.942930",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Weak hands watch the screen, strong hands watch the story. Platforms don\u2019t get validated and commercialised overnight, patience is the key.",
          "sentiment": 0.5,
          "engagement": "222",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718365+00:00"
      },
      {
        "event_id": "SOCIAL-Today1148-gtc1507-33673315",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.943428",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "It is disappointing to see it go up and down. I think we\u2019ll be in a range until there is news of success. The company said it might take time to convert, but we need to see the signs that optimal actually is attractive. They were in discussions last February on optimal with clients according to answers the hub, I think we\u2019re all hoping that they convert to sales sooner rather than later to demonstrate what they say is market leading actually can deliver. If they are right then we should be onto a winner it\u2019s all on the execution now.",
          "sentiment": 0.0,
          "engagement": "1,202",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718383+00:00"
      },
      {
        "event_id": "SOCIAL-Today1147-Rocka-83447131",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.943915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mm hater, we are all guilty of feeling anxious from time to time, but these things do take time, the way i see it is none of these institutions would buy at 13p if they didn\u2019t believe in FAB. I\u2019m holding and topping up as and when funds are available.  Obviously not  all of the  placing has  gone to sticky hands, there are some that will be happy with a 10% profit. Just hold and we\u2019ll all be rewarded.",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718400+00:00"
      },
      {
        "event_id": "SOCIAL-Today1140-mmhater--1130287",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.944409",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Lol\u2026.. i do see your point\u2026. Been here 3 years since it caught my eye when it dropped from the highs of covid. The company has been promising amazing things and just want to see them come to fruition\u2026. I thought the launch in December was going to be great but was a damp squib! i\u2019m just frustrated\u2026.. And what\u2019s today\u2019s drop all about?",
          "sentiment": 0.0,
          "engagement": "667",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718418+00:00"
      },
      {
        "event_id": "SOCIAL-Today1137-Rocka-66683667",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.944882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, you change your opinion every couple of days, if the sp retraces slighter you go into negative mode. I honestly don\u2019t think stock trading is for you .",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718436+00:00"
      },
      {
        "event_id": "SOCIAL-Today1111-mmhater--7551252",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.945382",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Company really need to get their finger out their back sides! IF we are the best in the world for antibodies i would have expected a lot more action in the share price. 6 weeks on from launch of Optimal and expect more than what we are seeing!",
          "sentiment": 0.0,
          "engagement": "667",
          "price_at_post": "15.00",
          "thread_title": "Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-10T23:46:26.718454+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-evman27-44398336",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.945886",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "\"It was never my thinking that made the big money for me, it always was sitting... sitting tight\" - Jesse Livermore Small term movements don't bother me when I know what I own.",
          "sentiment": 0.0,
          "engagement": "186",
          "price_at_post": "15.00",
          "thread_title": "Know what you own",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=648A18DB-23B4-4D15-BAE6-C6BCA075BA1F"
        },
        "ingested_at": "2026-02-10T23:46:26.718479+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261800-Cheapsha-23291182",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.682514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Oooh bless you Alice $$$ Year of the Fusion- jump in!",
          "sentiment": 0.5,
          "engagement": "2,677",
          "price_at_post": "16.00",
          "thread_title": "RE: Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-10T23:46:26.718499+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261619-Rocka--1363785",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.683225",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Alice, at best 130p plus add a zero to 13p.",
          "sentiment": 0.0,
          "engagement": "198",
          "price_at_post": "16.00",
          "thread_title": "RE: Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-10T23:46:26.718518+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261610-Seancadm--1983092",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.683905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Don\u2019t think you\u2019ll get your buy in price this time Alice! I\u2019ll focus on the funded balance sheet and validated tech rather than short term price guesses.",
          "sentiment": 0.0,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-10T23:46:26.718537+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261550-Alice-Wr-86391897",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.684583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alice-Wright",
          "content": "At worst.",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "16.00",
          "thread_title": "Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-10T23:46:26.718555+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261103-gtc1507-11392175",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.685263",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some decent delayed prints continuing today. Feels like someone accumulating",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-10T23:46:26.718573+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260848-Seancadm-55836528",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.685925",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "NCI/NIH better funded, Fusion fully funded, OptiMAL already validated and in continued use discussions... feels like all the pieces are lining up.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-10T23:46:26.718592+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-gtc1507-49587062",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.686647",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "\u201cNIH and NCI Receive Funding Increases The FY26 bill provides $47.2 billion for the National Institutes of Health (NIH) and $7.4 billion for the National Cancer Institute (NCI), representing increases over current funding levels. At the same time, the measure maintains flat funding of $1.5 billion for the Advanced Research Projects Agency for Health (ARPA-H). Together, these appropriations reinforce federal support for the cancer research pipeline, including discovery science, translational research, clinical trials infrastructure, and efforts to improve prevention and outcomes across diverse populations.\u201d Good to see discovery science specifically mentioned\u2026. https://oncodaily.com/public-health/nih-fy26",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-10T23:46:26.718610+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261827-gtc1507--8267919",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.687448",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I think it\u2019s good to reflect back on what the company have actually told us about Optimal and why it\u2019s supposed to be a game changer. Based on Fusion\u2019s own published data and comparisons reported in the scientific literature, OptiMAL appears to be materially more effective than competing antibody discovery platforms. The most important metric is efficiency. Fusion reports that OptiMAL achieves over 70% gene integration, meaning most cells produce a working antibody. Published data for competing mammalian display systems typically show efficiencies of only 1\u201310%. In plain terms, OptiMAL seems to waste far less effort and deliver far more usable output. That efficiency advantage apparently allows OptiMAL to do something competitors generally cannot: screen more than one billion functional antibodies. Fusion states that OptiMAL can generate functional libraries greater than 10\u2079 antibodies, whereas most competing platforms are limited to millions. Antibody discovery is a numbers game, and searching a much larger, fully functional library should significantly increases the chances of finding a high-quality drug candidate, particularly for difficult targets. Importantly, the data suggests this is about quality as well as scale. Fusion has shown antibodies from OptiMAL with nanomolar binding strength, which aligns with the standards needed for real drug development. This indicates the platform can deliver clinically relevant candidates, not just early-stage research hits. They say OptiMAL is also designed to closely mimic real human antibodies. Using human antibodies should reduce the risk of antibodies failing later due to safety or manufacturing issues, which would be a major cost for drug developers. For investors, the implication is straightforward. Platforms that improve success rates and reduce risk should command higher fees and if truly different should mean they can generate more and more repeat business Based on the published performance gap versus competitors, my investment thesis is therefore that OptiMAL appears to offer Fusion a defensible edge that should hopefully support stronger commercial traction and long-term value. If they can get in early with clients, be valuable partners then they have a better chance of getting royalty and milestone entitlements. If they found the next Keytruda for example and had even 0.1% royalty on future sales that could add up to $31.7 million per year for fusion. If we start to see contracts coming through, which with clients under NDA looks likely, then it would appear to me they have genuinely found a market gap and if they can scale should generate good returns for us. DYOR and best of luck!",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T23:46:26.718629+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261750-Seancadm--1806678",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.688107",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "NCI-validated tech, big conference buzz, partners circling, pipeline building... feels like Fusion could be sitting on something seriously interesting here.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T23:46:26.718646+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261731-Rocka--3761231",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.688764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Feeling very positive here, locked and loaded, bring on 20p pre contract news and we\u2019ll be at 40p in a flash post news imo.",
          "sentiment": 0.0,
          "engagement": "198",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T23:46:26.718665+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261234-gtc1507-12474201",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.689434",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The company also said they want to \u201cinvest in strategic partnerships\u201d in the placing RNS. What sorts of tie ups might we see!",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T23:46:26.718683+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261106-evman27--6124342",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.690131",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "I like the theory Sean. We've seen that in this industry there are lot of NDAs so we can never know the whole picture no matter how positive it looks from the outside. Fusion do set themselves up to be a partner for big pharma, after all they have worked with 8/10 of the worlds biggest pharma companies in the past! When I was at the AGM, I got a tour of the labs, the scientists working in there told me they were doing work for the NCI, highlighting that 'partner' approach.",
          "sentiment": 0.0,
          "engagement": "184",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T23:46:26.718701+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261047-Seancadm-63684372",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.690831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time. The above from the recent RNS. I am interested in why Fusion included 'and the company' in the above. It suggests that interest isn't limited to a single product, does this suggest that Pharma see Fusion as a partner organisation rather than just a vendor selling one product. In other words, the opportunity is bigger than just one product. Does this mean that Fusion is being viewed as a credible antibody discovery company with multiple valuable assets? I know people are eager for news but there are clues in recent RNSs that suggest Fusion is doing a lot behind the scenes.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T23:46:26.718719+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261035-gtc1507--3743909",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.691506",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "#FAB looks strong for a move this week, risen nicely after placing at 13p, sitting well above key moving averages and weekly slingshot now in play. 200ma on the weekly is 19.49, with 52 week high of 21p. With potential catalyst news coming in short to medium term, cash in the bank and technicals all lining up the next move could be pretty impressive",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-10T23:46:26.718738+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261303-gtc1507-12079838",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.692178",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I suspect we\u2019lll soon see evidence that Optimal is attractive to their clients. At that point it\u2019s just a case of seeing how big this can scale. If they\u2019re to be believed it will be game changing for the company and the drug discovery industry",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718756+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261144-evman27-14740414",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.692876",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Incase you all need a reminder of what Adrian said at the last presentation \u201cWe are now market leader, Optimal is best and first in class at what it does\u201d \u201cFusions platform is the best as evidenced by the data in this launch presentation\u201d \u201cIf that means we become more visible, I think it will and therefore more noticed by those considering acquiring companies like ours, well then so be it\u201d Happy holding!!",
          "sentiment": 0.0,
          "engagement": "184",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718774+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261359-Sanibel-23048355",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.693583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Some nice buys Nothing is certain but this has to be a worthwhile investment for those who have researched. A big contract or a number of would be transformational here with \u00a31 or more easily achievable Im holding tight GL Sani",
          "sentiment": 0.0,
          "engagement": "4,570",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718792+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261342-gtc1507--7757818",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.694262",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Looks like someone took 260k in the space of 15 mins earlier one this morn, must be confident",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718810+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261256-gtc1507--1278898",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.694929",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice to see some chunky delayed buys coming through today. Is somone accumulating or are many people realising just wha the potential is here",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718827+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261211-gtc1507-80683795",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.695604",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "A close at these or near levels will be very strong weekly setup. Bodes well for next week",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718845+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Seancadm-58404689",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.696280",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I'm not expecting fireworks overnight, but with NCI validation, institutions increasing, and funding risk reduced, the setup looks better than it did a few months ago. Now it's about waiting for the first OptiMAL commercial foothold. Even a small evaluation or platform-access agreement would change how the market values Fusion.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718863+00:00"
      },
      {
        "event_id": "SOCIAL-Today1359-Sanibel-23048355",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.729743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Some nice buys Nothing is certain but this has to be a worthwhile investment for those who have researched. A big contract or a number of would be transformational here with \u00a31 or more easily achievable Im holding tight GL Sani",
          "sentiment": 0.0,
          "engagement": "4,569",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718881+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507--7757818",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.730217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Looks like someone took 260k in the space of 15 mins earlier one this morn, must be confident",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718899+00:00"
      },
      {
        "event_id": "SOCIAL-Today1256-gtc1507--1278898",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.730651",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice to see some chunky delayed buys coming through today. Is somone accumulating or are many people realising just wha the potential is here",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718916+00:00"
      },
      {
        "event_id": "SOCIAL-Today1211-gtc1507-80683795",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731073",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "A close at these or near levels will be very strong weekly setup. Bodes well for next week",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718934+00:00"
      },
      {
        "event_id": "SOCIAL-Today1008-Seancadm-58404689",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731511",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I'm not expecting fireworks overnight, but with NCI validation, institutions increasing, and funding risk reduced, the setup looks better than it did a few months ago. Now it's about waiting for the first OptiMAL commercial foothold. Even a small evaluation or platform-access agreement would change how the market values Fusion.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718952+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261902-Troutiso-31692812",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I think apart from the initial 60k trade which was a buy, all the rest of the delayed trades over 50k look to be sells. Not a problem they got a good price and those shares will be bought up by others.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.25",
          "thread_title": "RE: Big trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=D96A8918-A1B6-42AA-B090-11B604330C21"
        },
        "ingested_at": "2026-02-10T23:46:26.718970+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261853-Troutiso--5722298",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.732355",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "A little different last year as they issued some shares and the others after a GM. However Canaccord Genuity Group Inc did announce their TR1 last of the three, probably as they are based in Vancouver. Their holding and the dilution mean they could add nearly 1.94m shares and not need to TR1 as still within the 7% band.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.718989+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261851-mmhater--7067211",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.732769",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Well there has been a lot of big trades today. hard to tell if buys or sells but i think are delayed buys. Market makers have played the price sneakily dropping nothing. i expect a large rise tomorrow to counter the false drop.",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "15.25",
          "thread_title": "Big trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=D96A8918-A1B6-42AA-B090-11B604330C21"
        },
        "ingested_at": "2026-02-10T23:46:26.719008+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261319-gtc1507-66531887",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.733200",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes they are already holders - they took 7% at last years placing. Think the rns this time talked about existing and new investors demonstrating confidence. There is a possibility cannacord took more but we might have seen an rns by now perhaps",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719028+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261315-Cheapsha--5756250",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.733614",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Who is the 3rd institution, we seen 2 x RNSs Is that Cannacord?",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "15.75",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719046+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261149-Sanibel-12625733",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734033",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "All looking very good here. All thats needed is patience. Gl all Sani",
          "sentiment": 0.0,
          "engagement": "4,569",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719065+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260902-chrishut-85655637",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734466",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Was going to edit that but the word is funny so leaving it ha",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719083+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260901-chrishut--2869428",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734875",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Will we see a cancrod rns today?",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719122+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260838-gtc1507--3433390",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.735327",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Also I\u2019m glad to see stt has bought in. I think deep down we\u2019re on the same page, about the strength of fab.  the company said they would always consider raise for growth if they thought was right thing and that\u2019s what happened. They also said they were on track for breakeven without a raise but chose to take the brakes off and raise to accelerate growth. They are credible enough to convince big funds like these that the prospects are materially good enough to justify at market price investment. They\u2019ve filled the war chest now let the battle for market share with their new discovery tools commence!",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719144+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260809-gtc1507-34852531",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.735821",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "You\u2019re totally right Sean. It\u2019s kudos to them that they were able to secure that investment at zero discount from funds lik that",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719162+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260749-Seancadm-49519773",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.736277",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Most AIM companies can't attract this level of institutional capital, they don't just buy on 'hope. They Perform due diligence Speak directly to management Stress test the story. Fusion must have gained a hell of a lot of credibility! Having the backing of 3 institutional funds means the company has passed enough internal filters for serious capital to stay involved and even increase. I'm confident people are going to take notice of this backing over the coming weeks and jump on board.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719181+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262117-mmhater--4528809",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.736682",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Just waiting for a tie for tat rely a lowlife would do\u2026.. standing by.",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719200+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262047-stt1-15289662",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737139",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Buying in the placing or post placing made sense. It's hardly surprising....I also added after the placing and before today's rns, as per my assertion that they needed a placing. I've said the company needed another placing to advance their projects and that's what they have done. Rampers were claiming the company doesn't need a placing, they have cash runway until 2027. The rampers also claimed the company would be winning contracts as soon as they launch their platform. It's now 2 months and still no contracts. Newsflow has been as expected. I'll look to trade as and when as the company still face hurdles...",
          "sentiment": 0.0,
          "engagement": "4,531",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719218+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262013-steven49--6358486",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737548",
        "source": "LSE_CHAT",
        "data": {
          "author": "steven49",
          "content": "From placing",
          "sentiment": 0.0,
          "engagement": "13,711",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719237+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261941-Rocka-87367538",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737956",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Could well hit 20p this week and move on to 30-50p on contract rns",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719256+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261925-evman27--3343285",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.738402",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Great post GTC and as far as I am aware that is all correct. Things are turning here now, there are so many reasons to be invested here and I'm expecting the highly geared returns to start taking shape this year. The future is FAB!",
          "sentiment": 0.0,
          "engagement": "182",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719274+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261856-gtc1507--2889881",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.738823",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "\u2026.Counters the case that now is their time to shine? DYOR and fact check me but I think we\u2019re in for an exciting time",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719293+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261855-gtc1507-81709300",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.739377",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some substantial delayed trades printed after hours. Feels like then market is finally waking up to the positive potential here. Cashed up with large volumes going at discount to sticky institutions all while\u2026. \u2022 OptiMAL now LIVE \u2013 world-first antibody discovery platform, with multiple customers already engaging under NDA \u2022 OptiMAL deal economics step-change \u2013 programmes identified by Allenby potentially at \u00a3200k\u2013\u00a32m per deal, depending on scope, versus current revenue guidance of ~\u00a32.25m for FY26 \u2022 Clear headroom vs history \u2013 revenues were close to \u00a35m pre-downturn, highlighting recovery plus upside potential \u2022 Platform shift underway \u2013 moving from services \u2192 scalable discovery platform, structurally improving margins \u2022 Lean, cost-efficient operation \u2013 capital disciplined, with strong operating leverage as revenues scale \u2022 Margin recovery underway \u2013 mix shifting toward higher-value discovery work, reversing historic pressure \u2022 National Cancer Institute fully open \u2013 boosted FY budget and active negotiations on a multi-target collaboration \u2022 Potential peer-reviewed publications \u2013 NCI work could translate into high-impact journals, boosting credibility \u2022 Sales momentum building \u2013 brokers guiding to >80% revenue growth in h2, before any premium discovery revenues \u2022 potential for Longer, stickier client engagements \u2013 discovery work keeps clients involved earlier and for longer \u2022 Cashed up and confident \u2013 recent raise removes funding risk and unlocks growth ambition \u2022 OptiPhage licence decision pending \u2013 asymmetric upside if converted to an exclusive deal \u2022 US patent secured \u2013 strengthens IP moat in the most important biotech market \u2022 IP footprint expanding \u2013 additional patents progressing in key jurisdictions \u2022 Prestige access via Future Medicines Institute \u2013 world-class ecosystem, talent pipeline, plus \u00a31m grant and \u00a35m capital access \u2022 Local ecosystem strengthening \u2013 academia\u2013biotech\u2013industry collaboration deeper than ever in Northern Ireland \u2022 Client funding conditions improving \u2013 biotech risk appetite back, with SPDR S&P Biotech ETF at multi-year highs \u2022 Hiring from strength \u2013 attracting staff from big-name competitors \u2022 Clear geographic growth plans \u2013 expansion targeted in US and Asia \u2022 AI-enabled discovery play \u2013 OptiMAL sits squarely in the AI drug discovery sweet spot \u2022 Legacy royalties & milestones still live \u2013 historic deals mean unexpected upside remains possible \u2022 DR5 time asset nearing conclusion \u2013 project due to complete this year with licensing potential \u2022 Strategic antibody partnership with Finn therapeutics\u2013 leveraging patented antibody asset \u2022 Collaboration with Eurofins Discovery \u2013 validation and access to a global pharma client base Valuation angle: Is FAB still trading closer to a cash-backed services multiple, despite OptiMAL-sized deals that could move revenues with only a handful of wins? Genuine question: Am I missing anything that meaningfully co",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719312+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261707-Stan36--5369912",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.739787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "@Troutisout1 I'm in with 202k shares average 13.95p. Wasn't tempted to sell at 19p. Happy to wait. Good to see these tr1 confirmations and the 9.4% rise today.",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "15.75",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719331+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261706-Laura202-48394027",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.740199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Buys in the 13s looking very healthy",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "15.75",
          "thread_title": "Great day",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C6467160-466B-42CC-A9F0-BEED146D848D"
        },
        "ingested_at": "2026-02-10T23:46:26.719349+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261658-Cheapsha-32566752",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.784626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Good news overall big guns adding Hopefully soon 20p before some contracts hit the RNS Then got a better base and higher base to jump from",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719369+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261652-Troutiso-70540035",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.785367",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes their last Holdings RNS was a little confusing naming at least 5 different entities, but it is another 2,212,084 shares they have purchased for \u00a3287.6k, There's another \u00a3862k out there, so still room for another TR1, but I reckon more likely to have gone to new IIs at under 3%. Cannacord though, could still update.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719387+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261641-Dw198-31014581",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.786053",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dw198",
          "content": "Ignore, it is  Rathbones Investment Management Ltd who is the owner of the nominee account :-). Great news",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719406+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261637-Dw198--4757160",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.786745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dw198",
          "content": "It\u2019s a nominee account isn\u2019t it? So it is not Rathbones who made the investment decision, it would be the holder of the nominee account, whoever that may be",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719425+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261630-Troutiso--1212708",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.787475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Stan, I bought 200k at 13p on the 28th Jan, so others could have done so too, it wasn't just the placees. Great to see another holder from last year's placing increase again on this one, do we think we might see something from Cannacord as well? That would be great, but the realisation will now dawn that the placing shares are tightly held for the second year running.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719444+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261619-rp6577-85013525",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.788164",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Looking solid. Setting us up very nicely for news to blast us through 20p",
          "sentiment": 0.0,
          "engagement": "899",
          "price_at_post": "16.00",
          "thread_title": "RE: Another tr1",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34E599B3-B512-45C9-AF92-5E920C8E28AF"
        },
        "ingested_at": "2026-02-10T23:46:26.719463+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261603-Stan36-52651748",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.788816",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "And those investors who paid 13p in the placing are already 23% up. Where's Alice? She did predict a placing bless her \ud83d\udc8b\ud83e\udd20",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719481+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261600-NornIron-48738124",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.789509",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Go Rathbones ! Although investors like myself and many of you guys here will do our own research before investing in any share, the comprehensiveness and depth of any research most of us do will obviously never touch that of the big institutions. Buck eejits like my myself maybe think we do research at times, but the reality is we'll never get access to the info or individuals where 'real' info can be gained to make an informed buy or sell decision on any holding/s. Companies like Rathbones can do !   Although it's still heads or tails for them whether a share goes up or down going forward, they're making the investment decision knowing more than we PI's will ever know. This is a BIGGIE with Rathbones buying more  ! !",
          "sentiment": 0.0,
          "engagement": "461",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719499+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261548-chrishut-16815810",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.790197",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Boom Up we go",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-10T23:46:26.719518+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261536-AnnaRobi-47781095",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.790856",
        "source": "LSE_CHAT",
        "data": {
          "author": "AnnaRobinson",
          "content": "They didn\u2019t have that before so assuming they grossed up in the placing?",
          "sentiment": 0.0,
          "engagement": "322",
          "price_at_post": "15.25",
          "thread_title": "Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-10T23:46:26.719536+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261533-gtc1507--7388679",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.791541",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Ratbones took another 2m shares",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "15.00",
          "thread_title": "Another tr1",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34E599B3-B512-45C9-AF92-5E920C8E28AF"
        },
        "ingested_at": "2026-02-10T23:46:26.719554+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261533-Humpalum--1887442",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.792213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Rathbones increased holding too \ud83d\udc4d",
          "sentiment": 0.5,
          "engagement": "1,595",
          "price_at_post": "15.25",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=68BAB7F0-F1B4-4AD2-9D69-A66FF8564B72"
        },
        "ingested_at": "2026-02-10T23:46:26.719573+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261514-gtc1507-49496504",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.792886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some serious chunks being bought up these past few days. Someone building a big position perhaps",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-10T23:46:26.719591+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261425-gtc1507-17983568",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.793593",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I asked chat gpt to do some technical analysis last night, this is what I got; Barring any unforeseen negative developments, bullish momentum is slowly shifting in on all timeframes \u2013 implying that the balance of risks for the next few days to months is tilted toward a continuation upward or at least stabilization, rather than a return to sustained bearishness. The technical setup thus points to a greater likelihood of bullish scenarios (momentum accelerating upward) ahead, with the caveat that the market must confirm this by clearing the remaining resistance zones. If those confirmations occur, Fusion Antibodies could very well be at the start of a significant bullish momentum shift after months of decline, with upside targets in the coming weeks and months substantially above today\u2019s closing 14.625p price.",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-10T23:46:26.719609+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261419-NornIron-39079156",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.794267",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I've just done a small top up there now of 29,889 for around 4.6k.  I got them at 15.39 and happy at that. Obviously prices can rise and fall, but i feel there are too many positives going for Fab not to take a chance with a few quid more. We could see this move up very very soon.",
          "sentiment": 0.0,
          "engagement": "461",
          "price_at_post": "15.25",
          "thread_title": "Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-10T23:46:26.719627+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261121-stan1234-24187591",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.794908",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "This will just keep going up",
          "sentiment": 0.0,
          "engagement": "210",
          "price_at_post": "15.25",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T23:46:26.719646+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261109-mmhater-63294286",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.795568",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Market makers allowing this to slowly climb now on the quiet. Some nice buys amongst tiny sells. Brakes are slowly coming off ready for a nice rns hopefully imminently which will send this nicely into the 20s or maybe 30s. Need to remember this was 50-60p and spikes to \u00a32 a few years ago on nothing compared to where we were now",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "15.25",
          "thread_title": "RE: Going well",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1A2E7CD6-748A-4AB7-A8D9-A6D8EB0D755E"
        },
        "ingested_at": "2026-02-10T23:46:26.719664+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260958-Laura202--7959981",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.796239",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected once 14p went",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "15.125",
          "thread_title": "Going well",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1A2E7CD6-748A-4AB7-A8D9-A6D8EB0D755E"
        },
        "ingested_at": "2026-02-10T23:46:26.719682+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260954-Troutiso-47876369",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.796904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There will be delayed trades behind that SP move.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.125",
          "thread_title": "RE: Sensitivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0268C929-5B5A-4561-A591-6FD2897DA7B1"
        },
        "ingested_at": "2026-02-10T23:46:26.719701+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260933-Stan36-58172764",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.797577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Net buys 44,000 shares today. Net value of buys \u00a36,600 and market cap increases by \u00a3700,000 100:1 factor.",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "14.75",
          "thread_title": "Sensitivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0268C929-5B5A-4561-A591-6FD2897DA7B1"
        },
        "ingested_at": "2026-02-10T23:46:26.719720+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260932-chrishut--2911695",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.798249",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This is heading higher",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T23:46:26.719738+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260927-Stan36--7454388",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.798904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Up 15% to 15p since the 13p placing. That shows investor confidence. And has happened with low volume. Any positive news and this will burst forth \ud83d\udca5",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T23:46:26.719756+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260926-gtc1507--8079266",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.799723",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The decision by the National Cancer Institute (NCI) to move forward with Fusion Antibodies\u2019 OptiMAL platform is highly significant. NCI is the largest single funder of cancer research in the world, with an annual budget measured in tens of billions of dollars and a mandate to apply exceptionally rigorous scientific, technical, and commercial scrutiny. US federal procurement frameworks are specifically designed to promote competition and multi-provider tenders. Progressing instead with a single-provider approach strongly suggests that OptiMAL is not merely competitive, but meaningfully differentiated. In that context, the decision itself lends real weight to management\u2019s description of OptiMAL as first-in-class and best-in-class, claims that are rarely validated so early by an institution of this calibre. Fusion has described this as the best deal the company has ever made strategically as much as financially. Within months, this collaboration could be showcased globally, with one of the world\u2019s most prestigious cancer research bodies actively deploying OptiMAL in live discovery programmes. That level of external validation is exceptionally rare and extremely hard to replicate.",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "15.125",
          "thread_title": "NCI significance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B5214597-2A26-4A40-8D06-C710908586C7"
        },
        "ingested_at": "2026-02-10T23:46:26.719774+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260900-Troutiso--4576796",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.800425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes looking good, just very low volume again, when that picks up this will motor...",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T23:46:26.719793+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260847-gtc1507-36244867",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.801005",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is looking strong - no shares available instantly here, feels like it\u2019s primed for a continuation of the move up today",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T23:46:26.719811+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260809-gtc1507-38967380",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.083149",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Multiple clients are under NDA for Optima discussions and just reading the update from Allenby they say that they understand a number of clients are evaluating proposals from fusion. That to me fees like the tail end of the business development cycle and we could be seeing some contract awards soon enough if things move positively! Will be exciting  to see just how effectively they can convert the potential of optimal to contracts.",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.75",
          "thread_title": "Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-10T23:46:26.719829+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261950-gtc1507--8134420",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.083682",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/article/government-shutdown-ice-funding-471e55ba4c3247051739ee1b50b2857a",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.625",
          "thread_title": "RE: Serious buying",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B732929B-3433-4DD4-A746-BD075AADC17D"
        },
        "ingested_at": "2026-02-10T23:46:26.719847+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261501-livinhop-73665223",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.084215",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Another 50k delayed shares purchase - serious buying going on at the moment, has to be a good sign....I hope!! L2  currently 2v2",
          "sentiment": 0.0,
          "engagement": "1,096",
          "price_at_post": "14.50",
          "thread_title": "Serious buying",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B732929B-3433-4DD4-A746-BD075AADC17D"
        },
        "ingested_at": "2026-02-10T23:46:26.719865+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261434-Troutiso--9215339",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.084715",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Vewry shortly I reckon.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: 15.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=79D1BEB9-25D7-49E1-B410-CBAED6C59387"
        },
        "ingested_at": "2026-02-10T23:46:26.719884+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261430-mmhater--8224555",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.085225",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Tick up on its way by end of play i guess",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "14.50",
          "thread_title": "15.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=79D1BEB9-25D7-49E1-B410-CBAED6C59387"
        },
        "ingested_at": "2026-02-10T23:46:26.719902+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261350-Troutiso-62415404",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.085701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Volume is very small at the moment but positive with buys regularly outweighing sells by some margin.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-10T23:46:26.719920+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261338-gtc1507-85510509",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.086217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - new investor would need to take just short of \u00a3500k to reach tr1 / more likely we\u2019ll see the others taking more. Not to say that\u2019s not impossible - cannacord came in cold with 500k last year",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.719938+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261314-Troutiso--6365283",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.086728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, I very much doubt any of the placing went to bucket shops, the twitter brigade or PIs, the clue is always in the discount. This was a well organised funding round, allowing IIs a chance to add to their holdings at a fair price.  These placings tend to see the SP react favourably, but often need a news catalyst to really ignite the SP rise. I hope to see some more TR1s but I am happy if there aren't more, there will be many IIs in here at less than 3% and probably won't move for more until the FAB valuation allows. We saw Maven sell out due to a change in Management of their fund and a different direction, many Fund Managers will be looking but not able to purchase through their fund due to investing criteria. I have now bought up all my headroom, so happy to sit back and enjoy the ride. I can see Rathbone or Cannacord adding enough for a TR1, maybe not a new investor though.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.719956+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261208-chrishut-24187591",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.087238",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This will just keep going up",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.719975+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261146-Rocka--1619652",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.087727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Hope you\u2019re right but i would still like to see more tr1 rns\u2019s.",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.719993+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261122-Seancadm--2858902",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.088210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I think there is a good chance that a large proportion of the raise has been taken up by institutional investors, as we found out yesterday with Unicorn adding, I also don\u2019t think we have to worry about smaller investors flipping, in the RNS Adrian said, \u2018supported by a number of our longstanding shareholders\u2019, sounds like sticky hands to me.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720011+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261038-Rocka-60709553",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.088705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "We do need more tr1\u2019s , if most of the placing has been taken up by pi\u2019s then there will be flipping. I hope most of it has been taken by institutions.",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720029+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260903-gtc1507--6031739",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.089223",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice \u00a310k buy on the bell just printed!",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720047+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260837-Troutiso-35990069",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.089724",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "This is just getting us back to the price of a month ago, the placing will have weighed on that during January and now that pressure has been removed we are able to move back to previous levels. Another TR1 would show the market the placing was taken by sticky hands as last year's one was and that will encourage more to jump aboard. I see this back in the high teens soon and then it's all about newsflow to get this into the 20p's.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720065+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260808-rp6577-36277483",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.090219",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Picking up\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "899",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-10T23:46:26.720082+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260752-gtc1507-15041059",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.090732",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "In amongst the noise about the us shutdown which looks to end shortly is this positive news:...NIH getting funding increase of $415m and NCI $128m in this financial year \ud83d\udc40 https://www.science.org/content/article/final-funding-bill-nih-pushes-back-against-trump-cuts",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "NCI budget increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=12E05045-67EF-4EEF-8C99-AC4E30F34994"
        },
        "ingested_at": "2026-02-10T23:46:26.720115+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260748-gtc1507-38550513",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.091246",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Certainly did! Might we see another TR1 today to catalyse the continuation upwards?",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-10T23:46:26.720135+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260653-Laura202--5177960",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.091737",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Well yesterday certainly looked like the start of the breakout",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-10T23:46:26.720154+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262341-Cheapsha--5875984",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.092242",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Penny has dropped well that\u2019s good news After 5p and 10p what comes? 20p then 50p Easy! \ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720171+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262127-gtc1507--7329892",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.092729",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The penny will start to drop\u2026.crushed a few of the key moving averages today, starting to look very positively setup",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720190+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261404-Rocka--1708569",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.093234",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "If we get more institutional investor rns\u2019s who taken the fill placing then i think we will be in the twenties pre contract news",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720208+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261358-Rocka-56177725",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.093725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Dark, never said i was selling 100%. I was frustrated with lack of news. I was considering wether to topup and i have topped up only \u00a35k not the full \u00a310k , i used the other \u00a35k to topup some bitcoin",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720227+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261314-Laura202--5599153",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.094204",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Excellent news",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "14.00",
          "thread_title": "Institutions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=80932BC0-29D6-499F-82C1-ABEFC7DCE7F1"
        },
        "ingested_at": "2026-02-10T23:46:26.720245+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261305-Darkryde-89658303",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.094697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocka, thought you were selling and moving on to pastures new? \ud83e\udd14 \ud83d\udea7\ud83d\udfe2",
          "sentiment": 0.5,
          "engagement": "554",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720263+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261228-gtc1507--7292582",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.095205",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Should be very attractive here, cash derisked all the other positives in play",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "13.75",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-10T23:46:26.720280+00:00"
      },
      {
        "event_id": "SOCIAL-Today2232-mmhater--6437567",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472383",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Sorry guys i sound like Sti!! Just a little frustrated and disappointed at the moment",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "RE: This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-02-10T23:46:26.720299+00:00"
      },
      {
        "event_id": "SOCIAL-Today2230-mmhater-78064681",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472835",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023. Why can\u2019t fusion even make a couple of million!!!! Thought we were best in world!!",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-02-10T23:46:26.720316+00:00"
      },
      {
        "event_id": "SOCIAL-Today2116-chrishut-78021190",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473268",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Don\u2019t miss the opportunity to get some stock before the big news comes.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720335+00:00"
      },
      {
        "event_id": "SOCIAL-Today2008-stt1-12429419",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473705",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc \"Once we start to see those contracts \" Another month gone. Nearly 2 months gone since Optimal Launch, where are all these millions of pounds of contracts that were ready and waiting and were supposed to announced when Optimal Launched?? There you go, exactly as expected, newsflow continues as expected.",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720352+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507-71682758",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474138",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Indeed - the fact that they said it\u2019s of sufficient scale to warrant NIH approval over NCI is encouraging. I think that they might be able to pull off some significant down stream entitlements like royalties and milestone payments if/when NCI licence those assets out to biotech/pharma.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720370+00:00"
      },
      {
        "event_id": "SOCIAL-Today1335-David195--8117352",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474551",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "The big unknown factor is the continuation with NCI and if renewed what the contract value will be.  It could be a few million $ pa.",
          "sentiment": 0.0,
          "engagement": "875",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720388+00:00"
      },
      {
        "event_id": "SOCIAL-Today1324-Laura202-51902773",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474965",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "I added at 13.5p this morning Good afternoon",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720406+00:00"
      },
      {
        "event_id": "SOCIAL-Today1254-chrishut-18969516",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475395",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "It has to go up, and up and up. Just patience needed and we will be laughing",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720424+00:00"
      },
      {
        "event_id": "SOCIAL-Today1227-gtc1507-22675156",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475809",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "It feels like everyone is holding back on forecasting the unknown of what the optimal contribution may be. Once we start to see those contracts and how quickly they come in once the first adopters take it on I suspect we\u2019ll see quick revisions upwards.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720443+00:00"
      },
      {
        "event_id": "SOCIAL-Today1223-rp6577-43990649",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476238",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "The Allenby note is much better than Shard\u2019s, with more forward looking comments.  My only niggle is that I felt the 2027 revenue estimate was a little underwhelming. Hopefully that is a prudent number and that Optimal contribution could kick into gear with the increased BD. Also I presume that it doesn\u2019t factor in any payment that could arise under the NCI agreement (or any other potential agreements for that matter). I would have liked to have seen break even early than 2028 but perhaps that is reflective of them investing more in spending now to get the revenue growth.",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720461+00:00"
      },
      {
        "event_id": "SOCIAL-Today1120-chrishut--8523611",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476643",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nice",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-10T23:46:26.720479+00:00"
      },
      {
        "event_id": "SOCIAL-Today1053-gtc1507--6043059",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477058",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://x.com/hybridanllp/status/2017171235352781200?s=46",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-02-10T23:46:26.720497+00:00"
      },
      {
        "event_id": "SOCIAL-Today0947-gtc1507-57882198",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477484",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "good coverage here too https://*********************/research/hybridan/friday-take-away-30-january-2026/14_922a0adc-24fc-4af3-83ed-fa76e67f06e7",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-02-10T23:46:26.720514+00:00"
      },
      {
        "event_id": "SOCIAL-Today0921-gtc1507--7127405",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477919",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some very interesting insight in here: At least 400k going into new kit to optimise optimal. Plus infrastructure IT upgrades - think this was the website upgrade Adrian mentioned before. Also new BD executives in USA and Asia planned. Allenby holding firm on the growth forecasts for h2 so should be fairly nailed on for that. Optimal pricing interesting insight there too with indications that projects could start around 200k but generate value up to \u00a32m each if they take the whole service. Indication that clients are already considering this. Talk of aiming to return base revenues to \u00a34m and that the new platforms could match and exceed that so over \u00a38m revenues aimed for medium term. Very exciting and interesting note",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-02-10T23:46:26.720532+00:00"
      },
      {
        "event_id": "SOCIAL-Today0828-gtc1507-11047810",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478348",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2026/01/20260130-Allenby-Capital-Fusion-Antibodies-plc-FAB.L-Update-1.pdf?c5187=on&_gl=1 *6ojkea*_ga*MTUzMjEwNjY0MC4xNzY5NTAxODU0*_ga_MZVZ4CNQ86*czE3Njk3NjEzMzYkbzExJGcxJHQxNzY5NzYxMzM5JGo1NyRsMCRoMA..",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-02-10T23:46:26.720550+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-gtc1507--2735708",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478764",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/live/donald-trump-news-updates-1-29-2026 Looking positive",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "Shutdown looks to be avoided! Roll on NCI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=3F614C0C-E9AC-4A45-8698-61C9AD6D520E"
        },
        "ingested_at": "2026-02-10T23:46:26.720568+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262124-Troutiso-76307107",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "31% up with a close of 13.25p , would suggest a price a year ago just north of 10p. It actually closed on 29th Jan at 8.75p and at 8.1p on the 30th Jan, so depending on where you would like the 12 months to start, either over 50% or for the 365 day version just over 60%. But that's nit-picking, it is up substantially on a year ago!",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T23:46:26.720587+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262123-gtc1507--3087410",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479606",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Guess depends what day shard wrote the note!",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T23:46:26.720605+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262052-Surfie19-46171460",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480016",
        "source": "LSE_CHAT",
        "data": {
          "author": "Surfie1961",
          "content": "\"But the momentum is building with the share price up nearly 60% over the last 12 months\". Er.... NO Ithink you will find it more like 31%.",
          "sentiment": 0.0,
          "engagement": "2,062",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T23:46:26.720623+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261951-stt1-78321084",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480486",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc, \"The raise matters\" A lot of hindsight views. After months of claiming they don't need to raise money, they have cash runway into 2027 etc etc, you're now agreeing with me that they DID needed a raise. Great to see you've changed your opinion and agree with me. Read and understand the company/sector newsflow. Your posts: https://www.lse.co.uk/profiles/gtc1507/?page=4 My post 9th Dec, 22.46 to Vikr: \"I believe they will use this higher sp to raise cash, as they need it to fund their project plans.\" https://www.lse.co.uk/profiles/stt1/?page=3 That's exactly what they have done. The company newsflow continues as expected. The rest of your posts are all ifs, coulds, buts and potential, which isn't surprising given you've been here years and holding since the sp was over 100p and so need investors to buy in..",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T23:46:26.720641+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261910-gtc1507-50019628",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480915",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Sorry thought I\u2019d copied it in: https://shardcapital.com/capital-markets/corporate-broking/research-portal/ Top note or filter for fab",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T23:46:26.720659+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261906-rp6577-90741750",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481335",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Are you able to share a link? Whenever I read their notes I always wish they would stick their neck out and state what they consider a fair market value of the company would be in their opinion",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T23:46:26.720678+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261607-gtc1507-37063284",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481756",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Investment case. In our assessment, Fusion is significantly undervalued relative to its peers. Its current market capitalisation of \u00a314m does not adequately reflect the investments made or the underlying technology. We believe the market has yet to fully recognise the ongoing recovery in sales and order book, as well as the potential of Fusion's novel proprietary platforms (OptiMAL\u00ae, OptiPhage\u2122, and AI/ML-Ab\u2122). But the momentum is building with the share price up nearly 60% over the last 12 months.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-10T23:46:26.720695+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261443-Laura202--6108862",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Be nice also if one person here would end their 14mth disruption of another share after your previous gracious plea fell on deaf ears 2mths ago Is that wishful thiking ?...who knows FAB hopefully rewards all concerned Best wishes all",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720714+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261440-druml-79511012",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482597",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Be rude not to buy some more. Been in for the penny looking for the \u00a3\u00a3\u00a3",
          "sentiment": 0.5,
          "engagement": "25",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720732+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261438-Laura202-63709144",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Chris I have taken that view also , it was clear with the drop in revenues H1 and slightly delayed launch they MAY needed funds for growth... I have bought today at 13.3p a few lots",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720750+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261335-gtc1507-10425241",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497848",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I expect we\u2019ll see a few tr1s for existing vc or II taking more as well as potentially new investors as indicated in the rns",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T23:46:26.720768+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261315-Troutiso-85945255",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Well there are 68k of buys in the sell column and a delayed buy just under 100k going through, so buying well outweighs sells here, the price is climbing within the quoted spread and I see another tick or two this afternoon if this continues. Realisation will come tomorrow (with the issue of placing shares) and next week, if the placing shares have gone to sticky IIs as the last did, then people will jump on board from the sidelines",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T23:46:26.720786+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261306-livinhop--4722804",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498703",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Excellent gtc, thank you!",
          "sentiment": 0.0,
          "engagement": "1,095",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T23:46:26.720805+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261303-gtc1507-65632658",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499226",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My reflections post raise\u2026..FAB now appears to be entering a very different phase with the launch of its world-first OptiMAL platform. 1) The raise matters \u2014 and it was done from strength The placing was completed at 13p with no discount to the prior bid. That\u2019s unusual on AIM. It removes near-term funding risk just as the company moves into commercial execution, allowing Fusion to accelerate growth rather than constrain it through cost control. 2) What OptiMAL is \u2014 and why it matters OptiMAL is a new antibody discovery platform designed to find brand-new, fully human antibodies faster and with lower risk. Management describes it as first- and best-in-class, targeting the most valuable part of the drug pipeline: discovery. Discovery work is higher margin than Fusion\u2019s traditional services and keeps clients engaged for longer. Crucially, they have updated that multiple clients are already engaging under NDA to discuss OptiMAL. Clients won\u2019t engage like this unless they are serious discussions. These are premium, additive services that materially improve earnings quality. 3) Validation, commercialisation \u2014 and IP protection OptiMAL has been validated by the US National Cancer Institute, delivering single-digit nanomolar hits directly from screening. NCI now wants to move to a commercial agreement to use OptiMAL across multiple targets and years. Fusion has said the proposed deal is large enough to require NIH approval \u2014 a powerful external endorsement. This may take time to get through but it is powerful none the less at this stage. The platform is also patent-protected, with US coverage secured and further decisions pending in Europe, China, and Japan. Strong IP underpins pricing power, licensing potential, and long-term strategic value. 4) Growth was already forecast before the raise Brokers were already modelling strong H2 growth (often cited around ~80% vs H1) and ~\u00a33m revenues by FY27 before the placing. The raise de-risks delivery and broker forecasts still exclude any OptiMAL contribution. 5) Cash burn is supported, not stressed Fusion also benefits from \u00a31m of non-dilutive Future Medicines Institute funding over five years, plus shared capital equipment \u2014 lowering burn while supporting scale-up. They also have the \u00a3545k Dr5 grant. Potential near-term catalysts: \u2022 OptiMAL NDAs converting to contracts \u2022 updates on Progress on an NIH-approved NCI deal \u2022 potentially Patent decisions in major jurisdictions \u2022 Outcome of the OptiPhage licence evaluation \u2022 Hiring momentum as the company scales \u2022 A potentially strong FY26 trading update This is Not advice. DYOR \u2014 but IMO this is the clearest setup Fusion has had in years: funded, validated, IP-protected, and launching higher-margin services.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-10T23:46:26.720823+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261107-chrishut--8259482",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499637",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720841+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261057-gtc1507-88544633",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500057",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720860+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261042-Troutiso-24901361",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720878+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261035-Troutiso-42701137",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720896+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261033-Gheko--3670458",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-02-10T23:46:26.720914+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261012-Rocka--7372005",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720931+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260846-Troutiso-79572188",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.720949+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260842-Troutiso-58315626",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.720968+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260824-gtc1507--4041791",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502979",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.720986+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260820-gtc1507-59471332",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503409",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721005+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260811-Rocka-86477697",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721022+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Seancadm--5255360",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721040+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Darkryde-82187917",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504671",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721059+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260754-gtc1507--5600675",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505088",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721077+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260745-Saintsmi-40781308",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505507",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721095+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260709-Darkryde--7913862",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721129+00:00"
      },
      {
        "event_id": "SOCIAL-Today1107-chrishut--8259482",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.749919",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721148+00:00"
      },
      {
        "event_id": "SOCIAL-Today1057-gtc1507-88544633",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.750538",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721170+00:00"
      },
      {
        "event_id": "SOCIAL-Today1042-Troutiso-24901361",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721188+00:00"
      },
      {
        "event_id": "SOCIAL-Today1035-Troutiso-42701137",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751618",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721206+00:00"
      },
      {
        "event_id": "SOCIAL-Today1033-Gheko--3670458",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-02-10T23:46:26.721224+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Rocka--7372005",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752748",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721242+00:00"
      },
      {
        "event_id": "SOCIAL-Today0846-Troutiso-79572188",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753371",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721260+00:00"
      },
      {
        "event_id": "SOCIAL-Today0842-Troutiso-58315626",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753974",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721278+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-gtc1507--4041791",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.754578",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721296+00:00"
      },
      {
        "event_id": "SOCIAL-Today0820-gtc1507-59471332",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755194",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721314+00:00"
      },
      {
        "event_id": "SOCIAL-Today0811-Rocka-86477697",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755779",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721332+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Seancadm--5255360",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721350+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Darkryde-82187917",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721367+00:00"
      },
      {
        "event_id": "SOCIAL-Today0754-gtc1507--5600675",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.757590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721385+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-Saintsmi-40781308",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721403+00:00"
      },
      {
        "event_id": "SOCIAL-Today0709-Darkryde--7913862",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721421+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262241-mmhater-71732574",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759247",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "So i\u2019ve been a big investor of FAB for the past year and am well in profit. I currently own over 1.3 million shares but this latest placement has left me sat on the fence\u2026.. I\u2019m a little fed up of the company telling us they are financially stable till time X but still keep raising money\u2026 The latest raise for 1.4 million is at a great price but i wonder if 1.4m was necessary? If deals are incoming surely  0.5m would have done\u2026.. My next thought is if the industry is worth so may billion a year why are we struggling to get a million pound of deals? surely we should be getting at least 5 percent of the market if we are best in the field. I\u2019m starting to lose faith Adrian\u2026. nearly put another 10k in here but your latest actions have made me dubious.",
          "sentiment": 0.0,
          "engagement": "656",
          "price_at_post": "13.125",
          "thread_title": "Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-10T23:46:26.721439+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262110-cbeadle--8819853",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759663",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I would do , but FAB my largest holding and I am very into mining stocks which are generally doing well.",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.125",
          "thread_title": "Buy More?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=9B999AB7-3C0D-4F49-942F-FD2729833E45"
        },
        "ingested_at": "2026-02-10T23:46:26.721457+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262033-gtc1507--9652402",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760077",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "That\u2019s some conviction Chris good to see. Hopefully a floor here. Looking forward to seeing the tr1s to see which institutions came in",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721475+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261838-chrishut--1032384",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760509",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I took 175k today and still had orders in, that didn\u2019t fill.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721493+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261805-gtc1507-56919676",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761183",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "ORDEEERRRR",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721511+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261744-Troutiso--2240028",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I count at least 200k of buys been put in the sell column,  150k were mine and the other looks to be a 50k buy just as the offer rose this morning. So the buys have it, the buys have it...",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721529+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261540-Troutiso--6014480",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.762581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Just sniped another 50k at the placing price",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721547+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261342-chrishut--3178607",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763155",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I added quite a few more today too, it is a no brainer now, cashed up and contracts likely to be a lot more frequent",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721565+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261341-chrishut-31571526",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763701",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nicely played trout",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721583+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261209-Troutiso--7359684",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.516994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There seems to be a few PI sellers, getting out at below the placing price. I think these may be short term investors looking at other grass is greener stocks. I have used the opportunity to add at the placing price for the moment, I believe that the shares will have gone to long term investors and as such think that in a few days this realisation will be apparent and others will start to add again. Looks like a few delayed 50k buys coming through now. MMs are playing around with this, but not enough conviction from buyers to get this moving upwards, hopefully start to see something next week, would be good now they have got this out of the way to get an update from the Company.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721601+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261037-gtc1507-51817164",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.517590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Positive mention in a research note yesterday on SP angel, healthcare conditions note/ https://www.spangel.co.uk/research/",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "12.875",
          "thread_title": "Research note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=574BB89D-C932-496A-80A3-2E9C64DACF5C"
        },
        "ingested_at": "2026-02-10T23:46:26.721619+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-Troutiso-18068581",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes me too, limits down to 10k now, well on the way to filling the headroom back up to 2.99%",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "12.875",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721638+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260930-chrishut--1138565",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518658",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Took another 75k",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.00",
          "thread_title": "I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-10T23:46:26.721656+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260733-Eurobuil--8191402",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Eurobuild1",
          "content": "Don\u2019t come gloating on here , keep your opinions to yourself if your giving it the big told you so",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "13.25",
          "thread_title": "RE: Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-02-10T23:46:26.721673+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262144-stt1-70258993",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519750",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "From the placing rns: \"The net proceeds of the fundraise, being approximately \u00a31.3m, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL platform, to invest in the company's commercial activities and for general working capital purposes.\" https://www.insidermedia.com/news/ireland/fusion-antibodies-raises-1.4m-to-drive-growth-plans From the grant rns, which they received less than a year ago: \"The Grant support to Fusion is to cover human resource needs, materials/consumables costs and overheads.\" https://www.londonstockexchange.com/news-article/FAB/approval-of-grant-funding/17002681 That suggests to me they have utilised all of the grant money to date and so needed more.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-02-10T23:46:26.721691+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262128-stt1--2598113",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520299",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Well done Alice for predicting a placing. I see you got a lot of abuse. I wouldn't wait for an apology from these clueless rampers.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: If Fusion places 100M share",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BCF5D778-E9D7-439C-990A-6D28AB648781"
        },
        "ingested_at": "2026-02-10T23:46:26.721709+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262117-stt1-49506986",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520864",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Humpalumps \"Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually\" Oh dear, can't handle the truth. My 1st post on FAB was a year ago, Jan 2025, after HVO pump and dumpers moved across to here. HVO crashed from c30p to c5p today on company newsflow, red flags I'd been warning about. https://www.lse.co.uk/profiles/stt1/?page=16 I can understand your frustration at being completely wrong and loading up c30p.. my posting history is there for all to see your lies about my posts... There's always one who's totally stupidity and incapable of reading the company newsflow. This from your post just a month ago....22nd Dec 13.51 \"They have a cash runway til FY27 which as has been confirmed on the investor hub didn't include NCI in the calculation so they're fine for cash\" https://www.lse.co.uk/profiles/humpalumps/ You need to read and understand company newsflow as it'll help you stop making those stupid mistakes.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-10T23:46:26.721727+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261929-Humpalum--9158242",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Jokes \ud83e\udd23 are we actually being lectured by the guy who told everyone to buy TLY that went bust while simultaneously warning people off FAB at circa 4p \ud83e\udd23\ud83e\udd23 Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually And finally this placing isn't a bad thing it sets a floor at the current price, was at 0 discount and will probably be last one this company will ever need Also I won't be replying to any of the crap you respond with because you're a terrible investor for point 1 in this comment \ud83c\udf1d",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-10T23:46:26.721745+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261816-stt1-59687648",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521921",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Antha, I'm glad I traded these and not held on, like you, at 30p.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Ha ha ha. sti sold a couple days ago",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=16F2F8FD-FC78-4AF1-834F-BFF85ACDD8C8"
        },
        "ingested_at": "2026-02-10T23:46:26.721763+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261804-stt1-12841059",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.522484",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Rocka, \"Sti so is now almost 20p , you are making yourself look very silly.\" I see there's a placing. Who's making themselves look very silly. I traded or you who was ramping at 20-30p. You should learn to read and understand company newsflow. The sp has fallen back exactly as predicted. Where's the clueless Humpalumps? he needs to learn and understand company newsflow. He was clueless as well, ramping these at 30p!!!",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-10T23:46:26.721781+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261757-stt1-91013954",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523018",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "There you go, exactly as predicted. Placing. Who was gullible enough to believe the clueless rampers!!!! Back to the same sp as before the previous pump/dump. Newsflow was exactly as expected.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Cash is low, so placing likely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=56D85761-47EE-47AB-BE35-44485A6673DC"
        },
        "ingested_at": "2026-02-10T23:46:26.721799+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261308-gtc1507--6781769",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523551",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes you\u2019re right! Sorry thought you were talking about smaller optimal screens. But yes the sliced bread analogy was a good one. We\u2019re already seeing the ITAS approach being mention in the RNS which is good. That last big pharma one Was referred to as an ITAS one so hopefully means we can retain them for more business",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721817+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261258-Troutiso-53906876",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524059",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Gtc, You are talking about full screens and AK did state that some companies may want smaller more focussed screens (if they had already developed some targets), He also stated that a full ITAS contract would be over \u00a31m, but some might want to take a more modular approach and contract to do some phases of the ITAS with FAB and that those companies will choose how many phases they would want to do with Fusion. These would likely not be RNSed due to their smaller size, piecemeal approach.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721835+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261248-Rocka--5677090",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Actually i said if there isn\u2019t any news, there has been today! Today\u2019s RNS isn\u2019t great but it\u2019s not bad news that will see the sp tank 50% as i\u2019ve been in such stocks.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721853+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261238-Troutiso--4987164",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Literally 23 hours ago you posted that if no news soon you would consider selling up.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721872+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261222-Rocka--5077174",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout, not a gambler at all. I\u2019ve been here for quite some time . I still believe in the longterm future here but the proof is in the pudding and this is what we will find out in the coming months( hopefully) Not planning on selling just considering whether i should buy more to bring my average down.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721889+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261215-gtc1507-62768389",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526095",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a good assessment, although, just to correct one piece. Adrian was clear they wouldn\u2019t get smaller contracts at the start as Optimal was designed to do full large scale screens. He said they may structure the deals differently to begin so that some of the client risk is reduced, potentially by reducing up fronts but including  success based milestone payments I.e when the screen delivers what fusion know it should then fritter payments will trigger. Slightly nuanced but still the overall value shouldn\u2019t change and the scale of the challenges will still be big but the point on the journey that fusion and the client risk profile is set and payments set may be adjusted to begin to incentivise early adopters. Adrian also said this will only be available for a limited period.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721907+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261209-Troutiso-53305521",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526590",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Realistic timeframes, valuations, etc.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721925+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261208-Troutiso--7224467",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Can I suggest having read back through your recent posts, that you are waving in the wind and seem to be very short term/big demands type of gambler. An investor wouldn't change their mind in a matter of days, unless there is a material change. You have been bemoaning news and after your post yesterday I nearly replied be careful what you wish for as a placing had entered my mind here. This is a medical CRO and they work in a field which takes a long time to get anyone to sign anything, rigorous checking and re-checking of the science, followed by rigorous checking and re-checking of the product before anyone is prepared to commit, it takes time. However, FAB has now launched OptiMAL and that is being assessed by prospective clients, this will take time but has been ongoing for some time. The Company have stated they are likely to get smaller OptiMAL use contracts to start, before some clients may come back for the chunkier full development contracts. That is the way of this particular industry. So whether or not you spend another \u00a310k here or you sell up or you spend \u00a310k elsewhere, my advice to you is to develop some patience (and that sometimes is very long term patience), while you are sitting there holding one company, others always look like they are doing better, but in reality that is not the case most of the time. Good Luck with whatever you do, but remember PIs and those on these BBs will always be ahead of reality, as they want short term gratification, when it always takes longer, costs more and can fail, invest and be patient and look at",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721944+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-Humpalum-61410437",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527465",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Personally I think there is a strong chance this will be the last placing this company ever needs - I can't really see a world where this company isn't profitable in the next 12-16 months which would be the kind of timeframe this money would last them without profitability",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721962+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-evman27-61095774",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527915",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It's always frustrating to see a placing happen but I believe this will be the last one fusion ever has. Back when the company was struggling they raised at 80% discount, the raise last year and today was at no discount, that counts for something. As many have said it puts us in a strong negotiating position, hard to get good deals when everyone knows your cash situation is tight. Since the raise last year the company has moved leaps and bounds, raised at 6.75p and SP hit 20p not long after, I suspect we will see similar here, we should be entering a news rich period too having commercially released Optimal. It is clear there is a lot of background interest in Fusion and Optimal, at least the buyout offer when it comes won't reflect a struggling company, it puts us in a stronger position to refuse a cheap offer. I'm still happy with my money here and have been since September 2024, the value on show here today is immense.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721980+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261144-Rocka--7110810",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.528425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I have \u00a310k funds clearing next week, i\u2019m tempted , i\u2019ll have to think about whether i\u2019ll buy more. Let\u2019s  just hope we start generating some serious income without needing to resort to more placings.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.721998+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261139-Rocka--5585668",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Not the RNS i was expecting, also i don\u2019t believe the BOD should get any bonuses until the company is generating a profit but hey ho it is what it is. Let\u2019s just hope we see some contracts and/or news on NCI. We need a catalyst to propel the sp.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722016+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261115-gtc1507--3432764",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529652",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Shares admitted on Friday 30th, suspect we\u2019ll see tr1s shortly after - be interesting to see who went for it",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722033+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260941-druml--3345831",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.278271",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Prudent decision by the board. Give the headroom for getting the deals in. Good to see director support.",
          "sentiment": 0.5,
          "engagement": "24",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722051+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260940-gtc1507-73562733",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279131",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "What does \u201cinvest in strategic partnerships\u201d mean do we think? \u201cThe successful validation and formal launch of our OptiMAL\u00ae platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time. \"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders.\"",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-10T23:46:26.722069+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260934-gtc1507--5951870",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279952",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - I took comfort there was no indication in the rns about weakness in the trading position also which I assume means they remain on track to achieve the 80% growth in h2. This was strong from the launch conference \u201c Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time\u201d.",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-10T23:46:26.722087+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260930-Cheapsha--5426027",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.280743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "After the raise and director shares the share count is bang on 125M share still very low. The bonus shares also issued at 13p. Market cap just under \u00a317M with this issue. To get to 50M cap we need about 40p share price very reasonable- actually that would still be cheap very cheap. But we do need some contracts signed should be here soon!",
          "sentiment": 0.5,
          "engagement": "2,671",
          "price_at_post": "13.375",
          "thread_title": "Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-10T23:46:26.722125+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-Bibzy7--2710496",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.281547",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Is this just the last chance for the ones in the know to get the cheap shares before this goes crazy Half full maybe outlook",
          "sentiment": 0.0,
          "engagement": "321",
          "price_at_post": "13.50",
          "thread_title": "Cheap",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34F59233-C112-41AC-AA13-18CE6878B383"
        },
        "ingested_at": "2026-02-10T23:46:26.722148+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-David195--2832940",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.282359",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "This is no surprise and positions FAB to move forward more quickly.  Potential customers need to be reassured the company is in good shape financially when due diligence is carried out.  A raise at current SP is excellent in current market conditions.  The discussions with NCI are crucial and FAB are able to conduct them from a stronger position. Getting the first contracts and renewing the agreement with NCI in the coming months is now more likely.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722167+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260824-Troutiso-52154035",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283156",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Both the bid and offer price rising within the wide quoted spread. I have a little more headroom to fill now, so have started with 50k.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722185+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260815-gtc1507--1393067",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The said they had runway to FY27 which is April. Good they have topped up the cash balance. Should help with due diligence for contracts. Buried line in the rns: \u201cMany of the organizations approached in the pre-launch phase have expressed an interest in the OptiMAL\u00ae platform including disclosure of target details under non-disclosure agreements\u201c Companies willing to share their target data with fusion is strong endorsement for their capability and expertise . This provides a very strong foundation to move forward in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722203+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Aldebara--7032166",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.284672",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Barely any discount. Seems ok to me",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722221+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Troutiso--5679985",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.285377",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Had a feeling this was coming, very quiet, lack of real trading and the timing were all tell tales, as was the tight lipped rumours. Last week SML another I have a large holding in (and seems to have been mirroring FAB prices albeit at a tenth of FAB) did a placing at 1.3p for \u00a34m they too have lots going on and are using the funds to accelerate drilling towards an earlier PFS. That was at 1.3p at no discount. The market although PIs were telling each other it had enough money has responded very positively and it closed yesterday at 1.9p. I felt it was possible that FAB would do the same and am pleased they have done so, this will accelerate OptiMAL rollout and was probably needed for some of the bigger new clients to sign any deal (they will not want to have contracts with companies who don't have a robust financial situation. I think the company have explained themselves well and don't see this as negative, if, and a big if, the shares have gone to long term IIs as the last one did. I have no reason to believe it hasn't as if this was a vulture driven firesale placing the SP would have been hammered and there would have been a 30%+ discount. I believe this is more to do with large investors wanting to add more, but not wanting to buy in the market and happy to do so in a placing at no or little discount. Overall happy with this and if the market reacts like it did last time we will soon be up at recent highs. This is nearly double the price they raised at last year, that is a sign of good progress!!! Stan it was 13.4p to buy yesterday so below mid anyway....",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722239+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260751-Seancadm--5329510",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "They had stated they had cash runway into \u201827 (financial year 27, which is from April \u201826 ). So in order to avoid a raise they would have needed contracts to drop in the next month and even then they couldn\u2019t have been certain to have money in the bank by then. So they are now fully funded, with, from the details in the RNS strong indications of OptiMal take up. This is good for the company putting a strong cash foundation under what could well become a company making year!",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722257+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260743-U_time--3287485",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286990",
        "source": "LSE_CHAT",
        "data": {
          "author": "U_time",
          "content": "Hard not to be negative about this placing. Comes at a time where we thought no placing was needed as the company was good financially and had enough contracts to manage day to day cash without a raise. Strange. Seems to suggest people are q'ing up for the 'best in class'. NCI deal now becomes even more crucial hopefully they can get it over the line otherwise FAB just becomes another one of those AIM companies that wants to keep raising funds on share holders dime until eventually they decide to delist... Hopefully wont come to that but its game time now.",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722275+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260727-bannside-54288455",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.287780",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "Tells me there no contracts ready to be signed",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722294+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260725-rp6577--1350448",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.288565",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Not the RNS I wanted to see. However, at least it is at the market price. Hopefully this now gives them the fire power to accelerate growth and really kick into gear",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722312+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260723-Stan36--3487422",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.289358",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Cheadle it is discounted from the mid price. And from the ask price ordinary investors would have to pay. So a discount of 3.8 to 7.6% NED participation during contract negotiation with NCI tells us he's not party to the details?",
          "sentiment": 0.0,
          "engagement": "863",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722329+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260710-rubarbru--5763409",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290150",
        "source": "LSE_CHAT",
        "data": {
          "author": "rubarbrubarb",
          "content": "And director involvement",
          "sentiment": 0.0,
          "engagement": "60",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722347+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260708-cbeadle--7849810",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290933",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Quite encouraging it\u2019s at the market price and not discounted at all",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722365+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260705-cbeadle-28790123",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.291707",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right news 50p to \u00a31 could happen really fast",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-02-10T23:46:26.722383+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260703-Laura202--8638642",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.292433",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Out",
          "sentiment": 0.0,
          "engagement": "15,342",
          "price_at_post": "13.50",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-10T23:46:26.722401+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262352-Clachair--8886333",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293116",
        "source": "LSE_CHAT",
        "data": {
          "author": "Clachair10",
          "content": "Hi, I have been in since near the very beginning. I need to see \u00a31/share to get my money back. Not sure that will ever happen? Could have made a killing when they floated but wasn\u2019t able to realise it. May have to bale when and if it hits 50p a share. Have been watching this for so many years waiting for the upside! C.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-02-10T23:46:26.722420+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262314-rp6577-47446710",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293774",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "My view is that they have something which is better that what their competitors have. Things can take time to get traction. However, if you are fundamentally better, then it is difficult not to see significant success down the road. Just got to sit tight and if you don\u2019t have your full position yet, add during these quiet times",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T23:46:26.722438+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262105-evman27-58025292",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.294509",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes I was there too, still holding and have added to my position since then on dips. It's clear Optimal and Fusion are dangerously undervalued and I feel very relaxed with my money here.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T23:46:26.722456+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-Seancadm-28399993",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.295238",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Anyone who is concerned about any lack of news since the launch (which to be fair was only a few weeks ago) should google how long diligence on a new platform takes, these things take time and there is certainly no need for concern at the moment. The NCI deal is progressing and as GTC says could well be bigger than anticipated due to NIH involvement. I agree though an update on progress so far would go a long way to calming investors.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T23:46:26.722474+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-NornIron--8767402",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296005",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Many thanks for that GTC.",
          "sentiment": 0.0,
          "engagement": "458",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T23:46:26.722491+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261616-gtc1507--5278488",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296852",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I\u2019m still here and was at the AGM. They were very positive about the future potential of the Optimal platform and as have said throughout all their engagements , it will take time to convince people to come onboard but they said it had the potential to be transformational for drug discovery. The brokers are predicting growth of 80% in h2 without any optimal contribution. they have historically not published every single contract they win as their view is their clients don\u2019t always enable that and it could be commercially damaging. All I know is we\u2019ve had nothing from the company to indicate anything materially different to their forecasts either up or down and all we can do is wait for news. They were hiring just before Christmas for 3 new roles so they must be confident about prospects given their cautious cash management approach. They have the grants from the FMI to help them balance those. We\u2019re just in that phase at the moment where we need to see the proof in the execution. I take comfort in the fact the NCI deal is of such a scale it requires NIH approval - that sort of deal will turn the heads of big pharma. They already have big pharma on the books as notified by the two rns at the end of summer autumn so they\u2019ll likely be engaging them about the benefits of optimal. We just need to give them time. They confirmed their cash runway into FY27 was not dependent on an NCI deal so they are. If the company are reading this tho I think investors would welcome something of an update though, silence on the hub, silence to emails, nothing on LinkedIn - all very quiet does feel like something may be bubbling behind the scenes in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-10T23:46:26.722509+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261516-gtc1507-76532865",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721015",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Still sitting 4 v 3 here. The l2 book Hasn\u2019t moved since open strangely despite some chunky buys",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722527+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261512-mmhater--6465911",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721463",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Has anyone got level 2? i imagine it will be getting stronger all the time. A tick up would be nice to see.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722545+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-chrishut--2714663",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721890",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A couple in the telegram group bought more today Great prices on offer",
          "sentiment": 0.0,
          "engagement": "17,380",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722563+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261215-mmhater--1991458",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722312",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I\u2019ve got far to many already\u2026. This is AIM at the end of the day and you never know when you are going to get screwed over. Expect the unexpected! On that note i don\u2019t expect 50p anytime soon.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722581+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261208-Rocka--7078708",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ideally i\u2019d like this at 20p pre news then i think we\u2019ll easily easily hit 40p min short term",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722599+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261207-Rocka--3381672",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723144",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "No ramping intended but if i had \u00a38k now i\u2019d put it all in FAB, topped up last week and expecting \u00a310k early Feb and i\u2019ll put it all in fab. This is a no brainer tbh especially at this price",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722617+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-gtc1507--5282213",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723563",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My gut says we will hear something next week",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722635+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261159-mmhater-53415459",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723976",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I did my little bit yesterday\u2026. I do have another 8k i\u2019m tempted to put in but haven\u2019t decided yet\u2026. Time is ticking and i\u2019m expecting news very soon. NCI wanted to carry on using optimal immediately so must need a deal soon??? Are FAB just letting them use it in the interim?? I still think this is getting bought out. Adrian\u2026 give us an update.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722653+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261138-evman27-66716992",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724413",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "250k is 14.6 Then 260k jumps to 20p!! Float disappearing fast, news will send this crazy, or if someone wants to do the honours now?!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722672+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261059-CHEATED--4879160",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724821",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "I suggest a new field of research that might be rewarding. The lack of mobility and the balance problems of stroke victims. You may have a winner here.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722690+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262332-cbeadle--4408846",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725238",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Something could happen very quickly with FAB",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722708+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261641-Rocka--3701279",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Well if it goes that high that quick i\u2019ll be equally happy as i hold quite a few already",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722726+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261637-Darkryde-79211227",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocks, I hope and think you\u2019ll only get 16,000 shares with your \u00a310k \ud83d\ude0a",
          "sentiment": 0.5,
          "engagement": "548",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722745+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261512-CHEATED--2457640",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726484",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "There should be a link-up with a large American antibody firm. Perhaps a partnership would be beneficial. Share price is in the doldrums and needs a boost of some kind. I cannot see the advantage  of the last addition of staff producing anything of great significance. Too many cooks spoil the broth. Try something new.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722763+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261456-Rocka--4271677",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019d put more in to if i had available funds, topped up last week. Expecting \u00a310k early Feb, hopefully i can buy at todays price once funds clear.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722781+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261415-evman27-52242082",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727321",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Nice buys, what a bargain price!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722799+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261405-mmhater-70274458",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727732",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "My 2 8k trades aren\u2019t showing. been a rise in trades past couple of days and i think this is going to pop soon. News is imminent. NCI have said they want to use optimal immediately so won\u2019t hang around doing deals for long\u2026",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-10T23:46:26.722817+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261338-mmhater-89210791",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728151",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I got fed up of being patient so bought another \u00a316000 worth\u2026 Come on Fusion\u2026 give us a update",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T23:46:26.722835+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261330-Antha-55246052",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "Everyone is just waiting for the NCI contract and other pharma contracts to be signed, until then the sp will just drift up and down between the 12-16p range, just need to be patient.",
          "sentiment": 0.0,
          "engagement": "2,740",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T23:46:26.722853+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261310-gtc1507--1972242",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728989",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Seems to be kicking into action again, some decent buys today. Investor relations seem to be answering questions on the hub too. Looks like the shareholder information has been updated too as of a few days ago, no sign of maven any more\u2026.. https://www.fusionantibodies-ir.com/content/investors/shareholder-information.asp",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-10T23:46:26.722871+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261100-stan1234--1902320",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729412",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "I am going to add today too. Just selling something else first.",
          "sentiment": 0.0,
          "engagement": "208",
          "price_at_post": "13.25",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-10T23:46:26.722889+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260810-formerly--1235985",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729827",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Purchased 10,000 at 13.3 via HL this morning. Wait and See!",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-10T23:46:26.722908+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261821-formerly-32870487",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730246",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T23:46:26.722926+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261812-gtc1507--3160230",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730660",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T23:46:26.722944+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261757-Cheapsha--4524891",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.731071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-10T23:46:26.722962+00:00"
      },
      {
        "event_id": "SOCIAL-Today1728-gtc1507--8728673",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.688368",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice to see buyers back today at 15p. Seems to be attractive still. Just a matter of time.",
          "sentiment": 0.0,
          "engagement": "1,203",
          "price_at_post": "15.50",
          "thread_title": "RE: Know what you own",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=648A18DB-23B4-4D15-BAE6-C6BCA075BA1F"
        },
        "ingested_at": "2026-02-11T18:55:20.682866+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261746-Cheapsha-81145049",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.688792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "I recon Feb 19th we get some juice. If I am wrong just feel free to poke fun at me. That's just my crystal ball",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.682897+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261633-evman27--4067921",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.689214",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Loving the quotes today guys! If no news, let's do poetry wednesdays tomorrow.",
          "sentiment": 0.0,
          "engagement": "186",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.682919+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261541-rp6577--6610027",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.689618",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "I just focus on the fact that if we are offering something that is better than the competition and in a massive market, then the results should surely follow. It might not be a straight line or quick, but you should eventually succeed",
          "sentiment": 0.0,
          "engagement": "900",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.682938+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261538-Cheapsha--5576779",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.690019",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Quite from Mr Google clarify: \u201cContext: Buffett uses this phrase to emphasize that patience, discipline, and a long-term perspective are the true keys to building wealth, rather than trying to time the market.\u201d",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.682956+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261534-Cheapsha-54913853",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.690447",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "News gonna come soon It\u2019s just a little patience that most people do not have Remember W Buffet \u201cStock market is a mechanism of transferring wealth from the impatient to the patient\u201d Obviously this applies to well run companies not losers; but FAB is very well run with a platform that the best players do want\u2026so\u2026",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.682974+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261229-Rocka--7221686",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.690842",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Nice quote\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.682992+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261220-Seancadm-14146517",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.691258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Weak hands watch the screen, strong hands watch the story. Platforms don\u2019t get validated and commercialised overnight, patience is the key.",
          "sentiment": 0.5,
          "engagement": "222",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683010+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261148-gtc1507-88093500",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.691659",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "It is disappointing to see it go up and down. I think we\u2019ll be in a range until there is news of success. The company said it might take time to convert, but we need to see the signs that optimal actually is attractive. They were in discussions last February on optimal with clients according to answers the hub, I think we\u2019re all hoping that they convert to sales sooner rather than later to demonstrate what they say is market leading actually can deliver. If they are right then we should be onto a winner it\u2019s all on the execution now.",
          "sentiment": 0.0,
          "engagement": "1,203",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683028+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261147-Rocka-84362070",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.692056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mm hater, we are all guilty of feeling anxious from time to time, but these things do take time, the way i see it is none of these institutions would buy at 13p if they didn\u2019t believe in FAB. I\u2019m holding and topping up as and when funds are available.  Obviously not  all of the  placing has  gone to sticky hands, there are some that will be happy with a 10% profit. Just hold and we\u2019ll all be rewarded.",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683054+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261140-mmhater-27160907",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.692461",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Lol\u2026.. i do see your point\u2026. Been here 3 years since it caught my eye when it dropped from the highs of covid. The company has been promising amazing things and just want to see them come to fruition\u2026. I thought the launch in December was going to be great but was a damp squib! i\u2019m just frustrated\u2026.. And what\u2019s today\u2019s drop all about?",
          "sentiment": 0.0,
          "engagement": "667",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683086+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261137-Rocka-13393856",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.692854",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, you change your opinion every couple of days, if the sp retraces slighter you go into negative mode. I honestly don\u2019t think stock trading is for you .",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683123+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261111-mmhater-35459370",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.693261",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Company really need to get their finger out their back sides! IF we are the best in the world for antibodies i would have expected a lot more action in the share price. 6 weeks on from launch of Optimal and expect more than what we are seeing!",
          "sentiment": 0.0,
          "engagement": "667",
          "price_at_post": "15.00",
          "thread_title": "Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683142+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261017-evman27-77264619",
        "event_type": "social_post",
        "date": "2026-02-11T18:55:12.693669",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "\"It was never my thinking that made the big money for me, it always was sitting... sitting tight\" - Jesse Livermore Small term movements don't bother me when I know what I own.",
          "sentiment": 0.0,
          "engagement": "186",
          "price_at_post": "15.00",
          "thread_title": "Know what you own",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=648A18DB-23B4-4D15-BAE6-C6BCA075BA1F"
        },
        "ingested_at": "2026-02-11T18:55:20.683160+00:00"
      },
      {
        "event_id": "SOCIAL-Today1746-Cheapsha-81145049",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.939863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "I recon Feb 19th we get some juice. If I am wrong just feel free to poke fun at me. That's just my crystal ball",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683179+00:00"
      },
      {
        "event_id": "SOCIAL-Today1633-evman27--4067921",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.940401",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Loving the quotes today guys! If no news, let's do poetry wednesdays tomorrow.",
          "sentiment": 0.0,
          "engagement": "186",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683197+00:00"
      },
      {
        "event_id": "SOCIAL-Today1541-rp6577--6610027",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.940895",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "I just focus on the fact that if we are offering something that is better than the competition and in a massive market, then the results should surely follow. It might not be a straight line or quick, but you should eventually succeed",
          "sentiment": 0.0,
          "engagement": "900",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683214+00:00"
      },
      {
        "event_id": "SOCIAL-Today1538-Cheapsha--5576779",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.941413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Quite from Mr Google clarify: \u201cContext: Buffett uses this phrase to emphasize that patience, discipline, and a long-term perspective are the true keys to building wealth, rather than trying to time the market.\u201d",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683232+00:00"
      },
      {
        "event_id": "SOCIAL-Today1534-Cheapsha-54913853",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.941924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "News gonna come soon It\u2019s just a little patience that most people do not have Remember W Buffet \u201cStock market is a mechanism of transferring wealth from the impatient to the patient\u201d Obviously this applies to well run companies not losers; but FAB is very well run with a platform that the best players do want\u2026so\u2026",
          "sentiment": 0.5,
          "engagement": "2,685",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683250+00:00"
      },
      {
        "event_id": "SOCIAL-Today1229-Rocka--7221686",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.942434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Nice quote\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683268+00:00"
      },
      {
        "event_id": "SOCIAL-Today1220-Seancadm-14146517",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.942930",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Weak hands watch the screen, strong hands watch the story. Platforms don\u2019t get validated and commercialised overnight, patience is the key.",
          "sentiment": 0.5,
          "engagement": "222",
          "price_at_post": "15.25",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683286+00:00"
      },
      {
        "event_id": "SOCIAL-Today1148-gtc1507-88093500",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.943428",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "It is disappointing to see it go up and down. I think we\u2019ll be in a range until there is news of success. The company said it might take time to convert, but we need to see the signs that optimal actually is attractive. They were in discussions last February on optimal with clients according to answers the hub, I think we\u2019re all hoping that they convert to sales sooner rather than later to demonstrate what they say is market leading actually can deliver. If they are right then we should be onto a winner it\u2019s all on the execution now.",
          "sentiment": 0.0,
          "engagement": "1,202",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683303+00:00"
      },
      {
        "event_id": "SOCIAL-Today1147-Rocka-84362070",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.943915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mm hater, we are all guilty of feeling anxious from time to time, but these things do take time, the way i see it is none of these institutions would buy at 13p if they didn\u2019t believe in FAB. I\u2019m holding and topping up as and when funds are available.  Obviously not  all of the  placing has  gone to sticky hands, there are some that will be happy with a 10% profit. Just hold and we\u2019ll all be rewarded.",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683321+00:00"
      },
      {
        "event_id": "SOCIAL-Today1140-mmhater-27160907",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.944409",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Lol\u2026.. i do see your point\u2026. Been here 3 years since it caught my eye when it dropped from the highs of covid. The company has been promising amazing things and just want to see them come to fruition\u2026. I thought the launch in December was going to be great but was a damp squib! i\u2019m just frustrated\u2026.. And what\u2019s today\u2019s drop all about?",
          "sentiment": 0.0,
          "engagement": "667",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683339+00:00"
      },
      {
        "event_id": "SOCIAL-Today1137-Rocka-13393856",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.944882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, you change your opinion every couple of days, if the sp retraces slighter you go into negative mode. I honestly don\u2019t think stock trading is for you .",
          "sentiment": 0.0,
          "engagement": "201",
          "price_at_post": "15.00",
          "thread_title": "RE: Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683357+00:00"
      },
      {
        "event_id": "SOCIAL-Today1111-mmhater-35459370",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.945382",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Company really need to get their finger out their back sides! IF we are the best in the world for antibodies i would have expected a lot more action in the share price. 6 weeks on from launch of Optimal and expect more than what we are seeing!",
          "sentiment": 0.0,
          "engagement": "667",
          "price_at_post": "15.00",
          "thread_title": "Disappointing price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C2799949-1298-45D9-BCC4-1BDCF0CB1E98"
        },
        "ingested_at": "2026-02-11T18:55:20.683375+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-evman27-77264619",
        "event_type": "social_post",
        "date": "2026-02-10T23:46:18.945886",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "\"It was never my thinking that made the big money for me, it always was sitting... sitting tight\" - Jesse Livermore Small term movements don't bother me when I know what I own.",
          "sentiment": 0.0,
          "engagement": "186",
          "price_at_post": "15.00",
          "thread_title": "Know what you own",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=648A18DB-23B4-4D15-BAE6-C6BCA075BA1F"
        },
        "ingested_at": "2026-02-11T18:55:20.683392+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261800-Cheapsha--2836445",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.682514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Oooh bless you Alice $$$ Year of the Fusion- jump in!",
          "sentiment": 0.5,
          "engagement": "2,677",
          "price_at_post": "16.00",
          "thread_title": "RE: Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-11T18:55:20.683411+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261619-Rocka-36128033",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.683225",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Alice, at best 130p plus add a zero to 13p.",
          "sentiment": 0.0,
          "engagement": "198",
          "price_at_post": "16.00",
          "thread_title": "RE: Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-11T18:55:20.683429+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261610-Seancadm--3506282",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.683905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Don\u2019t think you\u2019ll get your buy in price this time Alice! I\u2019ll focus on the funded balance sheet and validated tech rather than short term price guesses.",
          "sentiment": 0.0,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-11T18:55:20.683447+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261550-Alice-Wr-67790206",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.684583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alice-Wright",
          "content": "At worst.",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "16.00",
          "thread_title": "Back to 13p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=B8875AA3-11DC-4F2A-A4D3-31BE776EE164"
        },
        "ingested_at": "2026-02-11T18:55:20.683465+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261103-gtc1507--8248842",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.685263",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some decent delayed prints continuing today. Feels like someone accumulating",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-11T18:55:20.683483+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260848-Seancadm-64614784",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.685925",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "NCI/NIH better funded, Fusion fully funded, OptiMAL already validated and in continued use discussions... feels like all the pieces are lining up.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-11T18:55:20.683501+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-gtc1507--8593175",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.686647",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "\u201cNIH and NCI Receive Funding Increases The FY26 bill provides $47.2 billion for the National Institutes of Health (NIH) and $7.4 billion for the National Cancer Institute (NCI), representing increases over current funding levels. At the same time, the measure maintains flat funding of $1.5 billion for the Advanced Research Projects Agency for Health (ARPA-H). Together, these appropriations reinforce federal support for the cancer research pipeline, including discovery science, translational research, clinical trials infrastructure, and efforts to improve prevention and outcomes across diverse populations.\u201d Good to see discovery science specifically mentioned\u2026. https://oncodaily.com/public-health/nih-fy26",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "NCI funding boost",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=8F99388D-0F1F-4BCE-ACE0-7192DBC74357"
        },
        "ingested_at": "2026-02-11T18:55:20.683519+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261827-gtc1507--6129828",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.687448",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I think it\u2019s good to reflect back on what the company have actually told us about Optimal and why it\u2019s supposed to be a game changer. Based on Fusion\u2019s own published data and comparisons reported in the scientific literature, OptiMAL appears to be materially more effective than competing antibody discovery platforms. The most important metric is efficiency. Fusion reports that OptiMAL achieves over 70% gene integration, meaning most cells produce a working antibody. Published data for competing mammalian display systems typically show efficiencies of only 1\u201310%. In plain terms, OptiMAL seems to waste far less effort and deliver far more usable output. That efficiency advantage apparently allows OptiMAL to do something competitors generally cannot: screen more than one billion functional antibodies. Fusion states that OptiMAL can generate functional libraries greater than 10\u2079 antibodies, whereas most competing platforms are limited to millions. Antibody discovery is a numbers game, and searching a much larger, fully functional library should significantly increases the chances of finding a high-quality drug candidate, particularly for difficult targets. Importantly, the data suggests this is about quality as well as scale. Fusion has shown antibodies from OptiMAL with nanomolar binding strength, which aligns with the standards needed for real drug development. This indicates the platform can deliver clinically relevant candidates, not just early-stage research hits. They say OptiMAL is also designed to closely mimic real human antibodies. Using human antibodies should reduce the risk of antibodies failing later due to safety or manufacturing issues, which would be a major cost for drug developers. For investors, the implication is straightforward. Platforms that improve success rates and reduce risk should command higher fees and if truly different should mean they can generate more and more repeat business Based on the published performance gap versus competitors, my investment thesis is therefore that OptiMAL appears to offer Fusion a defensible edge that should hopefully support stronger commercial traction and long-term value. If they can get in early with clients, be valuable partners then they have a better chance of getting royalty and milestone entitlements. If they found the next Keytruda for example and had even 0.1% royalty on future sales that could add up to $31.7 million per year for fusion. If we start to see contracts coming through, which with clients under NDA looks likely, then it would appear to me they have genuinely found a market gap and if they can scale should generate good returns for us. DYOR and best of luck!",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-11T18:55:20.683537+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261750-Seancadm-20604785",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.688107",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "NCI-validated tech, big conference buzz, partners circling, pipeline building... feels like Fusion could be sitting on something seriously interesting here.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-11T18:55:20.683555+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261731-Rocka--1886358",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.688764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Feeling very positive here, locked and loaded, bring on 20p pre contract news and we\u2019ll be at 40p in a flash post news imo.",
          "sentiment": 0.0,
          "engagement": "198",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-11T18:55:20.683573+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261234-gtc1507--6939316",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.689434",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The company also said they want to \u201cinvest in strategic partnerships\u201d in the placing RNS. What sorts of tie ups might we see!",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-11T18:55:20.683591+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261106-evman27--4731766",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.690131",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "I like the theory Sean. We've seen that in this industry there are lot of NDAs so we can never know the whole picture no matter how positive it looks from the outside. Fusion do set themselves up to be a partner for big pharma, after all they have worked with 8/10 of the worlds biggest pharma companies in the past! When I was at the AGM, I got a tour of the labs, the scientists working in there told me they were doing work for the NCI, highlighting that 'partner' approach.",
          "sentiment": 0.0,
          "engagement": "184",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-11T18:55:20.683609+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261047-Seancadm-77801924",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.690831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time. The above from the recent RNS. I am interested in why Fusion included 'and the company' in the above. It suggests that interest isn't limited to a single product, does this suggest that Pharma see Fusion as a partner organisation rather than just a vendor selling one product. In other words, the opportunity is bigger than just one product. Does this mean that Fusion is being viewed as a credible antibody discovery company with multiple valuable assets? I know people are eager for news but there are clues in recent RNSs that suggest Fusion is doing a lot behind the scenes.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "16.00",
          "thread_title": "RE: Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-11T18:55:20.683627+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261035-gtc1507--6447860",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.691506",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "#FAB looks strong for a move this week, risen nicely after placing at 13p, sitting well above key moving averages and weekly slingshot now in play. 200ma on the weekly is 19.49, with 52 week high of 21p. With potential catalyst news coming in short to medium term, cash in the bank and technicals all lining up the next move could be pretty impressive",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "Looking well setup for this week",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=14C3F919-B324-4401-9F8F-8AEDDD52E52D"
        },
        "ingested_at": "2026-02-11T18:55:20.683645+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261303-gtc1507--1048214",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.692178",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I suspect we\u2019lll soon see evidence that Optimal is attractive to their clients. At that point it\u2019s just a case of seeing how big this can scale. If they\u2019re to be believed it will be game changing for the company and the drug discovery industry",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683664+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261144-evman27-44741717",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.692876",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Incase you all need a reminder of what Adrian said at the last presentation \u201cWe are now market leader, Optimal is best and first in class at what it does\u201d \u201cFusions platform is the best as evidenced by the data in this launch presentation\u201d \u201cIf that means we become more visible, I think it will and therefore more noticed by those considering acquiring companies like ours, well then so be it\u201d Happy holding!!",
          "sentiment": 0.0,
          "engagement": "184",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683682+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261359-Sanibel-40840534",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.693583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Some nice buys Nothing is certain but this has to be a worthwhile investment for those who have researched. A big contract or a number of would be transformational here with \u00a31 or more easily achievable Im holding tight GL Sani",
          "sentiment": 0.0,
          "engagement": "4,570",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683701+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261342-gtc1507--6299691",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.694262",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Looks like someone took 260k in the space of 15 mins earlier one this morn, must be confident",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683720+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261256-gtc1507-53641645",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.694929",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice to see some chunky delayed buys coming through today. Is somone accumulating or are many people realising just wha the potential is here",
          "sentiment": 0.5,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683739+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261211-gtc1507--1583742",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.695604",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "A close at these or near levels will be very strong weekly setup. Bodes well for next week",
          "sentiment": 0.0,
          "engagement": "1,201",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683758+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Seancadm--6051749",
        "event_type": "social_post",
        "date": "2026-02-10T00:34:07.696280",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I'm not expecting fireworks overnight, but with NCI validation, institutions increasing, and funding risk reduced, the setup looks better than it did a few months ago. Now it's about waiting for the first OptiMAL commercial foothold. Even a small evaluation or platform-access agreement would change how the market values Fusion.",
          "sentiment": 0.5,
          "engagement": "221",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683776+00:00"
      },
      {
        "event_id": "SOCIAL-Today1359-Sanibel-40840534",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.729743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "Some nice buys Nothing is certain but this has to be a worthwhile investment for those who have researched. A big contract or a number of would be transformational here with \u00a31 or more easily achievable Im holding tight GL Sani",
          "sentiment": 0.0,
          "engagement": "4,569",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683794+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507--6299691",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.730217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Looks like someone took 260k in the space of 15 mins earlier one this morn, must be confident",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683812+00:00"
      },
      {
        "event_id": "SOCIAL-Today1256-gtc1507-53641645",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.730651",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice to see some chunky delayed buys coming through today. Is somone accumulating or are many people realising just wha the potential is here",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683830+00:00"
      },
      {
        "event_id": "SOCIAL-Today1211-gtc1507--1583742",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731073",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "A close at these or near levels will be very strong weekly setup. Bodes well for next week",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683848+00:00"
      },
      {
        "event_id": "SOCIAL-Today1008-Seancadm--6051749",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731511",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I'm not expecting fireworks overnight, but with NCI validation, institutions increasing, and funding risk reduced, the setup looks better than it did a few months ago. Now it's about waiting for the first OptiMAL commercial foothold. Even a small evaluation or platform-access agreement would change how the market values Fusion.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683867+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261902-Troutiso--3006735",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.731926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I think apart from the initial 60k trade which was a buy, all the rest of the delayed trades over 50k look to be sells. Not a problem they got a good price and those shares will be bought up by others.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.25",
          "thread_title": "RE: Big trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=D96A8918-A1B6-42AA-B090-11B604330C21"
        },
        "ingested_at": "2026-02-11T18:55:20.683885+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261853-Troutiso--6227828",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.732355",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "A little different last year as they issued some shares and the others after a GM. However Canaccord Genuity Group Inc did announce their TR1 last of the three, probably as they are based in Vancouver. Their holding and the dilution mean they could add nearly 1.94m shares and not need to TR1 as still within the 7% band.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683904+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261851-mmhater-40074395",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.732769",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Well there has been a lot of big trades today. hard to tell if buys or sells but i think are delayed buys. Market makers have played the price sneakily dropping nothing. i expect a large rise tomorrow to counter the false drop.",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "15.25",
          "thread_title": "Big trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=D96A8918-A1B6-42AA-B090-11B604330C21"
        },
        "ingested_at": "2026-02-11T18:55:20.683922+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261319-gtc1507--2113121",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.733200",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes they are already holders - they took 7% at last years placing. Think the rns this time talked about existing and new investors demonstrating confidence. There is a possibility cannacord took more but we might have seen an rns by now perhaps",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683940+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261315-Cheapsha--2620918",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.733614",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Who is the 3rd institution, we seen 2 x RNSs Is that Cannacord?",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "15.75",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683958+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261149-Sanibel--2531618",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734033",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sanibel",
          "content": "All looking very good here. All thats needed is patience. Gl all Sani",
          "sentiment": 0.0,
          "engagement": "4,569",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683976+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260902-chrishut-30442706",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734466",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Was going to edit that but the word is funny so leaving it ha",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.683995+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260901-chrishut-62309600",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.734875",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Will we see a cancrod rns today?",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684013+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260838-gtc1507--6262943",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.735327",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Also I\u2019m glad to see stt has bought in. I think deep down we\u2019re on the same page, about the strength of fab.  the company said they would always consider raise for growth if they thought was right thing and that\u2019s what happened. They also said they were on track for breakeven without a raise but chose to take the brakes off and raise to accelerate growth. They are credible enough to convince big funds like these that the prospects are materially good enough to justify at market price investment. They\u2019ve filled the war chest now let the battle for market share with their new discovery tools commence!",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684039+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260809-gtc1507-48908872",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.735821",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "You\u2019re totally right Sean. It\u2019s kudos to them that they were able to secure that investment at zero discount from funds lik that",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684058+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260749-Seancadm--5810808",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.736277",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Most AIM companies can't attract this level of institutional capital, they don't just buy on 'hope. They Perform due diligence Speak directly to management Stress test the story. Fusion must have gained a hell of a lot of credibility! Having the backing of 3 institutional funds means the company has passed enough internal filters for serious capital to stay involved and even increase. I'm confident people are going to take notice of this backing over the coming weeks and jump on board.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684076+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262117-mmhater--1535219",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.736682",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Just waiting for a tie for tat rely a lowlife would do\u2026.. standing by.",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684095+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262047-stt1--2484260",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737139",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Buying in the placing or post placing made sense. It's hardly surprising....I also added after the placing and before today's rns, as per my assertion that they needed a placing. I've said the company needed another placing to advance their projects and that's what they have done. Rampers were claiming the company doesn't need a placing, they have cash runway until 2027. The rampers also claimed the company would be winning contracts as soon as they launch their platform. It's now 2 months and still no contracts. Newsflow has been as expected. I'll look to trade as and when as the company still face hurdles...",
          "sentiment": 0.0,
          "engagement": "4,531",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684129+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20262013-steven49-11486203",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737548",
        "source": "LSE_CHAT",
        "data": {
          "author": "steven49",
          "content": "From placing",
          "sentiment": 0.0,
          "engagement": "13,711",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684148+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261941-Rocka--7274093",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.737956",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Could well hit 20p this week and move on to 30-50p on contract rns",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684167+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261925-evman27--3018364",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.738402",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Great post GTC and as far as I am aware that is all correct. Things are turning here now, there are so many reasons to be invested here and I'm expecting the highly geared returns to start taking shape this year. The future is FAB!",
          "sentiment": 0.0,
          "engagement": "182",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684185+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261856-gtc1507--7295416",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.738823",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "\u2026.Counters the case that now is their time to shine? DYOR and fact check me but I think we\u2019re in for an exciting time",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684203+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261855-gtc1507--1655570",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.739377",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some substantial delayed trades printed after hours. Feels like then market is finally waking up to the positive potential here. Cashed up with large volumes going at discount to sticky institutions all while\u2026. \u2022 OptiMAL now LIVE \u2013 world-first antibody discovery platform, with multiple customers already engaging under NDA \u2022 OptiMAL deal economics step-change \u2013 programmes identified by Allenby potentially at \u00a3200k\u2013\u00a32m per deal, depending on scope, versus current revenue guidance of ~\u00a32.25m for FY26 \u2022 Clear headroom vs history \u2013 revenues were close to \u00a35m pre-downturn, highlighting recovery plus upside potential \u2022 Platform shift underway \u2013 moving from services \u2192 scalable discovery platform, structurally improving margins \u2022 Lean, cost-efficient operation \u2013 capital disciplined, with strong operating leverage as revenues scale \u2022 Margin recovery underway \u2013 mix shifting toward higher-value discovery work, reversing historic pressure \u2022 National Cancer Institute fully open \u2013 boosted FY budget and active negotiations on a multi-target collaboration \u2022 Potential peer-reviewed publications \u2013 NCI work could translate into high-impact journals, boosting credibility \u2022 Sales momentum building \u2013 brokers guiding to >80% revenue growth in h2, before any premium discovery revenues \u2022 potential for Longer, stickier client engagements \u2013 discovery work keeps clients involved earlier and for longer \u2022 Cashed up and confident \u2013 recent raise removes funding risk and unlocks growth ambition \u2022 OptiPhage licence decision pending \u2013 asymmetric upside if converted to an exclusive deal \u2022 US patent secured \u2013 strengthens IP moat in the most important biotech market \u2022 IP footprint expanding \u2013 additional patents progressing in key jurisdictions \u2022 Prestige access via Future Medicines Institute \u2013 world-class ecosystem, talent pipeline, plus \u00a31m grant and \u00a35m capital access \u2022 Local ecosystem strengthening \u2013 academia\u2013biotech\u2013industry collaboration deeper than ever in Northern Ireland \u2022 Client funding conditions improving \u2013 biotech risk appetite back, with SPDR S&P Biotech ETF at multi-year highs \u2022 Hiring from strength \u2013 attracting staff from big-name competitors \u2022 Clear geographic growth plans \u2013 expansion targeted in US and Asia \u2022 AI-enabled discovery play \u2013 OptiMAL sits squarely in the AI drug discovery sweet spot \u2022 Legacy royalties & milestones still live \u2013 historic deals mean unexpected upside remains possible \u2022 DR5 time asset nearing conclusion \u2013 project due to complete this year with licensing potential \u2022 Strategic antibody partnership with Finn therapeutics\u2013 leveraging patented antibody asset \u2022 Collaboration with Eurofins Discovery \u2013 validation and access to a global pharma client base Valuation angle: Is FAB still trading closer to a cash-backed services multiple, despite OptiMAL-sized deals that could move revenues with only a handful of wins? Genuine question: Am I missing anything that meaningfully co",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684221+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261707-Stan36-65818130",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.739787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "@Troutisout1 I'm in with 202k shares average 13.95p. Wasn't tempted to sell at 19p. Happy to wait. Good to see these tr1 confirmations and the 9.4% rise today.",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "15.75",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684240+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261706-Laura202-63047645",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:55.740199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Buys in the 13s looking very healthy",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "15.75",
          "thread_title": "Great day",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=C6467160-466B-42CC-A9F0-BEED146D848D"
        },
        "ingested_at": "2026-02-11T18:55:20.684258+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261658-Cheapsha--4232894",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.784626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Good news overall big guns adding Hopefully soon 20p before some contracts hit the RNS Then got a better base and higher base to jump from",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684276+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261652-Troutiso-50959866",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.785367",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes their last Holdings RNS was a little confusing naming at least 5 different entities, but it is another 2,212,084 shares they have purchased for \u00a3287.6k, There's another \u00a3862k out there, so still room for another TR1, but I reckon more likely to have gone to new IIs at under 3%. Cannacord though, could still update.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684295+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261641-Dw198--1069558",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.786053",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dw198",
          "content": "Ignore, it is  Rathbones Investment Management Ltd who is the owner of the nominee account :-). Great news",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684314+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261637-Dw198-66547018",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.786745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dw198",
          "content": "It\u2019s a nominee account isn\u2019t it? So it is not Rathbones who made the investment decision, it would be the holder of the nominee account, whoever that may be",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684333+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261630-Troutiso-50696863",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.787475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Stan, I bought 200k at 13p on the 28th Jan, so others could have done so too, it wasn't just the placees. Great to see another holder from last year's placing increase again on this one, do we think we might see something from Cannacord as well? That would be great, but the realisation will now dawn that the placing shares are tightly held for the second year running.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "16.00",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684351+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261619-rp6577-73801506",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.788164",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Looking solid. Setting us up very nicely for news to blast us through 20p",
          "sentiment": 0.0,
          "engagement": "899",
          "price_at_post": "16.00",
          "thread_title": "RE: Another tr1",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34E599B3-B512-45C9-AF92-5E920C8E28AF"
        },
        "ingested_at": "2026-02-11T18:55:20.684369+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261603-Stan36--5589369",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.788816",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "And those investors who paid 13p in the placing are already 23% up. Where's Alice? She did predict a placing bless her \ud83d\udc8b\ud83e\udd20",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "15.50",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684387+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261600-NornIron--5488101",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.789509",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Go Rathbones ! Although investors like myself and many of you guys here will do our own research before investing in any share, the comprehensiveness and depth of any research most of us do will obviously never touch that of the big institutions. Buck eejits like my myself maybe think we do research at times, but the reality is we'll never get access to the info or individuals where 'real' info can be gained to make an informed buy or sell decision on any holding/s. Companies like Rathbones can do !   Although it's still heads or tails for them whether a share goes up or down going forward, they're making the investment decision knowing more than we PI's will ever know. This is a BIGGIE with Rathbones buying more  ! !",
          "sentiment": 0.0,
          "engagement": "461",
          "price_at_post": "15.25",
          "thread_title": "RE: Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684406+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261548-chrishut--1812003",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.790197",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Boom Up we go",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-11T18:55:20.684423+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261536-AnnaRobi-90554792",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.790856",
        "source": "LSE_CHAT",
        "data": {
          "author": "AnnaRobinson",
          "content": "They didn\u2019t have that before so assuming they grossed up in the placing?",
          "sentiment": 0.0,
          "engagement": "322",
          "price_at_post": "15.25",
          "thread_title": "Major endorsement With Rathbones in for 7%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=706C625A-88AE-4BD6-9D3A-A91BEE2CB842"
        },
        "ingested_at": "2026-02-11T18:55:20.684442+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261533-gtc1507-18714217",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.791541",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Ratbones took another 2m shares",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "15.00",
          "thread_title": "Another tr1",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34E599B3-B512-45C9-AF92-5E920C8E28AF"
        },
        "ingested_at": "2026-02-11T18:55:20.684461+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261533-Humpalum-41005718",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.792213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Rathbones increased holding too \ud83d\udc4d",
          "sentiment": 0.5,
          "engagement": "1,595",
          "price_at_post": "15.25",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=68BAB7F0-F1B4-4AD2-9D69-A66FF8564B72"
        },
        "ingested_at": "2026-02-11T18:55:20.684479+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261514-gtc1507--3711360",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.792886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some serious chunks being bought up these past few days. Someone building a big position perhaps",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-11T18:55:20.684497+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261425-gtc1507-96546237",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.793593",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I asked chat gpt to do some technical analysis last night, this is what I got; Barring any unforeseen negative developments, bullish momentum is slowly shifting in on all timeframes \u2013 implying that the balance of risks for the next few days to months is tilted toward a continuation upward or at least stabilization, rather than a return to sustained bearishness. The technical setup thus points to a greater likelihood of bullish scenarios (momentum accelerating upward) ahead, with the caveat that the market must confirm this by clearing the remaining resistance zones. If those confirmations occur, Fusion Antibodies could very well be at the start of a significant bullish momentum shift after months of decline, with upside targets in the coming weeks and months substantially above today\u2019s closing 14.625p price.",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "15.25",
          "thread_title": "RE: Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-11T18:55:20.684516+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261419-NornIron-48270290",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.794267",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "I've just done a small top up there now of 29,889 for around 4.6k.  I got them at 15.39 and happy at that. Obviously prices can rise and fall, but i feel there are too many positives going for Fab not to take a chance with a few quid more. We could see this move up very very soon.",
          "sentiment": 0.0,
          "engagement": "461",
          "price_at_post": "15.25",
          "thread_title": "Confident to top-up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1074BC0D-EB34-48BE-9F14-5F90FB59B672"
        },
        "ingested_at": "2026-02-11T18:55:20.684534+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261121-stan1234--7336028",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.794908",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "This will just keep going up",
          "sentiment": 0.0,
          "engagement": "210",
          "price_at_post": "15.25",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-11T18:55:20.684552+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261109-mmhater-73401318",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.795568",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Market makers allowing this to slowly climb now on the quiet. Some nice buys amongst tiny sells. Brakes are slowly coming off ready for a nice rns hopefully imminently which will send this nicely into the 20s or maybe 30s. Need to remember this was 50-60p and spikes to \u00a32 a few years ago on nothing compared to where we were now",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "15.25",
          "thread_title": "RE: Going well",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1A2E7CD6-748A-4AB7-A8D9-A6D8EB0D755E"
        },
        "ingested_at": "2026-02-11T18:55:20.684570+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260958-Laura202--4852332",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.796239",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "As expected once 14p went",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "15.125",
          "thread_title": "Going well",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1A2E7CD6-748A-4AB7-A8D9-A6D8EB0D755E"
        },
        "ingested_at": "2026-02-11T18:55:20.684588+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260954-Troutiso-16083182",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.796904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There will be delayed trades behind that SP move.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "15.125",
          "thread_title": "RE: Sensitivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0268C929-5B5A-4561-A591-6FD2897DA7B1"
        },
        "ingested_at": "2026-02-11T18:55:20.684607+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260933-Stan36-53305528",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.797577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Net buys 44,000 shares today. Net value of buys \u00a36,600 and market cap increases by \u00a3700,000 100:1 factor.",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "14.75",
          "thread_title": "Sensitivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0268C929-5B5A-4561-A591-6FD2897DA7B1"
        },
        "ingested_at": "2026-02-11T18:55:20.684625+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260932-chrishut-51558124",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.798249",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This is heading higher",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-11T18:55:20.684644+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260927-Stan36-15246408",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.798904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Up 15% to 15p since the 13p placing. That shows investor confidence. And has happened with low volume. Any positive news and this will burst forth \ud83d\udca5",
          "sentiment": 0.5,
          "engagement": "894",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-11T18:55:20.684662+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260926-gtc1507--7011129",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.799723",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The decision by the National Cancer Institute (NCI) to move forward with Fusion Antibodies\u2019 OptiMAL platform is highly significant. NCI is the largest single funder of cancer research in the world, with an annual budget measured in tens of billions of dollars and a mandate to apply exceptionally rigorous scientific, technical, and commercial scrutiny. US federal procurement frameworks are specifically designed to promote competition and multi-provider tenders. Progressing instead with a single-provider approach strongly suggests that OptiMAL is not merely competitive, but meaningfully differentiated. In that context, the decision itself lends real weight to management\u2019s description of OptiMAL as first-in-class and best-in-class, claims that are rarely validated so early by an institution of this calibre. Fusion has described this as the best deal the company has ever made strategically as much as financially. Within months, this collaboration could be showcased globally, with one of the world\u2019s most prestigious cancer research bodies actively deploying OptiMAL in live discovery programmes. That level of external validation is exceptionally rare and extremely hard to replicate.",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "15.125",
          "thread_title": "NCI significance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B5214597-2A26-4A40-8D06-C710908586C7"
        },
        "ingested_at": "2026-02-11T18:55:20.684680+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260900-Troutiso-67875502",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.800425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes looking good, just very low volume again, when that picks up this will motor...",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-11T18:55:20.684698+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260847-gtc1507--5847394",
        "event_type": "social_post",
        "date": "2026-02-06T23:52:59.801005",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is looking strong - no shares available instantly here, feels like it\u2019s primed for a continuation of the move up today",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.75",
          "thread_title": "RE: Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-11T18:55:20.684716+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260809-gtc1507--2917996",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.083149",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Multiple clients are under NDA for Optima discussions and just reading the update from Allenby they say that they understand a number of clients are evaluating proposals from fusion. That to me fees like the tail end of the business development cycle and we could be seeing some contract awards soon enough if things move positively! Will be exciting  to see just how effectively they can convert the potential of optimal to contracts.",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.75",
          "thread_title": "Multiple clients under nda for optimal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F93502E8-616B-4883-8C43-AE88F8F35456"
        },
        "ingested_at": "2026-02-11T18:55:20.684734+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261950-gtc1507--6228178",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.083682",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/article/government-shutdown-ice-funding-471e55ba4c3247051739ee1b50b2857a",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.625",
          "thread_title": "RE: Serious buying",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B732929B-3433-4DD4-A746-BD075AADC17D"
        },
        "ingested_at": "2026-02-11T18:55:20.684752+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261501-livinhop--1033281",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.084215",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Another 50k delayed shares purchase - serious buying going on at the moment, has to be a good sign....I hope!! L2  currently 2v2",
          "sentiment": 0.0,
          "engagement": "1,096",
          "price_at_post": "14.50",
          "thread_title": "Serious buying",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=B732929B-3433-4DD4-A746-BD075AADC17D"
        },
        "ingested_at": "2026-02-11T18:55:20.684770+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261434-Troutiso-11214451",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.084715",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Vewry shortly I reckon.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: 15.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=79D1BEB9-25D7-49E1-B410-CBAED6C59387"
        },
        "ingested_at": "2026-02-11T18:55:20.684788+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261430-mmhater--3611484",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.085225",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Tick up on its way by end of play i guess",
          "sentiment": 0.0,
          "engagement": "665",
          "price_at_post": "14.50",
          "thread_title": "15.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=79D1BEB9-25D7-49E1-B410-CBAED6C59387"
        },
        "ingested_at": "2026-02-11T18:55:20.684806+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261350-Troutiso--5613196",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.085701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Volume is very small at the moment but positive with buys regularly outweighing sells by some margin.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-11T18:55:20.684824+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261338-gtc1507--6491864",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.086217",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - new investor would need to take just short of \u00a3500k to reach tr1 / more likely we\u2019ll see the others taking more. Not to say that\u2019s not impossible - cannacord came in cold with 500k last year",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.684842+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261314-Troutiso--5617733",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.086728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, I very much doubt any of the placing went to bucket shops, the twitter brigade or PIs, the clue is always in the discount. This was a well organised funding round, allowing IIs a chance to add to their holdings at a fair price.  These placings tend to see the SP react favourably, but often need a news catalyst to really ignite the SP rise. I hope to see some more TR1s but I am happy if there aren't more, there will be many IIs in here at less than 3% and probably won't move for more until the FAB valuation allows. We saw Maven sell out due to a change in Management of their fund and a different direction, many Fund Managers will be looking but not able to purchase through their fund due to investing criteria. I have now bought up all my headroom, so happy to sit back and enjoy the ride. I can see Rathbone or Cannacord adding enough for a TR1, maybe not a new investor though.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.684860+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261208-chrishut--7336028",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.087238",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "This will just keep going up",
          "sentiment": 0.0,
          "engagement": "17,402",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.684878+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261146-Rocka--9332933",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.087727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Hope you\u2019re right but i would still like to see more tr1 rns\u2019s.",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.684896+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261122-Seancadm--4650203",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.088210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "I think there is a good chance that a large proportion of the raise has been taken up by institutional investors, as we found out yesterday with Unicorn adding, I also don\u2019t think we have to worry about smaller investors flipping, in the RNS Adrian said, \u2018supported by a number of our longstanding shareholders\u2019, sounds like sticky hands to me.",
          "sentiment": 0.5,
          "engagement": "217",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.684915+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261038-Rocka-12169510",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.088705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "We do need more tr1\u2019s , if most of the placing has been taken up by pi\u2019s then there will be flipping. I hope most of it has been taken by institutions.",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.684933+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260903-gtc1507--8062352",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.089223",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Nice \u00a310k buy on the bell just printed!",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.684950+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260837-Troutiso-26234925",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.089724",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "This is just getting us back to the price of a month ago, the placing will have weighed on that during January and now that pressure has been removed we are able to move back to previous levels. Another TR1 would show the market the placing was taken by sticky hands as last year's one was and that will encourage more to jump aboard. I see this back in the high teens soon and then it's all about newsflow to get this into the 20p's.",
          "sentiment": 0.0,
          "engagement": "1,625",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.684968+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260808-rp6577--4359777",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.090219",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Picking up\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "899",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-11T18:55:20.684986+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260752-gtc1507-54869216",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.090732",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "In amongst the noise about the us shutdown which looks to end shortly is this positive news:...NIH getting funding increase of $415m and NCI $128m in this financial year \ud83d\udc40 https://www.science.org/content/article/final-funding-bill-nih-pushes-back-against-trump-cuts",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "NCI budget increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=12E05045-67EF-4EEF-8C99-AC4E30F34994"
        },
        "ingested_at": "2026-02-11T18:55:20.685004+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260748-gtc1507-87262826",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.091246",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Certainly did! Might we see another TR1 today to catalyse the continuation upwards?",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-11T18:55:20.685021+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260653-Laura202--7047534",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.091737",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Well yesterday certainly looked like the start of the breakout",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "14.50",
          "thread_title": "RE: 14p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CD4B32B5-E6AD-408F-8582-61813C7CC50B"
        },
        "ingested_at": "2026-02-11T18:55:20.685039+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262341-Cheapsha-59781233",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.092242",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Penny has dropped well that\u2019s good news After 5p and 10p what comes? 20p then 50p Easy! \ud83d\ude02",
          "sentiment": 0.5,
          "engagement": "2,675",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.685058+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262127-gtc1507--6223331",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.092729",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The penny will start to drop\u2026.crushed a few of the key moving averages today, starting to look very positively setup",
          "sentiment": 0.5,
          "engagement": "1,195",
          "price_at_post": "14.50",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.685075+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261404-Rocka--8769520",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.093234",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "If we get more institutional investor rns\u2019s who taken the fill placing then i think we will be in the twenties pre contract news",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.685093+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261358-Rocka-46747870",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.093725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Dark, never said i was selling 100%. I was frustrated with lack of news. I was considering wether to topup and i have topped up only \u00a35k not the full \u00a310k , i used the other \u00a35k to topup some bitcoin",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.685129+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261314-Laura202-18209192",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.094204",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Excellent news",
          "sentiment": 0.0,
          "engagement": "15,551",
          "price_at_post": "14.00",
          "thread_title": "Institutions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=80932BC0-29D6-499F-82C1-ABEFC7DCE7F1"
        },
        "ingested_at": "2026-02-11T18:55:20.685148+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261305-Darkryde-81898480",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.094697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocka, thought you were selling and moving on to pastures new? \ud83e\udd14 \ud83d\udea7\ud83d\udfe2",
          "sentiment": 0.5,
          "engagement": "554",
          "price_at_post": "14.00",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.685166+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261228-gtc1507--4929376",
        "event_type": "social_post",
        "date": "2026-02-06T23:53:04.095205",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Should be very attractive here, cash derisked all the other positives in play",
          "sentiment": 0.0,
          "engagement": "1,195",
          "price_at_post": "13.75",
          "thread_title": "RE: Holdings increase",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0F4E2468-459E-4CFA-A6AB-13C160721638"
        },
        "ingested_at": "2026-02-11T18:55:20.685185+00:00"
      },
      {
        "event_id": "SOCIAL-Today2232-mmhater-56417432",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472383",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Sorry guys i sound like Sti!! Just a little frustrated and disappointed at the moment",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "RE: This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-02-11T18:55:20.685202+00:00"
      },
      {
        "event_id": "SOCIAL-Today2230-mmhater--6732233",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.472835",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023. Why can\u2019t fusion even make a couple of million!!!! Thought we were best in world!!",
          "sentiment": 0.0,
          "engagement": "659",
          "price_at_post": "13.50",
          "thread_title": "This is my point!!! 253 billion",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=A5B4FEEE-3ABF-480D-B0B9-A2DC7AFAD054"
        },
        "ingested_at": "2026-02-11T18:55:20.685220+00:00"
      },
      {
        "event_id": "SOCIAL-Today2116-chrishut-88642055",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473268",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Don\u2019t miss the opportunity to get some stock before the big news comes.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685238+00:00"
      },
      {
        "event_id": "SOCIAL-Today2008-stt1-85731818",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.473705",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc \"Once we start to see those contracts \" Another month gone. Nearly 2 months gone since Optimal Launch, where are all these millions of pounds of contracts that were ready and waiting and were supposed to announced when Optimal Launched?? There you go, exactly as expected, newsflow continues as expected.",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685256+00:00"
      },
      {
        "event_id": "SOCIAL-Today1342-gtc1507-81914297",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474138",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Indeed - the fact that they said it\u2019s of sufficient scale to warrant NIH approval over NCI is encouraging. I think that they might be able to pull off some significant down stream entitlements like royalties and milestone payments if/when NCI licence those assets out to biotech/pharma.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685274+00:00"
      },
      {
        "event_id": "SOCIAL-Today1335-David195-25496207",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474551",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "The big unknown factor is the continuation with NCI and if renewed what the contract value will be.  It could be a few million $ pa.",
          "sentiment": 0.0,
          "engagement": "875",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685292+00:00"
      },
      {
        "event_id": "SOCIAL-Today1324-Laura202-83678703",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.474965",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "I added at 13.5p this morning Good afternoon",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.50",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685310+00:00"
      },
      {
        "event_id": "SOCIAL-Today1254-chrishut--8655189",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475395",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "It has to go up, and up and up. Just patience needed and we will be laughing",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685327+00:00"
      },
      {
        "event_id": "SOCIAL-Today1227-gtc1507--6533887",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.475809",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "It feels like everyone is holding back on forecasting the unknown of what the optimal contribution may be. Once we start to see those contracts and how quickly they come in once the first adopters take it on I suspect we\u2019ll see quick revisions upwards.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685345+00:00"
      },
      {
        "event_id": "SOCIAL-Today1223-rp6577--6876078",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476238",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "The Allenby note is much better than Shard\u2019s, with more forward looking comments.  My only niggle is that I felt the 2027 revenue estimate was a little underwhelming. Hopefully that is a prudent number and that Optimal contribution could kick into gear with the increased BD. Also I presume that it doesn\u2019t factor in any payment that could arise under the NCI agreement (or any other potential agreements for that matter). I would have liked to have seen break even early than 2028 but perhaps that is reflective of them investing more in spending now to get the revenue growth.",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.375",
          "thread_title": "RE: Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685362+00:00"
      },
      {
        "event_id": "SOCIAL-Today1120-chrishut--6782326",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.476643",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nice",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.375",
          "thread_title": "Multiple broker notes Fab = Undervalued!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=DE4A24DC-2441-48AF-B7E2-B477F410F0A5"
        },
        "ingested_at": "2026-02-11T18:55:20.685380+00:00"
      },
      {
        "event_id": "SOCIAL-Today1053-gtc1507-79796181",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477058",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://x.com/hybridanllp/status/2017171235352781200?s=46",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.375",
          "thread_title": "RE: Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-02-11T18:55:20.685398+00:00"
      },
      {
        "event_id": "SOCIAL-Today0947-gtc1507--2686935",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477484",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "good coverage here too https://*********************/research/hybridan/friday-take-away-30-january-2026/14_922a0adc-24fc-4af3-83ed-fa76e67f06e7",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Hybridian Friday takeaway",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=4EED8C4B-035B-44AF-AD2F-D1F604EEDCE6"
        },
        "ingested_at": "2026-02-11T18:55:20.685416+00:00"
      },
      {
        "event_id": "SOCIAL-Today0921-gtc1507-53997557",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.477919",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Some very interesting insight in here: At least 400k going into new kit to optimise optimal. Plus infrastructure IT upgrades - think this was the website upgrade Adrian mentioned before. Also new BD executives in USA and Asia planned. Allenby holding firm on the growth forecasts for h2 so should be fairly nailed on for that. Optimal pricing interesting insight there too with indications that projects could start around 200k but generate value up to \u00a32m each if they take the whole service. Indication that clients are already considering this. Talk of aiming to return base revenues to \u00a34m and that the new platforms could match and exceed that so over \u00a38m revenues aimed for medium term. Very exciting and interesting note",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-02-11T18:55:20.685434+00:00"
      },
      {
        "event_id": "SOCIAL-Today0828-gtc1507-70042005",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478348",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2026/01/20260130-Allenby-Capital-Fusion-Antibodies-plc-FAB.L-Update-1.pdf?c5187=on&_gl=1 *6ojkea*_ga*MTUzMjEwNjY0MC4xNzY5NTAxODU0*_ga_MZVZ4CNQ86*czE3Njk3NjEzMzYkbzExJGcxJHQxNzY5NzYxMzM5JGo1NyRsMCRoMA..",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Allenby note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=6F9746CF-2527-479B-B135-BFC05FF3D4D9"
        },
        "ingested_at": "2026-02-11T18:55:20.685451+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-gtc1507-13912051",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.478764",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Https://apnews.com/live/donald-trump-news-updates-1-29-2026 Looking positive",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.50",
          "thread_title": "Shutdown looks to be avoided! Roll on NCI",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=3F614C0C-E9AC-4A45-8698-61C9AD6D520E"
        },
        "ingested_at": "2026-02-11T18:55:20.685469+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262124-Troutiso-46486220",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "31% up with a close of 13.25p , would suggest a price a year ago just north of 10p. It actually closed on 29th Jan at 8.75p and at 8.1p on the 30th Jan, so depending on where you would like the 12 months to start, either over 50% or for the 365 day version just over 60%. But that's nit-picking, it is up substantially on a year ago!",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-11T18:55:20.685487+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262123-gtc1507-49643696",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.479606",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Guess depends what day shard wrote the note!",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-11T18:55:20.685505+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262052-Surfie19--7290372",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480016",
        "source": "LSE_CHAT",
        "data": {
          "author": "Surfie1961",
          "content": "\"But the momentum is building with the share price up nearly 60% over the last 12 months\". Er.... NO Ithink you will find it more like 31%.",
          "sentiment": 0.0,
          "engagement": "2,062",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-11T18:55:20.685523+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261951-stt1--3768054",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480486",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Gtc, \"The raise matters\" A lot of hindsight views. After months of claiming they don't need to raise money, they have cash runway into 2027 etc etc, you're now agreeing with me that they DID needed a raise. Great to see you've changed your opinion and agree with me. Read and understand the company/sector newsflow. Your posts: https://www.lse.co.uk/profiles/gtc1507/?page=4 My post 9th Dec, 22.46 to Vikr: \"I believe they will use this higher sp to raise cash, as they need it to fund their project plans.\" https://www.lse.co.uk/profiles/stt1/?page=3 That's exactly what they have done. The company newsflow continues as expected. The rest of your posts are all ifs, coulds, buts and potential, which isn't surprising given you've been here years and holding since the sp was over 100p and so need investors to buy in..",
          "sentiment": 0.0,
          "engagement": "4,530",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-11T18:55:20.685540+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261910-gtc1507--7041174",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.480915",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Sorry thought I\u2019d copied it in: https://shardcapital.com/capital-markets/corporate-broking/research-portal/ Top note or filter for fab",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-11T18:55:20.685558+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261906-rp6577--8261549",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481335",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Are you able to share a link? Whenever I read their notes I always wish they would stick their neck out and state what they consider a fair market value of the company would be in their opinion",
          "sentiment": 0.0,
          "engagement": "897",
          "price_at_post": "13.25",
          "thread_title": "RE: Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-11T18:55:20.685576+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261607-gtc1507--5733516",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.481756",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Investment case. In our assessment, Fusion is significantly undervalued relative to its peers. Its current market capitalisation of \u00a314m does not adequately reflect the investments made or the underlying technology. We believe the market has yet to fully recognise the ongoing recovery in sales and order book, as well as the potential of Fusion's novel proprietary platforms (OptiMAL\u00ae, OptiPhage\u2122, and AI/ML-Ab\u2122). But the momentum is building with the share price up nearly 60% over the last 12 months.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Shard research note out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=53299DEC-7F61-499B-91EC-0DA5608108CF"
        },
        "ingested_at": "2026-02-11T18:55:20.685594+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261443-Laura202--3946246",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Be nice also if one person here would end their 14mth disruption of another share after your previous gracious plea fell on deaf ears 2mths ago Is that wishful thiking ?...who knows FAB hopefully rewards all concerned Best wishes all",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685612+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261440-druml-23831226",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:45.482597",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Be rude not to buy some more. Been in for the penny looking for the \u00a3\u00a3\u00a3",
          "sentiment": 0.5,
          "engagement": "25",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685629+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261438-Laura202-78819062",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Chris I have taken that view also , it was clear with the drop in revenues H1 and slightly delayed launch they MAY needed funds for growth... I have bought today at 13.3p a few lots",
          "sentiment": 0.0,
          "engagement": "15,394",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685647+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261335-gtc1507--4910457",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.497848",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I expect we\u2019ll see a few tr1s for existing vc or II taking more as well as potentially new investors as indicated in the rns",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-11T18:55:20.685665+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261315-Troutiso-10310261",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Well there are 68k of buys in the sell column and a delayed buy just under 100k going through, so buying well outweighs sells here, the price is climbing within the quoted spread and I see another tick or two this afternoon if this continues. Realisation will come tomorrow (with the issue of placing shares) and next week, if the placing shares have gone to sticky IIs as the last did, then people will jump on board from the sidelines",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-11T18:55:20.685683+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261306-livinhop-53253899",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.498703",
        "source": "LSE_CHAT",
        "data": {
          "author": "livinhope",
          "content": "Excellent gtc, thank you!",
          "sentiment": 0.0,
          "engagement": "1,095",
          "price_at_post": "13.25",
          "thread_title": "RE: Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-11T18:55:20.685701+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261303-gtc1507-53456167",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499226",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My reflections post raise\u2026..FAB now appears to be entering a very different phase with the launch of its world-first OptiMAL platform. 1) The raise matters \u2014 and it was done from strength The placing was completed at 13p with no discount to the prior bid. That\u2019s unusual on AIM. It removes near-term funding risk just as the company moves into commercial execution, allowing Fusion to accelerate growth rather than constrain it through cost control. 2) What OptiMAL is \u2014 and why it matters OptiMAL is a new antibody discovery platform designed to find brand-new, fully human antibodies faster and with lower risk. Management describes it as first- and best-in-class, targeting the most valuable part of the drug pipeline: discovery. Discovery work is higher margin than Fusion\u2019s traditional services and keeps clients engaged for longer. Crucially, they have updated that multiple clients are already engaging under NDA to discuss OptiMAL. Clients won\u2019t engage like this unless they are serious discussions. These are premium, additive services that materially improve earnings quality. 3) Validation, commercialisation \u2014 and IP protection OptiMAL has been validated by the US National Cancer Institute, delivering single-digit nanomolar hits directly from screening. NCI now wants to move to a commercial agreement to use OptiMAL across multiple targets and years. Fusion has said the proposed deal is large enough to require NIH approval \u2014 a powerful external endorsement. This may take time to get through but it is powerful none the less at this stage. The platform is also patent-protected, with US coverage secured and further decisions pending in Europe, China, and Japan. Strong IP underpins pricing power, licensing potential, and long-term strategic value. 4) Growth was already forecast before the raise Brokers were already modelling strong H2 growth (often cited around ~80% vs H1) and ~\u00a33m revenues by FY27 before the placing. The raise de-risks delivery and broker forecasts still exclude any OptiMAL contribution. 5) Cash burn is supported, not stressed Fusion also benefits from \u00a31m of non-dilutive Future Medicines Institute funding over five years, plus shared capital equipment \u2014 lowering burn while supporting scale-up. They also have the \u00a3545k Dr5 grant. Potential near-term catalysts: \u2022 OptiMAL NDAs converting to contracts \u2022 updates on Progress on an NIH-approved NCI deal \u2022 potentially Patent decisions in major jurisdictions \u2022 Outcome of the OptiPhage licence evaluation \u2022 Hiring momentum as the company scales \u2022 A potentially strong FY26 trading update This is Not advice. DYOR \u2014 but IMO this is the clearest setup Fusion has had in years: funded, validated, IP-protected, and launching higher-margin services.",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "Reflections post raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=CBD294A3-4057-4765-8EE7-71F16206C813"
        },
        "ingested_at": "2026-02-11T18:55:20.685719+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261107-chrishut-82204643",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.499637",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,392",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685737+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261057-gtc1507-50817840",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500057",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685754+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261042-Troutiso-17888071",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500475",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685772+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261035-Troutiso--3347303",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.500895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685790+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261033-Gheko--5764321",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-02-11T18:55:20.685807+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261012-Rocka-17489842",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.501728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685825+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260846-Troutiso--1217886",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.685843+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260842-Troutiso-53913012",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,592",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.685862+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260824-gtc1507--7041303",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.502979",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.685879+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260820-gtc1507--4745250",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503409",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.685897+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260811-Rocka-13296815",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.503813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.685915+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Seancadm-34373805",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.685933+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260758-Darkryde-10678014",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.504671",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.685951+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260754-gtc1507-41042875",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505088",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,171",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.685968+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260745-Saintsmi--3565243",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505507",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.685986+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260709-Darkryde-90573438",
        "event_type": "social_post",
        "date": "2026-01-30T23:46:48.505917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686004+00:00"
      },
      {
        "event_id": "SOCIAL-Today1107-chrishut-82204643",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.749919",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Buying post placing is nearly always a safe bet, whether bringing average down, adding or simply starting a position.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686022+00:00"
      },
      {
        "event_id": "SOCIAL-Today1057-gtc1507-50817840",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.750538",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Trout I\u2019m aligned with your thinking. I can\u2019t see there have been any weakness in the trading position for them to be able to get that raise away at that price. Can\u2019t fathom they would release a trading update that says expectations aren\u2019t going to be met at this stage.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686039+00:00"
      },
      {
        "event_id": "SOCIAL-Today1042-Troutiso-17888071",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "They raised the bid, but actual buy price was lower than earlier,  so added another 35k there.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686057+00:00"
      },
      {
        "event_id": "SOCIAL-Today1035-Troutiso--3347303",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.751618",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "The Company have told us that will take months as it will need NIH approval, so how can they do that any quicker? I am looking for confirmation they are on track with market expectations, the tiny discount on the placing suggests there aren't any skeletons in the trading cupboard, but a market update would be good. Contracts wise, I hope to see some OptiMAL business signed in the next couple of months, but also other contracts coming through. I don't see NCI full deal until the Summer.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686075+00:00"
      },
      {
        "event_id": "SOCIAL-Today1033-Gheko--5764321",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gheko",
          "content": "Tiny market cap here for what we have. Only 125 million shares in issue too so the upside is huge when the contracts currently being negotiated land. As we know, when this moves it moves quickly.",
          "sentiment": 0.5,
          "engagement": "1,206",
          "price_at_post": "13.25",
          "thread_title": "Prospects",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=1162A5E3-0FB4-4838-9649-CAE3143F3E4D"
        },
        "ingested_at": "2026-02-11T18:55:20.686093+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-Rocka-17489842",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.752748",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout who knows, anything is possible, if we get a positive rns then yes i will topup. I think the nci deal needs to be concluded asap, that will open doors.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686125+00:00"
      },
      {
        "event_id": "SOCIAL-Today0846-Troutiso--1217886",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753371",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I took 200k in total yesterday at the placing price, I have room for another 100k approx (haven't done the maths). CBeadle I think we share one of those mining stocks and it has done brilliantly since it's own placing at no discount a week ago, I see FAB doing similar once the shares are issued tomorrow and if it proves they are again in sticky hands. An update next week would be particularly helpful if this is the case, fingers XXD",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686143+00:00"
      },
      {
        "event_id": "SOCIAL-Today0842-Troutiso-53913012",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.753974",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, As I said the other day you don't seem to have the patience to be invested in medical stocks, whether they are developing drugs or medical equipment/platforms. It takes years and years and is full of cautious people who really take their time before committing to a contract. Then we have the fact we are coming off one of the worse times for Pharma/Biotech and therefore CROs, after Trump's policies have upended their World, so have a bit more patience or move on. I probably see you buying your \u00a310k's worth next week when it is freed up and then you start singing a different tune.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686162+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-gtc1507--7041303",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.754578",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Don\u2019t disagree with either rocka or MM - the proof will be in the pudding but can\u2019t lie that having a strong cash position will be a good thing for due diligence. Allenby note in October last year actually called that out on look back saying that their low balance back them could impact their ability to secure bigger contracts due to due diligence. That problem is gone now. It\u2019s all in the execution now - this is there moment and chance and I agree if we\u2019re sitting here in 12 months and in the same position they\u2019ve not got something that people want",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686180+00:00"
      },
      {
        "event_id": "SOCIAL-Today0820-gtc1507--4745250",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755194",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "They were given that. But they\u2019ve clearly said in the RNS they want to purchase additional kit to optimise optimal. The FMI is available to them for 5 years and may not be bespoke for Optimals needs so can see a strong justification for investing here if it strengthens their proposition.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686198+00:00"
      },
      {
        "event_id": "SOCIAL-Today0811-Rocka-13296815",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.755779",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Mmhater, i agree 100% most here want to sugarcoat the RNS and will  become very defensive when you say things like this. If it\u2019s the best in the industry then deals will come in, yes we all know it takes time bu it doesn\u2019t seem like companies are queuing up for optimal. I will give it more time but if there isn\u2019t any signs of developments and its just jam tomorrow i will be gone.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686215+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Seancadm-34373805",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "This is AIM, you raise when you have leverage not when you\u2019re desperate, if they had just raised \u00a30.5 they would have been criticised for raising again in a few months if deal money took extra time to get through bureaucracy. They now have a buffer which will strengthen their position in negotiations. Judging by the price of the raise they could probably have raised more but which is a great position for an AIM company to be in.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686233+00:00"
      },
      {
        "event_id": "SOCIAL-Today0758-Darkryde-10678014",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.756980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "I understood they were given free used of all the best equipment in the world along with the grant, plus 20 graduate scientists?",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "12.75",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686251+00:00"
      },
      {
        "event_id": "SOCIAL-Today0754-gtc1507-41042875",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.757590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I guess it depends on the size of the capital machinery investment they have stated they are making with the raise to improve the Optima platform. Would be good to see the balance of that versus working capital for commercialisation",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686269+00:00"
      },
      {
        "event_id": "SOCIAL-Today0745-Saintsmi--3565243",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saintsmith",
          "content": "Very good question and I am in a similar position with the same thoughts .",
          "sentiment": 0.0,
          "engagement": "2,137",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686287+00:00"
      },
      {
        "event_id": "SOCIAL-Today0709-Darkryde-90573438",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.758776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Fair observation  & comment, but I\u2019m very confident the SP will be much, much higher this time next year ! \ud83d\ude03\ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "551",
          "price_at_post": "13.125",
          "thread_title": "RE: Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686305+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262241-mmhater-90439210",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759247",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "So i\u2019ve been a big investor of FAB for the past year and am well in profit. I currently own over 1.3 million shares but this latest placement has left me sat on the fence\u2026.. I\u2019m a little fed up of the company telling us they are financially stable till time X but still keep raising money\u2026 The latest raise for 1.4 million is at a great price but i wonder if 1.4m was necessary? If deals are incoming surely  0.5m would have done\u2026.. My next thought is if the industry is worth so may billion a year why are we struggling to get a million pound of deals? surely we should be getting at least 5 percent of the market if we are best in the field. I\u2019m starting to lose faith Adrian\u2026. nearly put another 10k in here but your latest actions have made me dubious.",
          "sentiment": 0.0,
          "engagement": "656",
          "price_at_post": "13.125",
          "thread_title": "Not sure what to think..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=0A90EB91-ECD3-4FAA-9671-D66D04D50B83"
        },
        "ingested_at": "2026-02-11T18:55:20.686322+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262110-cbeadle--5929515",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.759663",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "I would do , but FAB my largest holding and I am very into mining stocks which are generally doing well.",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.125",
          "thread_title": "Buy More?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=9B999AB7-3C0D-4F49-942F-FD2729833E45"
        },
        "ingested_at": "2026-02-11T18:55:20.686340+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262033-gtc1507--7331917",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760077",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "That\u2019s some conviction Chris good to see. Hopefully a floor here. Looking forward to seeing the tr1s to see which institutions came in",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686359+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261838-chrishut-16662475",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.760509",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I took 175k today and still had orders in, that didn\u2019t fill.",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686377+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261805-gtc1507--3263859",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761183",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "ORDEEERRRR",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686395+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261744-Troutiso-67933445",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.761880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "I count at least 200k of buys been put in the sell column,  150k were mine and the other looks to be a 50k buy just as the offer rose this morning. So the buys have it, the buys have it...",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686413+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261540-Troutiso--6951606",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.762581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Just sniped another 50k at the placing price",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686431+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261342-chrishut-40748960",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763155",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "I added quite a few more today too, it is a no brainer now, cashed up and contracts likely to be a lot more frequent",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686449+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261341-chrishut--3033308",
        "event_type": "social_post",
        "date": "2026-01-29T12:04:56.763701",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Nicely played trout",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686467+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261209-Troutiso-30091032",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.516994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "There seems to be a few PI sellers, getting out at below the placing price. I think these may be short term investors looking at other grass is greener stocks. I have used the opportunity to add at the placing price for the moment, I believe that the shares will have gone to long term investors and as such think that in a few days this realisation will be apparent and others will start to add again. Looks like a few delayed 50k buys coming through now. MMs are playing around with this, but not enough conviction from buyers to get this moving upwards, hopefully start to see something next week, would be good now they have got this out of the way to get an update from the Company.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.125",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686484+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261037-gtc1507--3363303",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.517590",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Positive mention in a research note yesterday on SP angel, healthcare conditions note/ https://www.spangel.co.uk/research/",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "12.875",
          "thread_title": "Research note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=574BB89D-C932-496A-80A3-2E9C64DACF5C"
        },
        "ingested_at": "2026-02-11T18:55:20.686502+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-Troutiso-48166118",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Yes me too, limits down to 10k now, well on the way to filling the headroom back up to 2.99%",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "12.875",
          "thread_title": "RE: I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686520+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260930-chrishut--4188030",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.518658",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "Took another 75k",
          "sentiment": 0.0,
          "engagement": "17,389",
          "price_at_post": "13.00",
          "thread_title": "I bought some",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=21953BB8-F50D-4DB3-A452-849654AD314A"
        },
        "ingested_at": "2026-02-11T18:55:20.686538+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260733-Eurobuil--3729978",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Eurobuild1",
          "content": "Don\u2019t come gloating on here , keep your opinions to yourself if your giving it the big told you so",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "13.25",
          "thread_title": "RE: Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-02-11T18:55:20.686556+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262144-stt1--5062241",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.519750",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "From the placing rns: \"The net proceeds of the fundraise, being approximately \u00a31.3m, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL platform, to invest in the company's commercial activities and for general working capital purposes.\" https://www.insidermedia.com/news/ireland/fusion-antibodies-raises-1.4m-to-drive-growth-plans From the grant rns, which they received less than a year ago: \"The Grant support to Fusion is to cover human resource needs, materials/consumables costs and overheads.\" https://www.londonstockexchange.com/news-article/FAB/approval-of-grant-funding/17002681 That suggests to me they have utilised all of the grant money to date and so needed more.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "Placing, Grant money",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F36A9486-274F-4828-9080-7C8E74C0C8D8"
        },
        "ingested_at": "2026-02-11T18:55:20.686574+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262128-stt1--1822188",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520299",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Well done Alice for predicting a placing. I see you got a lot of abuse. I wouldn't wait for an apology from these clueless rampers.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: If Fusion places 100M share",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=BCF5D778-E9D7-439C-990A-6D28AB648781"
        },
        "ingested_at": "2026-02-11T18:55:20.686592+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262117-stt1-41406439",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.520864",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Humpalumps \"Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually\" Oh dear, can't handle the truth. My 1st post on FAB was a year ago, Jan 2025, after HVO pump and dumpers moved across to here. HVO crashed from c30p to c5p today on company newsflow, red flags I'd been warning about. https://www.lse.co.uk/profiles/stt1/?page=16 I can understand your frustration at being completely wrong and loading up c30p.. my posting history is there for all to see your lies about my posts... There's always one who's totally stupidity and incapable of reading the company newsflow. This from your post just a month ago....22nd Dec 13.51 \"They have a cash runway til FY27 which as has been confirmed on the investor hub didn't include NCI in the calculation so they're fine for cash\" https://www.lse.co.uk/profiles/humpalumps/ You need to read and understand company newsflow as it'll help you stop making those stupid mistakes.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-11T18:55:20.686610+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261929-Humpalum--6139885",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Jokes \ud83e\udd23 are we actually being lectured by the guy who told everyone to buy TLY that went bust while simultaneously warning people off FAB at circa 4p \ud83e\udd23\ud83e\udd23 Also STT when you call a placing every few weeks for about 2 years you will get lucky eventually And finally this placing isn't a bad thing it sets a floor at the current price, was at 0 discount and will probably be last one this company will ever need Also I won't be replying to any of the crap you respond with because you're a terrible investor for point 1 in this comment \ud83c\udf1d",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-11T18:55:20.686627+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261816-stt1--9045638",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.521921",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Antha, I'm glad I traded these and not held on, like you, at 30p.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Ha ha ha. sti sold a couple days ago",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=16F2F8FD-FC78-4AF1-834F-BFF85ACDD8C8"
        },
        "ingested_at": "2026-02-11T18:55:20.686645+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261804-stt1--8494246",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.522484",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "Rocka, \"Sti so is now almost 20p , you are making yourself look very silly.\" I see there's a placing. Who's making themselves look very silly. I traded or you who was ramping at 20-30p. You should learn to read and understand company newsflow. The sp has fallen back exactly as predicted. Where's the clueless Humpalumps? he needs to learn and understand company newsflow. He was clueless as well, ramping these at 30p!!!",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=5A385447-3F72-4CC8-805B-D746C297983E"
        },
        "ingested_at": "2026-02-11T18:55:20.686663+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261757-stt1-40019756",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523018",
        "source": "LSE_CHAT",
        "data": {
          "author": "stt1",
          "content": "There you go, exactly as predicted. Placing. Who was gullible enough to believe the clueless rampers!!!! Back to the same sp as before the previous pump/dump. Newsflow was exactly as expected.",
          "sentiment": 0.0,
          "engagement": "4,527",
          "price_at_post": "13.25",
          "thread_title": "RE: Cash is low, so placing likely",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=56D85761-47EE-47AB-BE35-44485A6673DC"
        },
        "ingested_at": "2026-02-11T18:55:20.686681+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261308-gtc1507-54654999",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.523551",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Yes you\u2019re right! Sorry thought you were talking about smaller optimal screens. But yes the sliced bread analogy was a good one. We\u2019re already seeing the ITAS approach being mention in the RNS which is good. That last big pharma one Was referred to as an ITAS one so hopefully means we can retain them for more business",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686699+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261258-Troutiso-10418927",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524059",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Gtc, You are talking about full screens and AK did state that some companies may want smaller more focussed screens (if they had already developed some targets), He also stated that a full ITAS contract would be over \u00a31m, but some might want to take a more modular approach and contract to do some phases of the ITAS with FAB and that those companies will choose how many phases they would want to do with Fusion. These would likely not be RNSed due to their smaller size, piecemeal approach.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686717+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261248-Rocka--5030541",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.524572",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Actually i said if there isn\u2019t any news, there has been today! Today\u2019s RNS isn\u2019t great but it\u2019s not bad news that will see the sp tank 50% as i\u2019ve been in such stocks.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686735+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261238-Troutiso-86999657",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Literally 23 hours ago you posted that if no news soon you would consider selling up.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686753+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261222-Rocka-42819124",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.525589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Trout, not a gambler at all. I\u2019ve been here for quite some time . I still believe in the longterm future here but the proof is in the pudding and this is what we will find out in the coming months( hopefully) Not planning on selling just considering whether i should buy more to bring my average down.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686771+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261215-gtc1507-49122330",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526095",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "This is a good assessment, although, just to correct one piece. Adrian was clear they wouldn\u2019t get smaller contracts at the start as Optimal was designed to do full large scale screens. He said they may structure the deals differently to begin so that some of the client risk is reduced, potentially by reducing up fronts but including  success based milestone payments I.e when the screen delivers what fusion know it should then fritter payments will trigger. Slightly nuanced but still the overall value shouldn\u2019t change and the scale of the challenges will still be big but the point on the journey that fusion and the client risk profile is set and payments set may be adjusted to begin to incentivise early adopters. Adrian also said this will only be available for a limited period.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686789+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261209-Troutiso-51574192",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.526590",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Realistic timeframes, valuations, etc.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686807+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261208-Troutiso--7231719",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Rocka, Can I suggest having read back through your recent posts, that you are waving in the wind and seem to be very short term/big demands type of gambler. An investor wouldn't change their mind in a matter of days, unless there is a material change. You have been bemoaning news and after your post yesterday I nearly replied be careful what you wish for as a placing had entered my mind here. This is a medical CRO and they work in a field which takes a long time to get anyone to sign anything, rigorous checking and re-checking of the science, followed by rigorous checking and re-checking of the product before anyone is prepared to commit, it takes time. However, FAB has now launched OptiMAL and that is being assessed by prospective clients, this will take time but has been ongoing for some time. The Company have stated they are likely to get smaller OptiMAL use contracts to start, before some clients may come back for the chunkier full development contracts. That is the way of this particular industry. So whether or not you spend another \u00a310k here or you sell up or you spend \u00a310k elsewhere, my advice to you is to develop some patience (and that sometimes is very long term patience), while you are sitting there holding one company, others always look like they are doing better, but in reality that is not the case most of the time. Good Luck with whatever you do, but remember PIs and those on these BBs will always be ahead of reality, as they want short term gratification, when it always takes longer, costs more and can fail, invest and be patient and look at",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686825+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-Humpalum--8516582",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527465",
        "source": "LSE_CHAT",
        "data": {
          "author": "Humpalumps",
          "content": "Personally I think there is a strong chance this will be the last placing this company ever needs - I can't really see a world where this company isn't profitable in the next 12-16 months which would be the kind of timeframe this money would last them without profitability",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686842+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261200-evman27--8260801",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.527915",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "It's always frustrating to see a placing happen but I believe this will be the last one fusion ever has. Back when the company was struggling they raised at 80% discount, the raise last year and today was at no discount, that counts for something. As many have said it puts us in a strong negotiating position, hard to get good deals when everyone knows your cash situation is tight. Since the raise last year the company has moved leaps and bounds, raised at 6.75p and SP hit 20p not long after, I suspect we will see similar here, we should be entering a news rich period too having commercially released Optimal. It is clear there is a lot of background interest in Fusion and Optimal, at least the buyout offer when it comes won't reflect a struggling company, it puts us in a stronger position to refuse a cheap offer. I'm still happy with my money here and have been since September 2024, the value on show here today is immense.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686860+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261144-Rocka--5615040",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.528425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I have \u00a310k funds clearing next week, i\u2019m tempted , i\u2019ll have to think about whether i\u2019ll buy more. Let\u2019s  just hope we start generating some serious income without needing to resort to more placings.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686878+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261139-Rocka--1156794",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Not the RNS i was expecting, also i don\u2019t believe the BOD should get any bonuses until the company is generating a profit but hey ho it is what it is. Let\u2019s just hope we see some contracts and/or news on NCI. We need a catalyst to propel the sp.",
          "sentiment": 0.0,
          "engagement": "188",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686895+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261115-gtc1507--1008606",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:01.529652",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Shares admitted on Friday 30th, suspect we\u2019ll see tr1s shortly after - be interesting to see who went for it",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686913+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260941-druml--4084287",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.278271",
        "source": "LSE_CHAT",
        "data": {
          "author": "druml",
          "content": "Prudent decision by the board. Give the headroom for getting the deals in. Good to see director support.",
          "sentiment": 0.5,
          "engagement": "24",
          "price_at_post": "13.375",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.686931+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260940-gtc1507--7572107",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279131",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "What does \u201cinvest in strategic partnerships\u201d mean do we think? \u201cThe successful validation and formal launch of our OptiMAL\u00ae platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time. \"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders.\"",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-11T18:55:20.686948+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260934-gtc1507--3819374",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.279952",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Agree - I took comfort there was no indication in the rns about weakness in the trading position also which I assume means they remain on track to achieve the 80% growth in h2. This was strong from the launch conference \u201c Fusion's attendance at the conference generated significant interest in both the OptiMAL\u00ae platform and the Company as well as provided further encouragement that the OptiMAL\u00ae platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time\u201d.",
          "sentiment": 0.5,
          "engagement": "1,159",
          "price_at_post": "13.375",
          "thread_title": "RE: Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-11T18:55:20.686966+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260930-Cheapsha-21823827",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.280743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "After the raise and director shares the share count is bang on 125M share still very low. The bonus shares also issued at 13p. Market cap just under \u00a317M with this issue. To get to 50M cap we need about 40p share price very reasonable- actually that would still be cheap very cheap. But we do need some contracts signed should be here soon!",
          "sentiment": 0.5,
          "engagement": "2,671",
          "price_at_post": "13.375",
          "thread_title": "Share count",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=2898AE02-AE63-4E67-BFAA-E47EF4BB30D9"
        },
        "ingested_at": "2026-02-11T18:55:20.686983+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-Bibzy7-35757381",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.281547",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bibzy7",
          "content": "Is this just the last chance for the ones in the know to get the cheap shares before this goes crazy Half full maybe outlook",
          "sentiment": 0.0,
          "engagement": "321",
          "price_at_post": "13.50",
          "thread_title": "Cheap",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=34F59233-C112-41AC-AA13-18CE6878B383"
        },
        "ingested_at": "2026-02-11T18:55:20.687001+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260842-David195--2292121",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.282359",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "This is no surprise and positions FAB to move forward more quickly.  Potential customers need to be reassured the company is in good shape financially when due diligence is carried out.  A raise at current SP is excellent in current market conditions.  The discussions with NCI are crucial and FAB are able to conduct them from a stronger position. Getting the first contracts and renewing the agreement with NCI in the coming months is now more likely.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687019+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260824-Troutiso--1072007",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283156",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Both the bid and offer price rising within the wide quoted spread. I have a little more headroom to fill now, so have started with 50k.",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687037+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260815-gtc1507--1736603",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.283886",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "The said they had runway to FY27 which is April. Good they have topped up the cash balance. Should help with due diligence for contracts. Buried line in the rns: \u201cMany of the organizations approached in the pre-launch phase have expressed an interest in the OptiMAL\u00ae platform including disclosure of target details under non-disclosure agreements\u201c Companies willing to share their target data with fusion is strong endorsement for their capability and expertise . This provides a very strong foundation to move forward in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.25",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687054+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Aldebara-76720361",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.284672",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Barely any discount. Seems ok to me",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687072+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260759-Troutiso--8155508",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.285377",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troutisout1",
          "content": "Had a feeling this was coming, very quiet, lack of real trading and the timing were all tell tales, as was the tight lipped rumours. Last week SML another I have a large holding in (and seems to have been mirroring FAB prices albeit at a tenth of FAB) did a placing at 1.3p for \u00a34m they too have lots going on and are using the funds to accelerate drilling towards an earlier PFS. That was at 1.3p at no discount. The market although PIs were telling each other it had enough money has responded very positively and it closed yesterday at 1.9p. I felt it was possible that FAB would do the same and am pleased they have done so, this will accelerate OptiMAL rollout and was probably needed for some of the bigger new clients to sign any deal (they will not want to have contracts with companies who don't have a robust financial situation. I think the company have explained themselves well and don't see this as negative, if, and a big if, the shares have gone to long term IIs as the last one did. I have no reason to believe it hasn't as if this was a vulture driven firesale placing the SP would have been hammered and there would have been a 30%+ discount. I believe this is more to do with large investors wanting to add more, but not wanting to buy in the market and happy to do so in a placing at no or little discount. Overall happy with this and if the market reacts like it did last time we will soon be up at recent highs. This is nearly double the price they raised at last year, that is a sign of good progress!!! Stan it was 13.4p to buy yesterday so below mid anyway....",
          "sentiment": 0.0,
          "engagement": "1,588",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687090+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260751-Seancadm-26304458",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "They had stated they had cash runway into \u201827 (financial year 27, which is from April \u201826 ). So in order to avoid a raise they would have needed contracts to drop in the next month and even then they couldn\u2019t have been certain to have money in the bank by then. So they are now fully funded, with, from the details in the RNS strong indications of OptiMal take up. This is good for the company putting a strong cash foundation under what could well become a company making year!",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687121+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260743-U_time--7166952",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.286990",
        "source": "LSE_CHAT",
        "data": {
          "author": "U_time",
          "content": "Hard not to be negative about this placing. Comes at a time where we thought no placing was needed as the company was good financially and had enough contracts to manage day to day cash without a raise. Strange. Seems to suggest people are q'ing up for the 'best in class'. NCI deal now becomes even more crucial hopefully they can get it over the line otherwise FAB just becomes another one of those AIM companies that wants to keep raising funds on share holders dime until eventually they decide to delist... Hopefully wont come to that but its game time now.",
          "sentiment": 0.0,
          "engagement": "237",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687140+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260727-bannside--2036375",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.287780",
        "source": "LSE_CHAT",
        "data": {
          "author": "bannsider",
          "content": "Tells me there no contracts ready to be signed",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687158+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260725-rp6577--8985564",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.288565",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "Not the RNS I wanted to see. However, at least it is at the market price. Hopefully this now gives them the fire power to accelerate growth and really kick into gear",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687176+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260723-Stan36-48065286",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.289358",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stan36",
          "content": "Cheadle it is discounted from the mid price. And from the ask price ordinary investors would have to pay. So a discount of 3.8 to 7.6% NED participation during contract negotiation with NCI tells us he's not party to the details?",
          "sentiment": 0.0,
          "engagement": "863",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687194+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260710-rubarbru--2162808",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290150",
        "source": "LSE_CHAT",
        "data": {
          "author": "rubarbrubarb",
          "content": "And director involvement",
          "sentiment": 0.0,
          "engagement": "60",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687213+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260708-cbeadle--3354318",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.290933",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Quite encouraging it\u2019s at the market price and not discounted at all",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687231+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260705-cbeadle-34367049",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.291707",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "With the right news 50p to \u00a31 could happen really fast",
          "sentiment": 0.0,
          "engagement": "347",
          "price_at_post": "13.50",
          "thread_title": "RE: FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-02-11T18:55:20.687249+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260703-Laura202-27085542",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.292433",
        "source": "LSE_CHAT",
        "data": {
          "author": "Laura2022",
          "content": "Out",
          "sentiment": 0.0,
          "engagement": "15,342",
          "price_at_post": "13.50",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=F228F2A1-918E-47CD-A368-586C2381B84B"
        },
        "ingested_at": "2026-02-11T18:55:20.687267+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262352-Clachair-56397596",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293116",
        "source": "LSE_CHAT",
        "data": {
          "author": "Clachair10",
          "content": "Hi, I have been in since near the very beginning. I need to see \u00a31/share to get my money back. Not sure that will ever happen? Could have made a killing when they floated but wasn\u2019t able to realise it. May have to bale when and if it hits 50p a share. Have been watching this for so many years waiting for the upside! C.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "FAB",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=01EC424D-4AE5-4621-8E7E-C56E0722156A"
        },
        "ingested_at": "2026-02-11T18:55:20.687285+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262314-rp6577-54696111",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.293774",
        "source": "LSE_CHAT",
        "data": {
          "author": "rp6577",
          "content": "My view is that they have something which is better that what their competitors have. Things can take time to get traction. However, if you are fundamentally better, then it is difficult not to see significant success down the road. Just got to sit tight and if you don\u2019t have your full position yet, add during these quiet times",
          "sentiment": 0.0,
          "engagement": "895",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-11T18:55:20.687303+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20262105-evman27--5943198",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.294509",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Yes I was there too, still holding and have added to my position since then on dips. It's clear Optimal and Fusion are dangerously undervalued and I feel very relaxed with my money here.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-11T18:55:20.687321+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-Seancadm--4257784",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.295238",
        "source": "LSE_CHAT",
        "data": {
          "author": "Seancadman",
          "content": "Anyone who is concerned about any lack of news since the launch (which to be fair was only a few weeks ago) should google how long diligence on a new platform takes, these things take time and there is certainly no need for concern at the moment. The NCI deal is progressing and as GTC says could well be bigger than anticipated due to NIH involvement. I agree though an update on progress so far would go a long way to calming investors.",
          "sentiment": 0.5,
          "engagement": "214",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-11T18:55:20.687343+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261624-NornIron--3920945",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296005",
        "source": "LSE_CHAT",
        "data": {
          "author": "NornIron",
          "content": "Many thanks for that GTC.",
          "sentiment": 0.0,
          "engagement": "458",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-11T18:55:20.687361+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261616-gtc1507-80539441",
        "event_type": "social_post",
        "date": "2026-01-29T12:05:06.296852",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "I\u2019m still here and was at the AGM. They were very positive about the future potential of the Optimal platform and as have said throughout all their engagements , it will take time to convince people to come onboard but they said it had the potential to be transformational for drug discovery. The brokers are predicting growth of 80% in h2 without any optimal contribution. they have historically not published every single contract they win as their view is their clients don\u2019t always enable that and it could be commercially damaging. All I know is we\u2019ve had nothing from the company to indicate anything materially different to their forecasts either up or down and all we can do is wait for news. They were hiring just before Christmas for 3 new roles so they must be confident about prospects given their cautious cash management approach. They have the grants from the FMI to help them balance those. We\u2019re just in that phase at the moment where we need to see the proof in the execution. I take comfort in the fact the NCI deal is of such a scale it requires NIH approval - that sort of deal will turn the heads of big pharma. They already have big pharma on the books as notified by the two rns at the end of summer autumn so they\u2019ll likely be engaging them about the benefits of optimal. We just need to give them time. They confirmed their cash runway into FY27 was not dependent on an NCI deal so they are. If the company are reading this tho I think investors would welcome something of an update though, silence on the hub, silence to emails, nothing on LinkedIn - all very quiet does feel like something may be bubbling behind the scenes in my view.",
          "sentiment": 0.0,
          "engagement": "1,159",
          "price_at_post": "13.50",
          "thread_title": "RE: Rumours?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&share=FAB&thread=D1199700-664B-4FF7-ABFF-23F3D7294FB7"
        },
        "ingested_at": "2026-02-11T18:55:20.687379+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261516-gtc1507--7765618",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721015",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Still sitting 4 v 3 here. The l2 book Hasn\u2019t moved since open strangely despite some chunky buys",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687397+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261512-mmhater-62992210",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721463",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "Has anyone got level 2? i imagine it will be getting stronger all the time. A tick up would be nice to see.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687415+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-chrishut--5916071",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.721890",
        "source": "LSE_CHAT",
        "data": {
          "author": "chrishutch",
          "content": "A couple in the telegram group bought more today Great prices on offer",
          "sentiment": 0.0,
          "engagement": "17,380",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687433+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261215-mmhater-20141866",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722312",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I\u2019ve got far to many already\u2026. This is AIM at the end of the day and you never know when you are going to get screwed over. Expect the unexpected! On that note i don\u2019t expect 50p anytime soon.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687451+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261208-Rocka-33401430",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.722727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Ideally i\u2019d like this at 20p pre news then i think we\u2019ll easily easily hit 40p min short term",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687469+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261207-Rocka-31173921",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723144",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "No ramping intended but if i had \u00a38k now i\u2019d put it all in FAB, topped up last week and expecting \u00a310k early Feb and i\u2019ll put it all in fab. This is a no brainer tbh especially at this price",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687486+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-gtc1507--5533704",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723563",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "My gut says we will hear something next week",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687504+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261159-mmhater--2417503",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.723976",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I did my little bit yesterday\u2026. I do have another 8k i\u2019m tempted to put in but haven\u2019t decided yet\u2026. Time is ticking and i\u2019m expecting news very soon. NCI wanted to carry on using optimal immediately so must need a deal soon??? Are FAB just letting them use it in the interim?? I still think this is getting bought out. Adrian\u2026 give us an update.",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687522+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261138-evman27-46930005",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724413",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "250k is 14.6 Then 260k jumps to 20p!! Float disappearing fast, news will send this crazy, or if someone wants to do the honours now?!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687539+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261059-CHEATED--7597565",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.724821",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "I suggest a new field of research that might be rewarding. The lack of mobility and the balance problems of stroke victims. You may have a winner here.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687557+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262332-cbeadle--6026412",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725238",
        "source": "LSE_CHAT",
        "data": {
          "author": "cbeadle",
          "content": "Something could happen very quickly with FAB",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687575+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261641-Rocka-95013357",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.725648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "Well if it goes that high that quick i\u2019ll be equally happy as i hold quite a few already",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687593+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261637-Darkryde--3479995",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Darkryder",
          "content": "Rocks, I hope and think you\u2019ll only get 16,000 shares with your \u00a310k \ud83d\ude0a",
          "sentiment": 0.5,
          "engagement": "548",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687611+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261512-CHEATED--6410910",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726484",
        "source": "LSE_CHAT",
        "data": {
          "author": "CHEATED",
          "content": "There should be a link-up with a large American antibody firm. Perhaps a partnership would be beneficial. Share price is in the doldrums and needs a boost of some kind. I cannot see the advantage  of the last addition of staff producing anything of great significance. Too many cooks spoil the broth. Try something new.",
          "sentiment": 0.0,
          "engagement": "679",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687629+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261456-Rocka--5595765",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.726897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rocka",
          "content": "I\u2019d put more in to if i had available funds, topped up last week. Expecting \u00a310k early Feb, hopefully i can buy at todays price once funds clear.",
          "sentiment": 0.0,
          "engagement": "180",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687647+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261415-evman27-29159465",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727321",
        "source": "LSE_CHAT",
        "data": {
          "author": "evman27",
          "content": "Nice buys, what a bargain price!",
          "sentiment": 0.0,
          "engagement": "177",
          "price_at_post": "13.50",
          "thread_title": "RE: Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687665+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261405-mmhater--1786864",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.727732",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "My 2 8k trades aren\u2019t showing. been a rise in trades past couple of days and i think this is going to pop soon. News is imminent. NCI have said they want to use optimal immediately so won\u2019t hang around doing deals for long\u2026",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "Going to move soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=FC35AF19-4643-4EA5-8E7B-30FCD286BBCC"
        },
        "ingested_at": "2026-02-11T18:55:20.687682+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261338-mmhater--8080576",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728151",
        "source": "LSE_CHAT",
        "data": {
          "author": "mmhater",
          "content": "I got fed up of being patient so bought another \u00a316000 worth\u2026 Come on Fusion\u2026 give us a update",
          "sentiment": 0.0,
          "engagement": "654",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-11T18:55:20.687700+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261330-Antha--7185978",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Antha",
          "content": "Everyone is just waiting for the NCI contract and other pharma contracts to be signed, until then the sp will just drift up and down between the 12-16p range, just need to be patient.",
          "sentiment": 0.0,
          "engagement": "2,740",
          "price_at_post": "13.50",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-11T18:55:20.687718+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261310-gtc1507--1317126",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.728989",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Seems to be kicking into action again, some decent buys today. Investor relations seem to be answering questions on the hub too. Looks like the shareholder information has been updated too as of a few days ago, no sign of maven any more\u2026.. https://www.fusionantibodies-ir.com/content/investors/shareholder-information.asp",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.50",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-11T18:55:20.687736+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261100-stan1234--6365110",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729412",
        "source": "LSE_CHAT",
        "data": {
          "author": "stan1234",
          "content": "I am going to add today too. Just selling something else first.",
          "sentiment": 0.0,
          "engagement": "208",
          "price_at_post": "13.25",
          "thread_title": "RE: Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-11T18:55:20.687754+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260810-formerly--2794868",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.729827",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "Purchased 10,000 at 13.3 via HL this morning. Wait and See!",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "Added",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=08987DE6-1E9B-4DEF-AE76-C004BFF610BE"
        },
        "ingested_at": "2026-02-11T18:55:20.687772+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261821-formerly--7067938",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730246",
        "source": "LSE_CHAT",
        "data": {
          "author": "formerlyeasyp",
          "content": "I read the comments ref news but saw things slightly differently.  I consider myself a long term holder LTH and thought at market open tomorrow I will buy some more shares in FAB.  A matter of confidence?",
          "sentiment": 0.0,
          "engagement": "1,642",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-11T18:55:20.687790+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261812-gtc1507--2644161",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.730660",
        "source": "LSE_CHAT",
        "data": {
          "author": "gtc1507",
          "content": "Would be good if the company were able to provide a trading update at the end of January to confirm the trajectory of growth. 80% growth expectation is significant. Equally would be lovely to see some traction on optimal or other contracts. January hasn\u2019t historically been an RNS heavy month, however they hadn\u2019t just launched their flagship platform\u2026.",
          "sentiment": 0.5,
          "engagement": "1,143",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-11T18:55:20.687807+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261757-Cheapsha-62985632",
        "event_type": "social_post",
        "date": "2026-01-24T02:20:38.731071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheapsharesboy",
          "content": "Very low volume today Waiting for the news",
          "sentiment": 0.5,
          "engagement": "2,670",
          "price_at_post": "13.25",
          "thread_title": "RE: Time for an update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=FAB&thread=941353FD-E7D7-408B-9A3D-0FA39EF799AB"
        },
        "ingested_at": "2026-02-11T18:55:20.687825+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2025-12-12"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "FAB.L presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_is_real": false
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 71.1,
      "signal": "HIGH_PANIC",
      "interpretation": "\ud83d\udfe0 Fear dominant - watch for reversal signs",
      "breakdown": {
        "price_destruction": 39.1,
        "volume_death": 6,
        "social_silence": 6,
        "news_sentiment": 20
      },
      "is_opportunity": true,
      "opportunity_reason": "\u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 39/40 points",
        "\ud83d\udcf0 Negative news: 20/20 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 488% proven capacity"
      ],
      "verdict": "\ud83c\udfaf CONTRARIAN OPPORTUNITY - Fear dominates but facts support recovery potential"
    },
    "crashhunter_signals": [
      {
        "type": "HIGH_PANIC",
        "icon": "\ud83d\udfe0",
        "text": "Fear 71/100",
        "color": "#f59e0b"
      },
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Total Voting Rights",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Issue of Director Shares",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Placing and Subscription to raise approx \u00a31.4m",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "71/100",
          "pass": true,
          "icon": "\ud83d\udd34"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "49/100",
          "pass": false,
          "icon": "\u26a0\ufe0f"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "1 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "4/5"
    },
    "contrarian_panic": {
      "total_score": 34,
      "band": "\ud83d\udfe2 MILD COMPRESSION (Top 50% - WATCHLIST)",
      "components": {
        "compression": {
          "score": 14,
          "max": 40,
          "signals_30d": 2,
          "signals_60d": 2,
          "signals_90d": 5,
          "signals_per_week": 0.38,
          "total_signals": 19,
          "rsi_extreme_count": 3,
          "rsi_ultra_count": 1,
          "escalation_count": 1,
          "density_score": 3,
          "rsi_score": 7,
          "escalation_score": 4,
          "description": "0.4 signals/week | 3 RSI<20 | 1 escalations | \ud83c\udfaf MILD COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "DEEP CRASH BOTTOM",
            "DEEP CRASH BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 0,
          "max": 15,
          "relative_volume": 1.43,
          "description": "Normal volume"
        },
        "pop_potential": {
          "score": 15,
          "max": 15,
          "best_historical_rally": 501.6,
          "avg_rally": 310.1,
          "signal_count": 19,
          "description": "BIG POPPER - Historical 5x+ (502%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "FAB.L",
      "signal_date": "2024-05-01",
      "total_signals_history": 19
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +10 (AI_Technical_Score=8.0/20)",
      "Drawdown reversion potential: +19 (Drawdown_Pct=92.7%)",
      "Volume confirmation: +3 (Relative_Volume=1.4)",
      "Pattern reliability: +5 (Rally_Count=2.0)",
      "Upside history: +12 (best_rally_pct=488%)"
    ],
    "technical_score": {
      "points": 10,
      "ai_score": 8.0,
      "reason": "AI Technical Score 8.0/20 translates to 10/25 points"
    },
    "drawdown_score": {
      "points": 19,
      "drawdown_pct": 92.72,
      "reason": "Drawdown of 92.7% gives 19/20 points"
    },
    "volume_score": {
      "points": 3,
      "rel_volume": 1.43,
      "reason": "Relative volume 1.43x gives 3 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 2.0,
      "reason": "2.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 12,
      "best_rally_pct": 487.79,
      "reason": "Best rally of 488% gives 12/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=309.2%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2024-05-01"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.63,
    "current_run_pct": 309.16,
    "avg_historical_run_pct": 487.79
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 49/100 APEX score. Historical data shows 2 rallies averaging 488% upside. Current position: +309.2%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  },
  "report_version": "5.0",
  "comprehensive_apex": {
    "score": 49,
    "rating": "LOW QUALITY",
    "color": "#ef4444",
    "calculation": "APEX Score: 49/100",
    "components": {
      "setup": {
        "score": 40,
        "weight": 0.25
      },
      "trust": {
        "score": 40,
        "weight": 0.2
      },
      "panic": {
        "score": 71.1,
        "weight": 0.3
      },
      "compression": {
        "score": 34,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "EARLY_BUILD",
      "multiplier": 1.0
    }
  }
};</script>
  <script src="../../apex_trust_panel.js"></script>
</body>
</html>
